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SUMMARY 
Alzheimer’s disease (AD) is the most common neurodegenerative disease in industrial 
nations. Its prevalence increases with advanced age. The most important histopathological 
markers in the brain of AD-patients are neuritic Aβ plaques and neurofibrillary tangles, 
contributing to the degeneration of neurons in the brains of affected patients. Numerous 
epidemiological studies suggest that genetic factors - together with lifestyle and environment 
dependent determinants – have an implication on the development of this multifactorial 
disease. Mutations in three genes (PS1, PS2 und APP) cause an autosomal dominant, early-
onset familial form of AD (EOAD). A fourth gene, ApoE, increases the risk of the more 
common late-onset familial (LOAD) and sporadic forms of AD, when the ApoE ε4 allele is 
present. Moreover, several linkage studies have defined susceptibility regions for AD on 
several chromosomes. 
In the present work, a fine-mapping of functional and positional candidate genes was 
carried out in previously identified linkage regions. Selected SNPs were genotyped in a local 
case-control collective and were subsequently tested for an association with Alzheimer’s 
disease. The focus of the presented work was the APP gene and genes involved in the 
processing of APP and therefore Aβ formation.  
39 SNPs from APP were thoroughly selected and subsequently genotyped by means of 
Matrix-Assisted Laser Desorption / Ionization Time Of Flight (MALDI TOF MS). The initial 
statistical single-marker, haplotype and sliding-window analyses revealed significant 
association signals (p < 0.05) within two marker peak regions spanning intron 3 to 8 and in 
intron 1, respectively. A selection of SNPs with strongest association signals underwent 
replication in a second large independent case-control series from Sweden, including a pooled 
analysis, as well as a discordant sib-pairs cohort. The replication analyses confirmed signals 
for eight SNPs (rs9941877, rs2830012, rs3787644, rs2070655, rs2830035, rs1041420, 
rs6516727 und rs2830099) and therefore, their implication to Alzheimer’s disease. A 
following association analysis of genotyping results from all 39 SNPs with clinical measures 
(MMSE score and age at onset) yielded a positive result for rs1783016 in intron 14 of APP. 
The risk allele (rs1783016-G) appears to be coupled with a later age of onset, but a more rapid 
decline in cognition. Subsequently, SNPs from the peak regions underwent further analyses in 
post mortem isolated brain samples to ascertain the functional implications of polymorphisms 
across the APP gene on the transcriptional, translational and post-translational level. The 
identified risk allele (T) of SNP rs1041420 located in intron 3 was associated with elevated 
APP mRNA levels in the brain, suggesting that the rs1041420-T allele might contribute to the 
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development of AD due to altered amounts of APP protein and not due to altered APP 
processing. For SNPs rs6516727 and rs2830099 - located in intron 1 - an association of the 
formerly identified risk allele (rs6516727-T and rs2830099-G) with lower soluble total Aβ 
and lower Aβ40 contents was found. The respective protective C variants (rs6516727-C und 
rs2830099-C) seem to favor the formation of the soluble Aβ40. The majority of present Aβ42 
may already have formed plaques in the affected brains. Therefore, the risk alleles 
(rs6516727-T and rs2830099-G) are rather associated with altered processing than higher 
substrate levels, since no affect on the gene expression was observed. The applied approach - 
examination of functional implications of the identified SNP variants in brain samples - was 
well-chosen and is applicable for our experiments, but needs to be repeated in a greater 
collective. From the data analysis performed in the scope of this study, it is assumed that 
common variations within the APP gene contribute to the development of AD. 
The proteins encoded by ADAM10 and BACE1 are involved in APP processing and 
therefore the development of Aβ, due to their function as α- or ß-secretase, respectively. 
Hence, 38 SNPs from both genes were thoroughly selected, genotyped and statistically 
evaluated accordingly. None of the examined SNPs from ADAM10 or BACE1 showed a 
significant association with AD. For this reason it is assumed that common genetic variations 
in either BACE1 or ADAM10 are not associated with an increased risk to develop AD. 
Furthermore, two genes (ABCA1 and LIPC) involved in lipid metabolism were 
examined. Two of the 30 investigated SNPs from ABCA1 showed a weak association with 
AD (rs2525606 and rs2066720). The results could be confirmed in the Swedish replication 
study. During the following gene expression experiment the risk allele rs206676-G was 
associated with elevated ABCA1 mRNA levels in brain samples, probably due to increased 
ApoE lipidation. The 25 investigated SNPs from LIPC showed no replicable significant 
association with AD, therefore seems an impact of SNP variants in LIPC on the implication of 
Alzheimer’s disease unlikely. 
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ZUSAMMENFASSUNG 
Die Alzheimer Krankheit ist die am häufigsten auftretende neurodegenerative 
Erkrankung in den westlichen Industrieländern und zeigt eine steigende Prävalenz mit 
zunehmendem Alter (Bassiony, Rosenblatt et al. 2004; Potyk 2005). Die histopathologischen 
Merkmale dieser Erkrankung sind Aβ-Plaques und neurofibrilläre Tangles, sowie 
Neuronenverlust in den Gehirnen der Betroffenen. Zahlreiche epidemiologische Studien 
weisen auf einen zentralen Einfluss genetischer Faktoren hin, die zusammen mit Umwelt-, 
bzw. Lebensstilfaktoren einen Beitrag zur Alzheimer Krankheit leisten. Während 
Punktmutationen in drei Genen (PS1, PS2 und APP) die autosomal-dominante Form der 
Erkrankung schon vor dem 60. Lebensjahr auslösen können, erhöht das ApoE ε4 Allel die 
Wahrscheinlichkeit mit zunehmendem Alter an Alzheimer zu erkranken. Weiterhin wurden in 
zahlreichen genetisch-epidemiologischen Studien signifikante Loci in verschiedenen 
chromosomalen Regionen identifiziert. 
In dieser Arbeit wurde eine Feinkartierung von funktionellen und positionellen 
Kandidatengenen in vorher identifizierten Kopplungsregionen durchgeführt. Die 
ausgewählten SNPs wurden anhand eines Fall-Kontroll Kollektivs aus München genotypisiert 
und anschließend auf eine Assoziation mit der Alzheimer Krankheit getestet. 
Hauptaugenmerk wurde auf das Gen APP gerichtet, welches maßgeblich an der Ausprägung 
von AD durch die Bildung von Aβ beteiligt ist. 
Insgesamt wurden 39 SNPs aus APP sorgfältig ausgewählt und anschließend mittels 
Matrix-Assisted Laser Desorption/Ionization Time Of Flight (MALDI TOF MS) 
genotypisiert. Die statistischen Auswertungen (Einzelmarker, Haplotypen und Sliding 
Window) der Genotypisierungsdaten ergab zwei chromosomale „hot-spot“ Regionen mit 
signifikanten Ergebnissen (p < 0.05), welche sich über 5 untersuchte SNPs in Intron 1; und 11 
SNPs von Intron 3 bis Intron 8 erstrecken. Die am stärksten assoziierten SNPs wurden in 
einer weiteren unabhängigen Fall-Kontroll Studie aus Schweden, inklusiver einer gepoolten 
Auswertung, sowie in einem diskordanten Geschwisterpaarkollektiv aus Deutschland 
repliziert. Die Replikationsanalyse bestätigte eine Assoziation mit AD für acht SNPs 
(rs9941877, rs2830012, rs3787644, rs2070655, rs2830035, rs1041420, rs6516727 und 
rs2830099). Eine anschließende Assoziationsanalyse der gefundenen Genotypen aller 39 
SNPs mit klinischen Größen (MMSE Punktzahl und Ausbruchsalter) lieferte ein positives 
Ergebnis für rs1783016 in Intron 14. Das Risikoallele (rs1783016-G) scheint mit einem 
späteren Erkrankungsalter, aber einer schnelleren Abnahme der kognitiven Fähigkeiten 
assoziiert zu sein. Nachfolgend wurde eine Auswirkung der vorher identifizierten Risikoallele 
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in post mortem isoliertem humanen Hirngewebe von Alzheimer Patienten und gesunden 
Kontrollhirnen untersucht, um funktionelle Auswirkungen der Polymorphismen auf 
transkriptionaler, translationaler und post-translationaler Ebene zu untersuchen. Das 
identifizierte Risikoallel T des SNPs rs1041420 aus Intron 3 zeigte eine erhöhte 
Genexpression von APP. Demnach würde das rs1041420-T Risikoallel einen Beitrag zur 
Ausbildung der AD durch erhöhte APP Substratmengen und nicht infolge 
überdurchschnittlicher Prozessierung leisten. Für die beiden SNPs rs6516727 und rs2830099 
aus Intron 1 wurde jeweils eine Assoziation des vorher identifizierten Risikoallels 
(rs6516727-T und rs2830099-G) mit niedrigerem löslichen GesamtAβ-Gehalt und 
niedrigerem Aβ40-Gehalt gefunden. Die entsprechenden protektiven C-Varianten 
(rs6516727-C und rs2830099-C) scheinen eine Bildung der löslichen Aβ40-Form zu 
begünstigen, während Aβ42 in den betroffenen Hirnproben vermutlich bereits neuritische 
Plaques gebildet hat. Demnach würden die Risikoallele der beiden SNPs rs6516727 und 
rs2830099 möglichwerweise einen Beitrag zur Ausbildung von AD durch erhöhte APP 
Prozessierung und nicht infolge steigender Substratmengen leisten. Die angewandte Methode 
- die funktionelle Untersuchung der Einwirkung der assoziierten SNP Varianten auf die 
Entstehung von AD - sollte in einem größeren Kollektiv an Hirngewebsproben wiederholt 
werden. Insgesamt konnte nachgewiesen werden, dass verschiedene SNP-Varianten im APP 
Gen ein starker Risikofaktor für die Ausprägung der Alzheimer Krankheit sind. 
Da die Proteine von ADAM10 und BACE1 durch ihre Funktion als α-, bzw. ß-
Sekretase an der Prozessierung von APP und somit an der Entstehung von Aβ beteiligt sind, 
wurden 38 SNPs aus beiden Genen sorgfältig ausgewählt und analog zu APP genotypisiert 
und statistisch analysiert. Keiner der untersuchten SNPs aus ADAM10 oder BACE1 zeigte 
eine signifikante Assoziation mit AD. Deswegen wird angenommen, dass SNP-
Polymorphismen in ADAM10 und BACE1 keinen wesentlichen Einfluss auf die Ausprägung 
der Alzheimer Krankheit haben. 
Des Weiteren wurden zwei Gene (ABCA1 und LIPC) untersucht, die am 
Lipidmetabolismus und somit am Aβ-Abbau und -Transport beteiligt sind. Von den 30 
untersuchten SNPs aus ABCA1 zeigten zwei (rs2525606 und rs2066720) eine sehr schwache 
Assoziation mit AD. Diese Ergebnisse konnten in der schwedischen Replikationsstudie 
jedoch bestätigt werden. Bei der folgenden Genexpressionsanalyse war das Risikoallel 
rs206676-G mit erhöhten ABCA1 mRNA Levels in Hirnproben assoziiert, vermutlich durch 
erhöhte ApoE-Lipidation. Die 25 untersuchten SNPs aus LIPC zeigten keine replizierbare 
signifikante Assoziation mit AD, weswegen ein wesentlicher Einfluss von SNP-Varianten in 
LIPC auf die Ausprägung der Alzheimer Krankheit ausgeschlossen werden kann. 
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List of Abbreviations 
Aβ Beta Amyloid
ABCA1 Member 1 of Human Transporter Sub-family ABCA
AD Alzheimer’s Disease, Morbus Alzheimer
ADAM10 Disintegrin Metalloproteinase
ADRDA Alzheimer’s Disease and Related Disorders Association 
APP Amyloid Precursor Protein
APO Apolipoprotein
bp Base Pairs 
BACE1 Beta-site Amyloid Beta A4 Precursor Protein-cleaving Enzyme 1 
CAD Coronary Artery Disease
cCT Craniale Computertomographie
cDNA Complementary DNA
CERAD Consortium to Establish a Registry of Alzheimer’s Disease 
Ch./Chr. Chromosome
cMRT Craniale Magnetic Resonance Tomography
Da Dalton 
DNA Desoxyribonucleic Acid
dNTP Desoxyribonukleosidtriphosphate
DSM Diagnostic and Statistical Manual of Mental Disorders 
EOAD Early Onset Alzheimer’s Disease
HDL High-densitiy Lipoprotein
hME Homogenous Mass Extension
HSD Multiple Testing Using Tukey HSD = Honest Significant Difference 
ICD International Classification of Disease
LD Linkage Disequilibrium
LDL Low-densitiy Lipoprotein
LIPC Hepatic Triglyceride Lipase
LOAD Late Onset Alzheimer’s Disease
LSD Multiple Testing Using Tukey LSD = Least Significant Difference 
M Molar 
MALDI TOF Matrix-Assisted Laser Desorption/Ionization Time Of Flight 
min Minute 
MMSE Mini Mental Status Examination
mRNA Messenger Ribonucleic Acid
MS Mass Spectrometry
MUC Munich Sample Collective
NFT Neurofibrillary Tangles
NINCDS National Institute of Neurological an Communicative Disorders 
PCR Polymerase Chain Reaction
PHF Paired Helical Filaments
PS Presenilin 
RNA Ribonucleic Acid
rRNA Ribosomal Ribonucleic Acid
RT-PCR Reverse Transcription Polymerase Chain Reaction
RTQ-PCR Real Time Quantitative Polymerase Chain Reaction 
SAP Shrimp Alkaline Phosphatase
SF Straight Filament
SNP Single Nucleotide Polymorphism
S-TDT Sib Transmissions-Disequilibrium-Tests
SWE Swedish Sample Collective
TICS-M Telephone Interview for Cognitive Status-Modified
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1 Introduction 
 
Dementias are the most common mental-health problems in the elderly (Jellinger, 
Danielczyk et al. 1990). According to the traditional definition, dementia (from latin „de“ = 
without, „mens“ = mind) is a secondary, advancing impairment of a formerly greater 
intellectual capacity (Rosler, Wichart et al. 2001). Dementia is not regarded as a specific 
syndrome, but rather as a genus for multiple cognitive deficits of the brain, which are caused 
by degenerative, vascular and trauma-caused disorders (Letenneur 2004). 
The prevalence of dementias increases massively with advanced age (Bondy, Guo-
Ross et al. 1998; Bassiony, Rosenblatt et al. 2004; Potyk 2005). Around the age of 60 
intermediate and severe dementias play - with a prevalence of 1 % (Rosler, Wichart et al. 
2001) - only a comparatively minor roll in industrial nations. Although in the age group 
between 70 and 74 years only ~3 % of individuals are affected, in the age group over 80 
years, the percentage of affected persons increases up to 20 % (Letenneur 2004). Prevalence 
amongst the 95 – 99 year old even reaches 45 % emphasizing the age-dependency of the 
disease (Teri, McCurry et al. 1997). In Germany about 1 million people are suffering from a 
dementia (Forstl 2000; Bickel 2001). From these about 70% are suffering from Morbus 
Alzheimer (Alzheimer’s disease, AD) (Bickel 2000). 
Due to the strongly reserved quality of life of affected people and enormous economic 
costs for care and therapy (Letenneur 2004), exploration of the course of disease and the 
development of effective methods of treatment are of utmost importance. 
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1.1 Alzheimer´s Disease: Definition and Introduction 
 
Alzheimer´s disease was described for the first time by Alois Alzheimer in 1906 at a 
convention meeting in Tübingen. AD is characterized by a lingering beginning and a 
progressive course of disease, where cognitive impairments (affecting memory, power of 
judgment, intellectual power, language and learning), behavioral problems (disinhibition, 
euphoria, low frustration tolerance, emotional instability, crankiness, aggressiveness, changed 
sexual behavior) and an increasing loss of daily living skills occur (Forstl 2000). Additionally, 
unspecific accessory symptoms (depression, anxiety, misperception, delusion-like 
phenomenon, etc.) can appear. On the individual level, AD can proceed in varying degrees 
and does not follow a coarse division into single stages. The most commonly used diagnosis 
criteria are defined in the 10th edition of „International Classification of Disease“ (ICD 10), as 
well as in the 4th edition of „Diagnostic and Statistical Manual of Mental Disorders“ (DSM 
IV) of the American Psychiatric Association. Another concept was submitted by a 
collaboration of the workgroups of the „National Institute of Neurological and 
Communicative Disorders and Stroke“ (NINCDS) and the „Alzheimer’s Disease and Related 
Disorders Association“ (ADRDA). Diagnosis criteria are listed in the Appendix (§ 7.1). 
Two different forms of AD can be distinguished – the sporadic form, occurring in ~75 % 
of the cases and the familial form (FAD, approx. 25 % of cases). Depending on the age of 
onset of the affected people the familial form is subdivided into two sub-forms: late-onset AD 
(LOAD) und early-onset AD (EOAD). LOAD occurs after the age of 65 and is prevalent in 
the majority of FAD-cases (Rademakers, Cruts et al. 2003). LOAD exhibits numerous non-
Mendelian anomalies that suggest an epigenetic component in disease etiology (Wang, Oelze 
et al. 2008). The amount of patients suffering from the rarer EOAD is approx. 5 % 
(Kowalska, Pruchnik-Wolinska et al. 2004), where genetic influences seem to play a more 
significant role. 
The severity of the disease can be defined by the individual’s ability of an autonomous 
conduct of life. With a weak severity an independent life is possible, but complex daily 
activities can not be conducted any longer. At an intermediate stage clear impairments of 
independent living occur and the affected person needs assistance. With a severe dementia a 
self-governing life is impossible. 
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Histopathological Markers 
 
As the most important histopathological markers in the brain of AD-patients, neuritic 
plaques and neurofibrillary bundles (so-called “tangles”) are presented (Fig. 1). Neuritic 
plaques are made of extracellular beta amyloid (Aβ) deposits (Verdile, Fuller et al. 2004). 
Neurofibrillary tangles are intracellular, abnormal (stretched or twisted) filaments, which 
consist primarily of a hyper-phosphorylated (Dickson 2004; Garcia and Jay 2004; Gomez-
Ramos, Smith et al. 2004) and hyper-glycosed (Gong, Liu et al. 2005) form of the tau protein. 
Together with inflammatory occurrences in the brain, these histopathological markers 
contribute to the degeneration of neurons.  
 
 
 
Fig. 1: Schematic of a normal and an AD affected neuron: 
A normal neuron is shown on the left side. Communication between neurons in an AD affected brain (right side) 
is disrupted by beta-amyloid plaques and tau tangles. The pathological deposits cause degeneration of neurons, 
producing cell death and brain atrophy  
(Garcia and Jay 2004; Gomez-Ramos, Smith et al. 2004; Verdile, Fuller et al. 2004). 
 
According to the widely accepted „beta amyloid theory“, the Aβ protein is the key 
molecule in AD pathogenesis (Hardy and Selkoe 2002; Sennvik, Bogdanovic et al. 2004; 
Verdile, Fuller et al. 2004). Aβ is produced by the so-called amyloidogenic pathway through 
proteolytic cleavage of the amyloid precursor protein (APP), a transmembrane glycoprotein 
(Cribbs, Poon et al. 2004; Verdile, Fuller et al. 2004). During the first step APP is cleaved by 
the β-secretase (BACE1, β-site cleaving enzyme). Thus, a soluble form of APP (APPsβ) and a 
C-terminal APP fragment (APP-CTFβ) are released (Verdile, Fuller et al. 2004). Thereafter, 
the enzymatic activity of the γ- secretase cleaves the APP-CTFβ molecule and Aβ is finally 
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generated (Sennvik, Bogdanovic et al. 2004). Gamma secretase is a multi-subunit protease 
complex, consisting of a catalytic sub-unit and three cofactors - Nicastrin (NCSTN), Anterior 
Pharynx Defective 1 (APH1A & APH1B) and the Presenilin Enhancer (PEN2) (Verdile, 
Fuller et al. 2004). The catalytic subunit of the γ-secretase is Presenilin 1 (PS1) or Presenilin 2 
(PS2). The varying length of the Aβ protein is caused by the different γ-secretase-cleaving 
sites (Qi-Takahara, Morishima-Kawashima et al. 2005). 
 
 
Fig. 2: Two possibilities of the proteolytic cleavage of APP: 
The above described amyloidogenic pathway (right side) results through β- und γ-secretase activity in Aβ release 
and therefore enables forming of plaques. BACE1 was characterized as as β-secretase (Vassar, Bennett et al. 
1999). The non-amyloidogenic (physiological) pathway (left side) is characterized by enzymatic activity of α-
secretase, where APP is cleaved in the Aβ protein sequence (Postina, Schroeder et al. 2004). Thereby, the soluble 
carboxyl-truncated form of APP (sAPPα) and a C-terminal APP fragment (APP-CTFα) are released. In the next 
step, APP- CTFα is cleaved by γ-secretase and a non-amyloidogenic fragment (p3) is built. ADAM 10, ADAM 17 
und MDC9 were described as α-secretase candidate (Postina, Schroeder et al. 2004; Verdile, Fuller et al. 2004; 
Postina 2008). The non-amyloidogenic pathway is also enabled by means of the protein kinase C (PKC) 
(Verdile, Fuller et al. 2004; Zheng and Koo 2006)  
http://www.ebi.ac.uk/interpro/potm/2006_7/Page2.htm 
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With increasing length of the Aβ protein the tendency of self-aggregation and thus 
amyloidicity increases. Soluble Aβ proteins are 39 to 40 amino acids long and can also be 
detected in blood plasma and liquor of healthy individuals. These forms are not involved until 
later phases of the disease (Verdile, Fuller et al. 2004). However, proteins with a length of 41 
– 43 amino acids (Aβ 41-43) are insoluble and interact, due to their beta-sheet structure, with 
each other and aggregate immediately. To a minor degree these proteins are also present in 
healthy individuals. They form hardly soluble or insoluble oligomers, so-called neuritic 
plaques. Neuritic plaques are characterized by a dense amyloid-core and can achieve a size up 
to 0.2 mm. In addition to Aβ, apolipoprotein (APO) E und J, α1–antichymotrypsin and 
proteoglycan appear in neuritic plaques (Dickson 2004). Intensified plaque formation involves 
loss of communication ability between different nerve cells. In almost all Alzheimer patients, 
amyloid sediments appear not only as plaques in the neurons, but also perivascular (Forstl 
2000; Davis, Wagner et al. 2003). In these cases a reduced oxygen- and energy-supply of 
affected brain regions are the result, which can cause cerebral hemorrhage and strokes in 
advanced stages (Davis, Wagner et al. 2003; Melchor, Pawlak et al. 2003). In addition, 
pathological Aβ deposit may form an inflamed region, which in turn promotes the deposition 
of additional proteins (Combs, Bates et al. 2001).  
The second histopathological AD marker is the formation of Alzheimer-fibrils or 
neurofibrillary tangles (NFT), which consists of paired helical filaments (PHF). In some 
cases, NFTs comprising PHF and SF (straight filament) or only SF are found. Both PHF and 
SF disturb the vital functions of neurons (Garcia and Jay 2004; Rissman, Poon et al. 2004). 
Although NFTs form inside of neuronal cells, extracellular tangles can be found as well. 
Apparently, the NFTs are released after cell death (Lovestone and Reynolds 1997). The major 
constituent of the NFTs is the hyper-phosphorylated and hyper-glycosylated tau protein 
(Garcia and Jay 2004; Rissman, Poon et al. 2004; Gong, Liu et al. 2005). In AD, Tau proteins 
are hyper-phosphorylated, due to an inbalance between kinases und phosphatases that affect 
Tau processing (Rissman, Poon et al. 2004). Due to an increased phosphorylation the protein 
is released from tubulin, a central part of microtubules. As a consequence, a stabilization of 
the cytoskeleton (Hartmann, Almeida et al. 2004), as well as axonal transport are inhibited 
(Garcia and Jay 2004). Because of its low solubility, released hyper-phosphorylated tau 
aggregates and forms NFTs or PHFs, respectively Tau is partly phosphorylated after NFT-
building (Lovestone and Reynolds 1997). Overall, all of these pathological changes contribute 
to cell death. Besides phosphor-tau, ubiquitin can be present in NFTs (Rissman, Poon et al. 
2004) and ApoE. Ubiquitin and ApoE are found in the cyst of the NFTs. Elevated phosphor-
  1   Introduction 
16 
tau-levels and NFTs can also be determined in patients which are suffering from other 
neurodegenerative diseases, e.g. fronto temporal dementia, vascular dementia, Creutzfeld-
Jakob-disease, HIV-dementia, normal-pressure hydrocephalus, meningocephalitis, Lewy-
Body-disease and corticobasal degeneration (Buee, Bussiere et al. 2000). Accordingly, 
phosphor-tau has no significant diagnostic value as specific AD marker, but can only be used 
in combination with other markers (Sergeant, Delacourte et al. 2005).  
Both extra- and intracellular pathological sediments yield loss of brain substance 
(cerebral atrophy) and their density strongly correlate with the severity of the disease (Bauer, 
Hull et al. 1995). In comparison to same-aged healthy individuals, the weight of the brain of 
Alzheimer patients is significantly reduced, whereby different brain regions are not affected 
alike. In particular degradation of the cerebral cortex, especially the parietal-, temporal- and 
frontal lobe as well as the hippocampus formation are observed (Smith and Jobst 1996; De 
Leon, George et al. 1997; Nagy, Hindley et al. 1999; Pantel, Schonknecht et al. 2004). 
Neuronal cell death inhibits the transportation of material into healthy cells and also inhibits 
signal transduction pathways by means of neurotransmitters. The underrepresentation of 
acetylcholine is the most substantial neurotransmitter modification observed in AD patients, 
although it is not the only one. Eventually, a decreased acetylcholine level results in loss of 
memory, concentration and attention (Grossberg 2005). To a minor degree, concentrations of 
glutamate, noradrenaline, serotonin and several neuropeptides are reduced as well 
(Whitehouse 1987). 
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1.2 Risk Factors for Alzheimer´s Disease 
 
AD is a complex, multi-factorial disease. It is influenced by lifestyle and environment 
dependent determinants as well as by genetic factors. The most frequently discussed risk 
factor for AD is age, with which the prevalence increases exponentially (Bassiony, Rosenblatt 
et al. 2004). According to estimations, 20 % of the population above 80 years is affected in 
western countries (Rosler, Wichart et al. 2001; Letenneur, Larrieu et al. 2004). 
Intriguingly, the prevalence for LOAD in females is higher than in males (Colucci, 
Cammarata et al. 2006). One potential explanation for that phenomenon is the declined 
estrogen level or estrogen deficit during and after menopause, respectively (Balistreri, 
Grimaldi et al. 2006; Candore, Balistreri et al. 2006), as well as on average, a higher length of 
life of women (Corder, Ghebremedhin et al. 2004). 
 
1.2.1 Lifestyle and Environment Dependent Risk Factors 
 
Traumatic brain injuries, hyper-cholesterol anemia, as well as mental disorders were 
discussed as most important factors triggering AD (Grossman, Bergmann et al. 2006; Reid, 
Urano et al. 2007). Also complex, systemic diseases like diabetes mellitus (Gasparini, Netzer 
et al. 2002; Xu, Qiu et al. 2004) and hyperinsulin anemia (Luchsinger, Tang et al. 2004) were 
proven to be AD risk factors in several studies. Moreover, Itzhaki and coworkers showed, that 
the herpes simplex virus type 1 (HSV1) can contribute to development of AD in ApoE4 
carriers (Itzhaki 2004; Itzhaki, Dobson et al. 2004). 
Another aspect, which has often been discussed in combination with Alzheimer 
studies, was the education degree of patients (Karp, Kareholt et al. 2004; Colucci, Cammarata 
et al. 2006). Larger cognitive reserves and a life-long intellectual activity seem to delay the 
occurrence of dementia (Stern, Gurland et al. 1994; Qiu, Karp et al. 2003; Smyth, Fritsch et 
al. 2004). 
In many clinical trials, an association between smoking and occurrence of AD was 
examined. Unlike few case-control-studies, where smoking was assumed to be a protective 
factor (van Duijn and Hofman 1991; Hellstrom-Lindahl, Mousavi et al. 2004), in most of the 
cohort-studies a negative influence on the occurence of AD was observed (Ott, Slooter et al. 
1998; Juan, Zhou et al. 2004; Ott, Andersen et al. 2004) 
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The influence of alcohol consumption on appearance of AD was tested in numerous 
studies, too. Small doses of alcohol showed a potentially protective effect (Ruitenberg, van 
Swieten et al. 2002; Truelsen, Thudium et al. 2002; Letenneur 2004), whereas frequent 
alcohol consumption seems to increase the risk for AD (Luchsinger and Mayeux 2004). 
Moreover, redox-active metal-ions, especially Aluminium (Becaria, Campbell et al. 2002), 
copper (Rottkamp, Raina et al. 2001; Perry, Sayre et al. 2002) and iron (Rottkamp, Raina et 
al. 2001; Perry, Sayre et al. 2002), are discussed as potential triggers for the formation of 
plaques and tangles. 
Although the above mentioned lifestyle- and environmental risk factors can be 
consistently detected after the onset of AD, the prediction of onset and course of disease, on 
basis of presence of the factors, are not very reliable. 
 
1.2.2 Genetic Risk Factors 
 
Growing prevalence of AD can mainly be ascribed to the increasing life expectancy in 
the population. Although lifestyle and environmental conditions influence quality of life and 
therewith development and course of disease, the probability of suffering from AD cannot just 
be explained with these factors. It seems to be more likely, that AD arises by reason of an 
interaction between several genetic factors and different environmental factors (Huang, Qiu et 
al. 2004). 
Several genetic epidemiological studies gave indications on the influence of genes on 
the development of AD. Autosomal-dominant mutations in the Presenilin 1 (PS1) gene on 
chromosome 14, in the Presenilin 2 (PS2) gene on chromosome 1 and in the Amyloid 
Precursor Protein (APP) gene on chromosome 21 partly explain the significantly higher risk 
of onset for EOAD (Kowalska, Pruchnik-Wolinska et al. 2004; Zekanowski, Religa et al. 
2004; Rebeck, LaDu et al. 2006). The pathological mutations in those three genes cause an 
increased Aβ production, especially of Aβ 42 (Ozturk, Minster et al. 2007). Nevertheless, in 
total, only a few hundred of families worldwide were reported to carry these mutations. 
Up to now, only the ε4 allele of the ApoE gene was confirmed as a clear risk factor for 
LOAD (Rademakers, Cruts et al. 2003; Zekanowski, Religa et al. 2004). The ApoE gene is 
located on chromosome 19 and is found in three allelic variations, ε2, ε3 und ε4 (Mahley and 
Rall 2000). Inheritance of one or two ε4-alleles increases the dose-dependent risk of later 
occurrence of Morbus Alzheimer and moreover reduces the age of onset (Olarte, Schupf et al. 
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2006). Patients heterozygous for the ε4-allele sicken on average 4 years earlier, whereas 
homozygote patients with two copies of the risk allele are affected 6 – 8 years earlier than 
patients completely lacking the ε4-allele (Daw, Payami et al. 2000). 
 
 
 
1.3 Genome-wide Search for Genetic Risk Factors 
 
First informative data on disease-related chromosomal regions were originally provided 
by genome-wide linkage and association studies. The advantage of such genome-wide 
analyses is that no hypothetical assumptions concerning the pathophysiology of the disease is 
required. 
In linkage studies, genetic markers that are distributed over the whole genome are 
determined within affected families and then genotyped. Micro-satellites serve as markers. 
Subsequently, the collective inheritance of these markers in families is investigated. A linkage 
between the marker allele and disease incidence is suggested when both occur together at a 
higher than average frequency. This approach enables the identification of chromosomal 
regions (so-called linkage regions), which are inherited in combination with the disease. In the 
next step – the so-called fine-mapping – the genes that are localized in the linkage region 
showing a probable involvement in the development of the disease are analyzed in detail (de 
la Chapelle and Wright 1998; Bleck, McGrath et al. 2001). Those loci are called positional 
candidate genes. For complex diseases with a late age of onset (e.g. Morbus Alzheimer), a 
linkage analysis is carried out for the affected individual and the siblings, due to the usually 
missing information of the parents. First significant linkage findings in EOAD families were 
reported for the chromosome-wide studies of the chromosomal regions Ch1q31-42 (Levy-
Lahad, Wijsman et al. 1995), Ch14q24.3 (Nechiporuk, Fain et al. 1993; Cruts, Backhovens et 
al. 1995) and Ch21q21 (Goate, Haynes et al. 1989). Genome-wide linkage studies for LOAD 
pointed to several chromosomal regions (chromosomes: 1, 3, 5, 6, 9, 10, 12, 19, 21 and x) 
(Myers, Holmans et al. 2000; Lee, Cheng et al. 2006). Highest LOD (logarithm of the odds)-
Scores, as a measure of the probability for linkage between selected markers and occurrence 
of the disease, were achieved for chromosomes 9, 10, 12 and 19 (Pericak-Vance, Bass et al. 
1998; Kehoe, Wavrant-De Vrieze et al. 1999; Myers, Wavrant De-Vrieze et al. 2002; Blacker, 
Bertram et al. 2003). 
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The most applied current genetic research methods are based on genome-wide association 
studies. For this purpose, in a very large amount of subjects (>1000), approx. 500.000 SNP 
markers are genotyped in parallel on microarray-chips and subsequently tested for association 
with the disease. Genome-wide association studies are often carried out in a three-phase 
design. In the first phase (screening phase) selected SNPs are analyzed and the genotyping 
results are statistically evaluated. Significantly associated SNPs are subsequently validated in 
independent cohorts (phase two). In the third phase fine-mapping of the formerly analyzed 
region is carried out (Pearson, Huentelman et al. 2007). In all the genome-wide association 
studies that were performed up to now, the ApoE locus on chromosome 19 was confirmed as 
the most important genetic risk factor for LOAD (Coon, Myers et al. 2007; Reiman, Webster 
et al. 2007; Li, Wetten et al. 2008; Feulner, Laws et al. 2009). Amongst others, an association 
with AD was also reported for markers on chromosome 9 and 10 (Li H et al, 2008, Gruppe A 
et al. 2007). GOLPH2, EBF3 und SORCS1, located in these chromosomal regions were 
identified as positional candidate genes. In our group, additional to the ApoE locus on 
chromosome 19, the top ten disease-associated genes, as presented from AlzGene´s version of 
07-May-2008 (www.alzforum.org) were confirmed to be associated with AD. This finding 
demonstrates that genome-wide association studies are valuable for the identification of 
genetic variants associated with AD (Feulner, Laws et al. 2009). 
Genome-wide association studies for EOAD have not been carried out up to now. 
 
 
 
1.4 Candidate Genes for Alzheimer´s Disease 
 
Preferentially, genes were analyzed, whose mutation could, according to nowadays 
knowledge, trigger the neuro-pathological process and therefore AD or could influence its 
course. Since former studies have proven a correlation between occurrence of AD and amount 
and presence of Aβ (Hardy and Higgins 1992), the main focus of the presented work was on 
the APP gene and the genes that are involved in the processing of APP. Additionally, genes 
involved in the lipid metabolism, such as the major genetic risk factor for AD, apolipoprotein 
E (ApoE) were taken into consideration during selection of candidate genes. 
Moreover, results from genome-wide linkage studies were taken into account in the 
selection of candidate genes. 
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1.4.1 Amyloid Precursor Protein (APP) 
 
The amyloid precursor protein (APP) is an integral membrane protein with a single 
membrane spanning region. It is expressed in many tissues and can be found concentrated in 
the synapses of neurons. It was assumed that it plays a decisive role in the formation and 
repair of synapses (Priller, Bauer et al. 2006) and neural plasticity (Turner, O'Connor et al. 
2003), although its normal biological function has not been completely clarified up to now. 
The gene for APP (APP) is located on chromosome 21 (21q21) and contains at least 18 exons 
spanning 240 kilobases (Yoshikai, Sasaki et al. 1990; Lamb, Sisodia et al. 1993). Several 
isoforms of APP have been observed in humans, due to alternative splicing, ranging in length 
from 365 to 770 amino acids. Predominant transcripts are APP695 (exons 1 – 6 and 9 – 18), 
APP751 (exons 1 – 7 and 9 – 18) and APP770 (exons 1 – 13 and 14 – 18) (Ling, Morgan et 
al. 2003). Since certain isoforms seem to be preferentially expressed in neurons; changes in 
the neuronal ratio of these isoforms have been associated with Alzheimer's disease (Matsui, 
Ingelsson et al. 2007). 
Due to APPs major role during AD pathogenesis, as described before in detail (see 
§ 1.1), this gene is a major functional candidate gene. 
Linkage studies have provided evidence for other susceptibility loci for late-onset 
Alzheimer’s disease. One locus, on chromosome 21 (Myers, Wavrant De-Vrieze et al. 2002; 
Olson, Goddard et al. 2002; Blacker, Bertram et al. 2003), is of particular interest due to its 
characteristics of harboring one of the aforementioned genes, APP. Previously, coding 
mutations in APP have been associated with EOAD (Goate, Chartier-Harlin et al. 1991), 
however, this linkage region was largely observed in families with a later age of onset (Olson, 
Goddard et al. 2002). The APP gene represents a strong functional candidate for AD risk on 
many levels. Firstly, it is the parent molecule from which the core peptide of amyloid plaques, 
beta-amyloid (Aβ), is derived. Secondly, complete or partial trisomy of chromosome 21 leads 
to Down Syndrome including AD pathology only when the APP gene is present in three 
copies, suggesting that overexpression of APP may be a risk factor for LOAD (Rumble, 
Retallack et al. 1989; Prasher, Farrer et al. 1998). Furthermore, an APP locus duplication in 
trisomy 21 leads to elevated levels of circulating Aβ peptide (Schupf, Patel et al. 2001). 
Likewise, a recent study has reported that duplication of the APP locus is associated with a 
familial disorder that is characterized by dementia and cerebral amyloid angiopathy (CAA) 
(Rovelet-Lecrux, Hannequin et al. 2006). Taken together these observations suggest that APP 
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is a strong functional candidate for conferring risk for sporadic forms of AD with variability 
in APP expression providing the functional mechanism for this association. However, it is 
interesting to note that, despite this evidence, there are relatively few studies that have 
examined the role of APP as a risk factor in sporadic forms of AD. 
A part from the study of Nowotny and colleagues (Nowotny, Simcock et al. 2007), 
where no association was observed in any of the 44 SNPs investigated, all previous studies 
have focused on a select number of polymorphisms, predominantly in the promoter region of 
the APP gene, and have to date presented inconclusive results. In a population of African 
American and Caribbean Hispanic ethnicity (Athan, Lee et al. 2002), the SNP rs459543 was 
presented to have an association in patients lacking the ApoE ε4 allele. Two other promoter 
polymorphisms rs466448 and rs11911934 have also been reported to influence the risk for 
LOAD by changing expression levels of APP (Lahiri, Ge et al. 2005). However, a subsequent 
study found no association of these SNPs, although an additional promoter polymorphism, 
rs463946, showed a weak association (Guyant-Marechal, Rovelet-Lecrux et al. 2007). 
Additionally, another study identified three rare variants in AD patients that, in vitro, showed 
neuron-specific increases in APP transcriptional activity (Theuns, Brouwers et al. 2006). 
Finally, Li and colleagues (Li, Perry et al. 1998) reported no association of a polymorphic 
tetra nucleotide repeat site, found in intron 7 of the APP gene, with LOAD.  
Although APP is a strong functional and positional candidate, only one of the 
aforementioned studies (Nowotny, Simcock et al. 2007) used a fine mapping approach of 
SNPs across the entire gene. Therefore, a whole fine mapping approach of APP is of utmost 
importance to verify or replicate the former findings and to get new results for the genomic 
loci spanning the APP gene. 
 
1.4.2 Candidate Genes Involved in APP Processing 
 
Central to AD pathogenesis is the amyloid cascade hypothesis (Hardy and Higgins 
1992). Today, this hypothesis remains valid, except that it is less clear which form of beta-
amyloid (Aβ), protofibrils or small oligomers, initiates the cascade. Key to this process is the 
consecutive cleavage of the amyloid precursor protein (APP) that occurs either through an 
amyloidogenic or a nonamyloidogenic pathway as described before (see Fig. 2 above). The 
amyloidogenic pathway results in the generation of beta-amyloid (Aβ) and is initiated through 
cleavage by the beta-site amyloid beta A4 precursor protein-cleaving enzyme 1 (BACE1). 
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The nonamyloidogenic pathway precludes the formation of Aβ through cleavage by alpha-
secretase, an enzymes activity demonstrated in a disintegrin metalloproteinase, ADAM10.  
 
1.4.2.1 Beta-site Amyloid Beta A4 Precursor Protein-cleaving Enzyme 1 (BACE1) 
 
Neurotoxic Aβ is generated by two proteases; β-secretase, identified as the Beta-site 
amyloid beta A4 precursor protein-cleaving enzyme 1 encoded by BACE1 at 11q23.2-q23.3, 
and the γ-secretase complex (Vassar, Bennett et al. 1999; Edbauer, Winkler et al. 2003).  
The encoded protein is a member of the peptidase A1 protein family and a type I 
integral membrane glycoprotein of 70 kDa. It functions as an aspartic protease that is found 
mainly in the Golgi apparatus (Haniu, Denis et al. 2000). The BACE1 gene contains 9 exons, 
producing four transcript variants encoding different isoforms: the full-length BACE1-501 
and the three minor transcripts BACE1-476, BACE1-457 and BACE1-432 which are 
generated by in-frame alternative splicing. It was shown, that BACE1-457 and BACE1-476 
isoforms showed weaker β-secretase activity than BACE1-501 (Tanahashi and Tabira 2001) 
or even no β-secretase activity at all (Ehehalt, Michel et al. 2002). 
It was shown, that the low density lipoprotein receptor-related protein-1 (LRP1) not 
only interacts and traffics with APP, but also with BACE1 on the cell surface in association 
with lipid rafts. The BACE-LRP1 interaction leads to increased LRP1 extracellular domain 
cleavage and subsequent release of the LRP1 intracellular domain from the membrane. It was 
therefore concluded that LRP1 is a BACE1 substrate (von Arnim, Kinoshita et al. 2005). 
Mice deficient in Bace1 seemed to be healthy, fertile, and appear normal in gross 
anatomy, tissue histology, hematology, and clinical chemistry according to investigations of 
Luo et al. They suggested that therapeutic inhibition of BACE1 for the treatment of 
Alzheimer disease may be free of mechanism-based toxicity (Luo, Bolon et al. 2001). In 
contrary, Willem and co-workers concluded from their studies that BACE1 is required for 
myelination and correct bundling of axons by Schwann cells (Willem, Garratt et al. 2006). 
Whilst BACE1 has been the subject of extensive study, these reports have focused on 
one or two exon 5 polymorphisms (for meta-anlaysis see the AlzGene database (Bertram, 
McQueen et al. 2007)) with only one study utilizing a whole-gene approach (Todd, McKnight 
et al. 2008). 
BACE1 represents, due to its involvement in APP processing, a prime functional 
candidate for AD. Furthermore, the location of BACE1 in the vicinity of suggestive AD 
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linkage peaks at 11q25 (Blacker, Bertram et al. 2003), also makes this gene a positional 
candidate.  
 
1.4.2.2 Disintegrin Metalloproteinase (ADAM10) 
 
An alternative cleavage pathway, involving α-secretase, precludes the formation of Aβ 
(Kojro and Fahrenholz 2005). ADAM10, a member of the ADAM (a disintegrin and 
metalloproteinase) family of proteinases, which is encoded by the ADAM10 gene on chr 
15q21-q23, has been shown to exhibit this α-secretase activity (Lammich, Kojro et al. 1999).  
The protein is a cell surface protein with a unique structure, possessing both potential 
adhesion and protease function. The ADAM10 gene contains 16 exons, 15 introns and covers 
about 160 kb (Prinzen, Muller et al. 2005). The protein contains a N-terminal signal sequence, 
followed by a prodomain, a metalloprotease-like domain, a disintegrin-like domain, a 
cysteine-rich region, an epidermal growth factor (EGF)-like repeat, a transmembrane domain, 
and a C-terminal cytoplasmic tail (Wolfsberg, Primakoff et al. 1995). 
It was shown in mice that carry a human APP mutation, that moderate neuronal 
overexpression of human ADAM10 increased the secretion of the neurotrophic soluble APP 
domain, which is released through alpha-secretase-activity. In addition, formation of amyloid 
beta peptides was reduced and their deposition in plaques prevented. Expression of mutant 
catalytically-inactive ADAM10 led to an enhancement of the number and size of amyloid 
plaques in the brain (Postina, Schroeder et al. 2004). 
Up to now, polymorphisms in ADAM10 have not received much attention in the 
literature (Prinzen, Muller et al. 2005). ADAM10 represents, due to its involvement in APP 
processing, a prime functional candidate for AD. Furthermore, the location of ADAM10 in the 
vicinity of suggestive AD linkage peaks at 15q22 (Scott, Hauser et al. 2003), also makes it a 
positional candidate.  
 
1.4.3 Candidate Genes Involved in Lipid Metabolism 
 
In addition to the aforementioned loci, genes involved in the lipid metabolism, such as the 
major genetic risk factor for AD, apolipoprotein E (ApoE), were taken into consideration 
during selection of candidate genes for this study. 
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1.4.3.1 Member 1 of Human Transporter Sub-family ABCA (ABCA1) 
 
ABCA1 is a membrane associated protein. It belongs to the ATP-binding cassette 
(ABC) transporters from sub-family A. Santamarina-Fojo and colleagues found that the 
ABCA1 gene spans 149 kb and contains 50 exons (Santamarina-Fojo, Peterson et al. 2000) 
and is located on chromosome 9 (9q31.1) (Luciani, Denizot et al. 1994).  
ABCA1 functions as a cholesterol and phospholipid efflux pump in the cellular lipid 
removal pathway. It was suggested that ABCA1 promotes cholesterol and phospholipid efflux 
by directly transporting both lipids as substrates. The ABCA1 gene expression is markedly 
increased in cholesterol-loaded cells. Upregulation of ABCA1 activity is known to form 
atheromatous deposits (plaques), especially on the innermost layer of arterial walls (Wang and 
Tall 2003). 
 
 
Fig. 3: Regulation of ABCA1-mediated cholesterol efflux 
ABCA1 performs a cellular cholesterol and phospholipid efflux. The substrates are donated to lipid-poor 
apolipoproteins. ApoA-I, the major apolipoprotein component of HDL, promotes ABCA1-mediated cholesterol 
and phospholipid efflux, probably by directly binding to ABCA1. ABCA1 contains a PEST-proline (P), 
glutamate (E), serine (S), and threonine (T)-sequence in the intracellular segment. PEST causes ABCA1 
degradation by a thiol protease, calpain. ApoA-I and apoE stabilize ABCA1 in a novel mode of regulation by 
decreasing PEST sequence-mediated calpain proteolysis.  
(Wang and Tall 2003) 
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The above described mechanism is the rate-limiting step in the production of nascent 
high-densitiy lipoprotein (HDL) (Oram and Lawn 2001). The finding, that in AD the lipid 
mechanism is likely disturbed, is supported by different findings: its genetic association with 
ApoE (Strittmatter, Weisgraber et al. 1993), the occurence of reduced HDL cholesterol levels 
in AD patients (Oram and Lawn 2001), and the observation that cholesterol influences Aβ 
metabolism (Sparks, Scheff et al. 1994). Moreover, it was shown that ABCA1 expression can 
directly affect Aβ levels (Koldamova, Lefterov et al. 2003). A mouse-model proved that 
overexpression of ABCA1 reduces Aβ deposits in the brain (Wahrle, Jiang et al. 2008). It was 
also shown, that deficiency of ABCA1 leads to the loss of approximately 80% of apoE in the 
brain, and the residual 20% that remains is poorly lipidated. Conversely, robust 
overexpression of ABCA1 in the brain promotes apoE lipidation and nearly eliminates the 
formation of mature amyloid plaques (Hirsch-Reinshagen, Burgess et al. 2008). 
Mutations in ABCA1 have been demonstrated to be associated with Tangier disease 
and a familial high-density lipoprotein deficiency (Bodzioch, Orso et al. 1999; Brooks-
Wilson, Marcil et al. 1999; Rust, Rosier et al. 1999). Tangier disease is characterized by 
dramatically lowered HDL and APOA1 concentrations as well as lowered cellular cholesterol 
efflux. This results in an increased risk for premature coronary artery diseases. Merched and 
coworkers have also observed reduced APOA1 levels in AD patients (Merched, Xia et al. 
2000). All of that makes ABCA1 to a potential functional candidate gene. 
Genome-wide linkage studies for LOAD pointed to several chromosomal regions 
(compare § 1.3). The highest LOD-Scores were associated with loci on chromosomes 9q and 
10q (Pericak-Vance, Bass et al. 1998; Kehoe, Wavrant-De Vrieze et al. 1999; Bertram, 
Blacker et al. 2000; Myers, Wavrant De-Vrieze et al. 2002; Blacker, Bertram et al. 2003). The 
location of ABCA1 on chromosome 9q, which is approximately 5 mb distal from previously 
identified loci linked with AD, makes the gene also to a potential positional candidate gene 
(Pericak-Vance, Bass et al. 1998; Kehoe, Wavrant-De Vrieze et al. 1999; Bertram, Blacker et 
al. 2000; Myers, Wavrant De-Vrieze et al. 2002; Blacker, Bertram et al. 2003). 
Studies investigating the association of genetic variants of ABCA1 with an increased 
risk for AD were performed before, but came out with contradictive findings. Moreover, most 
of the studies only investigated selected SNPs (1 – 5) from the promotor or the coding regions 
(Wollmer, Streffer et al. 2003; Katzov, Chalmers et al. 2004; Kolsch, Lutjohann et al. 2006; 
Shibata, Kawarai et al. 2006; Rodriguez-Rodriguez, Mateo et al. 2007; Wang and Jia 2007), 
or some isolated SNPs (9 and 10) that do not span the whole gene (Li, Tacey et al. 2004; 
Wahrle, Shah et al. 2007). Up to now only one study used an approximate fine-mapping 
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approach, however only including 19 SPNs in a Chinese cohort (Chu, Li et al. 2007). 
Therefore, a whole fine mapping approach of ABCA1 is of utmost importance to verify the 
former findings and to achieve new findings over the entire gene locus. 
 
1.4.3.2 Hepatic Triglyceride Lipase (LIPC) 
 
Hepatic lipase that is predominantly expressed in the liver is also known as hepatic 
triglyceride lipase (LIPC) and is encoded by the LIPC gene. LIPC functions as a triglyceride 
hydrolase and as a ligand/bridging factor for receptor-mediated lipoprotein uptake.  
LIPC is located on chromosome 15 (chr15q21 – q23) and contains 9 exons that span 
over 35 kb (Cai, Wong et al. 1989).  
Hepatic lipase plays a major role in the regulation of plasma lipids. The same function 
had been shown for lipoprotein lipase (LPL) and lecithin cholesterol acyltransferase (LCAT) 
(Cai, Wong et al. 1989). LPL and HL can be found at the endothelial surfaces of extra-hepatic 
and hepatic tissues, respectively. Already small deficiencies of one of these enzymes have 
been identified to be associated with pathologic levels of circulating lipoprotein particles.  
Variants in LIPC had previously been associated with elevated LDL or lowered HDL 
levels. (Kathiresan, Melander et al. 2008). 
As mentioned before, sporadic or late onset Alzheimer’s disease is a complex 
neurodegenerative disease that is associated with a variety of genetic and environmental risk 
factors. However, to date, only one undisputed genetic component has been identified, being 
the ε4 allele of ApoE (Saunders, Strittmatter et al. 1993; Martins, Clarnette et al. 1995). As a 
starting point for further genetic studies in AD, disorders intimately linked with ApoE have 
been investigated as a source of candidate genes. Besides AD, ApoE is also a strong genetic 
risk factor for increased LDL-cholesterol and coronary artery disease (CAD) (Baroni, Berni et 
al. 2003; Martins, Hone et al. 2006). As such, genes, or more specifically single nucleotide 
polymorphisms (SNP)s, that modulate cholesterol homeostasis provide important functional 
candidates for AD association studies (Wollmer, Sleegers et al. 2007). One such example is 
Hepatic lipase (LIPC, also known as hepatic triglyceride lipase) where several SNPs are 
associated with altered cholesterol concentrations and CAD (Baroni, Berni et al. 2003; 
Knoblauch, Bauerfeind et al. 2004). 
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Since LIPC is associated with altered lipid metabolism, much like the major genetic 
risk factor for Alzheimer’s disease - apolipoprotein E - this gene is a potential functional 
candidate for AD risk. 
 
 
 
1.5 Objective 
 
Morbus Alzheimer is the most frequently identified cause of dementia in advanced 
age. With increasing prevalence this disease is the fourth most frequent cause of death in 
industrialized countries. Many studies prove that besides external trigger factors 
(environmental conditions and life style), the genetic susceptibility also influences the course 
of disease. In addition to the currently known and probably most important candidate genes 
PS1, PS2, APP and ApoE, further linkage regions could be identified during genome-wide 
studies.  
Aim of the present study is identification of candidate genes due to their function and 
correlation with the above mentioned candidate genes and their location in the known linkage 
regions and finally their functional characterization. Therefore a contribution to the 
investigation of the molecular fundamentals of AD pathogenesis is supposed to be made. 
Correspondingly, the selection of the candidate genes was focused on these genes, whose 
modification could influence the development of the disease. Further selection criterion for 
candidate genes was their chromosomal localization. 
For the selected candidate genes noted SNPs are searched in public databases. The 
newly identified SNPs are thereafter genotyped by means of MALDI TOF MS in a case-
control cohort from Munich (as specified in the chapter below) and tested for an association 
with AD. Positive association signals are validated in other independent case-control, as well 
as sibling samples. Consecutively, strongest association results are to be investigated in 
appropriate functional studies. 
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2 Methods 
 
2.1 Phenotyping of Subjects - Neuropsychological Tests 
 
All subjects were undertaken detailed psychiatric, neurological, neuropsychological 
and clinical examinations. They included test of cognitive performance via standardized 
neuropsychological survey, self-anamnesis and medical history from important others, cranial 
imaging (cCT or cMRT), neurological findings and routine laboratory examinations 
(including determination of vitamin B12, folic acid, thyroid parameters, lyme serology and 
TPHA, etc.).  
For diagnosis of dementia the criteria of ICD-10 (see § 7.1.1) were applied. The 
clinical diagnosis of probable AD was established according to the NINCDS-ADRDA 
(National Institute of Neurological and Communicative disorders and Stroke-Alzheimer’s 
Disease and Related Disorder Association) criteria (see § 7.1.3). 
The control group was matched for age, gender, geographical location and ethnicity and 
consisted of cognitively healthy subjects. 
Standardized neuropsychological tests represent the most differentiated level of 
diagnostic findings. There are normal values for population random samples, so that test 
results of potential patients can be compared to those from healthy subjects of same age, 
gender and educational level. For diagnosing within the scope of this study Mini Mental 
Status Examination (MMSE) and Telephone Interview for Cognitive Status-modified (TICS-
M) tests were performed. 
 
2.1.1 Mini Mental Status Examination (MMSE) 
 
Mini Mental Status Examination (MMSE) test (Folstein, Folstein et al. 1975), also 
known as Folstein-Test (after the author Marshal F Folstein), is the most common screening 
test for survey of cognitive disorders. It only complements neuropsychological examinations 
and can not be used for diagnosing different forms of dementia. MMSE contains 30 items, 
which are subdivided into 5 categories (retentiveness, commemorative skills, orientation, 
concentration and language). However it is impossible to check complex cognitive functions 
with this test. 
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Analysis is performed by simple addition of the points given. Cognitive healthy 
subjects achieve results between 24 and 30 points. Subjects with light cognitive disabilities 
achieve 20 to 23 points. A dementia is assumed below 20 points. Cases with less than 10 
points are called severe dementia. It has to be bared in mind that there is a correlation between 
the obtained points and the educational level. Light cognitive restrictions of subjects with 
higher intelligence or good education are hard to diagnose. Those are suspected of having 
cognitive defect from 28 points and below. On the other hand MMSE test delivers false 
positive results for subjects with lacking education (De Jager, Hogervorst et al. 2003). To 
avoid that within this work control subjects with less than 28 points were excluded from the 
study (Riemenschneider, Blennow et al. 2006).  
Due to the easy practical performance (duration of the test ca. 10 min.), MMSE is 
applied in many standardized test batteries and big epidemiological studies. 
 
2.1.2 Telephone Interview for Cognitive Status-Modified (TICS-M) Test 
 
The Telephone Interview for Cognitive Status (TICS) Test (Brandt J et al., 1988) is a 
telephone version of the MMSE test and strongly correlates with the written form (Jarvenpaa, 
Rinne et al. 2002); (Jorm, Scott et al. 1988).A modified version of the TICS test (TICS-M) 
was applied in this study. TICS-M includes the questions of the original TICS in terms of 
orientation, concentration, memory, calculating, attention, language and conceptual thinking. 
Additionally to the immediate recall of a list of words TICS-M contains a delayed recall. In 
this part of the test verbal comprehension and practical are tested.  
The TICS-M test consists of 21 items and takes 6 to 8 minutes. Duration of education 
was taken into account for evaluation and the overall result was corrected accordingly. The 
maximum score is 50 points, at which a higher number of points refers to a better 
achievement. 
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2.2 Selection of SNPs 
 
Influence of genetic risk factors on the progression of the disease was tested by means 
of SNP association analysis. SNPs are variations of single base pairs in DNA-strands, which 
occur approx. every 200 bp in biallelic form (Rostoks, Mudie et al. 2005). SNPs were selected 
preferentially within coding/exon regions, promotor regions and TFBS (Transcription Factor 
Binding Sites). SNPs causing changes in the amino acids (missense mutations) were 
preferred. For the performed association analysis biallelic SNPs from public databanks (see § 
3.2.6) were chosen, analyzed through MALDI TOF MS genotyping and subsequently 
examined for associations with AD. Only validated SNPs with a minor allele frequency of at 
least 5% were taken for analysis.  
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2.3 Isolation of Nucleic Acids 
 
2.3.1 DNA Isolation 
 
DNA was isolated from whole blood with Puregene Genomic DNA-Isolation Kits 
(Gentra Systems, Minneapolis, USA). Acaryote erythrocytes were isolated from cells with 
intact nuclei by selective lysis and subsequent centrifugation. Thereafter lysis of the cells 
containing nuclei was performed after addition of a DNA-stabiliser. Furthermore, proteins 
were eliminated by a salt precipitation reaction. Precipitation of the solved genomic DNA 
from the supernatant was carried out using 100% isopropanol. Precipitated DNA was then 
washed with 70% ethanol and the dried pellet re-solved in 1-2 mL TE-buffer over night. On 
average 300 – 400 µg genomic DNA could be isolated from 9 – 10 mL whole blood with this 
method. Stock DNA solutions were stored in single tubes at 4°C. For further details see the kit 
instruction. 
 
2.3.2 RNA Isolation 
 
Unlike DNA, RNA is very instable. Therefore it is of most importance, to separate the 
stable RNases as fast as possible from the samples. RNA isolation from brain tissue was 
carried out with RNeasy® Lipid Tissue Mini Kit (Qiagen GmbH, Hilden, Germany). At first 
brain tissue was homogenized in QIAzol Lysis Reagent. It consits of guanidiniumthiocyanat 
(GTC) and phenol. GTC effects lysis of the cells and solution of the RNA. A high GTC 
concentration enables a selective precipitation of the cellular proteins, while the RNA remains 
in solution. At the same time phenol inactivates the RNases. After addition of chloroform and 
subsequent centrifugation, the mix separates into 3 phases. RNA is in the upper colorless 
watery phase, the genomic DNA in the lower reddish organic phase. The denaturated proteins 
form a insoluble interphase. Isopropanol is added to the watery phase, precipitating the RNA. 
Afterwards RNA is bound to the membrane of the Mini Spin Column. Salt and isopropanol 
carryovers are removed by washing with 75% ethanol. Isolated RNA was dissolved in 
nucleasefree water and stored in single tubes at -80°C. For further details see the kit 
instruction. 
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2.4 Determination of Concentration of Genomic DNA and RNA in 
Solutions 
 
Concentrations of DNA samples dissolved in water can be determined due to 
absorption of the nucleic acids at 260 nm. Artifacts from precipitation, derived from isolation 
of genomic DNA, also show maximum absorptions at 260 nm. Measured values for double 
stranded (ds) DNA are mainly falsified by single stranded (ss) DNA and RNA as well as 
single nucleotides. For calculation of the purity of the DNA, samples will be measured in the 
photometer at 280 nm as well. The ratio between the extinctions at 260 nm and 280 nm are 
taken to evaluate the purity of the samples. Pure DNA has a A260/A280 ratio of 1.8. Values 
below 1.8 shows contaminations with proteins, values above 2.0 are a sing of impurities from 
RNA (Lottspeich 1998). 
Purity of RNA is analyzed photometric at λ=260 nm and λ=280 nm accordingly. A 
ratio of 2.0 proves a clean RNA isolation (Lottspeich 1998). 
 
 
2.5 Test of DNA and RNA for Degradation 
 
Before starting with genotyping, the DNA was examined for possible degradations. 
For that purpose 1 µL of each undiluted sample that was resolved in 1xTE buffer was brought 
onto a 0.8% gel. A single and clear compression band after staining with ethidium bromide 
proved no degradation. A 10000 – 500bp marker was used (Bio-Rad Lab. GmbH, München, 
Germany). 
Quality of the RNA was tested on a 1.2% denaturating gel. For avoidance of 
hydrolytic activity of the RNases, the gel was prepared with DEPC water. Formaldehyde was 
used as denaturating agent. The aldehyde groups of the formaldehyde form Schiff´s bases 
with the amino groups of the nucleotide bases. Thus formation of intra- and intermolecular 
hydrogen bonds was inhibited and the RNA remains linear. On such a gel the complete intact 
RNA forms defined, clear 28S- and 18S-rRNA bands. The 28S-rRNA bands (5.1 kb for 
human RNA) are approx. double as intensive than the 18S-rRNA bands (1.9 kb for human 
RNA). The weak fluorescence between both bands and under the smaller band comes from 
mRNA. A 10000 – 500 bp marker was used (Bio-Rad Lab. GmbH, München, Germany). 
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2.6 Allocation on the Plates 
 
The DNA, which was onward genotyped via MALDI TOF MS, was diluted to a final 
concentration of 100 ng/µL and transferred into the wells of 96 microtiterplates. For 
preparation of the 384 microtiterplates the DNA was diluted to 3.33 ng/µL. DNA from four 
96 microtiterplates was combined on one 384 microtiterplate (5 µL per well) by means of the 
Tecan pipetting robot (Tecan AG, Crailsheim; Germany). For a later test of the quality of 
genotyping at least 10 DNA samples were applied in duplicate on each 384 microtiterplate 
and compared after analysis. 
 
2.7 DNA- and RNA-Electrophoresis 
 
Nucleic acids migrate to the anode of an electric field, due to its negative charge at the 
phosphate diester group. The speed of movement is indirect proportional to the molecular 
mass of the molecule. Depending on the size of the DNA and RNA fragments that were 
examined, 0.8 – 3 % agarose gels were prepared. Agarose was given in electrophoresis buffer 
(1x TBE buffer) and solubilized by heating. Ethidium bromide is added to the assay (end 
concentration of ~0.2 µg/mL). It intercalates in AT-rich sequences of the nucleic acid and 
makes it visible under UV light (302 nm). 
 
2.8 Polymerase Chain Reaction (PCR) 
 
The Polymerase Chain Reaction (PCR) (Saiki, Gelfand et al. 1988) was developed in 
the 80s by Dr. Kary B. Mullis. This method enables synthesis of a high number of copies of 
specific DNA sequences and cDNA sequences, respectively. During PCR DNA is amplified 
enzymaticly in vitro. A PCR consists of three main steps (denaturation, hybridization and 
elongation), which are repeated 30 to 45 times.  
The reaction starts with thermic denaturation (95°C) of the dsDNA, where 
complementary strands are divided. After denaturation the reaction mixture is cooled down. 
During decrease of temperature super concentrated primers (oligonucleotides) can align to the 
now single stranded DNA matrices. Primer sequences are designed so that they can align to 
the sense strand (anti-sense primer) as well as to the anti-sense strand (sense primer). Those 
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types of oligonucleotides are called antiparallel primers. Hence a primer is aligned to each 
ssDNA strand and the 3'-hydroxyl group of the primer will be beginning of the nascent 
(extending) DNA strand. After addition of DNA polymerase and all four dNTPs a new DNA 
strand complementary to the DNA template is synthesized in vitro during elongation step. Taq 
polymerase is used for extension, an enzyme isolated from the thermophilic bacterium 
Thermus aquaticus. The enzyme has its optimum activity temperature at 72°C. Since this 
polymerase is not inactivated at temperatures above 90°C, the PCR can be carried out cyclical 
in a periodically heat- and coolable metal block uninterrupted.  
After the first cycle a total of two partially doublestranded DNA strands are existent. 
Single repetition of the process delivers 4 copies of both template DNA strands. From the 
second cycle on the amount of replicated peaces increases exponentially. 
The amplification was carried out with PCR equipments from MJ Research (Boston, 
USA) and Applied Biosystems (CA, USA) under the following conditions:  
 
Tab. 1: Standard temperature profiles for PCR 
Time: Temperature: Step:
15 min 95°C Initialization 
20 sec 95°C Denaturation 
30 sec X°C Annealing 
1 min 72°C Elongation / Extension 
3 min 72°C Final elongation 
Permanent 4°C Final hold 
Steps Denaturation, Annealing and Elongation were repeated 45 times (45 cycles). Annealing temperature was 
adjusted for each assay and ranged between 56°C and 60°C. 
 
In the scope of this work those genomic regions, where SNPs are located, were 
amplified by means of the above described PCR method. For obtaining a high PCR-
efficiency, primers were designed so that PCR products were 80 to 120 bp. Sense and 
antisense-primer which were used for MALDI TOF MS analysis contained besides the 
sequence specific region an additional motive of 10 bases. This motive, the so-called “Tag”, 
fulfills several tasks. Firstly the amplification reaction is processed more evenly, when more 
PCR reactions are carried out in the same reaction tube. Secondly, mass of these primers has 
to be increased by means of these “Tags” insofar that they will not disturb subsequent 
MALDI TOF MS analyses. Since spare primers, which were not used up during PCR, are not 
removed during homogenous mass extension (hME), they are outside the mass region of the 
primer-extension product. 
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PCR reactions, which were part of the MALDI TOF MS genotyping method, were 
conducted in a reaction volume of 5 µL in 384 micro titer plates. Dried DNA was present in 
each well. Prepared master mix was pipetted into the wells by means of robotic workstation 
Genesis (Tecan GmbH, Crailsheim, Germany). The master mix was prepared according to the 
following scheme: 
 
Tab. 2: Pipetting scheme for PCR master mix 
 total volume of 5 µL and 5 µL dried DNA (1 ng/µL) 
Menge: Substance: Concentration:
2.850 µL H2O 
0.625 µL 10x buffer containing gelatine
0.100 µL dNTPs 25 mM dATP, dCTP, dGTP, dTTP each
1.000 µL Primer mix (forward and reverse) 10 pmol/µL each
0.325 µL MgCl2 25 mM
0.100 µL Hotstar Taq 5 U/µL
 
All used primers and lengths of individual PCR-fragments are reported in the Appendix. 
 
2.9 iPLEX Reaction 
 
The iPLEX reaction is a universal method for the detection of the different alleles of a 
SNP in formerly amplified DNA. The iPLEX process is subdivided in 4 main steps, which are 
described in detail below:  
 
2.9.1 SAP Reaction 
 
Before the properly iPLEX-reaction, the shrimp alkaline phosphatase (SAP)-reaction 
is performed. Surplus dNTPs from the PCR are cleaved by addition of this enzyme. This 
proceeding is necessary, since free nucleotides would generate other primer extension 
products, which would disturb the correct SNP detection. The SAP master mix was prepared 
according to the following scheme: 
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Tab. 3: Pipetting scheme for SAP master mix 
2 µL per well 
 
Volume for single reaction: Substance: Concentration: 
1.53 µL H2O
0.17 µL SAP buffer 10x 
0.30 µL SAP enzyme 1 U/µL 
7.00 µL PCR-product
 
and were carried out under the following conditions: 
 
Tab. 4: Conditions for SAP reaction 
Time: Temperature: Step:
40 min 37°C Incubation 
5 min 85°C Deactivation of SAP 
permanent 8°C Cooling
 
 
2.9.2 Extension Primer Adjustment 
 
Due to the fact, that the highest mass primer (~8500 Da) has a 25% lower peak intensity than 
the average of the lower mass primers, a primer adjustment to equilibrate signal-to-noise 
ratios is required. Low mass primers were concentrated higher to achieve equal peak 
intensity. The applied method to adjust high plex extension primers is to divide the primers 
into four groups, where the first group of low mass primers are mixed at 625 nM, the 
following group at 830 nM, the third group at 1.04 µM, and the higher mass group at 1.25 µM 
final reaction concentration 9 µl as shown below. This proceeding is important to achieve 
high call rates and good accuracy.  
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Fig. 4.: Primer extension adjustment according to the double 4-step method 
High mass primers show a higher peak intensity than low mass primers. To achieve similar peak intensities, 
primers are devided in to 4 groups according to their mass and are thereafter concentrated accordingly in the 
subsequent iPLEX reaction (SEQUENOM). 
 
2.9.3 iPLEX Reaction 
 
Subsequently, the iPLEX reaction was performed. Therefore an iPLEX reaction mix 
(primer, enzyme, buffer, termination mix) is added. Extension-Primers are designed that they 
end exact one base before the SNP to be analyzed. In the reaction mixture, all four mass-
modified nucleotides—A, T, C, and G—are present. During the iPLEX reaction, the primer is 
extended by one of the nucleotides, which terminates the extension of the primer. Thus, 
allele-specific extension products are generated, varying in length and mass depending on the 
present allele. 
iPLEX reaction was carried out according to the following instructions and conditions: 
 
Tab. 5: Pipetting scheme for iPLEX master mix 
2 µL per well 
Volume per reaction: Substance: Concentration: 
0.755 µL H2O 
0.200 µL iPLEX buffer 10x
0.200 µL iPLEX termination mix
0.804 µL Primer mix* 0.625 : 1.25 µM
0.041 µL iPLEX enzyme
9.000 µL PCR-Product (+SAP-Mix)
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Tab. 6: Conditions for iPLEX -reaction 
40 cycles were performed, where Hybridization and a short heat-up were repeated 5 times within each 
cycle 
Time: Temperature: Step:
30 sec 94°C Initial denaturation 
5 sec 94°C Denaturation 
5 sec 52°C Hybridization 
5 sec 80°C Short heat-up 
3 min 72°C Elongation 
permanent 8°C Cooling
 
 
All serial pipetting steps were conducted by the pipetting workstation Multimek96 
Automated Channelpipettor (Beckmann Coulter; Fullerton, USA) by means of programmed 
standard procedures (Sequenom, Hamburg, Germany). Thermocycling for SAP- and iPLEX-
reactions was carried out on PCR cyclers from MJ research und BA Gene under standard 
conditions (Manual Processing Procedure for the MassARRAY II System, Sequenom 
Hamburg, Germany). 
 
2.9.4 Cleaning up of iPLEX Reaction Products and Nanodispensing 
 
After elongation reaction an ion exchange resin (Spectro-CLEAN, Sequenom, 
Hamburg, Germany) was added to avoid adsorption/attachment of cations. Nucleic acids 
show a high affinity to alkali and alkaline earth ions. These cations disturb the MALDI TOF 
MS-analysis. The emerging single signals, which are attached to the actual molecule ion, 
cause a reduction of the signal-noise-ratio. Purification was carried out according to the 
standard protocol from Sequenom (Manual Processing Procedure fort he MassARRAY II 
System, Sequenom Hamburg, Germany). 
iPLEX-products were spotted onto a 384 silicon chip by means of a nanoliter spotter. 
The chip is covered with a crystalline (3-Hydroxypicolinacid). Besides the 384 matrix spots, 
onto which the samples are transferred, 10 additional matrix spots are located on the chip. 
Onto these chips a calibrant (Sequenom Hamburg, Germany) spotted, containing a mixtrue of 
3 oligonucleotides of known masses and serves for calibration of the analyzing system.  
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Fig. 5.: Schematic of iPLEX reaction 
Depending on the present allele, products differing in length and mass are generated. These differences are 
subsequently shown by MALDI TOF mass spectrometry  
(SEQUENOM, iPLEX Gold ApplicationGuide, November 2006). 
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2.10 SNP Detection by Means of Matrix-assisted Laser Desorption 
Ionisation (MALDI) Time of Flight (TOF) Mass Spectrometry (MS) 
 
MALDI TOF MS is an analytical method for determination of molecular masses of 
free ions in high vacuum. The MALDI TOF MS was developed 1987 by Hillenkamp und 
Karas. Formerly, this method was for mass determination of bigger molecules (such as 
peptides and proteins). Nowadays it is also used in SNP analysis. 
For sample preparation different techniques were developed, all guaranteeing 
intercalation of the analyte molecule into the lattice of the matrix (Karas and Hillenkamp 
1988); (Kirpekar, Nordhoff et al. 1998). A common matrix is 3-hydroxy-picolin-acid. This is 
an aromatic, carboxylcontaining acid, giving its proton to the negative oligonucleotides of the 
sample in a lattice structure and therefore allowing ionisation. Matrix substance absorbs 
radiated laser energy and protects, due to the 100- to 1000-times overplus, the analyte 
molecules from its degradation. Moreover the matrix is to avoid damaging of the analyte and 
interaction of analyte molecules among each other and between analyte and sample carrier 
(Hillenkamp, Karas et al. 1991). Analyte and matrix build a so-called MALDI-plum. 
During MALDI TOF MS the sample is irradiated few nanoseconds with short waved 
laser light. This yields a local breakup of the solid surface. The absorbed energy is passed 
down to the samples molecule, imbedded in the matrix. Through this the sample molecule is 
desorbed, ionized and vaporized. The whole process is carried out in a vacuum (Gut 2001); 
(Hillenkamp, Karas et al. 1991). 
A negative electrode, located next to the sample, generates an electrostatic field. 
Positive sample ions are accelerated from the sample surface towards the analyzer. For 
MALDI-analyses a time of flight spectrometer is used. Mass determination is accomplished 
by exact measurement of elapsed time between start of ion from the sample until arrival at the 
detector. Ions with smaller masses and equal kinetic energy can be accelerated more than 
heavier ions. At constant acceleration voltage and flight distance the measured time of flight 
correlates with a certain mass (Griffin and Smith 2000). 
Calibration is accomplished with a reference substance of known mass. Typical flight 
times at the MALDI TOF MS are around 100 microseconds and drift distance is 1 – 4 m (Fig. 
6). 
 
  2   Methods 
42 
 
Fig. 6.: Schematic of MALDI TOF mass spectrometry according to Griffin TJ et al. 
Vaporization of matrix by means of the laser the oligonucleotide is accelerated and moves in the field-free flight 
tube with mass- and chargedependent velocity towards the detector. Here dissociation and detection of two 
oligonucleotides with different masses/charges are described. 
 
Thanks to the development of MALDI TOF mass spectrometry it is now possible, to 
determine DNA fragments in the range of 1000 to 9000 Da, i.g. 3 – 30 bases with an accuracy 
of 0.1 to 0.01 %. Therefore a mass range is opened up, where SNP analysis via primer 
extension products can be performed. Adequate reaction conditions and primers were 
calculated by the SpectroDesigner Software (see § 3.2.3) and the respective allele of the 
selected SNPs were analyzed by means of MALDI TOF MS (Fig. 7). 
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Fig. 7.: MALDI TOF MS analysis of the primer extension reaction product  
MALDI TOF MS analysis of the primer extension reaction product of an example SNP [C/T]. A: shows the 
homozygot condition of the allele T, B: shows homozygot condition of the allele C and C: shows the heterozygot 
condition. (X axis – mass, Y axis – intensity) 
 
Genotyping was performed simultaneously for several SNPs (multiplex reaction) in a 
384-well format according to an optimized protocol. Primers were designed by the 
SpectroDesigner Software such that the received products can be divided by mass (Fig. 8.). 
Therewith, overlaps of different allelespecific products with the same mass were avoided. 
Another problem is the possible weak signal intensity of individual products.  
 
  2   Methods 
44 
 
 
Fig. 8.: MALDI TOF MS analysis of a multiplex reaction  
MALDI TOF MS analyis of a multiplex reaction of seven genotyped biallelic SNPs: The mass spectrum shows 
the analysis of the primer extension reaction for seven example SNPs, example SNP 1 [G/A] (marked red), 
example SNP 2 [G/A] (marked in green), example SNP 3 [C/T] (marked in blue), example SNP 4 [G/A] (marked 
in light blue), example SNP 5 [G/A] (marked in dark red), example SNP 6 [G/A] (marked in light green) und 
example SNP 7 [G/A] (marked in pink). Asterisks show the mass region, where the respective primers without 
extension were detected. 
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Fig. 9.: MALDI TOF MS analyses of extension primers for APP 
MALDI TOF MS analyses of example extension primers for APP. The x-axis presents the mass, the y-axis the intensity of the signal. Peaks for the same SNP are marked in the 
same colours. 
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2.11 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
 
Using RT-PCR (reverse transcription polymerase chain reaction) the amount and type 
of gene transcription and therewith the amount and type of gene expression can be 
determined.  
RNA – isolated as described in § 2.3.2 from brain samples – is specifically reverse 
transcribed. Control RNA of defined concentration (Applied Biosystems FirstChoice® 
Human Brain Reference RNA, 1 mg/mL, Part No. AM6050) was treated the same way, for 
calibration and checking of the procedure. The used enzyme, reverse transcriptase (RT) is a 
RNA-dependent DNA-polymerase. It allows efficient synthesis of first strand cDNA from 
RNA templates. For initiation of single stranded cDNA synthesis poly-(dT) primers are used. 
They allign to the poly-A-sequence and are used for transcription of mRNA, while rRNA - 
due to the lack of poly-A sequence - can not be reverse transcribed (Ando, Monroe et al. 
1997; Malhotra, Foltz et al. 1998). 
A commercial cDNA synthesis kit was used (RevertAidTM H Minus First Strand 
cDNA Synthesis Kit #K1631, Fermentas GmbH, 68789 St. Leon-Rot, Germany). 
 
Tab. 7: Pipetting scheme cDNA synthesis 
Volume: Substance Concentration
5 µL RNA 1-2 µg per approach 
1 µL Poly-(dT) Primer 0.5 µg/µL
4 µL 5x reaction buffer 250mM Tris-Hcl, 250mM MgCl2, 50mM 
DTT  
0.5 µL RNase Inhibitor 20 U/µL
2 µL dNTP-Mix 10mM each dNTP
1 µL RevertAid™ H Minus M-MuLV Reverse 200 U/µL
 
 
Tab. 8: Conditions for cDNA synthesis 
Time: Temperature: Step:
5 min 70°C Denaturation
5 min 37°C Incubation
60 min 42°C Reverse transcription 
10 min 70°C Inactivation of enzyme 
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Subsequently, the obtained cDNA was amplified via RTQ-PCR (real time quantitative 
PCR, see below). 
 
2.12 Real Time Quantitative Polymerase Chain Reaction (RTQ-PCR) - 
Gene Expression Analysis 
 
RTQ-PCR (real time quantitative PCR) is based on the principals of common PCR 
protocols (see above), but additionally allows a quantification of the obtained DNA. 
Quantification is accomplished by means of fluorescence measurements, which are recorded 
during each PCR cycle. Fluorescence signals increase proportional with the amount of RTQ-
PCR products. 
 
Fig. 10.: Schematic of RTQ-PCR 
(1) Probes and c DNA strand are hybridized and reporter fluorescence is still quenched. (2) During PCR, the 
probe is degraded by the Taq polymerase and the fluorescent reporter released 
(Pfaffl 2004) 
 
Gene expression analysis was carried out using ready made TaqMan® Gene 
Expression Assays (APP, Hs00169098_m1; ABCA1, Hs00194045_m1; 18S ribosomal RNA 
(endogenous control), Hs99999901_s1), Applied Biosystems, Foster City, California USA 
and TaqMan® Universal PCR Master Mix, NoAmpErase® UNG manufactured by Roche, 
Applied Biosystems, Branchburg, New Jersey USA) on a TaqMan 7300 system (Applied 
Biosystems, Foster City, California USA) as per the manufacturers instructions. Alignment 
maps for TaqMan® Gene Expression Assays of APP and ABCA1 are depicted in Fig. 11 and 
Fig. 12 below. Arbitrary units (AU) of gene expression were determined using the method 
described by Barrachina and colleagues (Barrachina, Maes et al. 2006). 
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Fig. 11.: Alignment map for TaqMan® gene expression assay for APP 
(https://products.appliedbiosystems.com) 
 
 
 
Fig. 12.: Alignment map for TaqMan® gene expression assay for ABCA1 
(https://products.appliedbiosystems.com) 
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Tab. 9: Pipetting scheme RTQ-PCR  
Volume: Substance Concentration
9 µL cDNA corresponding to cDNA from approx. 4 ng 
of RNA
1 µL 20×TaqMan® Gene Expression Assays
10 µL 2×TaqMan Universal PCR Master Mix
 
Tab. 10: Conditions for RTQ-PCR 
Time: Temperature: Step:
10 min 95°C Initial denaturation
15 sec 95°C Denaturation
1 min 60°C Primer annealing and extension 
 
 
2.13 Measurement of Different Aβ isoforms 
 
Measurement of different Aβ isoforms (Aβ38, Aβ40 and Aβ42) in total human brain 
homogenates was carried out with a commercial multi-plex ELISA kit (MSD® Human 
(6E10) Aβ 3-Plex 38/40/42 Kit, MULTI-SPOT®4, 96-well Plate, Merck & Co., Inc., 
whitehouse station, NJ, USA) as per the manufacturer’s instructions. An ELISA (enzyme-
linked immunosorbent assay) is an immunological assay on basis of an enzymatic 
fluorescence reaction.  
Total brain homogenates that were also used in the above assay were prepared in PBS, 
containing a protease inhibitor cocktail (5 µg/mL aprotinin, 5 µg/mL leupeptin, and 0.1 mM 
phenylmethylsulfonyl fluoride, all from Sigma, St. Louis, MO, USA), at a volume of 3 ml/g 
of tissue and homogenised for 15 seconds. The concentration of total protein in the tissue 
homogenate was determined using the micro-bicinchoninic acid protein assay kit (Pierce). 
Aβ42 levels were determined in CSF (cerebrospinal fluid), prepared as described 
above, using a commercial ELISA kit (INNOTESTTM ß-Amyloid(1-42), 
INNOGENETICS®, Gent, Belgium) as described in greater detail elsewhere (Vanderstichele, 
Van Kerschaver et al. 2000). Plasma Aβ42 levels were determined using the high-sensitivity 
protocol of the above ELISA kit. 
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2.14 Western Blot 
 
A western blot approach was optimized and carried out for total brain homogenates as 
described below. The used primary antibody, WO2, is a monoclonal antibody, which 
recognises the Aβ peptide and therefore unprocessed APP as well as β-secretase processed 
APP (CTFβ). 
Total protein amount of each brain sample was determined and thereafter, brain 
samples were diluted with gel loading buffer, so that 25 µg total protein were achieved. 
Thereafter, accordingly diluted samples (brain homogenates, standard or marker) were quick 
vortexed, quick centrifuged, boiled 5 min at 100°C, quick centrifuged and loaded onto a 10 – 
15 % SDS PAGE (sodium dodecylsulfate polyacrylamide gel electrophoresis) and processed 
at constant V (60mA per gel). Contained APP and Aβ is divided on the gel and form two 
bands, later on visible on the gel after performance of the western blot. The gel was 
transferred onto a preconditioned membrane (10 sec. in MeOH, 1-2 min in H2O, 10 sec in 
Transferbuffer for equilibration) over night in a TransBlotCell at 4°C and constant V, 250 
mA). Each membrane was then cut horizontally at different molecular weight marker levels to 
use different sections of the same membrane to probe for proteins with differing molecular 
weights. The next day, the membrane was treated as follows: 
- cooked in 1x PBS for 5 min  
- cooling down  
- blocked for 45 min in casein buffer 
- incubated for 2 h in the primary antibody (W02 1:2000 in TBST)  
- washed 4 times for 10 min in 1x TBST 
- incubated for 1 h in the secondary antibody (1:4000 anti mouse IgG in TBST) -
- washed 4 times for 10 min in 1x TBST 
- incubated for 5 min in substrate (ECL Plus Western Blotting Reagent Pack) 
If not otherwise noted, steps were carried out at room temperature under slow shaking. 
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Tab. 11: Buffers used for Western Blot 
Loading buffer for gel 900 µL SDS buffer 
100 µL β-MercaptoMeOH 
Transfer buffer 200 mL 10x Transfer 
1400 mL dd H2O 
400 mL MeOH 
10x TBS 200mM TrisHCl 
1.5 M NaCl 
1x TBST 100 mL 10x TBS Stock 
0.05% (v/v) Tween 20 (500 µL) 
ad 1L dd H2O 
Casein buffer 2.5 g Casein 
50 mL 1M NaOH 
950 mL dd H2O 
 
 
The recorded picture of the membrane was thereafter scanned and safed as a *.tif-file. Density 
was evaluated from this picture with ImageJ (a public domain, Java-based image processing 
program developed at the National Institutes of Health). Densities of the different bands (APP 
due to its higher mass the upper band in each lane and Aβ the lower band) were measured as 
“Integrated densities” by the program. Background correction was performed by subtraction 
of band-free gel background from each value.  
 
2.15 Isolation of Cerebrospinal Fluid 
 
Isolation of cerebrospinal fluid (CSF) was performed by physicians as described in the 
following paragraph. Spinal taps and venous punctures had previously been performed in 
these individuals after written consent had been obtained. CSF (5-8 mL) was collected in 
sterile polypropylene tubes using atraumatic canules placed in the intervertebral space L3/L4 
or L4/L5. Serum and EDTA plasma were obtained by venous puncture. In native CSF routine 
chemical parameters were within normal range in all subjects. These parameters included 
leukocyte and erythrocyte cell count as well as glucose and lactate measurement, total protein 
content, CSF to serum ratio of albumin and immunoglobulin G, and a screening for 
oligoclonal bands. CSF was centrifuged for 10 minutes at 4000 g. The remaining CSF 
supernatants were immediately frozen, in aliquots, at -80°C for subsequent analysis of Aβ42 
levels. 
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2.16 Statistical analyses 
 
2.16.1 Hardy-Weinberg-Equilibrium (HWE) 
 
For eradication of genotyping errors, the control group was tested for each SNP with 
the χ2 Test for deviations from the Hardy-Weinberg-Equilibrium (HWE). In the subsequent 
statistical analysis only those SNPs were taken into account, whose genotypic distribution 
showed no significant deviation from the HWE as set in the default settings of the Haploview 
software. Test for HWE was only performed for SNPs with sufficient genotyping efficacy (≥ 
95%). 
 
2.16.2 Allelic und Genotypic Test 
 
Association between allele or genotype distribution of each SNP and the AD 
phenotype was tested.  
Allelic and haplotypic associations were tested for significance using χ2-tests, as 
implemented in Haploview version 4.2 (Barrett, Fry et al. 2005). Genotypic associations with 
AD were tested by logistic regression analyses. For that gender and age at onset (for 
cases)/age (for controls) were included as covariates. For evaluation of pooled collectives 
population was additional included as covariate. Logistic regression analyses, using recessive 
trend model, were undertaken in the Statistical Package for Social Sciences (SPSS version 16; 
SPSS Inc., Chicago, Illinois, USA) or in STATA SE v9.2 (StataCorp, College Station, Texas, 
USA). 
Association analyses for the sib-pairs cohort was undertaken using Family Based 
Association Testing software (FBAT version 2.0.2C) (Laird, Horvath et al. 2000). Genotyping 
results from the sib-pairs cohort were analyzed for association with AD by means of Sib 
Transmission / Disequlibrium Test (S-TDT) (Spielman and Ewens 1998)). S-TDT is a 
modified version of the Transmission / Disequlibrium Test (TDT) (Spielman, McGinnis et al. 
1993). The TDT checks, whether heterozygote parents inherit an allele, which is associated 
with the disease, to their diseased children significantly more frequent, than according to 
Mendel´s laws (if no linkage or association exist). Late onset diseases have proven to be 
particularly problematic in terms of missing information about the parents. In this case the S-
TDT was applied. It applies reconstruction of parental alleles through the data of siblings. 
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2.16.3 Haplotype Analyses and Linkage Disequilibrium Structure 
 
As a measure of linkage disequilibrium (LD) between each possible pair of SNP loci, 
Lewontin’s disequilibrium coefficient D’ and the coefficient of determination r² (squared 
correlation coefficient) were estimated. Haplotype block definition was determined via the 
confidence interval approach of Gabriel et al., 2002 (Gabriel, Schaffner et al. 2002), all as 
implemented in Haploview version 4.2 (Barrett, Fry et al. 2005). Haplotype estimations and 
haplotype analyses were performed by EM algorithms implemented in Haploview (Barrett, 
Fry et al. 2005). Via Haploview frequencies of haplotype combinations were evaluated and 
their association with AD was tested.  
 
2.16.4 Sliding Window Analysis of 2- and 3-marker Haplotypes 
 
Sliding window analyses were carried out using the software package Haploview 
version 4.2. Frequencies for each haplotype combination of 2 or 3 adjacent SNPs were 
calculated and an association test was performed subsequently. Haplotype combinations with 
frequencies below 5% were not taken into account, since their occurrence seems to be very 
unlikely. 
A graphical sliding window approach of plotted p-values of 2 and 3-marker haplotypes 
as described above was thereafter conducted in Microsoft Excel 2003 (Microsoft Corp., 
Redmond, USA). 
 
2.16.5 Statistical Analysis of Functional Tests 
 
Genotypic associations with results from functional analysis (gene expression, analysis 
of different Aβ isoforms and Aβ42 levels) were undertaken for selected SNPs and were 
performed using The Statistical Package for Social Sciences (SPSS version 16; SPSS Inc., 
Chicago, Illinois, USA) using t-test or ANOVA (analysis of variance). Results from western 
blot analyses were evaluated with ANOVA. Multiple testing using Tukey LSD = Least 
Significant Difference and HSD = Honest Significant Difference was used for ANOVA also 
as implemented in SPSS. For parametric tests, normally distribution was tested by means of 
the Kolmogorov-Smirnov-Test as implemented in SPSS, as well. 
  2   Methods 
54 
Further, association of SNPs with clinical data were investigated using linear 
regression models, controlling for duration and gender (MMSE scores) or gender (age at 
onset), and were likewise performed within SPSS. 
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3 Materials 
 
3.1 Laboratory Equipment and Solutions 
 
3.1.1 Laboratory Equipment 
 
In the scope of this study, laboratory equipment as specified in Tab. 12 was used. 
 
Tab. 12: List of materials and providers – part 1 
Materials Type and Provider 
Pipets Eppendorf Pipets (Eppendorf AG, Hamburg, Germany) 
Gilson Pipets (Gilson Company Inc, Lewis Center, USA) 
Brand Pipets (Brand GmbH + Co KG, Wertheim, Germany) 
Centrifuge Centrifuge 5415 D (Eppendorf AG, Hamburg, Germany) 
Vortexer MS2 Minishaker (IKA-Works, Wilmington, USA) 
Gel electrophoresis 
apperature 
Power Pack PL (Biometra GmbH, Göttingen, Germany) 
Power Pac 3000 (Bio-Rad Lab. GmbH, München, Germany) 
Sunrise™, horizontal Gel Electrophoresis Apparatus 
(GibcoBRL, Life Technologies, Karlsruhe, Germany) 
Sub cell Model 192 (Bio-Rad Lab. GmbH, München, 
Germany) 
Gel documentation system  UVT-40M Transilluminator (Herolab, Wiesloch, Germany) 
Mighty Bright UVTM Transilluminator (Hoefer Inc., San 
Francisco, CA, USA) 
E.A.S.Y 429 K Kamera (Herolab, Wiesloch, Germany) 
Hoefer’s PhotoMan (Hoefer Inc., CA, USA) 
Centrifuge (for plates)  Sigma 4K15C (Sigma laborzentrifugen, Osterode, Germany) 
Rotanda 46RS (Hettich, Darmstadt, Germany) 
Zentrifuge 5810 R (Eppendorf AG, Hamburg, Germany) 
Microwave  Siemens 32L (Siemens, München, Germany) 
Photometer  Ultrospec 3100 pro (Biochrom Ltd., Cambridge, UK) 
Smart Spec™ (Bio-Rad Lab. GmbH, München, Germany) 
Ultrapure Water Purification 
System 
UltraClear UV (SG Wasseraufbereitung und Regenerisation 
GmbH, Barsbüttel, Germany) 
Millipore RiOs™ 8 (Millipore, Billerica, Mass., USA) 
Mass spectrometer  Autoflex (Bruker Franzen Analytik GmbH, Bremen, Germany)
Thermomixer Thermomixer comfort (Eppendorf AG, Hamburg, Germany) 
BT 130-2 (HLC Haep Labor Consult, Bovenden, Germany) 
Spotter  SpectroPoint™ Nanoliter Pipetting System 
(SEQUENOM GmbH, San Diego, CA, USA) 
PCR Cycler  PCR PTC 225 Tetrad, Peltier Thermal Cycler (MJ-Research, 
Boston, USA) 
Gene Amp™ PCR System 9700 (Applied Biosystems, Foster 
City, CA, USA) 
Primus 96 Plus (MWG-Biotech AG, Ebersberg, Germany) 
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Pipetting robot Genesis RSP 150 Work Station (Tecan AG, Crailsheim, 
Germany) 
Multimek 96 Automated 96-Channel Pipettor (Beckman 
Coulter, Fullerton, USA) 
Temo (Tecan AG, Crailsheim, Germany) 
Miniprep 75 (Tecan AG, Crailsheim, Germany) 
Balance BL 610 (Sartorius AG, Göttingen, Germany) 
BP 121 S (Sartorius AG, Göttingen, Germany) 
Ice machine AF 30 (Scotsman, Mailand, Italy) 
Shaker Taumelschüttler Unitwist 3D (UniEquip Laborgeräte + 
Vertriebs GmbH, München, Germany) 
ROTO-Shake Genie (Scientific Industries, Inc Bohemia, USA) 
Rocky (Fröbel GmbH, Lindau, Germany) 
Homogenizer Ultra-Turrax T8 (IKA-Werke GmbH & Co. KG, Staufen, 
Germany) 
T8.01 Netzgerät (IKA-Werke GmbH & Co. KG, Staufen, 
Germany) 
TransBlot Cell Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad 
Laboratories GmbH, München, Germany) 
 
3.1.2 Reagents, Solutions, Buffers and Kits 
 
Materials, their provider, as well as their usage are listed in the table below: 
 
Tab. 13: List of materials and providers – part 2 
Materials Methods Provider 
Puregene DNA Isolation Kit DNA Isolation Gentra, Mineapolis, USA 
TE Puffer 
[(Hydroxylmethyl)Aminomethan-
Ethylendiaminotetraacetyl-Säure] 
DNA Verdünnung Gentra, Mineapolis, USA 
Isopropanol DNA and RNA 
Isolation 
Sigma-Aldrich, Osterode, Germany
Ammoniumacetat DNA Isolation Pharmacy of TUM 
RNeasy Lipid Tissue Mini Kit RNA Isolation Qiagen GmbH, Hilden, Germany 
10x PCR Puffer PCR Qiagen GmbH, Hilden, Germany 
25mM MgCl2 PCR Qiagen GmbH, Hilden, Germany 
dNTPs PCR Paqlab, Erlangen, Germany 
Agarose Ultra Pure Gelelectrophoresis Paqlab, Erlangen, Germany 
TBE running buffer (Tris-Borat-
buffer) 
Gelelectrophoresis Merck KGaA,  Darmstadt, 
Germany 
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Ethidiumbromid Gelelectrophoresis Bio-Rad Lab. GmbH, München, 
Germany 
DNA loading buffer for agarose gels Gelelectrophoresis Bio-Rad Lab. GmbH, München, 
Germany 
Marker for DNA agarose gels Gelelectrophoresis Bio-Rad Lab. GmbH, München, 
Germany 
RNA loading buffer for agarose gels Gelelectrophoresis Sigma-Aldrich, Osterode, Germany
MOPS Buffer Gelelectrophoresis Sigma-Aldrich, Osterode, Germany
Formaldehyd Gelelectrophoresis Sigma-Aldrich, Osterode, Germany
iPLEX Buffer iPLEX Sequenom GmbH, San Diego, CA, 
USA 
iPLEX termination mix iPLEX Sequenom GmbH, San Diego, CA, 
USA 
iPLEX enzyme iPLEX Sequenom GmbH, San Diego, CA, 
USA 
Spectro CLEAN kit Cleaning up of 
iPLEX products 
Sequenom GmbH, San Diego, CA, 
USA 
Calibrant Spotting Sequenom GmbH, San Diego, CA, 
USA 
Acetic acid  Merck KGaA, Darmstadt, Germany
Ethanol  Merck KGaA, Darmstadt, Germany
Sodium hypochlorite  Sigma-Aldrich, Osterode, Germany
Sodium hydroxid  Merck KGaA, Darmstadt, Germany
Sodium acetate  Merck KGaA, Darmstadt, Germany
Ethylenediamine tetraacetic acid 
(EDTA) 
 Merck KGaA, Darmstadt, Germany
RiboLock™ RNase Inhibitor RT-PCR Fermentas GmbH, St. Leon-Rot, 
Germany 
Applied Biosystems FirstChoice® 
Human Brain Reference RNA, 1 
mg/mL, Part No. AM6050 
RT-PCR Applied Biosystems, Foster City, 
California USA 
TaqMan® Gene Expression Assays 
(Hs00169098_m1, Hs99999901_s1 
Hs00194045_m1 
RTQ-PCR Applied Biosystems, Foster City, 
California USA 
TaqMan® Universal PCR Master 
Mix 
RTQ-PCR Roche, Applied Biosystems, 
Branchburg, New Jersey USA 
NoAmpErase® UNG RTQ-PCR Roche, Applied Biosystems, 
Branchburg, New Jersey USA 
MSD® Human (6E10) Aβ 3-Plex 
38/40/42 Kit, MULTI-SPOT®4, 96-
well Plate, 
Aβ isoform 
determination 
Merck & Co., Inc., whitehouse 
station, NJ, USA 
INNOTESTTM ß-Amyloid(1-42) Aβ 42 
determination 
INNOGENETICS®, Gent, 
Belgium 
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ECL Plus Western Blotting Reagent 
Pack 
Western blot GE Healthcare, Amersham, UK 
Amersham Hybond™-P Western blot GE Healthcare, Amersham, UK 
Acryl amide Western blot Bio-Rad Laboratories GmbH, 
München, Germany 
W02 (primary antibody) Western blot Gift from Tobias Hartmann 
Anti mouse IgG HRP linked 
antibody 
Western blot Sigma-Aldrich, Osterode, Germany
Munich, Germany 
Casein Western blot Sigma-Aldrich, Osterode, Germany
β-mercaptoMeOH Western blot Sigma-Aldrich, Osterode, Germany
Tris HCL Western blot Sigma-Aldrich, Osterode, Germany
Tween 20 Western blot Bio-Rad Laboratories GmbH, 
München, Germany 
NaOH Western blot Sigma-Aldrich, Osterode, Germany
NaCl Western blot Sigma-Aldrich, Osterode, Germany
Rainbowmarker Western blot GE Healthcare, München, Germany
 
3.1.3 Enzymes 
 
Used enzymes in the present work, as well as their providers are reported in the table 
below: 
 
Tab. 14: List of enzymes and providers 
Enzyme Provider 
HotStar Taq DNA Polymerase  Qiagen GmbH, Hilden, Germany 
Shrimp Alkaline Phosphatase (SAP) Sequenom GmbH, San Diego, CA, USA 
Thermosequenase Sequenom GmbH, San Diego, CA, USA 
RevertAid™ H Minus M-MuLV Reverse Fermentas GmbH, St. Leon-Rot, Germany 
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3.1.4. Oligo-nucleotides 
 
PCR primers were synthesized by Metabion GmbH (Martinsried, Germany), Invitrogen 
(Karlsruhe, Germany) and MWG-Biotech AG (Ebersberg, Germany). They were HPLC-
purified and MALDI TOF MS documented. All PCR-primers, which were used for MALDI 
TOF MS, were tagged with hME-Tag (5´-ACGTTGGATG-3`). A list of all used primers is 
shown in the Appendix (see § 7.5.1). 
 
3.2 Software 
3.2.1 Software for Pipetting Robots 
 
• Gemini 3.5 (Visual Basic Programme), Tecan, Crailsheim, D 
• Bioworks, Beckmann Coulter, Fullerton, USA 
 
3.2.2 MALDI TOF MS Software 
 
• SpectroTyper RT™, Sequenom GmbH, San Diego, CA, USA  
• MassARRAY Typer, Sequenom GmbH, San Diego, CA, USA 
• SpectroREADER, Sequenom GmbH, San Diego, CA, USA 
• Pintool Software, Sequenom GmbH, San Diego, CA, USA, RoboDesign USA 
• SpectroDesigner™ 2.1, Sequenom GmbH, San Diego, CA, USA  
• SpectroImporter Sequenom GmbH, San Diego, CA, USA 
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3.2.3 Software for Primer Design and Determination of PCR Conditions 
 
• VectorNTI Suite 6.0, VectorNTI Suite 7.0, VectorNTI Advance 9.0 and VectorNTI 
Advance 10.3 
• SpectroDesigner™ , Sequenom GmbH, San Diego, CA, USA 
• FastPCR © v. 4.0 
• NCBI BLAST (http://130.14.29.110/BLAST/) 
• Human BLAT Search (http://genome.ucsc.edu/cgi-bin/hgBlat) 
 
3.2.4 Software for Analyses of Genomic DNA Sequences 
 
• VectorNTI Suite 6.0, VectorNTI Suite 7.0, VectorNTI Advance 9.0 and VectorNTI 
Advance 10.3 
 
3.2.5 Software for Evaluation of Western Blot 
 
• ImageJ (http://rsb.info.nih.gov/ij/developer/index.html) 
 
3.2.6 Databanks 
 
• National Center of Biotechnology Information (http://www.ncbi.nlm.nih.gov/) 
• ensEMBL (http://www.ensembl.org) 
• CHIP Bioinformatics Tools (http://www.snpper.chip.org/) 
• Celera (http://www.celeradiscoverysytem.com/) 
• HapMap (http://www.hapmap.org/) 
• NeoRef TAMAL (http://neoref.ils.unc.edu/tamal/) 
• UCSC Genome Bioinformatics (http://www.genome.ucsc.edu/) 
• Gene Regulation Biobase (http://www.gene-regulation.com/) 
• Genomatix (http://www.genomatix.com/) 
• NEBcutter V2.0 (http://tools.neb.com/NEBcutter2/) 
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• ESEfinder (http://rulai.cshl.edu/tools/ESE/) 
• European Bioinformatics Institute (http://www.ebi.ac.uk/) 
• Alzheimer Research Forum (http://www.alzforum.org/) 
 
3.2.7 Statistical Programs 
 
• Statistical Package for the Social Sciences (SPSS), Version 16.0 
• Haploview, Version 4.1 
• STATA SE 9.2 for Windows 
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4 Subjects 
 
4.1 Criteria of Inclusion 
 
Subjects investigated in this work were recruited and phenotyped in university 
hospitals in Germany and Sweden. 
The following criteria of inclusion were taken into account during selection of 
subjects: 
 
1. Due to ethical and legal reasons an informed consent in written form has to be 
available for each subject. For affected subjects their persons in charge had to sign. 
2. Only ethnic Germans were incorporated into the Munich collective of subjects. Thus, 
possible ethnic differences of genotype and phenotype are controlled for each study 
design. 
3. Phenotyping was carried out on basis of the criteria as described in chapter 2.1.  
 
4.2 Selection and Composition of Subjects for Alzheimer Studies 
 
4.2.1 Initial Case-Control Study from Munich 
 
The subjects for the Munich cohort (MUC) were recruited at „Klinik für Psychiatrie 
und Psychotherapie der TUM, Klinikum rechts der Isar“. Diagnoses were made according to 
the above mentioned criteria. 
The phenotypic association main study consisted of a total of 728 Caucasian subjects 
comprising 438 individuals with a diagnosis of probable AD (mean age, 72.2 years ± standard 
deviation 9.1; age at onset, 69.0 years ± 9.1; 41% males) and 290 cognitively healthy controls 
(mean age, 66.8 years ± 12.0; 44% males). Sub-collectives were composed of the main case– 
control cohort described above. For this purpose the main collective was divided by age of 
onset (sub-collective EOAD: onset ≤ 65 years, LOAD: onset > 65 years). Additional 
stratification by the presence of at least one copy of the ApoE ε4 allele was also performed in 
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the Munich cohort. A detailed table on the composition of the whole collective and the sub-
cohorts is shown in Tab. 45. 
Individuals from the main patient series were recruited from a university memory 
clinic from 1994 to 2004. The control group was matched for geographical location and 
ethnicity and consisted of cognitively healthy subjects who were recruited from spouses of 
those attending the memory clinics and community based geriatric daycare units. Information 
on age at onset of the disease was obtained from an informant. Age at onset was defined by 
the appearance of first clinical symptoms. After informed consent had been obtained, blood 
samples of each subject were taken by venous puncture. The study protocol was approved by 
the review board of the medical faculty, Technische Universität München. The clinical 
diagnosis of probable AD was established according to the NINCDS-ADRDA criteria. 
Cognitive impairment was assessed using the Cambridge Cognitive Examination or, 
alternatively, the Consortium to Establish a Registry for Alzheimer’s disease. Both 
instruments incorporate the Mini Mental State Examination, which was used to test cognitive 
performance in the control group. Control subjects with a MMSE score below were excluded 
from further analysis. All patients and controls underwent a thorough psychiatric, 
neurological and neuropsychological evaluation. The diagnostic workup also included an 
informant interview, a chemistry survey, structural magnetic resonance imaging (MRI) 
imaging and functional imaging in patients with AD whenever possible. 
 
4.2.2 Case-Control Studies for Replication 
 
Sigificant association results as identified in the Munich collective (MUC) were 
replicated in an additional case-control study. For replictation of the results subjects from 
Sweden (Stockholm) were genotyped and statistically evaluated.  
In collaboration with the Karolinska institute in Stockholm (Sweden) a replication 
study analysis consisting of a total of 883 Swedish subjects comprising 252 individuals with a 
diagnosis of probable AD (mean age and onset 67.9 years, standard deviation (s.d.) 6.1; 40% 
male) and 631 cognitively healthy controls (mean age, 73.1 years s.d. 8.9; 39.4% male).  
A detailed table on the composition of the collectives is shown in Tab. 46. 
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4.2.3 Pooled Study 
 
Further, a pooled sample set was generated from Munich (MUC) and Swedish (SWE) 
cohorts described above. Similar allele distribution was given in both cohorts, which was 
checked before pooling. The association pooled study consisted of a total of 1611 Caucasian 
subjects comprising 690 individuals with a diagnosis of probable AD (mean age, 70.7 years ± 
standard deviation 8.4; age at onset, 68.6 years ± 8.1; 41% males) and 921 cognitively healthy 
controls (mean age, 71.2 years ± 10.4; 41% males). 
A detailed table on the composition of the collectives is shown in Tab. 46. 
 
4.2.4 Sib-Pair Study 
 
Finally, the sib-pairs cohort consisted of 735 Caucasian subjects, from 287 families, 
consisting of 297 AD cases (mean age, 72.2 years ± 9.1; age at onset, 69.0 years ± 9.1; 41% 
males) and 438 cognitively healthy controls (mean age, 66.8 years ± 12.0; 44% males). The 
subjects were recruited and phenotyped in collaboration with 21 hospitals (see Tab. 15 below) 
from Bavaria. In addition, subjects were appealed for contribution in the study by the press. 
Selection of the sib-pairs was carried out on the basis of one affected sibling for which AD 
was diagnosed according to the NINCDS-ADRDA criteria. 
A detailed table on the composition of the collectives is shown in Tab. 46. 
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Tab. 15: Participating clinics in the sib-pairs cohort study 
1. Klinik für Psychiatrie und Psychotherapie der TUM, Klinikum rechts der Isar 
2. Psychiatrische Klinik, Agatharied
3. Bezirkskrankenhaus Ansbach, Klinik für Psychiatrie und Psychotherapie 
4. Psychiatrische Klinik, Bezirkskrankenhaus Augsburg
5. Neurologische Klinik, Bad Aibling
6. Bezirkskrankenhaus Bayreuth, Klinik für Psychiatrie und Psychotherapie 
7. Klinik für Psychiatrie, Bezirkskrankenhaus Gabersee
8. Bezirkskrankenhaus Günzburg, Fachkrankenhaus für Psychiatrie
9. Psychiatrische Klinik am Klinikum Ingolstadt
10. Bezirkskrankenhaus Kaufbeuren, Fachkrankenhaus für Psychiatrie
11. Bezirkskrankenhaus Landshut, Klinik für Psychiatrie und Psychotherapie 
12. Bezirkskrankenhaus Lohr am Main, Krankenhaus für Psychiatrie und Psychotherapie 
13. Psychiatrische Klinik, Bezirksklinikum Mainkofen
14. Neurologische Klinik, Städt. Krankenhaus Bogenhausen in München
15. Abteilung für Akutgeriatrie, Krankenhaus Neuperlach in München
16. Klinik und Poliklinik für Psychiatrie der Universität Regensburg
17. Bezirkskrankenhaus Taufkirchen
18. Universitätsklinikum Ulm, Poliklinik für Neurologie
19. Bezirkskrankenhaus Schloss Werneck
20. Bezirkskrankenhaus Haar in München
21. Universitätsklinik Freiburg 
 
 
4.2.5 Functional Study 
 
Functional analyses of selected SNPs, including gene expression, Western blot and 
differential Aβ isoform analysis, were carried out in 20 brain (frontal cortex) samples 
(Department Neuropathology, LMU München) unrelated to all aforementioned cohorts. These 
samples comprised 12 individuals with a diagnosis of probable AD (Braak stages III – V) and 
8 cognitively healthy controls (Braak stages 0 – II). The clinical diagnosis of probable AD 
was established as described above. 
Further functional analyses, Aβ42 levels, were undertaken in a total of 91 cerebro-
spinal fluid (CSF) samples, sourced from the Munich case-control cohort. A detailed table on 
the composition of the collectives is shown in Tab. 47.  
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5 Results 
 
In the present work 216 SNPs genes (see below) were analyzed and evaluated. Of 
these, 132 SNPs were tested for their association with AD and covered the following genes:  
• the APP gene itself 
• BACE1 and ADAM10; (genes involved in the processing of APP and therefore 
in the amount of present Aβ)  
• and the ABCA1 and LIPC genes (involved in the lipid metabolism).  
 
5.1 Analysis of SNPs from APP 
 
The APP gene is located in the region 21q21.3 and contains at least 18 exons within a 
240 kilobases region. APP plays a major role during AD pathogenesis, as described before in 
detail (see Introduction, § 1.4.1). Although APP is a strong functional and positional 
candidate, only one of the aforementioned studies (Nowotny, Simcock et al. 2007) used a fine 
mapping approach of SNPs across the entire gene. Thus, in a large German case-control 
cohort, the potential association of the APP gene in AD was thoroughly investigated by 
utilizing a fine mapping approach across the entire APP gene. When required, results 
underwent a replication in a second large independent case-control group as well as an 
independent sib-pairs cohort. Additionally, associated SNPs underwent further analyses to 
elucidate their potential functional implications, including their association with altered APP 
gene expression and effects on Aβ levels. 
 
5.1.1 Genotyping of SNPs from APP 
 
After researching several databanks, 73 SNPs were selected (Tab. 16). From these, 39 
could be confirmed to be polymorph in the Munich collective, i.e. they achieved a sufficient 
genotype frequency (>80%) and showed no deviation from the HWE in the controls (Tab. 17 
and Fig. 13). Incorporating results with insufficient genotype frequencies can lead to falsified 
distributions of the formerly matched cases and controls cohorts. Deviations from the HWE 
can be a sign of erroneous genotyping or a deficient population structure. 
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Tab. 16: Selected SNPs from the chromosomal region covering the APP gene. 
SNPs that yielded insufficient genotype frequencies (<80 %), significant deviations from HWE and minor allele 
frequencies <0.001 were not taken into account for the following statistical evaluations. SNPs passing all 
aforementioned criteria are highlighted in bold letters. Alleles are reported in alphabetical order as found on 
http://snpper.chip.org. 
SNP ID NCBI 
SNP Position 
NCBI Alleles Role 
rs2040124 26150106 C/G Intergenic
rs2829955 26155219 C/G Intergenic
rs6516704 26161592 A/T Intergenic
rs6516708 26166780 G/T 3' UTR
rs2242682 26170300 C/T 3' UTR
rs214483 26174597 A/G 3' UTR
rs11549660 26175202 A/G Exon
rs373521 26179531 A/C Intron
rs2070653 26185464 C/T Intron
rs1800557 26185978 C/T Coding exon 
rs2829975 26190408 G/T Intron
rs1700999 26195753 G/T Intron
rs1783016 26201909 C/T Intron
rs2829983 26206976 G/T Intron
rs6516711 26212927 G/T Intron
rs7510374 26219072 C/T Intron
rs214481 26224519 C/G Intron
rs9981102 26229733 A/T Intron
rs2829993 26235536 A/C Intron
rs216772 26241140 A/T Intron
rs216781 26246376 C/T Intron
rs1967945 26248681 A/T Intron (boundary) 
rs2186301 26252378 A/G Intron
rs216762 26258039 C/T Intron
rs7277169 26264038 C/G Intron
rs3737413 26270243 A/G Intron (boundary) 
rs4817076 26275931 C/T Intron
rs762479 26281147 C/G Intron
rs7278134 26287627 A/T Intron
rs9978555 26292577 A/G Intron
rs10084562 26298651 C/G Intron
rs2409166 26304288 C/G Intron
rs2830005 26309855 A/C Intron
rs9941877 26314397 C/T Intron
rs2830012 26319478 A/G Intron
rs2830019 26324683 C/T Intron
rs768039 26329891 C/T Intron
rs7275712 26334570 C/T Intron
rs3787644 26340941 A/G Intron
rs2070655 26345432 A/C Intron (boundary) 
rs3991 26350127 G/T Intron
rs2830035 26355571 A/G Intron
rs743532 26360372 C/G Intron
rs1041420 26365521 A/G Intron
rs2830042 26370641 C/T Intron
rs17001673 26376058 A/G Intron
rs2830046 26380577 A/G Intron
rs8130594 26384648 C/G Intron
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rs6516725 26388197 C/G Intron
rs2830053 26393582 C/T Intron
rs4817089 26398796 A/T Intron
rs2234989 26404833 C/T Intron
rs11549661 26406210 C/T Coding exon 
rs2246115 26409179 C/G Intron
rs2830065 26415397 G/T Intron
rs2830069 26420461 G/T Intron
rs462278 26426266 A/G Intron
rs2830082 26431745 A/G Intron
rs1788283 26436966 A/C Intron
rs2830092 26442148 A/C Intron
rs6516727 26447377 A/G Intron
rs2830099 26452481 C/G Intron
rs4817090 26456132 C/T Intron
rs465984 26460990 C/T Intron
rs459543 26464920 C/G Exon
rs466433 26465834 A/G Promoter
rs364048 26465912 C/T Promoter
rs2156079 26470201 A/G Promoter
rs1235885 26473927 C/T Promoter
rs370293 26474586 C/T Promoter
rs8131261 26479553 C/T Intergenic
rs2830105 26484522 C/T Intergenic
rs460029 26488824 C/T Intergenic
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Fig. 13: Schematic of the APP gene. 
The positions of the analyzed SNPs (shown with rs numbers) and exons in the APP gene are shown. Exons are marked with green bars on the forward strand from left to right. 
The arrow shows direction of transcription. 
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The subsequent allelic tests yielded an association between 4 SNPs and AD in the 
complete Munich collective. The strongest association signal was found for the intronic SNP 
rs3787644 (p = 0.015, # 20). A detailed analysis stratified for age at onset yielded a weaker p-
value of 0.023 in subjects with EOAD and no significance was detected in subjects with 
LOAD (p = 0.323). 
The association with AD was also confirmed for the non ApoE ε4 sub-collective, but 
with a p-value of 0.034. The risk allele for SNP # 20 (rs3787644) was the major allele C, with 
a higher allele frequency in the cases. Significant p-values were also detected for the intronic 
SNPs rs9941877 (p = 0.018, # 17), rs6516727 (p = 0.035, # 35) and rs2830099 (p = 0.049, # 
36). Unlike SNP # 16 and 36, the result for SNP # 35 could be confirmed in subjects with 
LOAD, although with a weaker association as for the whole collective (p = 0.041). For SNPs 
# 35 and 36 the major alleles (T and G) were determined as risk alleles with a higher 
frequency in the AD cases. For SNP # 16 the minor allele (A) was associated with appearance 
of AD, while the major allele was more prominent in the controls. 
Several additional SNPs were calculated to have moderate significance in the sub-
collectives divided by age at onset, which had shown no significance in the whole Munich 
cohort: One SNP (# 19) in subjects with EOAD and 7 more SNPs (# 14, 15, 21, 22, 24, 25 
and 34) in subjects with LOAD. 
For the historical role of the ApoE gene, the samples were also stratified according to 
the presence or absence of the ApoE ε4 allele. However, no major differences were observed 
between both groups and yielded no further significant p-values. 
Results from allelic tests of all SNPs performed for the Munich collective are depicted 
in Tab. 17.  
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Tab. 17: Results from allelic tests for the APP gene. 
Significance of allelic association was calculated using a χ2-test, as implemented in Haploview version 4.2. The statistical analyses were carried out for the whole collective as 
well as for sub-collectives divided by age/onset (EOAD ≤ 65 years, LOAD > 65 years) and presence of at least one ApoE4 allele (ApoE4 = at least one ApoE4 allele, nonApoE4 
= no ApoE4 allele) for cases and controls. All of the listed SNPs yielded genotype frequencies of at least 80 %, no significant deviation from HWE and minor allele frequencies 
were at least 0.001. Significant results are highlighted in bold letters. 
 
Allelic test results 
Allelic p-values 
# SNP Associated 
allele 
Major allele frequency 
MUC complete        
(cases, controls) 
MUC complete 
(N=728) 
EOAD 
subcollective 
(N=281) 
LOAD subcollective 
(N=444) 
ApoE ε4 
subcollective       
(N = 295)  
non ApoE ε4 
subcollective      
(N = 433) 
1 rs2040124 C 0.989, 0.986 0.558 0.975 0.511 0.883 0.921 
2 rs2829955 G 0.525, 0.538 0.638 0.879 0.641 0.381 0.808 
3 rs6516704 A 0.542, 0.540 0.946 0.855 0.865 0.714 0.605 
4 rs6516708 A 0.507, 0.527 0.473 0.854 0.533 0.357 0.993 
5 rs11549660 T 0.998, 1.000 0.247 0.161 0.929 0.454 - 
6 rs373521 G 0.571, 0.566 0.845 0.932 0.544 0.638 0.992 
7 rs2070653 C 0.743, 0.760 0.476 0.618 0.858 0.196 0.929 
8 rs2829975 C 0.876, 0.889 0.470 0.362 0.583 0.251 0.160 
9 rs1783016 G 0.757, 0.734 0.334 0.102 0.280 0.663 0.371 
10 rs2829983 C 0.881, 0.896 0.391 0.867 0.389 0.849 0.801 
11 rs216781 G 0.927, 0.940 0.325 0.757 0.216 0.427 0.601 
12 rs2186301 C 0.977, 0.970 0.382 0.969 0.859 0.747 0.439 
13 rs216762 G 0.533, 0.525 0.760 0.489 0.105 0.683 0.716 
14 rs762479 G 0.772, 0.808 0.108 0.652 0.016 0.654 0.237 
15 rs9978555 C 0.953, 0.963 0.348 0.324 0.039 0.341 0.411 
16 rs9941877 A 0.688, 0.746 0.018 0.256 0.287 0.057 0.266 
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17 rs2830012 T 0.669, 0.710 0.099 0.160 0.160 0.125 0.542 
18 rs2830019 G 0.959, 0.967 0.462 0.463 0.517 0.402 0.650 
19 rs768039 C 0.701, 0.654 0.062 0.017 0.119 0.860 0.053 
20 rs3787644 C 0.674, 0.611 0.015 0.023 0.323 0.206 0.034 
21 rs2070655 C 0.713, 0.670 0.089 0.065 0.036 0.813 0.087 
22 rs3991 G 0.804, 0.764 0.072 0.766 0.044 0.059 0.657 
23 rs2830035 C 0.762, 0.731 0.187 0.872 0.531 0.357 0.522 
24 rs743532 G 0.957, 0.945 0.308 0.405 0.037 0.136 0.862 
25 rs1041420 T 0.728, 0.765 0.121 0.703 0.033 0.131 0.673 
26 rs2830046 T 0.766, 0.729 0.109 0.961 0.481 0.100 0.723 
27 rs8130594 C 0.689, 0.690 0.942 0.650 0.850 0.743 0.680 
28 rs2830053 A 0.896, 0.910 0.364 0.161 0.259 0.991 0.207 
29 rs2246115 G 0.848, 0.879 0.104 0.243 0.629 0.764 0.116 
30 rs2830069 C 0.897, 0.912 0.353 0.293 0.171 0.899 0.154 
31 rs462278 C 0.971, 0.977 0.503 0.431 0.507 0.670 0.819 
32 rs2830082 T 0.896, 0.912 0.325 0.365 0.155 0.937 0.202 
33 rs1788283 G 0.567, 0.541 0.350 0.959 0.482 0.238 0.841 
34 rs2830092 T 0.896, 0.914 0.257 0.262 0.011 0.948 0.108 
35 rs6516727 T 0.711, 0.659 0.035 0.644 0.041 0.104 0.200 
36 rs2830099 G 0.741, 0.693 0.049 0.433 0.171 0.142 0.284 
37 rs465984 A 0.972, 0.977 0.536 0.385 0.173 0.663 0.830 
38 rs1235885 G 0.961, 0.965 0.719 0.365 0.395 0.161 0.664 
39 rs456565  T 0.569, 0.551 0.488 0.864 0.864 0.216 0.688 
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For all of the 39 SNPs (Tab. 17), genotypic analyses were performed using logistic 
regression with gender and age at onset as covariates. In the complete Munich collective the 
same 4 SNPs - found before by using allelic tests - could be shown to be associated with AD. 
The strongest association signal was again found for the intronic SNP rs3787644 (# 20), with 
an even more significant p-value of 0.006. A before, detailed analyses stratified by age at 
onset yielded an equally strong association in subjects with EOAD (p = 0.007) and again no 
significance in subjects with LOAD. The association with AD was also confirmed for the non 
ApoE ε4 sub-collective with a p-value of 0.017. The p-values detected for the intronic SNPs 
rs9941877 (# 17), rs6516727 (# 35) and rs2830099 (# 36) were 0.031, 0.049 and 0.030, 
respectively. In the genotypic approach all three SNPs could be confirmed in subjects with 
LOAD with stronger association signals as for the whole collective (# 17: p = 0.016, # 35: p = 
0.014 and # 35: p = 0.011. Furthermore, this stratification identified additional association 
signals for SNPs 9, 17, 19 (EOAD group) and 15 (LOAD group).  
All formerly determined risk alleles were confirmed using genotypic tests. Results 
from genotypic tests of all SNPs performed for the Munich collective are depicted in Tab. 18. 
Stratification for presence of the ApoE ε4 allele was also performed for the genotypic 
approach. One additional significant signal was found for SNP # 2 (rs2829955), but only with 
a very weak borderline value of 0.05. Results for stratification for presence of ApoE ε4 allele 
are presented in the Appendix (§ 7.3.1, Tab. 48).  
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Tab. 18: Results from genotypic tests for the APP gene. 
Genotypic associations were tested for significance using logistic regression, all as implemented in STATA/SE 9.2. The statistical analysis was carried out for the whole 
collective as well as for sub-collectives divided by age/onset (EOAD ≤ 65 years, LOAD > 65 years) and presence of at least one ApoE4allele (ApoE4 = at least one ApoE4 allele, 
nonApoE4 = no ApoE4 allele) for cases and controls. Gender and age/onset were taken into account as covariates. Significant results are highlighted in bold font. Note that SNP 
# 5 could not be evaluated, due to absence of the minor allele in the control group. 
 
Genotypic test results 
Genotype frequencies MUC complete 
(cases, controls) 
AD affection genotypic p-values for major allele unless otherwise noted              
(associated allele); OR (95%CI) with covariates (sex and onset) # SNP 
Alleles 
(major/ 
minor) 
AA Aa aa MUC complete (N=728) EOAD subcollective (N=281) 
LOAD subcollective 
(N=444) 
1 rs2040124 C/G 0.981, 0.975 0.016, 0.021 0.002, 0.004 0.595 0.634 0.913 
2 rs2829955 C/G 0.290, 0.290 0.470, 0.497 0.240, 0.214 0.931 0.780 0.821 
3 rs6516704 A/T 0.305, 0.288 0.474, 0.505 0.221, 0.207 0.596 0.779 0.742 
4 rs6516708 C/A 0.267, 0.281 0.481, 0.491 0.252, 0.228 0.687 0.896 0.583 
6 rs373521 G/T 0.340, 0.317 0.464, 0.498 0.197, 0.185 0.577 0.582 0.587 
7 rs2070653 T/C 0.543, 0.572 0.400, 0.375 0.057, 0.052 0.394 0.826 0.381 
8 rs2829975 A/C 0.770, 0.787 0.211, 0.202 0.019, 0.010 0.672 0.302 0.948 
9 rs1783016 G/A 0.575, 0.552 0.361, 0.365 0.064, 0.083 0.660 0.045 (G); 1.64 (1.01-2.7) 0.333 
10 rs2829983 A/C 0.779, 0.802 0.205, 0.186 0.016, 0.010 0.489 0.819 0.334 
11 rs216781 A/G 0.861, 0.880 0.132, 0.120 0.007, 0.000 0.482 0.734 0.344 
12 rs2186301 C/T 0.957, 0.940 0.040, 0.060 0.002, 0.000 0.210 0.770 0.342 
13 rs216762 G/A 0.274, 0.286 0.519, 0.477 0.208, 0.237 0.788 0.962 0.518 
14 rs762479 C/G 0.598, 0.647 0.349, 0.322 0.053, 0.031 0.207 0.703 0.137 
15 rs9978555 T/C 0.909, 0.930 0.089, 0.066 0.002, 0.003 0.271 0.374 0.018 (C); 3.33 (1.3-10.0) 
16 rs9941877 G/A 0.469, 0.550 0.439, 0.391 0.093, 0.059 0.031 (A); 1.39 (1.03-2.0) 0.680 0.016 (A); 1.64 (1.1-2.5) 
17 rs2830012 C/T 0.455, 0.502 0.427, 0.417 0.118, 0.081 0.236 0.032 (T); 2.58 (1.1-6.1) 0.094 
18 rs2830019 A/G 0.920, 0.937 0.077, 0.060 0.002, 0.004 0.425 0.451 0.052 
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19 rs768039 C/T 0.495, 0.439 0.411, 0.429 0.094, 0.131 0.155 0.032 (C); 1.69 (1.05-2.7) 0.947 
20 rs3787644 C/T 0.472, 0.366 0.406, 0.489 0.123, 0.144 0.006 (C); 1.55 (1.1-2.1) 0.007 (C); 1.99 (1.2-3.3) 0.109 
21 rs2070655 C/A 0.524, 0.471 0.374, 0.398 0.102, 0.131 0.174 0.094 0.660 
22 rs3991 G/T 0.633, 0.573 0.341, 0.381 0.026, 0.045 0.114 0.969 0.063 
23 rs2830035 C/T 0.560, 0.520 0.404, 0.423 0.035, 0.057 0.243 0.772 0.074 
24 rs743532 G/C 0.913, 0.893 0.087, 0.103 0.000, 0.003 0.315 0.349 0.458 
25 rs1041420 C/T 0.525, 0.579 0.407, 0.372 0.068, 0.049 0.127 0.983 0.059 
26 rs2830046 T/C 0.590, 0.532 0.354, 0.394 0.056, 0.074 0.114 0.967 0.077 
27 rs8130594 G/C 0.477, 0.473 0.422, 0.434 0.100, 0.093 0.882 0.444 0.923 
28 rs2830053 G/A 0.803, 0.831 0.185, 0.158 0.012, 0.012 0.327 0.090 0.774 
29 rs2246115 C/G 0.725, 0.778 0.241, 0.201 0.034, 0.021 0.119 0.090 0.244 
30 rs2830069 A/C 0.807, 0.835 0.181, 0.154 0.012, 0.011 0.350 0.235 0.537 
31 rs462278 T/C 0.944, 0.953 0.054, 0.047 0.002, 0.000 0.597 0.533 0.190 
32 rs2830082 C/T 0.806, 0.834 0.180, 0.156 0.014, 0.010 0.348 0.285 0.406 
33 rs1788283 G/T 0.286, 0.270 0.562, 0.541 0.153, 0.189 0.541 0.808 0.468 
34 rs2830092 G/T 0.803, 0.838 0.185, 0.151 0.012, 0.011 0.241 0.207 0.338 
35 rs6516727 T/C 0.486, 0.418 0.451, 0.481 0.063, 0.101 0.049 (T); 1.36 (1.001-1.8) 0.376 0.014 (T); 2.44 (1.3-5.0) 
36 rs2830099 G/C 0.530, 0.474 0.421, 0.439 0.049, 0.088 0.030 (G); 1.89 (1.1-5.0) 0.227 0.011 (G); 2.78 (1.3-5.0) 
37 rs465984 G/A 0.946, 0.954 0.052, 0.046 0.002, 0.000 0.643 0.490 0.171 
38 rs1235885 A/G 0.925, 0.933 0.073, 0.063 0.002, 0.004 0.675 0.520 0.143 
39 rs8131261 T/C 0.302, 0.296 0.534, 0.509 0.164, 0.195 0.805 0.916 0.864 
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The 39 SNPs covering the complete genetic region of the APP gene (330 kb, average 
inter-marker distance of 8.7 kb) determined the linkage disequilibrium (LD) structure, 
estimated by D’ and r2 and explored haplotype associations as implemented in Haploview. 
Within the genotyped region 5 LD blocks were identified on basis of D’ and r2 values (Fig. 
14). For each of the LD blocks, the haplotypes were calculated as depicted in the table below 
(Tab. 19). The 4 significant markers identified in the Munich collective before were found in 
two different LD blocks. SNP # 16 (rs9941877) is located at the border of block 2. Since 
allocation of SNP # 16 to this block is not distinct (D’ values below 0.9, but well above 0.8) 
correlations with the adjacent SNPs were tested. No correlation was found with the direct 
neighbor SNP # 15 (rs9978555, r² = 0.04, D’ = 0.66), but a slight correlation was shown with 
direct neighbor SNP # 17 (rs2830012, r² = 0.60, D’ = 0.82). SNP # 20 is located in the same 
block (block 2), SNPs # 34 and 35 in block 5.  
In total, the calculations predicted haplotypes with frequencies above 5 % within block 
2, spanning SNPs # 16-21. One of the haplotypes showed an association with AD (p = 0.037) 
with a frequency of 31.6 % in the controls and 26.5 % in the cases. 3 haplotypes with 
frequencies above 5 % were estimated within block 5, but none of the estimated haplotypes 
showed an association with AD. 
The signal in LD block 2 was the only association found during analysis of haplotype 
blocks. 
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Fig. 14: LD structure of the APP gene, including the haplotype block structure.  
The depicted values are used to represent D’ whereas colors were used to represent r2 (D’ values of 1.0 are never shown - the box is empty; black = high r2 value, white = low r2 
value). The blocks followed the haplotype block definition by Gabriel et al., (Gabriel, Schaffner et al. 2002) as implemented within Haploview 4.2.  
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Tab. 19: Haplotype blocks and frequencies for APP in Munich collective 
 
Haplotype ID Sequence Frequency (Case/Control) P-values 
Block 1
1.1 GTAG 0.465, 0.455 0.705 
1.2 CACT 0.419, 0.426 0.789 
1.3 CACG 0.091, 0.102 0.510 
Block 2 
2.1 GCACCC 0.323, 0.308 0.534 
2.2 GCATTA 0.265, 0.316 0.037 
2.3 ATACCC 0.223, 0.192 0.158 
2.4 GTACCC 0.058, 0.059 0.902 
Block 3 
3.1 GCGCTG 0.426, 0.399 0.310 
3.2 GCGTTC 0.260, 0.236 0.305 
3.3 TTGCCG 0.192, 0.223 0.157 
Block 4 
4.1 GCA 0.844, 0.876 0.086 
4.2 AGC 0.098, 0.088 0.504 
Block 5 
5.1 CGGTGGAT 0.543, 0.517 0.337 
5.2 CTGCCGAC 0.237, 0.268 0.177 
5.3 TTTTGGAC 0.100, 0.079 0.192 
Significant p values are highlighted in bold letters. 
 
The final analysis performed for the Munich cohort was a 2- and 3-marker sliding 
window approach to identify SNPs that contributed association signals (Fig. 15). In general 
two marker peaks were observed spanning SNPs # 14-24 and # 33-37. The strongest 
association was observed in the 3-marker haplotype 20.1 generated by SNPs # 20-22 (p = 
0.0028). Additional strong association signals were observed in 3-marker haplotypes 14.1 
from SNPs # 14-16 (p = 0.0057) and 21.1 from # 21-23 (p = 0.0119) and in the 2-marker 
haplotype 15.1 generated by SNPs # 15 and 16 (p = 0.0096). Within the two regions of the 
marker peaks haplotype associations were clearly higher than those of the single markers. 
A 2- and 3-marker sliding window approach was also performed for the stratified sub-
collectives divided by age at onset or presence of ApoE ε4 allele. Only the first marker peak 
from the whole Munich cohort could be observed in subjects with EOAD, but was shorter 
than in the whole cohort, only spanning from SNPs # 17 – 21. In the LOAD sub-collective the 
first peak was subdivided into two peaks, spanning from SNPs # 14 – 16 and # 20 – 28. The 
second peak was even broader compared to the one observed in the complete Munich cohort, 
spanning from SNPs # 31 – 37. No real differences between the two sub-cohorts that were 
divided by presence or absence of the ApoE ε4 allele were found. In both sub-cohorts, only 
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the first peak was found, but merely spanning from SNPs # 20 – 22 (ApoE ε4) or # 18 – 21 
(non-ApoE ε4), respectively. 
Detailed results from the 2- and 3-marker sliding window approach are depicted in the 
Appendix, as well as graphs for the sub-collectives (§ 7.4.1). Haplotypes with frequencies 
below 5% were not taken into account, due to their unlikely occurrence. 
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Fig. 15: Sliding window analysis of 2- and 3-marker haplotypes for APP 
Red circles represent -log p values for single marker SNPs genotyped. Lines between solid squares represent the -log p value of 2-marker haplotypes. Lines between solid 
triangles mark -log p values for 3-marker haplotypes. All 2- and 3-marker haplotypes were calculated with Haploview. The dotted lines at a -log p value of approximately 1.3 
demarcate the threshold of p = 0.05. Numbers on the X-axis correspond to the numbering assigned to SNPs by Haploview.  
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5.1.2 Replication of Association Results in Independent Studies 
 
Based on the analysis of the Munich cohort (MUC) a selection of SNPs (# 15-23, 25, 
35 and 36) was chosen for replication in independent sub-populations. In the scope of this 
study a large Swedish case-control cohort (SWE, N = 883) and a German discordant sib-pairs 
cohort (N = 735) were available. A subsequent pooling analysis of the Munich and Swedish 
cohort (pooled = MUC + SWE, N = 1611) was performed to increase power. Results from 
SNP # 19 had to be excluded, due to possible miscalling during genotyping in the Swedish 
sample, indicated by severe changes in the genotype frequencies.  
In the Swedish sample, association signals were replicated in SNPs # 17, 25 and 36. 
Overall, SNPs # 17 and 20 had relatively weak association signals (p < 0.05) in the pooled 
analysis, whereas stronger signals (p < 0.005) were observed for SNPs # 25 and 36. 
Stratification of the pooled sample strengthened the association of SNP # 20, but only in the 
EOAD group. SNPs # 25 and 36 had equivalent or slightly weaker association signals, 
respectively, but limited to the LOAD group. Detailed results of the genotypic tests are 
depicted in Tab. 20. Results of allelic test are shown in the Appendix (§ 7.3.1, Tab. 49). 
As with the Munich cohort, analysis of 2- and 3-marker loci in the Swedish and pooled 
cohorts were performed for SNPs # 15 – 25 and # 35-36, which are located next to each other. 
Analysis of 2- and 3-marker loci, previously identified in the Munich cohort, replicated the 
haplotype associations for SNPs 20-22 (Sweden, p = 0.0027) and SNPs # 35-36 (Sweden, p = 
1.35 x 10-6), however, the haplotype generated by SNPs # 21-23 failed to reach significance 
(see Appendix, § 7.4.1, Tab. 69 - Tab. 72, Fig. 37 and Fig. 38).  
Due to the limited amount of available DNA, analyses of SNPs in the sib-pairs cohort 
were only performed for the 4 SNPs that had shown significance in the complete Munich 
cohort (SNPs # 16, 20, 35 and 36) as well as for the adjacent SNPs of the strongest 
association marker - SNP # 20 - (SNPs # 19 and 21). The experiments failed to replicate 
signals for SNPs # 20 and 36; however, additional signals were identified at SNP # 16 
(rs9941877; FBAT, p < 0.05) and SNP 35 (rs6516727; FBAT, p < 0.05). Results of the tests 
are depicted in Tab. 20. 
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Tab. 20: Results of replication for selected SNPs of APP in independent studies – part 1 
SWE (N=883) pooled Population (MUC+SWE) (N=1611) 
AD affection genotypic p-values for major allele unless otherwise noted 
(associated allele); OR (95%CI) with covariates (sex and onset) 
AD affection genotypic p-values for major allele unless otherwise noted (associated 
allele); OR (95%CI) with covariates (sex, onset, population) # 
SWE complete            
(N=883) 
EOAD subcollective 
(N=220) 
LOAD subcollective 
(N=661) 
pooled complete       
(N=1611) 
EOAD subcollective 
(N=501) 
LOAD subcollective 
(N=1105) 
15 0.224 0.492 0.559 0.934 0.578 0.327
16 0.223 0.779 0.535 0.142 0.441 0.177
17 0.036 (T); 1.46 (1.3-2.1) 0.403 0.109 0.016 (T); 1.55 (1.1-2.2) 0.038 (T); 1.865 (1.03-3.4) 0.934
18 0.454 0.370 0.696 0.775 0.526 0.322
20 0.988 0.648 0.030 (T); 1.85 (1.1-3.2) 0.045 (C); 1.25 (1.005-1.6) 0.006 (C); 1.69 (1.2-2.5) 0.523
21 0.028 (A); 1.76 (1.1-2.9) 0.062 0.003 (A); 2.44 (1.4-4.4) 0.076 0.006 (C); 1.69 (1.2-2.5) 0.700
22 0.606 0.880 0.727 0.088 0.926 0.092
23 0.003 (T); 2.33 (1.3-4.0) 0.104 0.005 (T); 2.49 (1.3-4.8) 0.056 0.437 0.157
25 0.002 (T); 2.37 (1.4-4.1) 0.799 0.013 (T); 2.33 (1.2-4.6) 0.001 (T); 1.98 (1.3-3.0) 0.818 0.005 (T); 2.22 (1.3-3.9) 
35 0.863 0.768 0.793 0.686 0.628 0.912
36 0.029 (G); 1.44 (1.04-2.0) 0.224 0.091 0.004 (G); 1.38 (1.1-1.7) 0.065 0.017 (G); 1.42 (1.1-1.9) 
 
Tab. 20: Results of replication for selected SNPs of APP in independent studies – part 2 
SIB pairs      
(N=735) # SNP 
fbat100 fbat010 
16 rs9941877 0.026 0.012 
19 rs768039 0.382 0.382 
20 rs3787644 0.959 0.628 
21 rs2070655 0.638 0.449 
35 rs6516727 0.114 0.030 
36 rs2830099 0.377 0.173 
 
5   Results 
83 
5.1.3 Statistical Analyses of Clinical Measures for APP 
 
Linear regression analysis of clinical measures was performed, testing association 
between genotypes of the SNPs and age at onset and the scores on the Mini-mental State 
Examination (MMSE) within the whole Munich collective and for the complete set of 39 
SNPs. Note that MMSE scores were only available for 416 of the subjects. For the analysis, 
age at onset and gender were included as covariates to rule out results only driven by group-
specific effects. Resulting data revealed associations between SNP # 9 and age at onset (GG, 
68.9 ± 10.4 years; GA/AA, 67.1 ± 10.2: p = 0.032) as well as MMSE scores (GG, 17.9 ± 6.2; 
GA/AA, 19.4 ± 6.5: p = 0.018). SNP # 9 had already yielded a significant p-value when tested 
for association with AD in the whole Munich cohort after stratification by age at onset within 
the EOAD sub-collective. The G allele had been associated with a higher risk (compare § 
5.1.1, Tab. 18). Association was revealed between several other SNPs (# 13, 28, 30, 32 and 
34) and scores on the Mini-mental State Examination (MMSE). However, none of the SNPs 
that had shown associations before yielded significant results when tested for association with 
MMSE score. No other SNPs presented with significant associations with clinical measures. 
Detailed results are reported in the Appendix (§ 7.3.1, Tab. 50 and Tab. 51).  
 
5.1.4 Functional Analyses for APP in Brain Samples 
 
In order to determine possible functional effects of SNPs on APP expression and Aβ 
levels, a preliminary study with 20 brain samples (12 cases, 8 controls) was performed. 
As for the replication studies, based on the analysis of the Munich cohort a selection of 
SNPs (# 15-23, 25, 35 and 36) was chosen for analysis of possible functional effects. These 
SNPs had delivered association results before and span the two formerly identified marker 
peak regions (§ 5.1.1, Fig. 15).  
The formerly found associations of genotypes with AD were tested in the small study 
cohort of 20 brain samples. Only one of the SNPs (# 15, rs9978555) confirmed the formerly 
found association in plasma samples in the used brain samples when tested recessive for the 
major allele (t-test, p = 0.002). ANOVA analysis yielded no significant results for any of the 
tested SNPs. Results are presented in the table below (Tab. 21). Due to the small sample size 
(n = 20) and the explorative character of the functional study, the following investigations 
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were undertaken anyways, but results have to interpreted with caution. 
 
Tab. 21: Results of statistical analysis of APP genotypes in brain samples 
# SNP 
p-values from ANOVA 
(association between 
genotype and phenotype) 
p-values 
from t-test 
(recessive 
for major 
allele) 
15 rs9978555 0.264 0.002 
16 rs9941877 0.787 0.482 
17 rs2830012 0.519 0.519 
18 rs2830019 - 0.811 
19 rs768039 0.811 0.811 
20 rs3787644 0.811 0.811 
21 rs2070655 0.967 1.000 
22 rs3991 0.469 0.482 
23 rs2830035 0.220 0.332 
25 rs1041420 0.811 0.811 
35 rs6516727 0.578 0.388 
36 rs2830099 0.772 0.605 
- : no ANOVA possible, 2 groups only 
 
5.1.4.1 Gene Expression Analyses for APP in Brain Samples 
 
Using control RNA of defined concentration (Applied Biosystems FirstChoice® 
Human Brain Reference RNA, 1 mg/mL, Part No. AM6050) a calibration line was 
determined from which the RNA content of the samples was calculated (Fig. 16). 
APP
y = -3.6131x + 26.465
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Fig. 16: Calibration line for determination of APP mRNA 
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Gene expression analysis in AD and control brains revealed SNP # 25, which is 
located in intron 3, to have a significant impact on APP mRNA levels. The C allele was 
associated with lower mRNA levels, whereas the presence of a T seems to increase APP gene 
expression (all samples: CC (n=16) 1.69±0.99 Arbitrary Units (AU), CT/TT (n=3) 3.07±1.34 
AU; p = 0.049). This association signal strengthened when AD brains alone were examined 
(AD samples: CC (n=10) 1.68 ± 1.06 AU, CT/TT (n=2) 3.79 ± 0.70; p = 0.025). None of the 
other SNPs showed significant associations with expression changes. Note that for two SNPs 
(# 18 and 23) no ANOVA analysis was possible, due to occurrence of two different genotypes 
only. Therefore, for SNPs # 18 and 23 results of t-test recessive for major allele was 
performed and results are marked in italic font. The individual results for ANOVA analysis of 
each SNP are presented in the table below (Tab. 22). A scatter plot depicting the expression 
changes for SNP # 25 in the AD brains is shown below (Fig. 17).  
 
Tab. 22: Results from the statistical analysis measuring the influence of sequence variation 
on gene expression levels of APP 
 
# SNP 
p-values from ANOVA - 
association between 
genotype and APP mRNA 
level (in AD brains only) 
15 rs9978555 0.936
16 rs9941877 0.406
17 rs2830012 0.181
18 rs2830019 0.083
19 rs768039 0.414
20 rs3787644 0.414
21 rs2070655 0.392
22 rs3991 0.924
23 rs2830035 0.267
25 rs1041420 0.049 (0.025)
35 rs6516727 0.482
36 rs2830099 0.380
Results in italic letters: p-values from t-test, no ANOVA possible, 2 groups only 
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SNP # 25
 
Fig. 17: Effect of rs1041420 (SNP # 25) genotypes on APP expression 
The y-axis shows the arbitrary units (AU) calculated for each sample, the x-axis represents the determined 
genotypes. APP expression levels in the brain of AD patients in relation to rs1041420 genotypes were analyzed 
using ANOVA. Solid lines represent the mean of the measurements per genotype. 
 
 
5.1.4.2 Western Blot Analysis of Aβ peptides in Brain Samples 
 
A Western Blot was performed for the same 20 brain samples described above. The 
used primary antibody, WO2, is a monoclonal antibody, which recognises the Aβ peptide and 
therefore unprocessed APP as well as β-secretase processed APP (CTFβ). It was tested 
whether protein levels of APP and/or Aβ were elevated in subjects affected with AD in 
comparison to control brains. The results are shown in the Figure below (Fig. 18). 
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Fig. 18: Western Blot analysis for APP in brain samples 
The upper band shows the amount of APP protein levels, whereas the lower band shows the amount of present 
Aβ protein levels in the examined brain samples. Each test item was analyzed in duplicates in adjacent lanes. 4 
gels were run (I – IV) and inter-gel standardization was performed through repetition of test items on different 
gels. Note that controls are marked with 0, cases are marked with 1, M is the marker lane and S the used Aβ 
standard for check of the antibody. The test items are numbered alphabetically (controls 0a – 0 h, cases 1a – 1l). 
 
A clear presence of Aβ was found in all subjects affected with AD (marked with 1 in 
Fig. 18). In contrast, for the controls (marked with 0 in Fig. 18) no Aβ above the detection 
limit of the assay could be determined at all.  
Statistical analysis was performed for APP on basis of the revealed density of the 
bands for each sample. However, no significant association between the amount of present 
APP and the analyzed genotype in the brain samples was found. 
 
5.1.4.3 Analyses of Aβ levels in brain samples 
 
These same brain samples were then utilized to determine soluble levels of Aβ 
isoforms (Aβ38, 40, 42 and 40/42 ratio) using an ELISA. The results of the ANOVA analysis 
investigating the association of total Aβ, Aβ40 and Aβ42 with the determined genotypes are 
presented in the table below (Tab. 23). Significant results were stratified with post-hoc 
analyses (multiple testing using Tukey HSD = honest significant difference and LSD = least 
significant difference) to show which groups delivered the different results. SNPs # 35 
(rs6516727) and 36 (rs2830099) showed a significant impact on total Aβ as well as on Aβ40. 
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For SNP # 35, C was associated with higher levels of total Aβ (TT (n=10) 250±321, TC (n=8) 
310±382, CC (n=2) 1217±1431; p = 0.057, 0.046 (HSD), 0.020(LSD)) as well as with higher 
levels of Aβ40 (TT (n=10) 224±312, TC (n=8) 282±364, CC (n=2) 1169±1385; p = 0.057, 
0.046 (HSD), 0.018(LSD)). Similarly, for SNP # 36, the C allele was associated with higher 
levels of total Aβ (GG (n=11) 249±305, GC (n=7) 320±412, CC (n=2) 1217±1431; p = 0.056, 
0.047 (HSD), 0.019(LSD)) as well as with higher levels of Aβ40 (GG (n=11) 225±96, GC 
(n=7) 288±393, CC (n=2) 1169±1385; p = 0.053, 0.045 (HSD), 0.018(LSD)). SNP # 18 
(rs2830019) yielded a significant p-value when testing association between genotype and 
Aβ42 level (t-test: CC (n=13) 16.6 ± 12.5, CT/TT (n=2) 39.5 ± 36.1; p = 0.041). No other 
significant associations were observed. For some of the analyzed SNPs no ANOVA analysis 
was possible, since only two groups were observed. In those cases results of a t-test are 
reported and results are marked in italic font. 
 
 
Tab. 23: Results from the statistical analysis measuring the influence of sequence variation 
on total Aβ content. 
 
# SNP 
p-values from ANOVA 
(association between 
genotype and total Aβ) / 
HSD / LSD 
p-values from ANOVA 
(association between genotype 
and Aβ40) / HSD / LSD 
p-values from ANOVA 
(association between 
genotype and Aβ42) / HSD / 
LSD 
15 rs9978555 0.542 0.540 0.574 
16 rs9941877 0.857 0.848 0.404 
17 rs2830012 0.950 0.971 0.690 
18 rs2830019 0.422 0.413 0.041 
19 rs768039 0.799 0.812 0.422 
20 rs3787644 0.799 0.812 0.422 
21 rs2070655 0.550 0.565 0.733 
22 rs3991 0.949 0.417 0.117 
23 rs2830035 0.826 0.851 0.553 
25 rs1041420 0.675 0.647 0.866 
35 rs6516727 0.057 / 0.049 / 0.020 0.053 / 0.046 (C-T) / 0.018 (C-T) 0.220 
36 rs2830099 0.056 / 0.047 / 0.019 0.053 / 0.045 (G-C) / 0.018 (G-C) 0.220 
Results in italic letters: p-values from t-test, no ANOVA possible, 2 groups only 
HSD = Tukey honest significant difference and LSD = least significant difference post-hoc testing 
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5.1.5 Functional Analyses for APP in Cerebrospinal Fluid 
 
Additionally, a set of 85 cerebrospinal fluid (CSF) samples from AD patients was 
analyzed for their content of Aβ42. Due to the limited amount of these samples, only the 4 
SNPs (SNPs # 16, 20, 35 and 36), which had shown significance in the complete Munich 
cohort, as well as the adjacent SNPs of the strongest association marker - SNP # 20 - (SNPs # 
19 and 21) were selected for analyses. 
In a set of 85 cerebrospinal fluid (CRF) samples from AD patients Aβ42 levels were 
determined using an ELISA. SNP # 36 revealed a significant association of homozygosity of 
the major allele (G) with elevated CSF Aβ42 levels (GG (n=40) 563.95 ± 276.7ng/L, GC/CC 
(n=42) 431.02 ± 191.1ng/L, p = 0.015); however, no significant associations were observed 
for the remaining SNPs. The results of the statistical analysis are presented in the table below. 
 
 
Tab. 24: Results of statistical analysis of Aβ42 levels in CSF 
 
# SNP 
p-values from ANOVA 
(association between 
genotype and Aβ42 level 
in CSF) / HSD / LSD 
p-values from t-
test (recessive 
for major allele) 
16 rs9941877 0.990 0.923 
19 rs768039 0.830 0.874 
20 rs3787644 0.838 0.677 
21 rs2070655 0.749 0.774 
35 rs6516727 0.200 0.200 
36 rs2830099 0.048 / 0.061 / 0.024 0.015 
 
Note that lnAβ42 levels were used for evaluation so that normally distribution within the study cohort was given! 
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Fig. 19: Boxplot of Aβ42 levels in CSF for significant SNP rs2830099 (# 36) 
The x-axis presents the genotypes, the y-axis the measured Aβ42 in ng/L CSF. Boxplot shows median (bar), the 
interquartile range (box = 50 % of values) and the range (lines = 100 % of values without outliers and extremes) 
of Aβ42 levels (○: Outliers i.e., cases with values between 1.5 and 3 box lengths from the upper or lower edge of 
the box.) The box length is the interquartile range. Aβ42 levels were measured in ng/L CSF. 
 
GG CC GC
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5.2 Analysis of SNPs from Candidate Genes Involved in APP 
Processing 
 
Both BACE1 and ADAM10 represent, due to their involvement in APP processing, 
prime functional candidates for AD. Furthermore, the location of BACE1 and ADAM10 in the 
vicinity of suggestive AD linkage peaks at 11q25 (Blacker, Bertram et al. 2003) and 15q22 
(Scott, Hauser et al. 2003), also make them positional candidates. Whilst BACE1 has been the 
subject of study before, these reports have focused on one or two exon 5 polymorphisms (for 
meta-anlaysis see the AlzGene database (Bertram, McQueen et al. 2007)) with only one study 
utilizing a whole-gene approach (Todd, McKnight et al. 2008). On the other hand, 
polymorphisms in ADAM10 have not received much attention in the literature (Prinzen, 
Muller et al. 2005). As such, this study aimed to comprehensively investigate the genetic role 
of both genes in AD. 
 
5.2.1 Analysis of SNPs from BACE1 
 
The BACE1 gene is located in chromosomal region 11q23.2-q23.3 and contains 9 
exons spanning 30.6 kilobases. The beta-site amyloid beta A4 precursor protein-cleaving 
enzyme 1 (BACE1) initiates the generation of beta-amyloid (Aβ) and therefore plays a major 
role during AD pathogenesis, as described before in detail (see Introduction, § 1.4.2.1). 
The potential association of the BACE1 gene in AD was thoroughly investigated by 
utilizing a fine mapping approach across the entire BACE1 gene in a large German case-
control series.  
After several and thorough databank researches, 24 SNPs were selected for further 
study (Tab. 25). From these SNPs, 11 could be confirmed to be polymorphic in the Munich 
collective, achieved a sufficient genotype frequency (>80%) and showed no deviation from 
the HWE in the controls (Tab. 26 and Fig. 20). Incorporating results with insufficient 
genotype frequencies can lead to falsified distributions of the formerly matched cases and 
controls cohorts. Deviations from the HWE can be a sign of erroneous genotyping or a 
deficient population structure. 
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Tab. 25: Selected SNPs from the BACE1 gene.  
SNPs that yielded insufficient genotype frequencies (<80 %), significant deviations from HWE and minor allele 
frequencies <0.001 were not taken into account for the following statistical evaluations. SNPs passing all 
aforementioned criteria are highlighted in bold font. Alleles are reported in alphabetical order as found on 
http://snpper.chip.org. 
 
 
SNP ID 
NCBI SNP Position NCBI Alleles Role 
rs7925044 116653197 A/G 3' UTR 
rs12292027 116654615 A/G 3' UTR 
rs2305821 116658630 C/T 3' UTR 
rs3180616 116661628 A/T Exon 
rs7083 116661762 C/T Exon 
rs1047964 116662103 C/G Exon 
rs539765 116665557 A/G Coding exon 
rs490460 116668975 G/T Intron (boundary) 
rs638405 116669034 C/G Coding exon 
rs507805 116672357 A/G Intron 
rs548381 116676547 C/T Intron 
rs609332 116680368 C/G Intron 
rs522843 116681144 A/G Intron 
rs687740 116682813 A/C Intron 
rs473210 116683010 A/G Intron 
rs551662 116684213 A/G Intron 
rs676134 116685101 C/T Intron 
rs583161 116686131 C/T Intron 
rs656083 116687202 C/T Intron 
rs525493 116687918 G/T Intron 
rs2445939 116691283 A/T Intron 
rs3017609 116695997 A/T Promoter 
rs675228 116696661 A/G Promoter 
rs560564 116700838 A/C Promoter 
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Fig. 20: Schematic of the BACE1 gene.  
The positions of the analyzed SNPs (shown with rs numbers) and exons in the BACE1 gene are shown. Exons are marked with green bars on the forward strand from left to right. 
The arrow shows direction of transcription. 
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Single marker and haplotype associations were explored. Single marker analysis, within 
Haploview, of the 11 BACE1 SNPs (Tab. 26) revealed no allelic associations with AD. 
Logistic regression analysis of genotypes with age and gender as covariates likewise revealed 
no significant associations (Tab. 27). The major allele frequencies (Tab. 26), as well as 
genotype frequencies (Tab. 27) were appropriately comparable in cases and controls and 
showed no clear differences. No single marker was associated with either increased risk, when 
stratified by age at onset of symptoms (see Appendix, § 7.3.2). 
 
Tab. 26: Results from allelic tests for the BACE1 gene. 
Allelic associations were tested for significance using χ2-tests, all as implemented in Haploview version 4.2. All 
of the listed SNPs yielded genotype frequencies of at least 80 %, no significant deviation from HWE and minor 
allele frequencies were at least 0.001.  
 
# SNP Associated 
allele 
Major allele 
frequency MUC 
complete        
(cases, controls) 
Allelic p-
values 
1 rs644215 A 0.634, 0.632 0.953 
2 rs12292027 T 0.953, 0.948 0.662 
3 rs1047964 C 0.936, 0.930 0.639 
4 rs638405 C 0.595, 0.600. 0.859 
5 rs507805 T 0.918, 0.905 0.370 
6 rs609332 G 0.860, 0.848 0.525 
7 rs522843 A 0.677, 0.656 0.407 
8 rs687740 G 0.669, 0.691 0.391 
9 rs473210 G 0.600, 0.583 0.515 
10 rs551662 G 0.904, 0.906 0.879 
11 rs525493 A 0.573, 0.551 0.395 
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Tab. 27: Results from genotypic tests for the BACE1 gene.  
Genotypic associations were tested for significance using a logistic regression recessive model [i.e. AA vs Aa,aa; 
where major allele is A] and are adjusted for age and gender (each SNP independently), all as implemented in 
SPSS. 
 
Genotype Frequency 
SNP 
Alleles 
(Major/Minor) 
Cases 
AA        Aa        aa 
Controls  
AA        Aa        aa 
p-values 
rs644215 A/T 0.422 0.422 0.154 0.407 0.449 0.142 0.731 
rs12292027 A/G 0.908 0.089 0.002 0.895 0.104 0.000 0.892 
rs1047964 C/G 0.876 0.118 0.004 0.862 0.133 0.003 0.615 
rs638405 C/G 0.350 0.489 0.160 0.353 0.493 0.153 0.826 
rs507805 A/G 0.841 0.154 0.004 0.820 0.169 0.010 0.905 
rs609332 C/G 0.737 0.243 0.018 0.730 0.235 0.034 0.748 
rs522843 A/G 0.456 0.440 0.103 0.447 0.416 0.136 0.911 
rs687740 A/C 0.464 0.408 0.126 0.472 0.437 0.090 0.740 
rs473210 G/A 0.358 0.482 0.158 0.327 0.510 0.161 0.454 
rs551662 A/G 0.824 0.159 0.016 0.819 0.173 0.007 0.911 
rs525493 T/G 0.330 0.486 0.183 0.300 0.500 0.199 0.488 
 
 
Thereafter, the LD structure for the BACE1 gene was determined on basis of the 11 
SNPs covering the complete genetic region. The average inter-marker distance was calculated 
to be 3.5 kb. Within the genotyped region 2 LD blocks were identified (Fig. 14). For each of 
them haplotypes were calculated as depicted in the table below (Tab. 28).  
3 haplotypes were estimated within block 1, spanning SNPs # 1-2, 7 haplotypes within 
block 2, spanning SNPs # 4 – 10. None of the estimated haplotypes showed an association 
with AD, confirming the former findings. 
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Fig. 21: LD structure of the the BACE1 gene, including the haplotype block structure.  
Values are used to represent D’ whereas shades of grey were used to encode r2 (D’ values of 1.0 are never shown 
- the box is empty; black = high r2 value, white = low r2 value). The blocks followed the haplotype block 
definition by Gabriel et al., (Gabriel, Schaffner et al. 2002) as implemented within Haploview 4.2.  
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Tab. 28: Haplotype blocks and frequencies for BACE1 in Munich collective 
 
Haplotype ID Sequence Frequency (Case/Control) P-values 
Block 1 
1.1 AT 0.587, 0.580 0.801 
1.2 TT 0.366, 0.368 0.954 
1.3 AC 0.047, 0.052 0.655 
Block 2 
2.1 GTGAGGA 0.315, 0.294 0.403 
2.2 GTCATGA 0.141, 0.153 0.524 
2.3 CTGGTAA 0.124, 0.117 0.667 
2.4 GTGATGA 0.111, 0.112 0.934 
2.5 CTGGTAG 0.091, 0.094 0.860 
2.6 CCGGTAA 0.080, 0.095 0.301 
2.7 CTGATAA 0.077, 0.074 0.808 
 
 
In addition, haplotype analysis within BACE1 also revealed no significant associations 
with AD. Results of the 2- and 3-marker sliding window approach to identify SNPs that 
contributed association signals are depicted in the figure below (Fig. 22). Detailed results from 
the 2- and 3-marker sliding window approach are depicted in the Appendix (§ 7.4.2). 
Haplotypes with frequencies below 5% were not taken into account, due to their unlikely 
occurrence. 
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Fig. 22: Sliding window analysis of 2- and 3-marker haplotypes for BACE1 
Red circles represent -log p values for single marker SNPs genotyped. Lines between solid squares represent the 
-log p value of 2-marker haplotypes. Lines between solid triangles mark -log p values for 3-marker haplotypes. 
All 2- and 3-marker haplotypes as calculated with Haploview. The dotted lines at a -log p value of approximately 
1.3 demarcate the association threshold of p = 0.05. Numbers correspond to those assigned to SNPs by 
Haploview. 
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5.2.2 Analysis of SNPs from ADAM10 
 
Central to AD pathogenesis is the amyloid cascade hypothesis (Hardy and Higgins 
1992). An alternative cleavage pathway, involving α-secretase, precludes the formation of Aβ 
(Kojro and Fahrenholz 2005). ADAM10, a member of the ADAM (a disintegrin and 
metalloproteinase) family of proteinases and encoded by the ADAM10 gene at 15q21-q23, has 
been shown to exhibit this α-secretase activity (Lammich, Kojro et al. 1999). The ADAM10 
gene contains 16 exons in 153.7 kilobases.  
The potential association of the ADAM10 gene in AD was thoroughly investigated by 
utilizing a fine mapping approach across the entire ADAM10 gene in a large German case-
control series.  
After several and thorough databank researches, 41 SNPs were selected (Tab. 29). 
From these, 27 SNPs could be confirmed to be polymorph in the Munich collective, achieved 
a sufficient genotype frequency (>80%) and showed no deviation from the HWE in controls 
(Tab. 30 and Fig. 23).  
 
Tab. 29: Selected SNPs from the ADAM10 gene.  
SNPs that yielded insufficient genotype frequencies (<80 %), significant deviations from HWE and minor allele 
frequencies <0.001 were not taken into account for the following statistical evaluations. SNPs passing all 
aforementioned criteria are highlighted in bold font. Alleles are reported in alphabetical order as found on 
http://snpper.chip.org. 
SNP ID 
NCBI 
SNP Position 
NCBI Alleles Role 
rs12438487 56666658 A/C 3' UTR 
rs1869135 56669261 C/T 3' UTR 
rs3764196 56674302 G/T 3' UTR 
rs7166076 56679702 C/T Intron 
rs1365772 56681600 C/T Intron 
rs7165035 56687089 A/C Intron 
rs1801973 56689928 G/T Coding exon 
rs2305421 56690375 A/G Intron 
rs8027151 56696272 A/G Intron 
rs8027618 56696273 A/G Intron 
rs12594872 56700041 C/T Intron 
rs1427282 56701618 C/T Intron 
rs8043406 56701924 A/G Intron 
rs972801 56708490 C/T Intron 
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rs7163733 56711611 C/T Intron 
rs7163733 56711611 C/T Intron 
rs7174386 56716605 C/T Intron 
rs9302203 56721161 A/T Intron 
rs6494031 56726560 C/T Intron 
rs11071392 56731962 G/T Intron 
rs8026668 56736062 A/T Intron 
rs11071393 56740318 C/G Intron 
rs1427280 56741612 A/G Intron 
rs1427281 56746565 C/T Intron 
rs4775086 56756584 A/G Intron 
rs4775087 56762196 C/T Intron 
rs7167528 56763010 A/C Intron 
rs2052805 56770279 A/G Intron 
rs2657125 56780693 C/G Intron 
rs347117 56788249 C/T Intron 
rs2054096 56796135 A/T Intron 
rs4238331 56799425 G/T Intron 
rs12441313 56802780 G/T Intron 
rs6494038 56807416 C/T Intron 
rs12439231 56812887 C/T Intron 
rs7173286 56818300 A/T Intron 
rs383902 56821466 C/T Intron 
rs653765 56829304 A/G Exon 
rs593742 56833066 A/G Promoter 
rs681711 56837343 A/G Promoter 
rs694335 56838189 C/T Promoter 
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Fig. 23: Schematic of the ADAM10 gene.  
The positions of the analyzed SNPs (shown with rs numbers) and exons in the ADAM10 gene are shown. Exons are marked with green bars on the forward strand from left to 
right. The arrow shows direction of transcription. 
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Single marker analysis, determined as implemented within Haploview, of the 27 
ADAM10 SNPs (Tab. 30) revealed no allelic associations with AD. Logistic regression 
analysis of genotypes likewise revealed no significant associations (Tab. 31). The major allele 
frequencies (Tab. 30), as well as genotype frequencies (Tab. 31) were similar in cases and 
controls and showed no notable differences. None of the single markers was associated with 
increased risk for AD, when stratified by age at onset of symptoms (see Appendix, § 7.3.3). 
 
Tab. 30: Results from allelic tests for the ADAM10 gene. 
Allelic associations were tested for significance using χ2-tests, all as implemented in Haploview version 4.2. All 
of the listed SNPs yielded genotype frequencies of at least 80 %, no significant deviation from HWE and minor 
allele frequencies had to be at least 0.001.  
 
# SNP Associated 
allele 
Major allele 
frequency MUC 
complete        
(cases, controls) 
Allelic p-
values 
1 rs12438487 T 0.888, 0.888 0.991 
2 rs1869135 G 0.782, 0.784 0.935 
3 rs7166076 G 0.881, 0.890 0.623 
4 rs7165035 T 0.882, 0.897 0.376 
5 rs2305421 C 0.881, 0.889 0.618 
6 rs12594872 G 0.628, 0.630 0.933 
7 rs1427282 T 0.669, 0.670 0.969 
8 rs7163733 A 0.886, 0.894 0.650 
9 rs7174386 G 0.877, 0.888 0.555 
10 rs9302203 T 0.881, 0.886 0.750 
11 rs6494031 A 0.894, 0.906 0.452 
12 rs11071392 C 0.876, 0.889 0.441 
13 rs8026668 A 0.890, 0.889 0.964 
14 rs11071393 G 0.877, 0.889 0.485 
15 rs1427280 C 0.893, 0.883 0.543 
16 rs1427281 G 0.755, 0.762 0.758 
17 rs4775086 T 0.767, 0.774 0.766 
18 rs2052805 C 0.891, 0.893 0.911 
19 rs2657125 C 0.856, 0.863 0.695 
20 rs347117 A 0.729, 0.731 0.945 
21 rs4238331 A 0.720, 0.733 0.612 
22 rs12441313 A 0.888, 0.898 0.526 
23 rs6494038 A 0.891, 0.895 0.828 
24 rs12439231 A 0.884, 0.898 0.413 
25 rs383902 A 0.703, 0.705 0.928 
26 rs653765 G 0.725, 0.737 0.604 
27 rs593742 C 0.711, 0.723 0.601 
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Tab. 31: Results from genotypic tests for the ADAM10 gene.  
Genotypic associations were tested for significance using a logistic regression recessive model [i.e. AA vs Aa,aa; 
where major allele is A] and are adjusted for age and gender (each SNP independently) all as implemented in 
SPSS 
Genotype Frequency 
SNP 
Alleles 
(Major/Minor) 
Cases 
AA        Aa        aa 
Controls  
AA        Aa        aa 
p-values 
rs12438487 C/A 0.800 0.176 0.024 0.794 0.188 0.018 0.899 
rs1869135 T/C 0.620 0.324 0.056 0.621 0.326 0.053 0.864 
rs7166076 T/C 0.784 0.195 0.021 0.797 0.185 0.017 0.622 
rs7165035 C/A 0.790 0.184 0.026 0.813 0.169 0.018 0.421 
rs2305421 A/G 0.783 0.196 0.021 0.796 0.186 0.018 0.606 
rs12594872 T/C 0.393 0.469 0.138 0.391 0.478 0.131 0.889 
rs1427282 C/T 0.451 0.435 0.114 0.434 0.472 0.094 0.777 
rs7163733 C/T 0.794 0.186 0.021 0.806 0.177 0.017 0.673 
rs7174386 T/C 0.778 0.200 0.023 0.792 0.190 0.017 0.597 
rs9302203 A/T 0.783 0.196 0.021 0.790 0.192 0.017 0.791 
rs6494031 C/T 0.807 0.174 0.019 0.831 0.151 0.018 0.427 
rs11071392 T/G 0.774 0.202 0.023 0.796 0.187 0.018 0.487 
rs8026668 A/T 0.805 0.171 0.024 0.800 0.179 0.021 0.916 
rs11071393 C/G 0.777 0.200 0.023 0.795 0.188 0.017 0.516 
rs1427280 G/A 0.816 0.156 0.028 0.780 0.206 0.014 0.271 
rs1427281 T/C 0.584 0.342 0.074 0.585 0.356 0.060 0.898 
rs4775086 G/A 0.598 0.340 0.063 0.596 0.354 0.049 0.960 
rs2052805 A/G 0.801 0.180 0.019 0.807 0.172 0.021 0.830 
rs2657125 C/G 0.734 0.243 0.023 0.743 0.240 0.017 0.618 
rs347117 C/T 0.576 0.307 0.117 0.542 0.378 0.080 0.381 
rs4238331 G/T 0.543 0.355 0.102 0.559 0.346 0.094 0.640 
rs12441313 G/T 0.794 0.187 0.019 0.814 0.168 0.018 0.562 
rs6494038 C/T 0.803 0.176 0.021 0.807 0.175 0.018 0.869 
rs12439231 C/T 0.789 0.190 0.021 0.813 0.170 0.017 0.463 
rs383902 C/T 0.518 0.369 0.112 0.511 0.388 0.101 0.838 
rs653765 A/G 0.544 0.362 0.094 0.536 0.401 0.062 0.848 
rs593742 A/G 0.515 0.391 0.094 0.529 0.388 0.083 0.735 
 
Finally, the LD structure for the ADAM10 gene was determined on basis of the 27 
SNPs, covering the complete genetic region. The average inter-marker distance was 
calculated to be 6.4 kb. Within the genotyped region 2 LD blocks were identified on basis of 
their D’ and r2 values (Fig. 24). For each of them, haplotypes were calculated as depicted in 
the table below (Tab. 32). The LD blocks span the entire gene, block 1 from SNPs # 1-24, 
block 2 from SNPs # 25-27. Since D’ values were high throughout all SNPs (majority values 
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>0.9), determination of one block spanning the whole genome would be possible as well. 
None of the estimated haplotypes showed an association with AD. 
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Fig. 24: LD structure of the ADAM10 gene, including the haplotype block structure. 
Numerical values are used to represent D’ whereas colors were used to encode r2 (D’ values of 1.0 are never shown - the box is empty; black = high r2 value, white = low r2 
value). The blocks followed the haplotype block definition by Gabriel et al., (Gabriel, Schaffner et al. 2002) as implemented within Haploview 4.2. 
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Tab. 32: Haplotype blocks and frequencies for ADAM10 in the Munich collective 
 
Haplotype ID Sequence Frequency (Case/Control) P-values 
Block 1 
1.1 GAAGTACGAAGAACCACTGGCCGG 0.534, 0.565 0.254 
1.2 GGAGTGTGAAGAACTGTTGACCGG 0.115, 0.126 0.532 
1.3 TAGTCGTAGTACTGCGTCGAAAAA 0.099, 0.098 0.962 
1.4 GGAGTGTGAAGAACCACTCGACGG 0.061, 0.059 0.853 
Block 2 
2.1 GAT 0.680, 0.677 0.903 
2.2 AGC 0.266, 0.245 0.356 
 
 
A 2- and 3-marker sliding window approach to identify SNPs that contributed 
association signals neither yielded any significant results (Fig. 25). Detailed results from the 
2- and 3-marker sliding window approach are depicted in the Appendix (§ 7.4.3). Haplotypes 
with frequencies below 5% were not taken into account, due to their unlikely occurrence. 
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Fig. 25: Sliding window analysis of 2- and 3-marker haplotypes for ADAM10 
Red circles represent -log p values for single marker SNPs genotyped. Lines between solid squares represent the -log p value of 2-marker haplotypes. Lines between solid 
triangles mark -log p values for 3-marker haplotypes. All 2- and 3-marker haplotypes as calculated with Haploview. The dotted lines at a -log p value of approximately 1.3 
demarcate the threshold of p = 0.05. Numbers correspond to those assigned to SNPs by Haploview. 
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5.3 Analysis of SNPs from Candidate Genes Involved in Lipid 
Metabolism 
 
Additionally, genes involved in the lipid metabolism, just like the major genetic risk 
factor for Alzheimer’s disease (AD), apolipoprotein E (ApoE) were taken into consideration 
during selection of candidate genes. 
 
5.3.1 Analysis of SNPs from ABCA1 
 
The ABCA1 gene is located on chromosome 9 (9q31.1), spans 149 kb and contains 50 
exons. Since the gene is present approximately 5 Mb distal from previously identified loci 
linked with AD it is a potential positional candidate gene. Involvement into lipid metabolism 
also makes it a functional candidate. Up to now only one study used an approximate fine-
mapping approach - still only including 19 SPNs, in a Chinese cohort (Chu, Li et al. 2007). 
Therefore, a whole fine mapping approach of ABCA1 is of utmost importance to verify the 
former findings and to get results for the entire gene locus. Significant results underwent 
replication in a second large independent case-control series, as well as in an independent sib-
pairs cohort. Additionally, associated SNPs underwent further analyses to elucidate their 
association with altered ABCA1 gene expression. 
 
5.3.1.1 Genotyping of SNPs from ABCA1 
 
After several databank researches, 48 SNPs were selected (Tab. 33). From these 30 
could be confirmed to be polymorph in the Munich collective, achieved a sufficient genotype 
frequency (>80%) and showed no deviation from the HWE in controls (Tab. 34 and Fig. 26).  
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Tab. 33: Selected SNPs from the ABCA1 gene. 
SNPs that yielded insufficient genotype frequencies (<80 %), significant deviations from HWE and minor allele 
frequencies <0.001 were not taken into account for the following statistical evaluations. SNPs passing all 
aforementioned criteria are highlighted in bold font. Alleles are reported in alphabetical order as found on 
http://snpper.chip.org. 
 
SNP ID NCBI 
SNP Position 
NCBI Alleles Role 
rs1858555 106552252 A/G Intron
rs2515606 106576716 C/T 3' UTR
rs10761085 106581889 G/T 3' UTR
rs363717 106584521 A/G Exon
rs1331924 106587443 C/G Intron (boundary) 
rs2274872 106589328 C/T Intron
rs2066720 106593890 A/G Intron
rs2777799 106598880 A/G Intron
rs2230808 106602625 A/G Coding exon 
rs1997618 106604190 C/T Coding exon 
rs2066716 106608526 A/G Coding exon 
rs2297409 106616067 A/G Intron
rs2297401 106619293 A/C Intron
rs3818689 106624837 C/G Intron (boundary) 
rs4149313 106626574 A/G Coding exon 
rs2066718 106629076 A/G Coding exon 
rs13306068 106633803 A/G Coding exon 
rs2297398 106638705 G/T Intron
rs2487062 106643260 C/G Intron
rs914544 106647033 C/T Intron
rs1175293 106653704 C/T Intron
rs2472445 106659171 G/T Intron
rs2230806 106660688 A/G Coding exon 
rs2230805 106663850 A/G Coding exon 
rs13301006 106669157 C/T Intron
rs2000069 106675690 C/T Intron
rs1999429 106680607 A/C Intron
rs2275542 106684901 C/T Intron
rs7043081 106689432 A/T Intron
rs2275545 106691347 A/G Intron (boundary) 
rs3847305 106697074 C/G Intron
rs2575875 106702315 A/G Intron
rs3758294 106704636 C/T Intron
rs7030810 106710980 C/T Intron
rs1175453 106716527 A/G Intron
rs2515616 106721816 C/T Intron
rs2515611 106727317 C/T Intron
rs1800977 106730271 C/T Promoter
rs2487042 106734343 A/G Promoter
rs2472490 106738148 A/G Promoter
rs4743765 106739189 A/T Promoter
rs2487035 106741245 A/G Intergenic
rs2487030 106746009 A/G Intergenic
rs7029538 106750844 C/T Intergenic
rs2472516 106756217 C/T Intergenic
rs4397467 106762399 A/G Intergenic
rs4743776 106767548 A/G Intergenic
rs737623 106774926 A/G Intergenic
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Fig. 26: Schematic of the ABCA1 gene.  
The positions of the analyzed SNPs (shown with rs numbers) and exons in the ABCA1 gene are shown. Exons are marked with green bars on the forward strand from left to right. 
The arrow shows direction of transcription. 
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The subsequent allelic tests yielded no significant association between any SNP and 
AD in the complete Munich collective. However, a detailed analyses stratified by age at onset 
yielded significant p-values for two SNPs (SNP # 25, rs2487042, p-value=0.028 and SNP # 
28, rs4397467, p-value=0.046) in subjects with EOAD. No significance was detected in 
subjects with LOAD. Stratification by presence or absence of the ApoE ε4 allele yielded 
another significant SNP (# 8, rs3818689, p-value=0.037). Allelic association tests yielded no 
further significant p-values. 
Results from allelic tests of all SNPs performed for the Munich collective are depicted 
in Tab. 17.  
Subsequently, genotyping analyses were performed for the same 30 SNPs using 
logistic regression with gender and age at onset as covariates. In the complete Munich 
collective 2 SNPs could be shown to be associated with AD. An association signal was found 
for the intronic SNP rs2066720 (# 3) with a p-value of 0.047. The major allele (G) was 
associated with a higher risk for AD (OR = 2.75). For the intronic SNP # 1 (rs2515606) a 
borderline value of 0.05 was observed. The C allele was associated with a higher risk for AD 
(OR = 1.53). In the genotypic approach none of the formerly associated SNPs could be 
confirmed in subjects with EOAD or LOAD, but stratification for EOAD identified an 
additional association signal for SNP # 26. Results from genotypic tests of all SNPs 
performed for the Munich collective are depicted in Tab. 35. Stratification for presence of the 
ApoE ε4 allele was also performed for the genotypic approach. SNPs # 1 was confirmed for 
the non ApoE ε4 sub-collective an equal p-value as for the whole collective. One additional 
significant signal was found for SNP # 28 (rs4397467) with a p- value of 0.015 in the non 
ApoE ε4 sub-collective. The association of SNP # 3 with AD was also confirmed for the 
ApoE ε4 sub-collective with a p-value of 0.045, but this time the A allele was associated with 
a higher risk. Results after stratification for presence of ApoE ε4 allele are presented in the 
Appendix (§ 7.3.4, Tab. 54).  
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Tab. 34: Results from allelic tests for ABCA1 gene. 
Allelic associations were tested for significance using χ2-tests, all as implemented in Haploview version 4.2. The statistical analysis were carried out for the whole collective as 
well as for sub-collectives divided by age/onset (EOAD ≤ 65 years, LOAD > 65 years) and presence of at least one ApoE4allele (ApoE4 = at least one ApoE4 allele, nonApoE4 
= no ApoE4 allele) for cases and controls. All shown SNPs yielded genotype frequencies of at least 80 %, no significant deviation from HWE and minor allele frequencies had to 
be at least 0.001. Significant results are highlighted in bold font. 
 
Allelic test results 
Allelic p-values 
# SNP Associated 
allele 
Major allele frequency 
MUC complete        
(cases, controls) 
MUC complete 
(N=728) 
EOAD 
subcollective 
(N=281) 
LOAD subcollective 
(N=444) 
ApoE ε4 
subcollective       
(N = 295)  
non ApoE ε4 
subcollective      
(N = 433) 
1 rs2515606 C 0.573, 0.624 0.058 0.129 0.292 0.956 0.063 
2 rs1331924 G 0.885, 0.864 0.239 0.939 0.216 0.247 0.435 
3 rs2066720 G 0.881, 0.869 0.533 0.986 0.448 0.065 0.453 
4 rs2777799 C 0.871, 0.884 0.457 0.296 0.814 0.973 0.788 
5 rs2230808 A 0.730, 0.743 0.578 0.184 0.735 0.072 0.803 
6 rs2066716 G 0.919, 0.910 0.528 0.949 0.308 0.303 0.941 
7 rs2297401 T 0.951, 0.943 0.528 0.764 0.455 0.459 0.982 
8 rs3818689 G 0.947, 0.962 0.190 0.065 0.912 0.037 0.533 
9 rs4149313 G 0.872, 0.893 0.224 0.113 0.914 0.852 0.131 
10 rs2066718 A 0.972, 0.973 0.851 0.311 0.528 0.887 0.518 
11 rs2297398 C 0.928, 0.940 0.415 0.235 0.929 0.343 0.229 
12 rs2487062 G 0.892, 0.901 0.620 0.619 0.393 0.691 0.974 
13 rs914544 G 0.952, 0.958 0.578 0.926 0.544 0.285 0.270 
14 rs1175293 A 0.930, 0.925 0.725 0.475 0.241 0.321 0.945 
15 rs2472445 T 0.855, 0.855 0.998 0.652 0.851 0.667 0.916 
16 rs2230806 A 0.691, 0.700 0.722 0.833 0.762 0.625 0.632 
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17 rs2230805 A 0.715, 0.729 0.570 0.755 0.923 0.560 0.455 
18 rs13301006 A 0.838, 0.868 0.125 0.140 0.506 0.761 0.373 
19 rs2000069 A 0.537, 0.556 0.474 0.326 0.892 0.684 0.913 
20 rs1999429 C 0.984, 0.972 0.126 0.727 0.095 0.631 0.401 
21 rs2275542 G 0.678, 0.667 0.645 0.507 0.853 0.259 0.543 
22 rs3847305 G 0.870, 0.873 0.879 0.710 0.970 0.950 0.996 
23 rs2575875 T 0.616, 0.617 0.963 0.876 0.943 0.297 0.891 
24 rs3758294 G 0.777, 0.790 0.562 0.706 0.491 0.302 0.778 
25 rs2487042 A 0.772, 0.796 0.283 0.028 0.795 0.865 0.310 
26 rs2487035 T 0.657, 0.655 0.956 0.073 0.289 0.183 0.424 
27 rs2472516 G 0.607, 0.615 0.767 0.394 0.858 0.135 0.174 
28 rs4397467 G 0.681, 0.719 0.127 0.046 0.370 0.633 0.036 
29 rs4743776 G 0.703, 0.708 0.833 0.141 0.351 0.251 0.584 
30 rs737623 G 0.576, 0.563 0.644 0.220 0.992 0.448 0.246 
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Tab. 35: Results from genotypic tests for ABCA1 gene. 
Genotypic associations were tested for significance using logistic regression, all as implemented in STATA/SE 9.2. The statistical analysis were carried out for the whole 
collective as well as for sub-collectives divided by age/onset (EOAD ≤ 65 years, LOAD > 65 years) and presence of at least one ApoE4allele (ApoE4 = at least one ApoE4 allele, 
nonApoE4 = no ApoE4 allele) for cases and controls. Gender and age/onset were taken into account as covariates. Significant results are highlighted in bold font. Note that SNP 
# 5 could not be evaluated, due to no occurrence of the minor allele in control group. 
 
Genotypic test results 
Genotype frequencies MUC complete 
(cases, controls) 
AD affection genotypic p-values for major allele unless otherwise noted              
(associated allele); OR (95%CI) with covariates (sex and onset) # SNP 
Alleles 
(major/ 
minor) 
AA Aa aa MUC complete (N=728) EOAD subcollective (N=281) 
LOAD subcollective 
(N=444) 
1 rs2515606 T/C 0.337, 0.380 0.473, 0.488 0.191, 0.133 0.050 (C); 1.53 (0.9-2.3) 0.365 0.219 
2 rs1331924 G/C 0.791, 0.754 0.192, 0.222 0.019, 0.025 0.310 0.561 0.549 
3 rs2066720 G/A 0.778, 0.782 0.207, 0.175 0.016, 0.044 0.047 (G); 2.75 (1.01-7.5) 0.647 0.841 
4 rs2777799 T/C 0.760, 0.786 0.222, 0.197 0.019, 0.018 0.357 0.372 0.599 
5 rs2230808 G/A 0.533, 0.560 0.397, 0.368 0.072, 0.074 0.444 0.290 0.952 
6 rs2066716 G/A 0.849, 0.827 0.143, 0.167 0.010, 0.008 0.467 0.602 0.428 
7 rs2297401 T/G 0.902, 0.890 0.099, 0.107 0.000, 0.004 0.671 0.789 0.712 
8 rs3818689 C/G 0.897, 0.928 0.102, 0.069 0.003, 0.004 0.184 0.158 0.727 
9 rs4149313 A/G 0.761, 0.819 0.223, 0.151 0.017, 0.032 0.087 0.089 0.368 
10 rs2066718 G/A 0.944, 0.951 0.057, 0.047 0.000, 0.004 0.682 0.208 0.950 
11 rs2297398 A/C 0.862, 0.894 0.134, 0.093 0.005, 0.015 0.254 0.213 0.455 
12 rs2487062 C/G 0.785, 0.802 0.216, 0.199 0.000, 0.000 0.528 0.599 0.535 
13 rs914544 A/G 0.906, 0.923 0.092, 0.071 0.003, 0.008 0.440 0.582 0.313 
14 rs1175293 A/G 0.874, 0.864 0.113, 0.123 0.014, 0.014 0.608 0.942 0.396 
15 rs2472445 G/T 0.725, 0.721 0.263, 0.270 0.014, 0.011 0.999 0.821 0.961 
16 rs2230806 G/A 0.481, 0.483 0.422, 0.436 0.099, 0.083 0.973 0.549 0.705 
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17 rs2230805 G/A 0.518, 0.525 0.398, 0.410 0.086, 0.067 0.887 0.810 0.801 
18 rs13301006 G/A 0.700, 0.761 0.277, 0.215 0.024, 0.025 0.096 0.105 0.899 
19 rs2000069 G/A 0.292, 0.316 0.491, 0.481 0.219, 0.204 0.551 0.401 0.446 
20 rs1999429 C/A 0.968, 0.944 0.033, 0.057 0.000, 0.000 0.137 0.736 0.160 
21 rs2275542 G/A 0.454, 0.447 0.451, 0.440 0.097, 0.114 0.821 0.832 0.766 
22 rs3847305 C/G 0.755, 0.767 0.232, 0.213 0.015, 0.022 0.774 0.642 0.671 
23 rs2575875 C/T 0.364, 0.388 0.505, 0.460 0.132, 0.154 0.584 0.580 0.786 
24 rs3758294 A/G 0.634, 0.645 0.288, 0.292 0.079, 0.065 0.695 0.987 0.466 
25 rs2487042 G/A 0.608, 0.629 0.329, 0.336 0.064, 0.036 0.590 0.061 0.389 
26 rs2487035 T/C 0.445, 0.456 0.424, 0.400 0.132, 0.145 0.836 0.033 (T); 2.47 (1.1-5.7) 0.173 
27 rs2472516 A/G 0.371, 0.388 0.472, 0.456 0.158, 0.158 0.662 0.449 0.817 
28 rs4397467 A/G 0.472, 0.513 0.419, 0.414 0.110, 0.075 0.280 0.352 0.443 
29 rs4743776 A/G 0.503, 0.502 0.402, 0.414 0.096, 0.085 0.774 0.201 0.400 
30 rs737623 G/A 0.354, 0.321 0.447, 0.486 0.200, 0.194 0.239 0.262 0.463 
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The 30 SNPs covering the complete genetic region of the ABCA1 gene (149 kb, 
average inter-marker distance of 6.8 kb) determined the linkage disequilibrium (LD) structure, 
estimated by D’ and r2 and explored haplotype associations as implemented in Haploview. 
Within the genotyped region 8 LD blocks were identified on basis of D’ and r2 values (Fig. 
27). For each of them, haplotypes were calculated as depicted in the table below (Tab. 43). 
The 2 significant markers identified in the Munich collective before were found outside of 
any block. SNP # 3 showed a slight correlation with the direct neighbor SNP # 2 (r² = 0.01, 
D’ = 0.88). No other correlation was found for SNPs # 1 or 3. None of the estimated 
haplotypes in the different blocks showed an association with AD.  
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Fig. 27: LD structure of the ABCA1 gene, including the haplotype block structure. 
Values are used to represent D’ whereas colors were used to encode r2 (D’ values of 1.0 are never shown - the box is empty; black = high r2 value, white = low r2 value). The 
blocks followed the haplotype block definition by Gabriel et al., (Gabriel, Schaffner et al. 2002) as implemented within Haploview 4.2.  
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Tab. 36: Haplotype blocks and frequencies for ABCA1 in the Munich collective 
Haplotype ID Sequence Frequency (Case/Control) P-values 
Block 1 
1.1 GTG 0.730, 0.739 0.683 
1.2 ATA 0.127, 0.134 0.687 
1.3 GCA 0.133, 0.110 0.202 
Block 2 
2.1 AA 0.872, 0.893 0.231 
2.2 GC 0.071, 0.061 0.466 
2.3 GA 0.056, 0.045 0.354 
Block 3 
3.1 AGGG 0.611, 0.614 0.909 
3.2 ATAA 0.140, 0.134 0.769 
3.3 AGAA 0.137, 0.124 0.482 
3.4 GGGG 0.070, 0.075 0.725 
Block 4 
4.1 GG 0.533, 0.556 0.401 
4.2 GA 0.304, 0.313 0.715 
4.3 AA 0.158, 0.130 0.141 
Block 5 
5.1 CG 0.662, 0.638 0.360 
5.2 CA 0.322, 0.333 0.646 
Block 6 
6.1 CC 0.614, 0.614 0.997 
6.2 CT 0.256, 0.259 0.904 
6.3 GT 0.128, 0.125 0.844 
Block 7 
7.1 GT 0.435, 0.457 0.414 
7.2 GC 0.336, 0.340 0.886 
7.3 AT 0.224, 0.198 0.229 
Block 8 
8.1 AG 0.573, 0.562 0.666 
8.2 GA 0.290, 0.290 0.991 
8.3 AA 0.134, 0.146 0.506 
 
 
The final analysis performed in the Munich cohort was a 2- and 3-marker sliding 
window to identify SNPs that contributed association signals (Fig. 28).  
Two haplotypes, both including SNP # 1 which had shown association before, yielded 
significant p-values. The strongest association was observed in the 3-marker haplotype 1.2, 
also including the other formerly significant SNP # 3, generated by SNPs # 1-3 (p = 0.025, 
frequency 33.2%). Additionally, the 2-marker haplotype 1.2 generated by SNPs # 1-3 (p = 
0.027, frequency 36.5%). For both haplotypes the 2- or 3- marker haplotype associations were 
clearly higher than those of the single markers. Another significant 3- marker haplotype was 
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observed spanning SNPs # 16-18 (haplotype 16.3) with a weak p-value of 0.047 and a low 
frequency of 8.2% only. None of the involved markers had shown single marker associations.  
Detailed results from the 2- and 3-marker sliding window approach are depicted in the 
Appendix. (§ 7.4.4). Haplotypes with frequencies below 5% were not taken into account, due 
to their unlikely occurrence. 
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Fig. 28: Sliding window analysis of 2- and 3-marker haplotypes for ABCA1 
Red circles represent -log p values for single marker SNPs genotyped. Lines between solid squares represent the -log p value of 2-marker haplotypes. Lines between solid 
triangles mark -log p values for 3-marker haplotypes. All 2- and 3-marker haplotypes as calculated with Haploview. The dotted lines at a -log p value of approximately 1.3 
demarcate the threshold of p = 0.05. Numbers correspond to those assigned to SNPs by Haploview.  
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5.3.1.2 Replication of Association Results in Independent Studies 
 
Based on the analysis of the Munich cohort two SNPs (# 1 and 3) were chosen for 
replication in independent studies. In the scope of this study a large Swedish case-control 
cohort (SWE, N = 883) and a German discordant sib-pairs cohort (N = 735) were available. A 
subsequent pooling analysis of the Munich and Swedish cohort (pooled = MUC + SWE, N = 
1611) was performed to increase statistical power. 
In the Swedish cohort association signals were replicated for both SNPs with clearly 
stronger associations than found in the Munich cohort (# 1, rs2515606: p < 0.001 and # 3, 
rs2066720: p = 0.002). SNP # 1 was even found to have a strong association signal (p < 
0.001) in the pooled analysis, whereas SNP # 3 could not be replicated. Stratification of the 
Swedish as well of the pooled sample confirmed association of SNP # 1, in both (the EOAD 
and the LOAD) sub-collectives, except with weaker signals. SNP # 3 had a slightly weaker 
association signal after stratification, but limited to the EOAD group of the Swedish 
collective. All risk alleles found before within the Munich cohort were confirmed. Detailed 
results of the genotypic tests are depicted in Tab. 37. Results of allelic test are shown in the 
Appendix (§ 7.3.4, Tab. 55). 
Analysis of SNPs in the sib-pairs cohort failed to replicate signals for both SNPs (# 1 
and # 2). Results of the tests are depicted in Tab. 37. 
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Tab. 37: Results of replication for selected SNPs of ABCA1 in independent studies – part 1 
 
SWE (N=883) Pooled Population (MUC+SWE) (N=1611) 
AD affection genotypic p-values for major allele unless otherwise noted 
(associated allele); OR (95%CI) with covariates (sex and onset) 
AD affection genotypic p-values for major allele unless otherwise noted (associated 
allele); OR (95%CI) with covariates (sex, onset, population) # 
SWE complete            
(N=883) 
EOAD subcollective 
(N=220) 
LOAD subcollective 
(N=661) 
pooled complete       
(N=1611) 
EOAD subcollective 
(N=501) 
LOAD subcollective 
(N=1105) 
1 <0.001 (C); 2.08 (1.4-3.0)  0.021 (C); 2.33 (1.1-4.8) 0.005 (C); 1.93 (1.2-3.1) <0.001 (C); 1.83 (1.4-2.4) 0.004 (C); 2.08 (1.3-3.4) 0.005 (C); 1.66 (1.2-2.4) 
3   0.002 (G); 2.03 (1.3-3.2) 0.003 (G); 3.42 (1.5-7.8) 0.084 0.055 0.090 0.168 
 
 
Tab. 37: Results of replication for selected SNPs of ABCA1 in independent studies – part 2 
 
p values 
# SNP 
fbat100 fbat010 
1 rs2515606 0.927 0.713 
3 rs2066720 0.115 0.271 
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5.3.1.3 Statistical Analyses of Clinical Measures for ABCA1 
 
For the complete set of 30 SNPs linear regression analysis of clinical measures was 
performed, testing association between genotypes of the SNPs and age at onset and the scores 
on the Mini-Mental State Examination (MMSE) within the whole Munich collective. Note 
that MMSE scores were only available for 416 of the subjects. Age at onset and gender were 
included as covariates during analysis to rule out results only affected by a specific sub-
population. None of the SNPs presented with significant associations. Detailed results are 
reported in the Appendix (§ 7.3.4, Tab. 56 and Tab. 57).  
 
5.3.1.4 Functional Analyses for ABCA1 in Brain Samples 
 
In order to determine possible functional effects of the affected SNPs on ABCA1 
expression, the same preliminary functional approach as used for APP before was performed 
in 20 brain samples (12 cases, 8 controls).  
As for the replication studies, based on the analysis of the Munich cohort, the two 
SNPs that had shown association before (SNPs # 1 and 2), were chosen for analysis of 
possible functional effects.  
The formerly identified associations of genotypes in ABCA1 with AD were also tested 
in the small study cohort of 20 brain samples. One of the SNPs (# 3, rs2066720) confirmed 
the formerly found association in plasma samples in the analyzed brain samples when tested 
recessive for the major allele (t-test, p = 0.002). ANOVA analysis yielded no significant 
results for the two tested SNPs. Results are presented in the table below (Tab. 38). Due to the 
small sample size (n = 20) and the explorative character of the functional study, the following 
investigations were undertaken anyways, but results have to interpreted with caution. 
 
Tab. 38: Results of statistical analysis of ABCA1 genotypes in brain samples 
# SNP 
p-values from ANOVA 
(association between 
genotype and phenotype) 
p-values 
from t-test 
(recessive 
for major 
allele) 
1 rs2515606 0.520 0.731 
3 rs2066720 0.139 0.002 
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5.3.1.4.1 Gene Expression Analyses for ABCA1 in Brain Samples 
 
Using control RNA of defined concentration (Applied Biosystems FirstChoice® 
Human Brain Reference RNA, 1 mg/mL, Part No. AM6050), a calibration line was 
determined from which the RNA content of the samples was calculated (Fig. 29). 
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Fig. 29: Calibration line for determination of ABCA1 mRNA levels. 
 
Gene expression analysis in AD and control brains revealed SNP # 3 to have a 
significant impact on ABCA1 mRNA levels, where the G allele was associated with a higher 
expression (All samples: GG (n=15) 9.44±10.8 Arbitrary Units (AU), GA/AA (n=3) 
0.50±0.34 AU; p = 0.006). SNP # 1 yielded no associations. The individual results for 
ANOVA analysis and t-test for recessive major of both SNPs are presented in the table below 
(Tab. 39). 
 
Tab. 39 Results of statistical analysis of gene expression of ABCA1 
# SNP p-value from t-test - association between genotype and APP mRNA level (recessive for major allel) 
1 rs2515606 0.316 
3 rs2066720 0.006 
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5.3.2 Analysis of SNPs from LIPC 
 
The LIPC gene is located in chromosomal region 15q21-q23 and contains 9 exons 
spanning 158 kilobases. Since hepatic triglyceride lipase (LIPC), much like the major genetic 
risk factor for Alzheimer’s disease (AD), apolipoprotein E (ApoE), is associated with altered 
lipid metabolism, it is a potential functional candidate for AD risk. 
The potential association of the LIPC gene in AD was thoroughly investigated by 
utilizing a fine mapping approach across the entire LIPC gene in a large German case-control 
series.  
After several thorough databank researches, 30 SNPs were selected (Tab. 40). From 
these SNPs, 25 could be confirmed to be polymorph in the Munich collective, achieved a 
sufficient genotype frequency (>80%) and showed no deviation from the HWE in controls 
(Tab. 41 and Fig. 30).  
5   Results 
126 
Tab. 40: Selected SNPs from the LIPC gene.  
SNPs that yielded insufficient genotype frequencies (<80 %), significant deviations from HWE and 
minor allele frequencies <0.001 were not taken into account for the statistical evaluations. SNPs passing all 
aforementioned criteria are highlighted in bold font. Alleles are reported in alphabetical order as found on 
http://snpper.chip.org. 
 
 
SNP ID NCBI SNP Position NCBI Alleles Role 
rs17468168 56501641 C/T Promoter 
rs4774297 56507723 A/C Promoter 
rs1800588 56510967 C/T Promoter 
rs17190517 56516436 C/T Intron 
rs261341 56518859 A/G Intron 
rs483140 56524427 C/G Intron 
rs261336 56529710 C/T Intron 
rs3825776 56534122 A/G Intron 
rs10518976 56538493 A/T Intron 
rs10518978 56543465 C/T Intron 
rs6494011 56547936 C/G Intron 
rs1968685 56555046 C/G Intron 
rs6494013 56560978 C/G Intron 
rs1869137 56565704 C/G Intron 
rs4561401 56571369 C/T Intron 
rs1973028 56578646 A/G Intron 
rs1869144 56584592 A/G Intron 
rs2899631 56589377 C/G Intron 
rs4774302 56595870 C/T Intron 
rs2899632 56599161 A/G Intron 
rs12899928 56606843 C/G Intron 
rs4775072 56613005 C/T Intron 
rs1971544 56616743 C/G Intron 
rs6078 56621285 A/G Coding exon 
rs2242064 56626564 G/T Intron 
rs871804 56631506 A/G Intron 
rs2414594 56638063 A/G Intron 
rs3829462 56640371 G/T Coding exon 
rs6074 56648255 A/C Coding exon 
rs4774308 56653448 C/T 3' UTR 
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Fig. 30: Schematic of the LIPC gene.  
The positions of the analyzed SNPs (shown with rs numbers) and exons in the LIPC gene are shown. Exons are marked with green bars on the forward strand from left to right. 
The arrow shows direction of transcription. 
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Single marker and haplotype associations were explored. Single marker analysis within 
Haploview of the 25 LIPC SNPs (Tab. 41) revealed no allelic associations with AD. One SNP 
within LIPC presented with a weak genotypic association with AD (rs483140; p=0.039), 
although this did not survive correction for multiple testing. No further significant association 
for genotypic single markers was found (Tab. 42). The major allele frequencies (Tab. 41), as 
well as genotype frequencies (Tab. 42) were comparable in cases and controls and showed no 
notable differences.  
Also no significant association when stratifying the patient sample in the subgroups of 
EOAD and LOAD observed (according to the age at onset; see Appendix, § 7.3.5, Tab. 58). 
 
Tab. 41: Results from allelic tests for LIPC gene.  
Allelic associations were tested for significance using χ2-tests, all as implemented in Haploview version 4.2. All 
shown SNPs yielded genotype frequencies of at least 80 %, no significant deviation from HWE and minor allele 
frequencies had to be at least 0.001.  
 
# SNP Associated 
allele 
Major allele 
frequency MUC 
complete        
(cases, controls) 
Allelic p-
values 
1 rs4774297 A 0.537, 0.535 0.938 
2 rs1800588 T 0.773, 0.805 0.155 
3 rs17190517 C 0.557, 0.542 0.597 
4 rs261341 A 0.708, 0.719 0.643 
5 rs483140 G 0.736, 0.692 0.068 
6 rs261336 G 0.819, 0.854 0.084 
7 rs3825776 T 0.677, 0.668 0.726 
8 rs10518976 T 0.916, 0.911 0.773 
9 rs10518978 T 0.883, 0.897 0.456 
10 rs6494011 C 0.847, 0.845 0.941 
11 rs1968685 C 0.579, 0.558 0.507 
12 rs1869137 C 0.570, 0.586 0.563 
13 rs1973028 T 0.649, 0.625 0.340 
14 rs2899631 G 0.794, 0.833 0.079 
15 rs4774302 C 0.625, 0.627 0.933 
16 rs2899632 A 0.805, 0.822 0.400 
17 rs12899928 G 0.980, 0.977 0.695 
18 rs4775072 C 0.981, 0.979 0.744 
19 rs6078 A 0.962, 0.969 0.498 
20 rs2242064 G 0.685, 0.677 0.744 
21 rs871804 T 0.876, 0.883 0.661 
22 rs2414594 G 0.991, 0.983 0.169 
23 rs3829462 A 0.991, 0.984 0.266 
24 rs6074 A 0.874, 0.880 0.760 
25 rs4774308 C 0.629, 0.644 0.555 
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Tab. 42: Results from genotypic tests for the LIPC gene.  
Genotypic associations were tested for significance using a logistic regression recessive model [i.e. AA vs Aa,aa; 
where major allele is A] and are adjusted for age and gender (each SNP independently) all as implemented in 
SPSS. 
Genotype Frequency 
SNP 
Alleles 
(Major/Minor) 
Cases 
AA        Aa        aa 
Controls  
AA        Aa        aa 
p-values 
rs4774297 A/C 0.307 0.458 0.235 0.297 0.472 0.231 0.664 
rs1800588 C/T 0.604 0.339 0.058 0.662 0.285 0.053 0.130 
rs17190517 C/T 0.327 0.459 0.214 0.336 0.412 0.252 0.731 
rs261341 A/G 0.509 0.397 0.094 0.536 0.366 0.098 0.491 
rs483140 C/G 0.532 0.408 0.06 0.458 0.468 0.074 0.039 
rs261336 C/T 0.664 0.311 0.025 0.736 0.236 0.028 0.055 
rs3825776 A/G 0.462 0.429 0.109 0.437 0.462 0.101 0.571 
rs10518976 A/T 0.834 0.162 0.005 0.827 0.166 0.007 0.978 
rs10518978 C/T 0.794 0.179 0.027 0.819 0.155 0.025 0.853 
rs6494011 C/G 0.716 0.260 0.023 0.704 0.282 0.014 0.733 
rs1968685 C/G 0.347 0.464 0.189 0.345 0.427 0.228 0.904 
rs1869137 C/G 0.303 0.533 0.163 0.340 0.486 0.174 0.375 
rs1973028 A/G 0.427 0.446 0.127 0.394 0.463 0.143 0.361 
rs2899631 C/G 0.654 0.279 0.066 0.696 0.274 0.03 0.364 
rs4774302 C/T 0.395 0.462 0.143 0.375 0.505 0.12 0.522 
rs2899632 A/G 0.644 0.319 0.037 0.678 0.287 0.035 0.286 
rs12899928 C/G 0.963 0.034 0.002 0.955 0.045 0.000 0.581 
rs4775072 C/T 0.965 0.033 0.002 0.958 0.042 0.000 0.625 
rs6078 A/G (V95M) 0.926 0.072 0.002 0.937 0.063 0.000 0.600 
rs2242064 G/T 0.476 0.418 0.106 0.444 0.465 0.091 0.431 
rs871804 A/G 0.77 0.207 0.023 0.784 0.199 0.017 0.794 
rs2414594 A/G 0.982 0.018 0.000 0.965 0.035 0.000 0.336 
rs3829462 G/T (F356L) 0.979 0.018 0.002 0.969 0.031 0.000 0.591 
rs6074 A/C 0.775 0.200 0.025 0.782 0.196 0.021 0.957 
rs4774308 C/T 0.398 0.464 0.138 0.419 0.455 0.126 0.544 
 
On basis of the 25 SNPs covering the complete genetic region, the LD structure for the 
LIPC gene was determined. The average inter-marker distance was calculated to be 6.1 kb. It 
could be shown that the entire genomic region at LIPC, from the promoter SNP rs4774297 
down to rs4774308, located downstream from LIPC, showed considerable variability in D’ 
values, thereby indicating a large DNA region of variable recombination. Likewise, the r2-
values for the pairwise comparisons are also highly variable, hence suggesting the presence of 
numerous marker blocks across the entire LIPC region Within the genotyped region, a total of 
6 LD blocks were identified on basis of the D’ and r2 values (Fig. 31). For each of the the 
blocks haplotypes were calculated as depicted in the table below (Tab. 43). The rarest 
estimated haplotype of block 1 showed an association with AD (p-value 0.025), but with a 
frequency of only 4.8% in cases and 7.6% in controls.  
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Fig. 31: LD structure of the LIPC gene, including the haplotype block structure. 
Values are used to represent D’ whereas colors were used to encode r2 (D’ values of 1.0 are never shown - the box is empty; black = high r2 value, white = low r2 value). The 
blocks followed the haplotype block definition by Gabriel et al., (Gabriel, Schaffner et al. 2002) as implemented within Haploview 4.2.  
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Tab. 43: Haplotype blocks and frequencies for LIPC in Munich collective 
 
Haplotype ID Sequence Frequency (Case/Control) P-values 
Block 1 
1.1 ACTGGA 0.414, 0.426 0.647 
1.2 CCCGCA 0.164, 0.172 0.680 
1.3 CTCAGG 0.142, 0.116 0.150 
1.4 CCCACA 0.048, 0.076 0.025 
Block 2 
2.1 TTCCCCT 0.307, 0.299 0.741 
2.2 CTCCGGC 0.242, 0.255 0.568 
2.3 TTTGGGT 0.139, 0.137 0.918 
2.4 TACCCCT 0.079, 0.081 0.913 
2.5 TTCCCGC 0.067, 0.068 0.960 
Block 3 
3.1 CT 0.626, 0.629 0.898 
3.2 GC 0.207, 0.176 0.142 
3.3 CC 0.167, 0.195 0.174 
Block 4 
4.1 GC 0.560, 0.560 0.999 
4.2 TC 0.316, 0.324 0.750 
4.3 GT 0.125, 0.117 0.651 
Block 5 
5.1 GA 0.991, 0.983 0.169 
Block 6 
6.1 CT 0.503, 0.524 0.439 
6.2 CC 0.371, 0.356 0.562 
6.3 AT 0.126, 0.120 0.742 
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Results of the 2- and 3-marker sliding window approach to identify SNPs that 
contributed association signals are depicted in the Figure below (Fig. 32). Detailed results 
from the 2- and 3-marker sliding window approach are depicted in the Appendix. (§ 7.4.5). 
Haplotypes with frequencies below 5% were not taken into account, due to their unlikely 
occurrence. One significant marker peak was observed spanning SNPs # 14-17. The strongest 
association was observed in the 3-marker haplotype 14.4 generated by SNPs # 14-16 (p = 
0.0065, frequency 7.1%). None of the involved markers had shown single marker 
associations. The haplotypes including SNP # 5, yielding a significant genotyping p-value 
before, yielded no significant results. 
Since the significant observations did not emerge for the same SNPs in different 
approaches, no replication in independent studies was performed. 
Since occurrence of this very rare haplotype is too unlikely, the result can not be 
regarded as a confirmation of the former association of SNP # 5. Since no other approach 
(sliding window, stratification, allelic association) confirmed the finding (also sliding window 
was the only observation of significance in the region spanning SNPs # 15-17), replication in 
another sample was not carried out. Moreover the p-value is only borderline significant (only 
slightly below 0.05). Additionally, literature does not suggest positive findings and LIPC is 
not directly involved in AD pathogenesis. 
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Fig. 32: Sliding window analysis of 2- and 3-marker haplotypes for LIPC 
Red circles represent -log p values for single marker SNPs genotyped. Lines between solid squares represent the -log p value of 2-marker haplotypes. Lines between solid 
triangles mark -log p values for 3-marker haplotypes. All 2- and 3-marker haplotypes as calculated with Haploview. The dotted lines at a -log p value of approximately 1.3 
demarcate the threshold of p = 0.05. Numbers correspond to those assigned to SNPs by Haploview. 
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6 Discussion 
 
Complex diseases like Morbus Alzheimer can not be traced back causally to one 
mechanism, but result from the interaction of different genetic, environmental and lifestyle 
dependant risk factors (Brown, Lockwood et al. 2005). Mutations in the genes PS1, PS2 and 
APP cause an increase in Aβ42 production, and therefore increase the deposit of amyloid 
plaques, one of the most important characteristics of AD (Ozturk, Minster et al. 2007). 
Another indication for an association with AD is constituted by numerous studies, proofing 
the ε4 allele in the ApoE gene to be the strongest risk factor for LOAD and sporadic forms of 
AD, respectively (Rebeck, LaDu et al. 2006). 
It can be assumed, that in addition to the above mentioned genetic risk factors many 
other genes or their mutations contribute to the development and course of Alzheimer´s 
disease. Preferentially, genes were analyzed, whose mutation could, according to nowadays 
knowledge, trigger the neuro-pathological process typical for AD or could influence the 
course of disease. Since former studies have proven a correlation between occurrence of AD 
and presence of Aβ (Hardy and Higgins 1992), focus of the presented work was the APP gene 
and genes involved in the processing of APP and Aβ formation. Additionally, genes involved 
in the lipid metabolism functionally similar to the major genetic risk factor for Alzheimer’s 
disease, apolipoprotein E (ApoE), were taken into consideration during selection of candidate 
genes. Moreover, results from genome-wide linkage studies (Myers, Holmans et al. 2000; 
Lee, Cheng et al. 2006) were taken into account for selection of candidate genes, tested for 
their association with AD and subsequently functionally characterized.  
Subsequently, quality of the data, study design, gained results of association and 
functional analyses, as well as relevance of the gained data for the development of Morbus 
Alzheimer are discussed. 
 
 
6.1 Advantages and Disadvantages of the Selected Study Designs 
 
Disease relevant genes can be identified by means of association studies. For this 
purpose two approaches can be used: the case-control and the family based study design. The 
most common study type in epidemiology is the case-control study with independent and 
unrelated samples (Lewis 2002). In the present work a case-control association study within a 
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German population was carried out, whose results served as starting point for further analyses. 
For exclusion of possible erroneous association results, which can occur in a case-control 
study, significant results were validated in another case-control study, as well as in a sib 
study. Both approaches have advantages and disadvantages. 
Genetic markers (SNPs) are usually identified by means of a case-control-study, 
resulting in significant differences regarding allele and genotype frequencies between affected 
individuals (cases) and independent healthy controls (Lewis 2002). For obtaining the same 
information in a sib pair approach, healthy siblings of affected individuals are included as 
control group (Whittemore and Tu 2000). For the investigation of disease with a long latency, 
as well as for clarification of reasons for an acute disease outbreak, case-control-studies are an 
important resource. In comparison to sib pair studies, case-control-studies are not as laborious 
and therefore cost-saving. Hence, examination of a large sample size within relatively short 
time is possible. However, careful selection of adequate controls is of utmost importance. 
Cases and controls have to be matched dependent on some major characteristics (same 
population group, age, gender, socio-economic status, etc.), so that both groups are 
comparable (Lewis 2002). Thereby, structural differences in the matching variables are 
eliminated, although stratification problems can not be completely precluded. Stratification is 
the observation, when cases and controls show a diversity in allele frequencies for markers, 
due to population structures which can not be ascribed to the disease. This can often lead to 
erroneous association results, which later may not be confirmed by independent experiments 
(Schork, Fallin et al. 2001). Population effects were minimized by stratification using 
appropriate tests. A regression analysis was chosen, since population characteristics, such as 
gender and age at onset, can be incorporated as covariates during examination. Additionally, 
deviations from the Hardy-Weinberg-equilibrium (HWE) within the control group and 
differing genotype frequencies between study cohorts can be a hint for stratification effects 
and was therefore calculated (Bickeboller and Fischer 2007). 
To rely entirely on data gained from case-control-studies has also disadvantages. Only 
one outcome can be examined at a time (Lewis 2002). Moreover, no prevalence or incidence 
estimation can be ascertained from a case-control approach, since the case / control ratio is 
defined by the amount of subjects included in the study and not by the frequency of cases in 
the population. Major sources for appointment of subjects to “cases” or “controls” are 
patient´s records and interviews with patients and their relatives. A differing ability of 
memory of cases and controls can cause a falsification, which is called “recall bias” (Brown, 
Lockwood et al. 2005). Another form of information bias can occur in those studies, where 
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not the affected persons are questioned concerning anamnesis of disease, but their family 
members and persons in support. Often, no detailed information about exposition, 
environmental and life style conditions are available in those cases (substitute-interview bias). 
An important advantage of the sib pair approach is the common genetic background of 
the participants. Statistical analysis of genotypes is conducted via „Sib Transmissions-
Disequilibrium Test“ (S-TDT) (Spielman and Ewens 1998), a modified version of the 
„Transmissions-Disequilibrium Tests“ (TDT) (Spielman, McGinnis et al. 1993) (see § 2.1). 
For this purpose, genotypes of the affected persons are compared directly to those of their 
healthy siblings. Therefore, falsifications, developed by stratified populations, can be avoided. 
Unlike case-control studies, accomplishment of this study type is costly in terms of time, 
since at least two family members – one affected and at least one healthy brother or sister – 
have to be recruited. In practice, extensive documentation of kinsmanlike relations of study 
participators forms another problem. Since only those siblings with demonstrated differences 
in allele frequencies can be incorporated in the statistical association analysis, a very low 
statistical power is the result (Whittemore and Tu 2000). In contrast, information about allele 
frequencies from all the subjects can be used in case-control studies. 
As a basis for the presented work, a case-control study design was utilized. Therefore, 
incorporation of a necessary great number of subjects into the study was performed, resulting 
in a sufficiently high power. Recruiting of informative sib pairs was hindered, because of the 
late age at onset for AD. Nevertheless, for exclusion of optionally occurring stratification 
problems, significant association results from the Munich sample were tested in two 
additional Caucasian samples – in an independent case-control cohort from Sweden and in 
one sib pair cohort from Germany.  
 
 
6.2 Is the Selected Study Approach still Up-to-date? 
 
The chosen approach, described and discussed in the paragraph above, was the high-
level choice when the practical part of this study was started in 2005. Meanwhile, analyzing 
methods, technologies and especially throughput have been improved. Nowadays, a different 
approach would have been used: a genome-wide association study (GWAS). In the formerly 
applied method typically few or at most some hundred markers located in each others vicinity 
could be analyzed at once. In contrast, a GWAS enables analysis of up to 105 – 106 SNPs 
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distributed over the whole genome at the same time, hence representing a superb approach for 
multi-factorial diseases involving several genes, such as Alzheimer´s Disease (AD). Another 
advantage of GWAS is, that it can also be carried out, when no candidate regions from 
linkage studies are known (Bickeboller and Fischer 2007). 
 
 
6.3 Summary and Discussion of the Main Results 
 
Genotyping data for the individual genes were analyzed by means of relevant 
statistical tests as described before (see § 2.16) and significant association results were 
replicated in independent studies. Although it is commonly used for association studies, 
multiple testing of the significant results according to the Bonferroni method was abandoned. 
This is due to the fact that the Bonferroni method decreases the α-significance level, so that 
the cumulative (and not the individual) significance threshold is 0.05. In this approach the 
significance threshold would have been divided by the total number of tested SNPs for each 
gene, e.g. decreasing the threshold for APP to 0.001 (= 0.05 / 39 SNPs). The disadvantage of 
such α adjustments is the decline of power of the tests. The probability to discover actually 
existent differences by multiple testing decreases with the amount of hypotheses to be tested. 
Thus, only highly significant results can lead to rejection of the null hypothesis.  
Since AD is a multifactorial disease and the genes that were investigated in the present 
study are none of the main genes, statistical results are unlikely to be highly significant, 
because the disease is probably not only triggered by one SNP variant alone, but by a 
combination of different variants. Moreover, due to the relatively high throughput, the amount 
of tested SNPs is very high and the significance level would hence be accordingly low. 
Therefore, multiple testing is not applicable for this approach. The crucial principle for the 
verification of a true association between polymorphisms and phenotype for complex diseases 
as AD, is the replication of the statistical significant results in independent cohorts. 
In the present work several SNPs yielded statistical significant associations (p-value < 
0.05), which would have not survived multiple testing. Nevertheless, validity of the 
significant findings from the screening sample could be confirmed by means of successful 
replication in independent study cohorts, which is of utmost importance and the better 
approach. 
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In the following paragraph the results are also compared to those from other groups. 
Discrepancies between the results from different studies are mainly suggestive of the 
heterogeneity of complex genetic diseases. Different study populations can differ in sample 
size, study designs, mean age at onset of subjects, gender distribution within the cohort, allele 
frequencies and correlation structures. In addition, study populations are exposed to different 
environmental conditions. All that are reasons for unequal results and can be quantitatively 
brought to one result by a meta-analysis (Crowther and Cook 2007). 
 
6.3.1 Summary and Discussion of Results for APP 
 
The APP gene represents a strong positional and functional candidate for AD risk on 
many levels. Linkage studies have provided strong evidence for a susceptibility loci 
potentially predisposing to LOAD in the vicinity of the APP gene on chromosome 21 (Myers, 
Wavrant De-Vrieze et al. 2002; Olson, Goddard et al. 2002; Blacker, Bertram et al. 2003). 
APP is the parent protein from which Aβ is derived and coding mutations in APP or 
duplications of the gene have been associated with EOAD (Goate, Chartier-Harlin et al. 
1991). Furthermore, mutations in other familial AD genes, such as PSEN1, lead to altered 
APP metabolism (Pastor and Goate 2004) and APP locus duplication in trisomy 21 can result 
in elevated levels of circulating Aβ peptide (Schupf, Patel et al. 2001). Additionally, complete 
or partial trisomy of chromosome 21 leads to Down Syndrome including AD pathology, 
however only when the APP gene is present in three copies (Rumble, Retallack et al. 1989; 
Prasher, Farrer et al. 1998). All this evidence suggests that factors such as genetic 
polymorphisms, that impact upon APP processing, may exacerbate the risk for AD. In this 
study we have attempted to comprehensively investigate the genetic role of APP in AD by 
genotyping 39 SNPs covering the complete genetic region of the APP gene in a large case-
control cohort. The initial single-marker, haplotype and sliding-window analyses revealed 
association signals within two marker peak regions (SNP # 14 – 25 and # 33 – 37) spanning 
from intron 3 to 8 and intron 1, respectively. A selection of SNPs underwent replication in a 
second large independent case-control series, including a pooled analysis, as well as an 
independent sib-pairs cohort. The replication analyses confirmed signals in SNPs # 16, 17, 20, 
21, 23, 25, 35 and 36 and therefore their implication to Alzheimer´s disease. 
One SNP (SNP # 9, rs1783016) outside the aforementioned marker peak regions, 
located in intron 14, yielded a slight association in the early onset AD sub-collective of the 
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Munich cohort, which was confirmed when tested for association with clinical measures. 
Identification of genetic factors, which induce an early onset of disease are of special interest. 
The associated allele of SNP # 9 was coupled with an approx. 2 year later age of onset; 
however it was also associated with a lower score on the MMSE, suggesting a more rapid 
decline in cognition in carriers of the rs1783016-G allele. 
SNPs from the peak regions underwent further analyses in brain samples to ascertain 
the functional implications of polymorphisms across the APP gene on the transcriptional level 
(gene expression), the translational level (Western Blot) and the post-translational level 
(ELISA for Aβ isoforms). Effects on APP expression was apparent in one SNP, (# 25, 
rs1041420) located in intron 3. In the case of SNP # 25 the risk allele (T) was associated with 
elevated APP mRNA levels in the brain; however no significant difference was observed with 
respects to altered APP protein levels or soluble Aβ levels in the same samples. These 
findings suggest that the rs1041420-T risk allele might contribute to the development of AD 
due to altered amounts of APP substrate and not due to altered APP processing, as seen in 
APP gene duplication (Schupf, Patel et al. 2001) and trisomy21 (Rumble, Retallack et al. 
1989; Prasher, Farrer et al. 1998). 
Although none of the samples tested on the Western blot showed significant 
differences, an association can not be ruled out. The applied assay may not have enough 
sensitivity to detect existing density distinctions. Nevertheless, the Western blot approach 
confirmed the clear elevated presence of Aβ in brain samples from affected subjects in 
comparison to healthy subjects, where no Aβ was present (Hardy and Selkoe 2002). 
Another observation during functional analysis was made for SNPs # 35 and # 36 
(rs6516727 and rs2830099), where total Aβ levels were lower in carriers of the risk alleles in 
the brain samples, but no significant associations were observed for APP mRNA levels. The 
observed Aβ levels seem to be counterintuitive, since one would expect higher Aβ levels in 
carriers of the risk allele. This observation may be explained by the fact that only soluble 
(unbound) Aβ can be measured by the applied ELISA and the majority of present Aβ42 may 
already have formed plaques in the affected brains. Moreover, an association in the same 
direction as for total Aβ was made for Aβ40. This also suggests, that the protective allele 
favors the formation of the soluble Aβ40, which does not form neuritic plaques (Verdile, 
Fuller et al. 2004). Therefore one might nevertheless argue, that the risk alleles (rs6516727-T 
and rs2830099-G) are rather associated with altered processing than higher substrate levels, 
since no affect on the gene expression was observed. Moreover, the small number of brain 
 6   Discussion 
140 
samples did not mirror the significant association of the genotypes and the phenotypes found 
in the Munich and Swedish case-control cohorts, another plausible explanation why the 
results seem not to fit perfectly. In another approach, SNP # 36 revealed a significant 
association of homozygosity of the major allele (G) with elevated CSF Aβ42 levels in a set of 
85 cerebrospinal fluid (CSF) samples from AD patients, fitting to the lower Aβ levels that 
were found in carriers of this allele in brain samples (Bouwman, Schoonenboom et al. 2008).  
Overall, the applied functional approach was well-chosen and is applicable for our 
experiments, since it can investigate the effect of the SNP variants on different stages 
(transcriptional, translational and processing level). Therefore, the implication of the present 
allele on altered APP expression or altered processing can be discovered. The fact, that the 
ELISA applied in brain samples can only detect soluble forms of Aβ combined with the small 
sample sizes, suggest that further study is required for confirmation of the results, in 
particularly the measurement of both soluble and insoluble fractions of Aβ42 in larger sample 
sizes. Moreover, all performed experiments in brain samples need to be repeated in a greater 
collective, since a too small sample size harbors the risk of introducing a bias due to random 
allele occurence or technical problems, which may not be representative of the real population 
structure. 
From the data analysis performed in the scope of this study, it is assumed, that 
common variations within the APP gene contribute to the development of AD, due to 
increased APP expression or plaque formation. 
There has previously been only one major study of polymorphisms across the entire 
APP gene (Nowotny, Simcock et al. 2007). Unlike the current study this prior study found no 
evidence for association with LOAD for either single SNPs or haplotypes in a non-stratified 
case-control cohort and only a weak evidence of association in an ApoE ε4 positive subset. 
The current study overlapped the prior study in seven instances and in all but one case the 
same association signal was observed in the non-stratified cohort. In six of these SNPs (SNP # 
14, 19, 21, 28 and 29 in the present study) no association was observed in both studies. 
However, in two cases, SNP # 17 (rs2830012) and SNP # 26 (rs2830046), association results 
differed in the two studies. For SNP # 26 (rs2830046), a weak association signal was 
observed for the study of Nowotny, when stratified by ApoE genotype (present in ε4 carriers 
only), whereas no such observation was made in our Munich collective. The other exception 
was observed for SNP # 17 (rs2830012), which was present with a weak association signal in 
the pooled analysis of this study and was not associated in the prior study of Nowotny and co-
workers. Correlation structures were comparable in both studies with LD blocks defined in 
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the same regions. A conservation of LD patterns across different European samples had been 
observed by Mueller and co-workers (Mueller, Lohmussaar et al. 2005). The collective used 
by Nowotny was no European sample, but a Caucasian sample from the Washington 
University Hospital. Therefore, our observation suggests a conservative LD structure in the 
region of the APP gene on chromosome 21q21 not only throughout different European 
samples, but also throughout Caucasian samples in general.  
The lack of association signals observed in the prior study was suggested to be 
possibly a result of selection criteria excluding individuals most likely to carry a LOAD risk 
factor in the APP gene, in particularly a recent history of a stroke. However, this exclusion 
criterion was also applied during the recruitment process of this study. A second caveat of the 
prior study was that it was designed to test whether common variations in APP explain any 
risk for AD and thus it could not rule out the possibility that multiple rare variants in APP 
may be responsible, as suggested by another study (Theuns, Brouwers et al. 2006). Likewise, 
this current study cannot rule out additional rare variants being associated with AD; however, 
the association signals that were observed, were located in SNPs with a minor allele 
frequency between 20 to 30%. 
In summary, this study is one of the two largest and most comprehensive analyses of 
the APP gene, as a risk factor for sporadic AD, reported to date. In contrast to the other study 
(Nowotny, Simcock et al. 2007) we observed evidence for an association with sporadic AD, 
which was replicated in additional sample sets. Additionally, we observed evidence to suggest 
that these SNPs have an impact on cognitive measures and both APP expression and 
processing. The applied functional approach seems to be adequate for the research of 
functional implications, although replication in a larger cohort of brain samples is of utmost 
importance to thoroughly investigate involvement of the analyzed SNPs. A sample size of 20 
does not give the statistical power to draw final conclusions, but only can give hints or show 
tendencies. Unfortunately, since brain samples from a sufficient number of AD patients and 
healthy controls are very difficult to obtain, this approach could not be undertaken during this 
study. 
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6.3.2 Summary and Discussion of Results for Genes Involved in APP Processing – 
BACE1 and ADAM10 
 
Both BACE1 and ADAM10 represent, due to their involvement in APP processing and 
location in the vicinity of suggestive linkage regions, strong functional and positional 
candidate genes for AD (Luo, Bolon et al. 2001; Blacker, Bertram et al. 2003; Scott, Hauser et 
al. 2003; Postina 2008). Using a carefully ascertained case-control sample we performed a 
whole gene approach by genotyping 38 SNPs (BACE1, n =11; ADAM10, n = 27) that covered 
the entire genomic region of both genes. Single marker as well as haplotype or sliding-
window analysis did not reveal evidence of a significant association of common BACE1 or 
ADAM10 variants with sporadic forms of AD. This current study represents the most 
thorough analysis undertaken of the ADAM10 gene. The only prior study to our knowledge 
presented data on only 4 polymorphisms, but likewise no significant association with AD was 
observed (Prinzen, Muller et al. 2005). Prior studies of the BACE1 gene have focused 
primarily on exon 5 polymorphisms, the most widely studied of which, rs638504, has shown 
inconclusive results (Bertram, McQueen et al. 2007), however, in this study we found no 
association regardless of ApoE genotype. Only one prior study, which had an approximate 
50% overlap of SNPs with the current study, used a similar approach as to that undertaken 
herein (Todd, McKnight et al. 2008) and likewise presented no associations with AD. Further, 
the LD structure for BACE1 in this study is similar to that presented in both the prior study 
and in HapMap. Likewise, the calculated LD structure of ADAM10 is very similar to that 
presented by HapMap. Whilst this study cannot categorically rule out the presence of an 
associated untyped variant, it appears unlikely due to the nature of the LD structures observed 
coupled with the number of SNPs analysed. As a power analysis revealed that, at a 
significance level of α=0.05, we had a power of 91% to detect a risk allele of 15% frequency 
mediating a relative risk of 1.6. In summary, this study, which represents the most thorough 
analysis of the ADAM10 and BACE1 genes, found no evidence for any involvement of these 
genes in AD. As such, this study, when combined with previously published data, suggests 
that common genetic variations in either BACE1 or ADAM10 are not associated with an 
increased risk to develop AD (Laws, Eckart et al. 2009). However, studies in much larger 
sample sizes would be required to categorically rule out their involvement. Another approach 
would be the investigation of epigenetic factors, pathway analysis or post-translational 
studies.  
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6.3.3 Summary and Discussion of Results for Genes Involved in Lipid Metabolism 
 
6.3.3.1 Summary and Discussion of Results for ABCA1 
 
The ABCA1 gene represents a positional and functional candidate for AD risk. The 
location of ABCA1 on chromosome 9q, which is approximately 5 Mb distal from previously 
identified loci linked with AD, makes the gene to a potential positional candidate gene 
(Pericak-Vance, Bass et al. 1998; Kehoe, Wavrant-De Vrieze et al. 1999; Bertram, Blacker et 
al. 2000; Myers, Wavrant De-Vrieze et al. 2002; Blacker, Bertram et al. 2003). The 
implication of ABCA1 in lipid metabolism and coronary artery disease (CAD), makes it also 
a reasonable functional candidate risk gene for AD. Moreover, it was shown that ABCA1 
expression can directly affect Aβ levels (Koldamova, Lefterov et al. 2003). In this study a 
whole fine mapping approach of ABCA1 over the entire gene was performed. Verification of 
former findings, which were contradictory and achievement of new insights were the aim. 
Therefore, a total of 30 SNPs were analyzed covering the complete genetic region of ABCA1 
in a large case-control cohort. The initial single-marker, haplotype and sliding-window 
analyses revealed weak association signals for two markers in the 3’UTR region (SNP # 1, 
rs2525606 and # 2, rs2066720). Both SNPs underwent replication in a second large 
independent case-control series, including a pooled analysis, as well as an independent sib-
pairs cohort. The formerly found associations were confirmed and suggest that the rs2525606-
C allele and the rs2066720-G allele within the ABCA1 gene are involved and contribute to the 
development of AD. For SNP # 1 the confidence interval (CI, 95%) for the odds ratio (OR = 
1.53 for the C allele) was 0.9 – 2.3 in the initial Munich screening cohort. OR values below 1 
indicate a protective function of the associated allele, whereas OR valaues above 1 indicate an 
increased disease risk associated with the allele. If CI of the OR spans 1 – the border between 
risk and protective – the results can not be regarded as trustworthy. Since SNP # 1 underwent 
replication and the former findings were confirmed with a higher and therefore better OR 
(2.08) and a reliable CI (1.4 – 3.0), C can be determined as risk allele. 
Implications of the polymorphisms on ABCA1 gene expression were tested and an 
effect was apparent for SNP # 3 (rs206676) located in an intron close to the 3’UTR of the 
gene. The risk allele (G) was associated with elevated ABCA1 mRNA levels in the brain and 
seems to increase the risk for AD. This finding supports the formerly made observations by 
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Wahrle et al., where overexpression of ABCA1 reduced amyloid deposition in a mouse model 
of Alzheimer´s disease, due to elevated ApoE lipidation (Wahrle, Jiang et al. 2008). Moreover 
it was shown by Koldamova and co-workers, that a lack of ABCA1 considerably increases 
amyloid deposition in APP23 mice, due to considerably decreased ApoE brain levels 
(Koldamova, Staufenbiel et al. 2005). These mechanisms are believed to include a role for 
ApoE in Aβ clearance (Schmitz, Kaminski et al. 2000; Canevari and Clark 2007; Hirsch-
Reinshagen, Burgess et al. 2008). A possible reason could be a feed-back response that 
regulates ApoE levels and is triggered by plaque formation.  
As already discussed for the APP results, the findings of the functional analyses have 
to be interpreted with caution, due to the small number of brain samples. Repetition of those 
experiments in a larger study cohort of brain samples is of utmost importance. 
The two SNPs (# 1 and # 3) that yielded significant associations with AD in the initial 
Munich screening cohort as well as the Swedish replication were not analyzed and published 
by other groups up to now. 6 other SNPs from our thorough screening of the whole ABCA1 
gene locus found attention in literature before and were characterized with varying results. 
Most studies were carried out for the three exonic SNPs rs2230808, rs4149313 and rs2230806 
(# 5, 9 and 16 in this study) (Wollmer, Streffer et al. 2003; Katzov, Chalmers et al. 2004; Li, 
Tacey et al. 2004; Kolsch, Lutjohann et al. 2006; Shibata, Kawarai et al. 2006; Chu, Li et al. 
2007; Rodriguez-Rodriguez, Mateo et al. 2007; Wahrle, Shah et al. 2007; Wang and Jia 
2007). The negative findings of Li, Rodriguez-Rodriguez, Shibata and Wahrle for the single 
marker associations were confirmed by the present study. In contrast, Katzov et al. found 
associations with AD for rs223080 and rs2230806 in one of the four examined collectives and 
Chu and Wang found an association with AD for rs2230808. Rodriguez-Rodriguez and co-
workers had found an association signal for the haplotype generated by the three exonic SNPs 
rs2230808, rs4149313 and rs2230806, which could also not be confirmed by this study. 
Moreover, a correlation (D’ and r2) between the SNPs was not evident in this study, and 
therefore, the generation of a haplotype would not make sense. Due to the great distance 
between the different SNPs (24 and 34 kb) the results of Rodriguez-Rodriguez have to be 
taken with caution. Association results for intronic SNPs rs2777799 (# 4) and rs2575875 (# 
23) were negative in the studies by Li et al. and Chu et al., respectively, which was confirmed 
by this study. SNP rs2066718 did not yield significant results in our Munich cohort of the 
present study, but had shown association with AD in one of the three studies by Li et al. and 
in one of the four studies by Katzov et al. 
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Different ethnic groups, size and composition of the cohorts and environmental 
influences - as already discussed before - are reasons for contradictive findings for the 
different study cohorts. With the exception of the studies from Chu and Wang, which were 
performed in Chinese subjects, the studied populations were similar and consisted all 
primarily of Caucasians with Northern European heritage. Hence, it seems to be most likely, 
that the examined SNPs only contribute a very small amount to the overall risk for AD.  
In summary, this study is the largest and most comprehensive association analyses of 
the ABCA1 gene, as a risk factor for sporadic AD, reported to date. In contrast to some of the 
prior studies, but in compliance with some other formerly published studies (Wollmer, 
Streffer et al. 2003; Katzov, Chalmers et al. 2004; Li, Tacey et al. 2004; Kolsch, Lutjohann et 
al. 2006; Shibata, Kawarai et al. 2006; Chu, Li et al. 2007; Rodriguez-Rodriguez, Mateo et al. 
2007; Wahrle, Shah et al. 2007; Wang and Jia 2007) we observed no evidence for an 
association of exonic SNPs (rs2230808, rs4149313, rs2066718 and rs2230806) with sporadic 
AD. However, we found weak associations between the 3’UTR SNP rs2515606 and intronic 
rs2066720, which was replicated in additional sample sets, but was not discussed in the 
literature before.  
 
6.3.3.2 Summary and Discussion of Results for LIPC 
 
LIPC represents, due to its implication in lipid metabolism and coronary artery disease 
(CAD), a reasonable functional candidate risk gene for AD. Using a carefully ascertained 
case-control sample we performed a whole gene approach by genotyping of 25 SNPs that 
covered the entire genomic region of LIPC and determined the LD structure. Single marker as 
well as haplotype analysis did not reveal evidence of a significant association of common 
LIPC variants with sporadic forms of AD. Due to the fact that markers at LIPC show 
considerable variability in D’ and r2 values, and thus form several small LD blocks across the 
entire gene, it was important that multiple SNPs were investigated, as opposed to the a priori 
selection of relatively few SNPs as previously reported (Zhu, Taylor et al. 2008), so as to limit 
the likelihood of an untyped associated variant. Whilst this study cannot categorically rule out 
the presence of an associated untyped variant, it appears unlikely. Likewise with statistical 
power, as a power analysis revealed that, at a significance level of α=0.05, we had a power of 
91% to detect a risk allele of 15% frequency mediating a relative risk of 1.6. In summary, this 
study combined with previously published data does not provide strong evidence that 
common genetic variations of LIPC are associated with an increased risk to develop AD. Our 
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genetic findings, however, do not rule out a possible functional involvement of LIPC in the 
pathogenesis of neurodegeneration in AD (Laws, Eckart et al. 2008). 
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6.4 Outlook 
 
The association results from this work on hand and their positive replication in 
independent studies argue for an involvement of the selected SNPs from the APP and the 
ABCA1 gene with the development of Alzheimer´s disease.  
However, these findings can only be regarded as a first indication in view of the 
function of the identified candidate genes. Nevertheless, this study adds another piece to the 
complex puzzle of development of the multifactorial disease Morbus Alzheimer (AD). 
Association signals within two marker peak regions spanning from intron 3 to 8 and 
intron 1, respectively in the APP gene were revealed for AD. According functional analyses 
are necessary to confirm the association results. Within this study we observed evidence to 
suggest that the identified SNPs have an impact on cognitive measures and both APP 
expression and processing. In the next step, the already applied functional approach should be 
repeated in a larger set of brain samples. It would also be worth looking for association with 
plaque formation, not only soluble Aß. 
For ABCA1 two SNPs had yielded significant association signals in our study cohorts. 
Since association signals were weak and previous studies from other laboratories had 
contradictive findings, the association study should be repeated in a larger collective to ensure 
association. Thereafter, a detailed functional approach, similar to the one applied for APP, 
should be performed to investigate the functional impact of the polymorphisms.  
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7 Appendix 
7.1 Diagnostic Criteria for the Dementia Syndrome 
7.1.1 ICD (International Classification of Diseases and Related Health Problems) 10 
Criteria 
 
Psychopathology: 
• impairment of memory, especially in keeping new information, in severe cases also in 
remembering formerly learned information 
• additional required impairments:  
1. decline of other cognitive abilities (judgment, rationalness), both proven by medical 
history from third party as well as neuropsychological examination or quantified cognitive 
methods  
2. decrease or affect control of initiative or social behaviour 
• diagnosis is relied by presence of aphasia, apraxia or agnosia 
 
Relevance for everyday life: 
impairment of daily activities due to impairment of memory as well as due to loss of 
cognitive abilities  
 
Duration: 
impairment of memory  and other coginitive abilities shall be present for at least 6 months 
 
Criterion of exclusion: 
• no impaired consciousness 
• exclusion of other mental disorders (e.g. HIV-infection, vascular mental disorders, 
Morbus Parkinson, Chorea Huntington, normal pressure hydrocephalus), systemic 
diseases (e.g. hypothyroidism, vitamin-B12 or folic acid deficiency, hypercalemia) 
and alcohol or drug abuse 
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7.1.2 DSM IV (Diagnostic and Statisical Manual of Mental Disorders) 
 
Psychopathology: 
• impairment of memory (in keeping new information or remembering formerly learned 
information) 
• additional required impairments:  
at least one of the following: aphasia, apraxia, agnosia, impairment of executive 
abilities (planning, organizing, sorting, abstracting) 
 
Relevance for everyday life: 
the cognitive disorders cause clear disorders in the social or job-related field and show a 
considerable impairment compared to the former niveau 
 
Duration: 
no determination 
 
Criterion of exclusion: 
deficits do not just occur during delirium 
 
7.1.3 NINCDS-ADRDA (National Institute of Neurological and Communicative 
Disorders and Stroke – Alzheimer’s Disease and Related Disorders 
Association) Criteria 
 
Possible AD 
• syndrome of dementia without neurological, psychiatric or systemic diseases, which 
could cause a dementia; also for different onset and clinical course 
• additional presence of systemic or cerebral diseases, which could cause a dementia, 
but are not assumed to be the cause 
• existence of a described, progressive, severe cognitive deficit, for which no other 
explanation is found 
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Probable AD 
• clinical examination and documenatation of a dementia by means of MMSE, Blessed 
Dementia Scale or other tests 
• deficit in at least two cognitive functions 
• progressive impairment of memory and other cognitive functions 
• no impaired consciousness 
• onset between the age of 40 and 90, mostly however after the age of 65 
• absence of systemic diseases or other diseases affecting the brain, which could explain 
the progressive loss of memory and cognition 
 
Markers conformable with the disease: 
• plateaus in progression of the disease 
• associated symptoms like depression, insomnia, incontinence, hallucination, 
misperception, delution, overly verbal, emotional, physical reactions and sexual 
disruptions, progressive speech disorder 
• other neurological abnormalities including symptoms in fine motor skills like elevated 
tonicity, myoclonia and apraxia 
• epileptic seizure 
• normal liquor, normal CT and EEG appropriate to age 
 
Criterion of exclusion: 
• sudden onset 
• focal finding during physical neurological examination (e.g. hemisyndrome, 
coordination disorder at early stage) 
• epileptic seizure or apraxia  at early stage 
 
Definitive AD 
• presence of the clinical criteria for probable AD 
• histopathological finding of biopsy or autopsy typical for AD 
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7.1.4 CERAD (Consortium to Establish a Registry for Alzheimer’s Disease) Criteria 
 
Normal with regard to AD and other dementia processes 
• no anamnesis of dementia, no histopathological indication on AD and no other 
neuropathological lesions, which could cause a dementia 
• an „A“ age-based plaque score and no anamnesis of dementia 
• anamnesis of dementia without neuropathological changes, which could cause a 
dementia 
 
Possible AD 
• an „A“ age-based plaque score, anamnesis of dementia and presence or absence of 
other neuropathological lesions, which could cause a dementia 
• a „B“ or „C“ age-based plaque score, but no clinical manifestation of dementia 
 
Probable AD 
• a „B“ age-based plaque score, anamnesis of dementia and presence or absence of other 
neuropathological lesions, which could cause a dementia 
 
Definitive AD 
• a „C“ age-based plaque score, anamnesis of dementia and presence or absence of other 
neuropathological lesions, which could cause a dementia 
 
Age-based plaque score / Semiquantitative determination of the maximum density of neuritic 
plaques at hundredfold magnification:  
Tab. 44: AD diagnostic according to CERAD criteria 
Density of neuritic plaques is rated as moderate, intermediate or frequent. This density is converted into an age-
based plaques score and reported as CERAD 0, A, B or C. (0 = no histological indication of AD, A = uncertain 
histological indication of AD, B = hist histological indication of AD and C = clear histological indication of 
AD). 
Frequency of neuritc plaques age at death 
no plaques moderate intermediate frequent 
< 50 0 C C C 
50 – 75 0 B C C 
> 75 0 A B C 
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7.2 Statistics of the Used Study Cohorts 
 
Tab. 45: Statistics and composition of the Munich study cohort, including sub-collectives 
  MUC complete MUC EOAD MUC LOAD MUC ApoE4 
MUC 
nonApoE4 
N (total) 728 281 444 295 433 
N (controls) 290 139 149 64 226 
Mean age (years) 66.8 56.6 76.3 67.1 66.7 
SD (years) 12.0 6.9 6.6 11.8 12.0 
% males 44.0 44.6 43.0 42.2 44.2 
N (cases) 438 142 295 231 207 
Mean age (years) 72.2 61.8 77.2 72.0 72.5 
SD (years) 9.1 5.6 5.5 8.3 9.9 
Mean age onset 
(years) 69.0 58.4 74.1 68.6 69.5 
SD (years) 9.1 5.1 5.5 8.4 9.7 
% males 41.0 51.4 35.9 39.4 42.5 
 
Tab. 46: Statistics and composition of the replication study cohorts, including sub-
collectives 
  SWE 
SWE 
EOAD 
SWE 
LOAD pooled 
pooled 
EOAD 
pooled 
LOAD sibs 
N (total) 883 220 661 1611 501 1105 735 
N (controls) 631 126 504 921 265 653 438 
Mean age (years) 73.1 60.0 76.4 71.2 58.2 76.4 68.4 
SD (years) 8.9 0.0 6.7 10.4 5.3 6.7 10.1 
% males 39.4 36.5 40.1 40.8 40.8 40.8 41.6 
N (cases) 252 94 157 690 236 452 297 
Mean age (years) - - - 70.7 61.4 75.3 72.0 
SD (years) - - - 8.4 4.7 5.6 9.1 
Mean age onset 
(years) 67.9 61.3 71.8 68.6 59.6 73.3 71.5 
SD (years) 6.1 2.5 3.7 8.1 4.5 5.1 5.1 
% males 40.0 39.4 40.5 40.6 46.6 37.4 41.6 
 
Tab. 47: Statistics and composition of the cerebrospinal fluid samples 
N (total) 85 
Mean age (years) 66.7 
SD (years) 9.5 
Mean age onset (years) 66.0 
SD (years) 9.3 
% males 52.9 
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7.3 Results from Additional Statistical Tests Referred to but not 
Included in the Text 
7.3.1 Additional Statistical Test Results for APP 
 
Tab. 48: Results from genotypic tests for APP gene in the ApoE ε4/non ApoE ε4 
subcollectives of the Munich study cohort 
 
Genotypic test results 
AD affection genotypic p-values for major allele unless otherwise 
noted                                                     
(associated allele); OR (95%CI)with covariates (sex and onset) # SNP 
ApoE ε4 subcollective          
(N = 295) 
nonApoE ε4 subcollective       
(N = 433) 
1 rs2040124 0.796 0.996
2 rs2829955 0.050 (G); 2.15 (1.01-4.6) 0.656
3 rs6516704 0.307 0.921
4 rs6516708 0.511 0.421
6 rs373521 0.404 0.770
7 rs2070653 0.150 0.767
8 rs2829975 0.071 0.143
9 rs1783016 0.922 0.645
10 rs2829983 0.982 0.893
11 rs216781 0.648 0.594
12 rs2186301 0.797 0.203
13 rs216762 0.684 0.365
14 rs762479 0.965 0.236
15 rs9978555 0.438 0.226
16 rs9941877 0.072 0.278
17 rs2830012 0.152 0.722
18 rs2830019 0.523 0.449
19 rs768039 0.766 0.067
20 rs3787644 0.130 0.017 (C); 1.61 (1.1-2.4) 
21 rs2070655 0.847 0.094
22 rs3991 0.092 0.739
23 rs2830035 0.390 0.579
24 rs743532 0.109 0.925
25 rs1041420 0.122 0.682
26 rs2830046 0.207 0.576
27 rs8130594 0.540 0.544
28 rs2830053 0.854 0.184
29 rs2246115 0.960 0.132
30 rs2830069 0.627 0.154
31 rs462278 0.753 0.919
32 rs2830082 0.845 0.208
33 rs1788283 0.188 0.628
34 rs2830092 0.788 0.104
35 rs6516727 0.156 0.213
36 rs2830099 0.160 0.491
37 rs465984 0.732 0.981
38 rs1235885 0.189 0.674
39 rs456565  0.330 0.312
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Tab. 49: Results from allelic tests for APP gene in the Swedish and pooled study cohorts 
 
SWE (N=883) pooled Population (MUC+SWE) (N=1611) 
Allelic p-values from Haploview Allelic p-values from Haploview 
# Associated 
allele 
Major allele 
frequency 
(cases, 
controls) SWE complete 
(N=883) 
EOAD 
subcollective 
(N=220) 
LOAD 
subcollective 
(N=661) 
Associated 
allele 
Major allele 
frequency 
(cases, 
controls) 
pooled 
complete 
(N=1611) 
EOAD 
subcollective 
(N=501) 
LOAD 
subcollective 
(N=1105) 
15 T 0.971, 0.958 0.215 0.755 0.077 C 0.959, 0.960 0.946 0.602 0.683 
16 G 0.757, 0.731 0.283 0.384 0.435 A 0.711, 0.735 0.134 0.755 0.101 
17 C 0.713, 0.693 0.481 0.652 0.618 T 0.681, 0.698 0.317 0.386 0.521 
18 A 0.963, 0.955 0.673 0.782 0.380 A 0.959, 0.959 0.913 0.425 0.685 
20 T 0.650, 0.666 0.549 0.183 0.090 C 0.666, 0.649 0.328 0.011 0.570 
21 A 0.703, 0.709 0.812 0.031 0.055 C 0.709, 0.697 0.457 0.006 0.300 
22 G 0.800, 0.798 0.920 0.852 0.862 G 0.803, 0.787 0.299 0.958 0.225 
23 C 0.756, 0.748 0.761 0.311 0.518 C 0.760, 0.743 0.280 0.628 0.396 
25 T 0.109, 0.747 0.131 0.259 0.295 T 0.722, 0.752 0.058 0.293 0.131 
35 C 0.686, 0.695 0.728 0.607 0.287 T 0.703, 0.684 0.252 0.542 0.367 
36 G 0.784, 0.735 0.040 0.077 0.393 G 0.755, 0.722 0.036 0.138 0.149 
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Tab. 50: Results from linear regression tests for APP gene - association between genotypes 
and Mini-Mental State Examination (MMSE) 
 
# SNP 
Linear regression 
(association between 
genotype and MMSE 
score, using gender and 
onset as covariates) 
1 rs2040124 0.397
2 rs2829955 0.275
3 rs6516704 0.467
4 rs6516708 0.350
5 rs11549660 0.171
6 rs373521 0.890
7 rs2070653 0.136
8 rs2829975 0.990
9 rs1783016 0.018
10 rs2829983 0.873
11 rs216781 0.979
12 rs2186301 0.442
13 rs216762 0.011
14 rs762479 0.175
15 rs9978555 0.676
16 rs9941877 0.828
17 rs2830012 0.734
18 rs2830019 0.934
19 rs768039 0.547
20 rs3787644 0.815
21 rs2070655 0.781
22 rs3991 0.856
23 rs2830035 0.800
24 rs743532 0.409
25 rs1041420 0.156
26 rs2830046 0.631
27 rs8130594 0.351
28 rs2830053 0.008
29 rs2246115 0.107
30 rs2830069 0.011
31 rs462278 0.342
32 rs2830082 0.006
33 rs1788283 0.153
34 rs2830092 0.014
35 rs6516727 0.744
36 rs2830099 0.797
37 rs465984 0.303
38 rs1235885 0.424
39 rs8131261 0.125
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Tab. 51: Results from linear regression tests for APP gene - association between genotypes 
and age at onset 
 
# SNP 
Linear regression 
(association between 
genotype and age at 
onset using gender as 
covariate) 
1 rs2040124 0.447
2 rs2829955 0.897
3 rs6516704 0.653
4 rs6516708 0.705
5 rs11549660 0.392
6 rs373521 0.311
7 rs2070653 0.759
8 rs2829975 0.931
9 rs1783016 0.032
10 rs2829983 0.501
11 rs216781 0.148
12 rs2186301 0.270
13 rs216762 0.201
14 rs762479 0.296
15 rs9978555 0.273
16 rs9941877 0.925
17 rs2830012 0.981
18 rs2830019 0.799
19 rs768039 0.486
20 rs3787644 0.160
21 rs2070655 0.281
22 rs3991 0.094
23 rs2830035 0.275
24 rs743532 0.600
25 rs1041420 0.908
26 rs2830046 0.122
27 rs8130594 0.958
28 rs2830053 0.821
29 rs2246115 0.431
30 rs2830069 0.676
31 rs462278 0.837
32 rs2830082 0.907
33 rs1788283 0.161
34 rs2830092 0.782
35 rs6516727 0.362
36 rs2830099 0.242
37 rs465984 0.948
38 rs1235885 0.657
39 rs8131261 0.152
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7.3.2 Additional Statistical Test Results for BACE1 
Tab. 52: Results from allelic tests for BACE1 gene in the sub-collectives of the Munich 
study cohort 
# SNP 
EOAD 
subcollective 
(N=281) 
LOAD 
subcollective 
(N=444) 
1 rs644215 0.427 0.454
2 rs12292027 0.806 0.587
3 rs1047964 0.424 0.853
4 rs638405 0.230 0.166
5 rs507805 0.709 0.653
6 rs609332 0.954 0.268
7 rs522843 0.148 0.893
8 rs687740 0.071 0.769
9 rs473210 0.058 0.415
10 rs551662 0.799 0.771
11 rs525493 0.287 0.913
 
7.3.3 Additional Statistical Test Results for ADAM10 
Tab. 53: Results from allelic tests for ADAM10 gene in the sub-collectives of the Munich 
study cohort 
# SNP 
EOAD 
subcollective 
(N=281) 
LOAD 
subcollective 
(N=444) 
1 rs12438487 0.712 0.862
2 rs1869135 0.663 0.516
3 rs7166076 0.693 0.434
4 rs7165035 0.820 0.440
5 rs2305421 0.672 0.413
6 rs12594872 0.713 0.982
7 rs1427282 0.723 0.954
8 rs7163733 0.691 0.510
9 rs7174386 0.641 0.330
10 rs9302203 0.612 0.564
11 rs6494031 0.959 0.485
12 rs11071392 0.670 0.300
13 rs8026668 0.606 0.846
14 rs11071393 0.641 0.260
15 rs1427280 0.928 0.528
16 rs1427281 0.455 0.332
17 rs4775086 0.822 0.644
18 rs2052805 0.482 0.693
19 rs2657125 0.309 0.971
20 rs347117 0.534 0.829
21 rs4238331 0.476 0.899
22 rs12441313 0.777 0.487
23 rs6494038 0.668 0.692
24 rs12439231 0.738 0.280
25 rs383902 0.284 0.525
26 rs653765 0.326 0.243
27 rs593742 0.270 0.189
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7.3.4 Additional Statistical Test Results for ABCA1 
 
Tab. 54: Results from genotypic tests for ABCA1 gene in the ApoE ε4/non ApoE ε4 
subcollectives of the Munich study cohort 
 
Genotypic test results 
AD affection genotypic p-values for major allele unless otherwise 
noted                                                     
(associated allele); OR (95%CI)with covariates (sex and onset) # SNP 
ApoE ε4 subcollective          
(N = 295) 
nonApoE ε4 subcollective       
(N = 433) 
1 rs2515606 0.846 0.050 (C); 1.75 (0.9-3.1) 
2 rs1331924 0.260 0.648 
3 rs2066720 0.045 (A); 2.73 (1.02-7.3) 0.763 
4 rs2777799 0.880 0.550 
5 rs2230808 0.080 0.968 
6 rs2066716 0.196 0.866 
7 rs2297401 0.654 0.992 
8 rs3818689 0.086 0.470 
9 rs4149313 0.984 0.079 
10 rs2066718 0.859 0.397 
11 rs2297398 0.600 0.238 
12 rs2487062 0.388 0.966 
13 rs914544 0.367 0.180 
14 rs1175293 0.261 0.935 
15 rs2472445 0.872 0.830 
16 rs2230806 0.925 0.950 
17 rs2230805 0.925 0.780 
18 rs13301006 0.474 0.381 
19 rs2000069 0.755 0.720 
20 rs1999429 0.584 0.457 
21 rs2275542 0.362 0.623 
22 rs3847305 0.659 0.952 
23 rs2575875 0.488 0.687 
24 rs3758294 0.377 0.861 
25 rs2487042 0.822 0.478 
26 rs2487035 0.131 0.580 
27 rs2472516 0.375 0.275 
28 rs4397467 0.751 0.015 (G); 2.35 (1.2-4.7) 
29 rs4743776 0.393 0.463 
30 rs737623 0.758 0.104 
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Tab. 55: Results from allelic tests for ABCA1 gene in the Swedish and pooled study cohorts 
 
SWE (N=883) pooled Population (MUC+SWE) (N=1611) 
Allelic p-values from Haploview Allelic p-values from Haploview 
# Associated 
allele 
Major allele 
frequency 
(cases, 
controls) SWE complete 
(N=883) 
EOAD 
subcollective 
(N=220) 
LOAD 
subcollective 
(N=661) 
Associated 
allele 
Major allele 
frequency 
(cases, 
controls) 
pooled 
complete 
(N=1611) 
EOAD 
subcollective 
(N=501) 
LOAD 
subcollective 
(N=1105) 
1 C 0.493, 0.432 0.031 0.050 0.189 C 0.447, 0.414 0.064 0.023 0.467 
3 G 0.918, 0.876 0.018 0.007 0.225 G 0.895, 0.874 0.086 0.078 0.349 
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Tab. 56: Results from linear regression tests for ABCA1 gene - association between 
genotypes and Mini-Mental State Examination (MMSE) 
 
# SNP 
Linear regression 
(association between 
genotype and MMSE 
score, using gender and 
onset as covariates) 
1 rs2515606 0.688 
2 rs1331924 0.576 
3 rs2066720 0.604 
4 rs2777799 0.590 
5 rs2230808 0.431 
6 rs2066716 0.821 
7 rs2297401 0.127 
8 rs3818689 0.958 
9 rs4149313 0.788 
10 rs2066718 0.879 
11 rs2297398 0.727 
12 rs2487062 0.845 
13 rs914544 0.115 
14 rs1175293 0.810 
15 rs2472445 0.360 
16 rs2230806 0.787 
17 rs2230805 0.920 
18 rs13301006 0.148 
19 rs2000069 0.133 
20 rs1999429 0.327 
21 rs2275542 0.216 
22 rs3847305 0.110 
23 rs2575875 0.367 
24 rs3758294 0.762 
25 rs2487042 0.358 
26 rs2487035 0.465 
27 rs2472516 0.755 
28 rs4397467 0.355 
29 rs4743776 0.941 
30 rs737623 0.807 
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Tab. 57: Results from linear regression tests for ABCA1 gene - association between 
genotypes and age at onset 
 
# SNP 
Linear regression 
(association between 
genotype and age at 
onset using gender as 
covariate) 
1 rs2515606 0.332 
2 rs1331924 0.790 
3 rs2066720 0.642 
4 rs2777799 0.531 
5 rs2230808 0.762 
6 rs2066716 0.337 
7 rs2297401 0.913 
8 rs3818689 0.812 
9 rs4149313 0.861 
10 rs2066718 0.756 
11 rs2297398 0.628 
12 rs2487062 0.131 
13 rs914544 0.681 
14 rs1175293 0.729 
15 rs2472445 0.502 
16 rs2230806 0.814 
17 rs2230805 0.436 
18 rs13301006 0.206 
19 rs2000069 0.106 
20 rs1999429 0.447 
21 rs2275542 0.908 
22 rs3847305 0.885 
23 rs2575875 0.731 
24 rs3758294 0.180 
25 rs2487042 0.739 
26 rs2487035 0.969 
27 rs2472516 0.271 
28 rs4397467 0.462 
29 rs4743776 0.399 
30 rs737623 0.162 
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7.3.5 Additional Statistical Test Results for LIPC 
 
Tab. 58: Results from allelic tests for LIPC gene in the sub-collectives of the Munich study 
cohort 
 
# SNP 
EOAD 
subcollective 
(N=281) 
LOAD 
subcollective 
(N=444) 
1 rs4774297 0.324 0.324 
2 rs1800588 0.143 0.143 
3 rs17190517 0.109 0.109 
4 rs261341 0.600 0.600 
5 rs483140 0.308 0.308 
6 rs261336 0.129 0.129 
7 rs3825776 0.931 0.931 
8 rs10518976 0.217 0.217 
9 rs10518978 0.404 0.404 
10 rs6494011 0.700 0.700 
11 rs1968685 0.940 0.940 
12 rs1869137 0.803 0.803 
13 rs1973028 0.632 0.632 
14 rs2899631 0.280 0.280 
15 rs4774302 0.776 0.776 
16 rs2899632 0.413 0.413 
17 rs12899928 0.556 0.556 
18 rs4775072 0.411 0.411 
19 rs6078 0.785 0.785 
20 rs2242064 0.900 0.900 
21 rs871804 0.776 0.776 
22 rs2414594 0.811 0.811 
23 rs3829462 0.803 0.803 
24 rs6074 0.830 0.830 
25 rs4774308 0.903 0.903 
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7.4 Results from Sliding Window Analyses 
Note that significant p-values (≤0.05) are reported in bold font. Haplotypes with frequencies 
< 5 % are not reported and were not taken into account for the graphs, due to their unlikely 
occurrence. 
7.4.1 Results from Sliding Window Analyses for APP 
Tab. 59: Results from sliding window analysis of 2-marker haplotypes for APP – complete 
Munich cohort 
 
Window Marker Haplotype ID Sequence Frequency p-values 
1 1-2 1.1 CC 0.519 0.6829 
  1.2 CG 0.469 0.5926 
2 2-3 2.1 CA 0.525 0.6166 
  2.2 GT 0.465 0.6780 
3 3-4 3.1 AC 0.516 0.5101 
  3.2 TA 0.464 0.6495 
4 4-5 4.1 CC 0.515 0.4801 
  4.2 AC 0.484 0.5350 
5 5-6 5.1 CG 0.568 0.9145 
  5.2 CT 0.431 0.8459 
6 6-7 6.1 TT 0.405 0.7805 
  6.2 GT 0.345 0.7840 
  6.3 GC 0.224 0.5833 
7 7-8 7.1 TA 0.631 0.2631 
  7.2 CA 0.250 0.4758 
  7.3 TC 0.119 0.4752 
8 8-9 8.1 AG 0.638 0.6667 
  8.2 AA 0.243 0.3013 
  8.3 CG 0.110 0.4913 
9 9-10 9.1 GA 0.635 0.7432 
  9.2 AA 0.252 0.3323 
  9.3 GC 0.113 0.4050 
10 10-11 10.1 AA 0.854 0.6672 
  10.2 CA 0.078 0.7650 
11 11-12 11.1 AC 0.906 0.7101 
  11.2 GC 0.068 0.3355 
12 12-13 12.1 CG 0.505 0.5446 
  12.2 CA 0.469 0.7363 
13 13-14 13.1 AC 0.442 0.4106 
  13.2 GC 0.344 0.6046 
  13.3 GG 0.186 0.3275 
14 14-15 14.1 CT 0.784 0.1301 
  14.2 GT 0.174 0.2549 
15 15-16 15.1 TG 0.701 0.0096 
  15.2 TA 0.256 0.0216 
16 16-17 16.1 GC 0.653 0.0446 
  16.2 AT 0.254 0.0482 
  16.3 GT 0.060 0.7345 
17 17-18 17.1 CA 0.686 0.0942 
  17.2 TA 0.278 0.2010 
18 18-19 18.1 AC 0.644 0.1263 
  18.2 AT 0.318 0.0618 
19 19-20 19.1 CC 0.643 0.0168 
  19.2 TT 0.313 0.0613 
20 20-21 20.1 CC 0.648 0.0186 
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  20.2 TA 0.309 0.0857 
21 21-22 21.1 CG 0.524 0.0144 
  21.2 AG 0.264 0.2669 
  21.3 CT 0.172 0.2091 
22 22-23 22.1 GC 0.744 0.0470 
  22.2 TT 0.206 0.1447 
23 23-24 23.1 CG 0.702 0.0892 
  23.2 TG 0.250 0.1965 
24 24-25 24.1 GC 0.695 0.3300 
  24.2 GT 0.257 0.1270 
25 25-26 25.1 CT 0.499 0.8353 
  25.2 TT 0.253 0.1736 
  25.3 CC 0.244 0.0771 
26 26-27 26.1 TG 0.445 0.2119 
  26.2 TC 0.307 0.9139 
  26.3 CG 0.244 0.1175 
27 27-28 27.1 GG 0.614 0.5769 
  27.2 CG 0.288 0.9946 
  27.3 GA 0.076 0.3791 
28 28-29 28.1 GC 0.857 0.0845 
  28.2 AG 0.096 0.5880 
29 29-30 29.1 CA 0.861 0.1127 
  29.2 GC 0.097 0.4446 
30 30-31 30.1 AT 0.877 0.2521 
  30.2 CT 0.097 0.3606 
31 31-32 31.1 TC 0.875 0.2258 
  31.2 TT 0.098 0.3259 
32 32-33 32.1 CG 0.555 0.3904 
  32.2 CT 0.347 0.1307 
  32.3 TT 0.097 0.3617 
33 33-34 33.1 GG 0.556 0.3942 
  33.2 TG 0.347 0.1107 
  33.3 TT 0.097 0.2569 
34 34-35 34.1 GT 0.595 0.1923 
  34.2 GC 0.308 0.0326 
  34.3 TT 0.095 0.2620 
35 35-36 35.1 TG 0.690 0.0298 
  35.2 CC 0.275 0.0712 
36 36-37 36.1 GG 0.696 0.0898 
  36.2 CG 0.278 0.0497 
37 37-38 37.1 GA 0.961 0.7698 
38 38-39 38.1 AT 0.561 0.4478 
  38.2 AC 0.402 0.3671 
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Tab. 60: Results from sliding window analysis of 3-marker haplotypes for APP – complete 
Munich cohort 
 
Window Marker Haplotype ID Sequence Frequency p-values 
1 1-3 1.1 CCA 0.514 0.6606 
  1.2 CGT 0.464 0.6313 
2 2-4 2.1 CAC 0.517 0.5118 
  2.2 GTA 0.462 0.7233 
3 3-5 3.1 ACC 0.516 0.5101 
  3.2 TAC 0.462 0.7124 
4 4-6 4.1 ACG 0.471 0.6203 
  4.2 CCT 0.426 0.7603 
  4.3 CCG 0.096 0.5811 
5 5-7 5.1 CTT 0.405 0.8079 
  5.2 CGT 0.345 0.7731 
  5.3 CGC 0.224 0.6027 
6 6-8 6.1 TTA 0.397 0.9140 
  6.2 GTA 0.234 0.3005 
  6.3 GCA 0.223 0.5376 
  6.4 GTC 0.112 0.3769 
7 7-9 7.1 TAG 0.500 0.8401 
  7.2 CAG 0.137 0.7227 
  7.3 TAA 0.131 0.0613 
  7.4 CAA 0.113 0.5785 
  7.5 TCG 0.111 0.5259 
8 8-10 8.1 AGA 0.528 0.9411 
  8.2 AAA 0.242 0.2932 
  8.3 AGC 0.110 0.4368 
  8.4 CGA 0.107 0.5190 
9 9-11 9.1 GAA 0.631 0.6780 
  9.2 AAA 0.223 0.4444 
  9.3 GCA 0.078 0.7242 
10 10-12 10.1 AAC 0.829 0.9487 
  10.2 CAC 0.078 0.7838 
11 11-13 11.1 ACG 0.474 0.6550 
  11.2 ACA 0.432 0.4964 
12 12-14 12.1 CAC 0.442 0.3924 
  12.2 CGC 0.318 0.8315 
  12.3 CGG 0.187 0.3273 
13 13-15 13.1 ACT 0.439 0.3731 
  13.2 GCT 0.346 0.6846 
  13.3 GGT 0.173 0.2802 
14 14-16 14.1 CTG 0.637 0.0057 
  14.2 CTA 0.147 0.0568 
  14.3 GTA 0.109 0.2528 
  14.4 GTG 0.065 0.6625 
15 15-17 15.1 TGC 0.645 0.0306 
  15.2 TAT 0.221 0.0523 
  15.3 TGT 0.058 0.6013 
16 16-18 16.1 GCA 0.651 0.0613 
  16.2 ATA 0.218 0.1151 
  16.3 GTA 0.060 0.7377 
17 17-19 17.1 CAC 0.373 0.7170 
  17.2 CAT 0.313 0.0409 
  17.3 TAC 0.272 0.2410 
18 18-20 18.1 ACC 0.605 0.0395 
  18.2 ATT 0.313 0.0615 
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19 19-21 19.1 CCC 0.641 0.0158 
  19.2 TTA 0.303 0.0650 
20 20-22 20.1 CCG 0.480 0.0028 
  20.2 TAG 0.268 0.2190 
  20.3 CCT 0.168 0.3273 
21 21-23 21.1 CGC 0.483 0.0119 
  21.2 AGC 0.261 0.3744 
  21.3 CTT 0.167 0.4016 
22 22-24 22.1 GCG 0.696 0.0185 
  22.2 TTG 0.206 0.1446 
23 23-25 23.1 CGC 0.445 0.8225 
  23.2 CGT 0.256 0.1166 
  23.3 TGC 0.250 0.2065 
24 24-26 24.1 GCT 0.452 0.5332 
  24.2 GTT 0.253 0.1783 
  24.3 GCC 0.242 0.0837 
25 25-27 25.1 CTG 0.439 0.3058 
  25.2 TTC 0.249 0.3021 
  25.3 CCG 0.241 0.0981 
  25.4 CTC 0.061 0.1622 
26 26-28 26.1 TGG 0.369 0.4554 
  26.2 TCG 0.286 0.8893 
  26.3 CGG 0.242 0.1014 
  26.4 TGA 0.076 0.3592 
27 27-29 27.1 GGC 0.574 0.1912 
  27.2 CGC 0.283 0.9287 
  27.3 GAG 0.073 0.5482 
28 28-30 28.1 GCA 0.857 0.0859 
  28.2 AGC 0.094 0.5044 
29 29-31 29.1 CAT 0.834 0.0790 
  29.2 GCT 0.097 0.4446 
30 30-32 30.1 ATC 0.875 0.2229 
  30.2 CTT 0.096 0.3315 
31 31-33 31.1 TCG 0.554 0.3891 
  31.2 TCT 0.321 0.0735 
  31.3 TTT 0.097 0.3608 
32 32-34 32.1 CGG 0.556 0.3648 
  32.2 CTG 0.347 0.1314 
  32.3 TTT 0.097 0.3641 
33 33-35 33.1 GGT 0.561 0.3590 
  33.2 TGC 0.305 0.0442 
  33.3 TTT 0.095 0.2532 
34 34-36 34.1 GTG 0.596 0.2040 
  34.2 GCC 0.275 0.0710 
  34.3 TTG 0.094 0.1915 
35 35-37 35.1 TGG 0.664 0.0559 
  35.2 CCG 0.275 0.0712 
36 36-38 36.1 GGA 0.690 0.0867 
  36.2 CGA 0.271 0.0563 
37 37-39 37.1 GAT 0.559 0.4303 
  37.2 GAC 0.402 0.3637 
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Fig. 33: Sliding window analysis of 2- and 3-marker haplotypes for APP – Munich EOAD subcollective 
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Tab. 61: Results from sliding window analysis of 2-marker haplotypes for APP – Munich 
EOAD subcollective 
 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 1-2 1.1 CC 0.535 0.8705 
  1.2 CG 0.450 0.8796 
2 2-3 2.1 CA 0.544 0.9529 
  2.2 GT 0.446 0.8832 
3 3-4 3.1 AC 0.527 0.7228 
  3.2 TA 0.443 0.8061 
4 4-5 4.1 CC 0.526 0.8556 
  4.2 AC 0.471 0.9881 
5 5-6 5.1 CG 0.567 0.9323 
  5.2 CT 0.429 0.9325 
6 6-7 6.1 TT 0.390 0.6994 
  6.2 GT 0.364 0.9369 
  6.3 GC 0.207 0.9912 
7 7-8 7.1 TA 0.632 0.2876 
  7.2 CA 0.247 0.6146 
  7.3 TC 0.121 0.3647 
8 8-9 8.1 AG 0.614 0.4742 
  8.2 AA 0.265 0.1424 
  8.3 CG 0.114 0.2341 
9 9-10 9.1 GA 0.622 0.1116 
  9.2 AA 0.272 0.1022 
  9.3 GC 0.107 0.8854 
10 10-11 10.1 AA 0.856 0.4952 
  10.2 CA 0.082 0.2682 
11 11-12 11.1 AC 0.916 0.8104 
  11.2 GC 0.062 0.7683 
12 12-13 12.1 CG 0.504 0.5005 
  12.2 CA 0.474 0.5025 
13 13-14 13.1 AC 0.454 0.5230 
  13.2 GC 0.335 0.7735 
  13.3 GG 0.191 0.7073 
14 14-15 14.1 CT 0.784 0.7992 
  14.2 GT 0.167 0.3670 
15 15-16 15.1 TG 0.717 0.2562 
  15.2 TA 0.234 0.0866 
16 16-17 16.1 GC 0.665 0.0995 
  16.2 AT 0.239 0.4510 
  16.3 GT 0.065 0.2345 
17 17-18 17.1 CA 0.690 0.1649 
  17.2 TA 0.275 0.0829 
18 18-19 18.1 AC 0.652 0.0094 
  18.2 AT 0.313 0.0170 
19 19-20 19.1 CC 0.654 0.0123 
  19.2 TT 0.309 0.0267 
20 20-21 20.1 CC 0.659 0.0273 
  20.2 TA 0.293 0.0505 
21 21-22 21.1 CG 0.532 0.1672 
  21.2 AG 0.256 0.1907 
  21.3 CT 0.176 0.7116 
22 22-23 22.1 GC 0.756 0.7450 
  22.2 TT 0.202 0.9034 
23 23-24 23.1 CG 0.714 0.7997 
  23.2 TG 0.237 0.8754 
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24 24-25 24.1 GC 0.673 0.9639 
  24.2 GT 0.277 0.7206 
25 25-26 25.1 CT 0.477 0.7530 
  25.2 TT 0.274 0.7654 
  25.3 CC 0.246 0.9650 
26 26-27 26.1 TG 0.428 0.8040 
  26.2 TC 0.323 0.7195 
  26.3 CG 0.246 0.8413 
27 27-28 27.1 GG 0.579 0.5690 
  27.2 CG 0.308 0.7259 
  27.3 GA 0.095 0.0892 
28 28-29 28.1 GC 0.856 0.1774 
  28.2 AG 0.112 0.3144 
29 29-30 29.1 CA 0.860 0.2619 
  29.2 GC 0.110 0.3775 
30 30-31 30.1 AT 0.869 0.5454 
  30.2 CT 0.107 0.2999 
31 31-32 31.1 TC 0.869 0.6283 
  31.2 TT 0.106 0.3670 
32 32-33 32.1 CG 0.558 0.9853 
  32.2 CT 0.336 0.5685 
  32.3 TT 0.106 0.3661 
33 33-34 33.1 GG 0.557 0.9517 
  33.2 TG 0.335 0.5011 
  33.3 TT 0.108 0.2620 
34 34-35 34.1 GT 0.591 0.8473 
  34.2 GC 0.302 0.5741 
  34.3 TT 0.103 0.3070 
35 35-36 35.1 TG 0.693 0.6042 
  35.2 CC 0.272 0.5288 
36 36-37 36.1 GG 0.700 0.2969 
  36.2 CG 0.277 0.4379 
37 37-38 37.1 GA 0.960 0.3650 
38 38-39 38.1 AT 0.562 0.7815 
  38.2 AC 0.397 0.9323 
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Tab. 62: Results from sliding window analysis of 3-marker haplotypes for APP – Munich 
EOAD subcollective 
 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 1-3 1.1 CCA 0.530 0.9435 
  1.2 CGT 0.446 0.8832 
2 2-4 2.1 CAC 0.527 0.7194 
  2.2 GTA 0.443 0.7533 
3 3-5 3.1 ACC 0.527 0.7228 
  3.2 TAC 0.440 0.6789 
4 4-6 4.1 ACG 0.457 0.9297 
  4.2 CCT 0.423 0.8694 
  4.3 CCG 0.112 0.8854 
5 5-7 5.1 CTT 0.390 0.7006 
  5.2 CGT 0.363 0.9925 
  5.3 CGC 0.205 0.9273 
6 6-8 6.1 TTA 0.381 0.6053 
  6.2 GTA 0.253 0.6679 
  6.3 GCA 0.206 0.9674 
  6.4 GTC 0.112 0.4360 
7 7-9 7.1 TAG 0.489 0.9190 
  7.2 TAA 0.144 0.1356 
  7.3 CAG 0.124 0.3407 
  7.4 CAA 0.121 0.6738 
  7.5 TCG 0.114 0.2497 
8 8-10 8.1 AGA 0.506 0.4414 
  8.2 AAA 0.266 0.1416 
  8.3 CGA 0.115 0.2264 
  8.4 AGC 0.107 0.8975 
9 9-11 9.1 GAA 0.618 0.1131 
  9.2 AAA 0.239 0.2442 
  9.3 GCA 0.081 0.2528 
10 10-12 10.1 AAC 0.837 0.5655 
  10.2 CAC 0.080 0.2717 
11 11-13 11.1 ACG 0.476 0.5751 
  11.2 ACA 0.440 0.4764 
12 12-14 12.1 CAC 0.455 0.5317 
  12.2 CGC 0.312 0.7788 
  12.3 CGG 0.192 0.7092 
13 13-15 13.1 ACT 0.448 0.6020 
  13.2 GCT 0.336 0.7675 
  13.3 GGT 0.168 0.3536 
14 14-16 14.1 CTG 0.652 0.1360 
  14.2 CTA 0.131 0.0895 
  14.3 GTA 0.103 0.5159 
  14.4 GTG 0.066 0.4926 
15 15-17 15.1 TGC 0.655 0.1054 
  15.2 TAT 0.202 0.1686 
  15.3 TGT 0.063 0.2676 
16 16-18 16.1 GCA 0.665 0.0998 
  16.2 ATA 0.207 0.3169 
  16.3 GTA 0.063 0.1654 
17 17-19 17.1 CAC 0.382 0.4060 
  17.2 CAT 0.309 0.0222 
  17.3 TAC 0.271 0.0619 
18 18-20 18.1 ACC 0.620 0.0084 
  18.2 ATT 0.309 0.0272 
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19 19-21 19.1 CCC 0.652 0.0158 
  19.2 TTA 0.292 0.0309 
20 20-22 20.1 CCG 0.488 0.0672 
  20.2 TAG 0.257 0.1386 
  20.3 CCT 0.171 0.7172 
21 21-23 21.1 CGC 0.506 0.2370 
  21.2 AGC 0.250 0.2970 
  21.3 CTT 0.166 0.5623 
22 22-24 22.1 GCG 0.706 0.4812 
  22.2 TTG 0.202 0.9034 
23 23-25 23.1 CGC 0.437 0.8366 
  23.2 CGT 0.273 0.6480 
  23.3 TGC 0.236 0.7786 
24 24-26 24.1 GCT 0.429 0.9991 
  24.2 GTT 0.274 0.7845 
  24.3 GCC 0.244 0.9684 
25 25-27 25.1 CTG 0.415 0.9923 
  25.2 TTC 0.266 0.9635 
  25.3 CCG 0.240 0.8931 
  25.4 CTC 0.065 0.7434 
26 26-28 26.1 TGG 0.334 0.5229 
  26.2 TCG 0.307 0.7698 
  26.3 CGG 0.244 0.9330 
  26.4 TGA 0.095 0.1387 
27 27-29 27.1 GGC 0.554 0.3661 
  27.2 CGC 0.302 0.9544 
  27.3 GAG 0.094 0.1563 
28 28-30 28.1 GCA 0.856 0.1778 
  28.2 AGC 0.108 0.3038 
29 29-31 29.1 CAT 0.836 0.4609 
  29.2 GCT 0.110 0.3775 
30 30-32 30.1 ATC 0.869 0.5636 
  30.2 CTT 0.107 0.3147 
31 31-33 31.1 TCG 0.555 0.9758 
  31.2 TCT 0.314 0.6924 
  31.3 TTT 0.106 0.3663 
32 32-34 32.1 CGG 0.557 0.9762 
  32.2 CTG 0.336 0.5181 
  32.3 TTT 0.107 0.3009 
33 33-35 33.1 GGT 0.562 0.9128 
  33.2 TGC 0.298 0.5221 
  33.3 TTT 0.101 0.3034 
34 34-36 34.1 GTG 0.590 0.8201 
  34.2 GCC 0.272 0.5275 
  34.3 TTG 0.103 0.2472 
35 35-37 35.1 TGG 0.669 0.4353 
  35.2 CCG 0.272 0.5288 
36 36-38 36.1 GGA 0.691 0.2322 
  36.2 CGA 0.269 0.3960 
37 37-39 37.1 GAT 0.561 0.7760 
  37.2 GAC 0.398 0.9384 
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Fig. 34: Sliding window analysis of 2- and 3-marker haplotypes for APP – Munich LOAD subcollective 
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Tab. 63: Results from sliding window analysis of 2-marker haplotypes for APP – Munich 
LOAD subcollective 
 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 1-2 1.1 CC 0.507 0.6681 
  1.2 CG 0.482 0.5757 
2 2-3 2.1 CA 0.510 0.6690 
  2.2 GT 0.479 0.6888 
3 3-4 3.1 AC 0.507 0.6990 
  3.2 TA 0.479 0.5929 
4 4-6 4.1 AG 0.483 0.7130 
  4.2 CT 0.426 0.8515 
  4.3 CG 0.086 0.6706 
5 6-7 5.1 TT 0.412 0.9188 
  5.2 GT 0.334 0.6506 
  5.3 GC 0.235 0.5269 
6 7-8 6.1 TA 0.630 0.5100 
  6.2 CA 0.252 0.5424 
  6.3 TC 0.119 0.8681 
7 8-9 7.1 AG 0.658 0.6787 
  7.2 AA 0.223 0.7420 
  7.3 CG 0.106 0.9105 
8 9-10 8.1 GA 0.647 0.2363 
  8.2 AA 0.236 0.5827 
  8.3 GC 0.117 0.3012 
9 10-11 9.1 AA 0.852 0.2960 
  9.2 CA 0.076 0.5470 
10 11-12 10.1 AC 0.900 0.9471 
  10.2 GC 0.072 0.3945 
11 12-13 11.1 CG 0.503 0.7853 
  11.2 CA 0.468 0.8906 
12 13-14 12.1 AC 0.437 0.6365 
  12.2 GC 0.347 0.3602 
  12.3 GG 0.184 0.3490 
13 14-15 13.1 CT 0.782 0.0997 
  13.2 GT 0.179 0.5404 
14 15-16 14.1 TG 0.691 0.0170 
  14.2 TA 0.270 0.1454 
15 16-17 15.1 GC 0.645 0.2213 
  15.2 AT 0.262 0.0568 
  15.3 GT 0.057 0.1555 
16 17-18 16.1 CA 0.681 0.3318 
  16.2 TA 0.279 0.6901 
17 18-19 17.1 AC 0.640 0.9475 
  17.2 AT 0.320 0.5164 
18 19-20 18.1 CC 0.637 0.1845 
  18.2 TT 0.314 0.4335 
19 20-21 19.1 CC 0.642 0.1259 
  19.2 TA 0.317 0.3380 
20 21-22 20.1 CG 0.520 0.0248 
  20.2 AG 0.267 0.5483 
  20.3 CT 0.170 0.0606 
21 22-23 21.1 GC 0.736 0.0128 
  21.2 TT 0.209 0.0651 
  21.3 GT 0.053 0.2604 
22 23-24 22.1 CG 0.694 0.0301 
  22.2 TG 0.259 0.0479 
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23 24-25 23.1 GC 0.708 0.0970 
  23.2 GT 0.245 0.0389 
24 25-26 24.1 CT 0.512 0.8300 
  24.2 CC 0.243 0.0236 
  24.3 TT 0.240 0.0560 
25 26-27 25.1 TG 0.454 0.2239 
  25.2 TC 0.298 0.5076 
  25.3 CG 0.244 0.0282 
26 27-28 26.1 GG 0.634 0.5648 
  26.2 CG 0.275 0.6168 
  26.3 GA 0.064 0.8613 
27 28-29 27.1 GC 0.856 0.2580 
  27.2 AG 0.087 0.9353 
  27.3 GG 0.053 0.0985 
28 29-30 28.1 CA 0.860 0.2565 
  28.2 GC 0.090 0.6568 
29 30-31 29.1 AT 0.881 0.2705 
  29.2 CT 0.091 0.6352 
30 31-32 30.1 TC 0.879 0.2038 
  30.2 TT 0.093 0.5071 
31 32-33 31.1 CG 0.550 0.1954 
  31.2 CT 0.357 0.0804 
  31.3 TT 0.091 0.5632 
32 33-34 32.1 GG 0.552 0.1903 
  32.2 TG 0.357 0.0747 
  32.3 TT 0.091 0.4822 
33 34-35 33.1 GT 0.595 0.0505 
  33.2 GC 0.314 0.0118 
  33.3 TT 0.091 0.4676 
34 35-36 34.1 TG 0.687 0.0101 
  34.2 CC 0.279 0.0460 
35 36-37 35.1 GG 0.692 0.1313 
  35.2 CG 0.281 0.0402 
36 37-38 36.1 GA 0.962 0.2322 
37 38-39 37.1 AT 0.558 0.3988 
  37.2 AC 0.406 0.1723 
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Tab. 64: Results from sliding window analysis of 3-marker haplotypes for APP – Munich 
LOAD subcollective 
 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 1-3 1.1 CCA 0.501 0.6960 
  1.2 CGT 0.477 0.6210 
2 2-4 2.1 CAC 0.508 0.7022 
  2.2 GTA 0.477 0.6536 
3 3-6 3.1 TAG 0.477 0.6528 
  3.2 ACT 0.421 0.9282 
  3.3 ACG 0.086 0.5983 
4 4-7 4.1 CTT 0.408 0.7955 
  4.2 AGT 0.251 0.9352 
  4.3 AGC 0.231 0.5758 
  4.4 CGT 0.082 0.6401 
5 6-8 5.1 TTA 0.406 0.8503 
  5.2 GCA 0.234 0.4584 
  5.3 GTA 0.223 0.3217 
  5.4 GTC 0.112 0.6333 
6 7-9 6.1 TAG 0.512 0.9523 
  6.2 CAG 0.145 0.6254 
  6.3 TAA 0.122 0.3883 
  6.4 TCG 0.108 0.9189 
  6.5 CAA 0.103 0.1564 
7 8-10 7.1 AGA 0.545 0.2918 
  7.2 AAA 0.222 0.7425 
  7.3 AGC 0.114 0.3081 
  7.4 CGA 0.102 0.9028 
8 9-11 8.1 GAA 0.642 0.2904 
  8.2 AAA 0.210 0.6970 
  8.3 GCA 0.077 0.5966 
9 10-12 9.1 AAC 0.824 0.6397 
  9.2 CAC 0.076 0.5373 
10 11-13 10.1 ACG 0.470 0.8431 
  10.2 ACA 0.429 0.8118 
11 12-14 11.1 CAC 0.437 0.6073 
  11.2 CGC 0.318 0.6419 
  11.3 CGG 0.185 0.3459 
12 13-15 12.1 ACT 0.436 0.4673 
  12.2 GCT 0.347 0.4910 
  12.3 GGT 0.177 0.5879 
13 14-16 13.1 CTG 0.626 0.0225 
  13.2 CTA 0.155 0.2648 
  13.3 GTA 0.114 0.4180 
  13.4 GTG 0.065 0.9980 
14 15-17 14.1 TGC 0.638 0.1416 
  14.2 TAT 0.232 0.1940 
  14.3 TGT 0.055 0.1086 
15 16-18 15.1 GCA 0.643 0.2595 
  15.2 ATA 0.223 0.2118 
  15.3 GTA 0.057 0.1546 
16 17-19 16.1 CAC 0.367 0.9687 
  16.2 CAT 0.314 0.3680 
  16.3 TAC 0.272 0.8859 
17 18-20 17.1 ACC 0.597 0.4545 
  17.2 ATT 0.314 0.4335 
18 19-21 18.1 CCC 0.636 0.1562 
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  18.2 TTA 0.309 0.3704 
19 20-22 19.1 CCG 0.476 0.0075 
  19.2 TAG 0.273 0.5322 
  19.3 CCT 0.166 0.1077 
20 21-23 20.1 CGC 0.470 0.0089 
  20.2 AGC 0.266 0.6332 
  20.3 CTT 0.167 0.1192 
21 22-24 21.1 GCG 0.688 0.0080 
  21.2 TTG 0.209 0.0650 
  21.3 GTG 0.052 0.2652 
22 23-25 22.1 CGC 0.448 0.7389 
  22.2 TGC 0.259 0.0411 
  22.3 CGT 0.246 0.0452 
23 24-26 23.1 GCT 0.465 0.6187 
  23.2 GCC 0.242 0.0225 
  23.3 GTT 0.241 0.0568 
24 25-27 24.1 CTG 0.453 0.3043 
  24.2 CCG 0.242 0.0224 
  24.3 TTC 0.238 0.0868 
  24.4 CTC 0.058 0.1235 
25 26-28 25.1 TGG 0.388 0.2425 
  25.2 TCG 0.275 0.5273 
  25.3 CGG 0.244 0.0300 
  25.4 TGA 0.065 0.9475 
26 27-29 26.1 GGC 0.585 0.2590 
  26.2 CGC 0.272 0.7172 
  26.3 GAG 0.061 0.7904 
27 28-30 27.1 GCA 0.857 0.2597 
  27.2 AGC 0.086 0.8455 
28 29-31 28.1 CAT 0.832 0.1019 
  28.2 GCT 0.090 0.6568 
29 30-32 29.1 ATC 0.878 0.2724 
  29.2 CTT 0.089 0.5231 
30 31-33 30.1 TCG 0.550 0.2126 
  30.2 TCT 0.328 0.0269 
  30.3 TTT 0.091 0.5613 
31 32-34 31.1 CGG 0.551 0.1939 
  31.2 CTG 0.356 0.0832 
  31.3 TTT 0.091 0.5791 
32 33-35 32.1 GGT 0.557 0.1492 
  32.2 TGC 0.312 0.0212 
  32.3 TTT 0.091 0.4677 
33 34-36 33.1 GTG 0.596 0.0567 
  33.2 GCC 0.280 0.0461 
  33.3 TTG 0.090 0.3688 
34 35-37 34.1 TGG 0.659 0.0411 
  34.2 CCG 0.279 0.0460 
35 36-38 35.1 GGA 0.687 0.1708 
  35.2 CGA 0.275 0.0532 
36 37-39 36.1 GAT 0.555 0.3734 
  36.2 GAC 0.406 0.1729 
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Fig. 35: Sliding window analysis of 2- and 3-marker haplotypes for APP – Munich ApoE ε4 subcollective 
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Tab. 65: Results from sliding window analysis of 2-marker haplotypes for APP – Munich 
ApoE ε4 subcollective 
 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 1-2 1.1 CC 0.513 0.3943 
  1.2 CG 0.480 0.3809 
2 2-3 2.1 CA 0.513 0.3916 
  2.2 GT 0.476 0.4353 
3 3-4 3.1 AC 0.502 0.3534 
  3.2 TA 0.472 0.4810 
4 4-5 4.1 CC 0.504 0.3629 
  4.2 AC 0.493 0.4105 
5 5-6 5.1 CG 0.562 0.7053 
  5.2 CT 0.434 0.6409 
6 6-7 6.1 TT 0.399 0.6793 
  6.2 GT 0.347 0.5307 
  6.3 GC 0.219 0.1876 
7 7-8 7.1 TA 0.618 0.6847 
  7.2 CA 0.253 0.1785 
  7.3 TC 0.129 0.2466 
8 8-9 8.1 AG 0.637 0.1936 
  8.2 AA 0.235 0.5606 
  8.3 CG 0.112 0.1664 
9 9-10 9.1 GA 0.618 0.8012 
  9.2 AA 0.251 0.6628 
  9.3 GC 0.132 0.8436 
10 10-11 10.1 AA 0.837 0.9043 
  10.2 CA 0.091 0.5664 
11 11-12 11.1 AC 0.909 0.3925 
  11.2 GC 0.072 0.4342 
12 12-13 12.1 CG 0.529 0.7559 
  12.2 CA 0.451 0.6861 
13 13-14 13.1 AC 0.416 0.6042 
  13.2 GC 0.351 0.8742 
  13.3 GG 0.199 0.7733 
14 14-15 14.1 CT 0.764 0.6076 
  14.2 GT 0.198 0.9036 
15 15-16 15.1 TG 0.689 0.0582 
  15.2 TA 0.273 0.1149 
16 16-17 16.1 GC 0.635 0.0878 
  16.2 AT 0.275 0.0951 
  16.3 GT 0.056 0.9154 
17 17-18 17.1 CA 0.669 0.1257 
  17.2 TA 0.295 0.2166 
18 18-19 18.1 AC 0.657 0.8790 
  18.2 AT 0.306 0.8595 
19 19-20 19.1 CC 0.644 0.3218 
  19.2 TT 0.299 0.7110 
20 20-21 20.1 CC 0.653 0.2216 
  20.2 TA 0.298 0.8682 
21 21-22 21.1 CG 0.563 0.2006 
  21.2 AG 0.245 0.8026 
  21.3 CT 0.144 0.1318 
22 22-23 22.1 GC 0.762 0.1825 
  22.2 TT 0.190 0.0881 
23 23-24 23.1 CG 0.719 0.1212 
  23.2 TG 0.235 0.3645 
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24 24-25 24.1 GC 0.684 0.4066 
  24.2 GT 0.270 0.1159 
25 25-26 25.1 CT 0.504 0.8661 
  25.2 TT 0.269 0.1702 
  25.3 CC 0.220 0.0719 
26 26-27 26.1 TG 0.455 0.4134 
  26.2 TC 0.318 0.5444 
  26.3 CG 0.224 0.1427 
27 27-28 27.1 GG 0.610 0.5593 
  27.2 CG 0.294 0.5361 
  27.3 GA 0.068 0.5952 
28 28-29 28.1 GC 0.850 0.7326 
  28.2 AG 0.095 0.8719 
  28.3 GG 0.053 0.5141 
29 29-30 29.1 CA 0.851 0.7760 
  29.2 GC 0.093 0.8151 
  29.3 GA 0.055 0.4587 
30 30-31 30.1 AT 0.881 0.9347 
  30.2 CT 0.087 0.7246 
31 31-32 31.1 TC 0.877 0.9040 
  31.2 TT 0.091 0.9092 
32 32-33 32.1 CG 0.560 0.3290 
  32.2 CT 0.345 0.2847 
  32.3 TT 0.093 0.9929 
33 33-34 33.1 GG 0.562 0.2975 
  33.2 TG 0.344 0.2945 
  33.3 TT 0.094 0.9483 
34 34-35 34.1 GT 0.609 0.1297 
  34.2 GC 0.297 0.1116 
  34.3 TT 0.094 0.9665 
35 35-36 35.1 TG 0.703 0.1197 
  35.2 CC 0.262 0.1377 
36 36-37 36.1 GG 0.709 0.1993 
  36.2 CG 0.261 0.1356 
37 37-38 37.1 GA 0.962 0.3365 
38 38-39 38.1 AT 0.580 0.2196 
  38.2 AC 0.383 0.0752 
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Tab. 66: Results from sliding window analysis of 3-marker haplotypes for APP – Munich 
ApoE ε4 subcollective 
 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 1-3 1.1 CCA 0.506 0.4050 
  1.2 CGT 0.476 0.4354 
2 2-4 2.1 CAC 0.503 0.3559 
  2.2 GTA 0.470 0.5163 
3 3-5 3.1 ACC 0.502 0.3534 
  3.2 TAC 0.469 0.5368 
4 4-6 4.1 ACG 0.480 0.4902 
  4.2 CCT 0.431 0.4908 
  4.3 CCG 0.082 0.7386 
5 5-7 5.1 CTT 0.399 0.6795 
  5.2 CGT 0.345 0.5002 
  5.3 CGC 0.217 0.2042 
6 6-8 6.1 TTA 0.392 0.9271 
  6.2 GTA 0.227 0.8091 
  6.3 GCA 0.216 0.1157 
  6.4 GTC 0.122 0.3556 
7 7-9 7.1 TAG 0.504 0.7287 
  7.2 CAG 0.131 0.1813 
  7.3 CAA 0.120 0.7253 
  7.4 TAA 0.117 0.2689 
  7.5 TCG 0.114 0.1665 
8 8-10 8.1 AGA 0.510 0.2338 
  8.2 AAA 0.235 0.5303 
  8.3 AGC 0.127 0.8978 
  8.4 CGA 0.107 0.1239 
9 9-11 9.1 GAA 0.613 0.6717 
  9.2 AAA 0.226 0.5651 
  9.3 GCA 0.090 0.5619 
10 10-12 10.1 AAC 0.818 0.8188 
  10.2 CAC 0.091 0.5688 
11 11-13 11.1 ACG 0.504 0.8736 
  11.2 ACA 0.404 0.4927 
12 12-14 12.1 CAC 0.417 0.6021 
  12.2 CGC 0.330 0.9490 
  12.3 CGG 0.200 0.7711 
13 13-15 13.1 ACT 0.414 0.5096 
  13.2 GCT 0.351 0.8129 
  13.3 GGT 0.195 0.9776 
14 14-16 14.1 CTG 0.618 0.0788 
  14.2 CTA 0.145 0.0775 
  14.3 GTA 0.127 0.7987 
  14.4 GTG 0.072 0.9379 
15 15-17 15.1 TGC 0.635 0.0881 
  15.2 TAT 0.236 0.1764 
  15.3 TGT 0.056 0.9128 
16 16-18 16.1 GCA 0.635 0.0885 
  16.2 ATA 0.238 0.1669 
  16.3 GTA 0.056 0.9096 
17 17-19 17.1 CAC 0.371 0.2630 
  17.2 CAT 0.298 0.7344 
  17.3 TAC 0.286 0.3001 
18 18-20 18.1 ACC 0.608 0.5117 
  18.2 ATT 0.299 0.7110 
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19 19-21 19.1 CCC 0.645 0.3177 
  19.2 TTA 0.288 0.8158 
20 20-22 20.1 CCG 0.510 0.0241 
  20.2 TAG 0.249 0.7815 
  20.3 CCT 0.143 0.1229 
21 21-23 21.1 CGC 0.515 0.3559 
  21.2 AGC 0.247 0.7997 
  21.3 CTT 0.143 0.1908 
22 22-24 22.1 GCG 0.716 0.0512 
  22.2 TTG 0.190 0.0881 
23 23-25 23.1 CGC 0.441 0.8921 
  23.2 CGT 0.276 0.1433 
  23.3 TGC 0.237 0.3353 
24 24-26 24.1 GCT 0.459 0.5364 
  24.2 GTT 0.269 0.1744 
  24.3 GCC 0.219 0.1155 
25 25-27 25.1 CTG 0.451 0.4473 
  25.2 TTC 0.264 0.1756 
  25.3 CCG 0.220 0.1572 
  25.4 CTC 0.054 0.1729 
26 26-28 26.1 TGG 0.382 0.5473 
  26.2 TCG 0.294 0.3817 
  26.3 CGG 0.225 0.1443 
  26.4 TGA 0.072 0.6635 
27 27-29 27.1 GGC 0.565 0.2776 
  27.2 CGC 0.285 0.3569 
  27.3 GAG 0.068 0.7311 
28 28-30 28.1 GCA 0.850 0.7326 
  28.2 AGC 0.093 0.8135 
  28.3 GGA 0.053 0.5142 
29 29-31 29.1 CAT 0.826 0.6923 
  29.2 GCT 0.089 0.6617 
  29.3 GAT 0.054 0.3725 
30 30-32 30.1 ATC 0.878 0.9159 
  30.2 CTT 0.089 0.8314 
31 31-33 31.1 TCG 0.559 0.3591 
  31.2 TCT 0.314 0.2326 
  31.3 TTT 0.093 0.9932 
32 32-34 32.1 CGG 0.560 0.3351 
  32.2 CTG 0.344 0.2909 
  32.3 TTT 0.094 0.9985 
33 33-35 33.1 GGT 0.569 0.2748 
  33.2 TGC 0.296 0.1193 
  33.3 TTT 0.094 0.9665 
34 34-36 34.1 GTG 0.610 0.1392 
  34.2 GCC 0.262 0.1377 
  34.3 TTG 0.094 0.9669 
35 35-37 35.1 TGG 0.676 0.1998 
  35.2 CCG 0.262 0.1379 
36 36-38 36.1 GGA 0.703 0.2668 
  36.2 CGA 0.259 0.1152 
37 37-39 37.1 GAT 0.580 0.2196 
  37.2 GAC 0.381 0.1052 
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Fig. 36: Sliding window analysis of 2- and 3-marker haplotypes for APP – Munich nonApoE ε4 subcollective 
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Tab. 67: Results from sliding window analysis of 2-marker haplotypes for APP – Munich 
nonApoE ε4 subcollective 
 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 1-2 1.1 CC 0.523 0.8342 
  1.2 CG 0.461 0.8529 
2 2-3 2.1 CA 0.532 0.8241 
  2.2 GT 0.458 0.7959 
3 3-4 3.1 AC 0.526 0.8946 
  3.2 TA 0.458 0.8991 
4 4-6 4.1 AG 0.466 0.9760 
  4.2 CT 0.423 0.9681 
  4.3 CG 0.106 0.9307 
5 6-7 5.1 TT 0.407 0.9782 
  5.2 GT 0.345 0.9004 
  5.3 GC 0.227 0.8817 
6 7-8 6.1 TA 0.639 0.4078 
  6.2 CA 0.248 0.9153 
  6.3 TC 0.113 0.1610 
7 8-9 7.1 AG 0.640 0.8232 
  7.2 AA 0.247 0.4306 
  7.3 CG 0.107 0.1045 
8 9-10 8.1 GA 0.647 0.5016 
  8.2 AA 0.253 0.3703 
  8.3 GC 0.100 0.8200 
9 10-11 9.1 AA 0.866 0.9110 
  9.2 CA 0.069 0.5733 
10 11-12 10.1 AC 0.907 0.8794 
  10.2 GC 0.064 0.4765 
11 12-13 11.1 CG 0.488 0.9734 
  11.2 CA 0.482 0.7675 
12 13-14 12.1 AC 0.460 0.9143 
  12.2 GC 0.340 0.3671 
  12.3 GG 0.177 0.5591 
13 14-15 13.1 CT 0.797 0.3344 
  13.2 GT 0.157 0.5073 
14 15-16 14.1 TG 0.709 0.1156 
  14.2 TA 0.245 0.2045 
15 16-17 15.1 GC 0.664 0.3500 
  15.2 AT 0.240 0.4330 
  15.3 GT 0.062 0.8432 
16 17-18 16.1 CA 0.695 0.5939 
  16.2 TA 0.266 0.7207 
17 18-19 17.1 AC 0.635 0.0890 
  17.2 AT 0.326 0.0535 
18 19-20 18.1 CC 0.642 0.0209 
  18.2 TT 0.323 0.0803 
19 20-21 19.1 CC 0.644 0.0437 
  19.2 TA 0.316 0.0727 
20 21-22 20.1 CG 0.495 0.1434 
  20.2 AG 0.279 0.2203 
  20.3 CT 0.193 0.9784 
21 22-23 21.1 GC 0.732 0.2633 
  21.2 TT 0.218 0.8273 
22 23-24 22.1 CG 0.690 0.4969 
  22.2 TG 0.260 0.5288 
23 24-25 23.1 GC 0.705 0.7524 
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  23.2 GT 0.245 0.6728 
24 25-26 24.1 CT 0.495 0.9419 
  24.2 CC 0.260 0.6565 
  24.3 TT 0.242 0.7730 
25 26-27 25.1 TG 0.438 0.4344 
  25.2 TC 0.300 0.5783 
  25.3 CG 0.258 0.6548 
26 27-28 26.1 GG 0.615 0.8261 
  26.2 CG 0.284 0.5487 
  26.3 GA 0.082 0.2974 
27 28-29 27.1 GC 0.862 0.0819 
  27.2 AG 0.097 0.4096 
28 29-30 28.1 CA 0.867 0.1232 
  28.2 GC 0.100 0.2100 
29 30-31 29.1 AT 0.877 0.1643 
  29.2 CT 0.100 0.1584 
30 31-32 30.1 TC 0.877 0.2038 
  30.2 TT 0.099 0.2031 
31 32-33 31.1 CG 0.552 0.7539 
  31.2 CT 0.349 0.2597 
  31.3 TT 0.099 0.2020 
32 33-34 32.1 GG 0.552 0.8228 
  32.2 TG 0.349 0.2133 
  32.3 TT 0.100 0.1075 
33 34-35 33.1 GT 0.586 0.7873 
  33.2 GC 0.315 0.1831 
  33.3 TT 0.096 0.1244 
34 35-36 34.1 TG 0.682 0.1721 
  34.2 CC 0.285 0.3617 
35 36-37 35.1 GG 0.687 0.3427 
  35.2 CG 0.289 0.2971 
36 37-38 36.1 GA 0.961 0.8030 
37 38-39 37.1 AT 0.547 0.7446 
  37.2 AC 0.415 0.6210 
 
 
Tab. 68: Results from sliding window analysis of 3-marker haplotypes for APP – Munich 
nonApoE ε4 subcollective 
 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 1-3 1.1 CCA 0.518 0.8498 
  1.2 CGT 0.456 0.8401 
2 2-4 2.1 CAC 0.526 0.8935 
  2.2 GTA 0.457 0.8506 
3 3-6 3.1 TAG 0.455 0.8987 
  3.2 ACT 0.419 0.9715 
  3.3 ACG 0.107 0.8769 
4 4-7 4.1 CTT 0.404 0.8349 
  4.2 AGT 0.245 0.8895 
  4.3 AGC 0.220 0.8829 
  4.4 CGT 0.100 0.9382 
5 6-8 5.1 TTA 0.400 0.9900 
  5.2 GTA 0.239 0.3795 
  5.3 GCA 0.227 0.8719 
  5.4 GTC 0.105 0.1514 
6 7-9 6.1 TAG 0.499 0.9598 
  6.2 TAA 0.140 0.2312 
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  6.3 CAG 0.140 0.7398 
  6.4 TCG 0.108 0.1151 
  6.5 CAA 0.107 0.8423 
7 8-10 7.1 AGA 0.540 0.6752 
  7.2 AAA 0.246 0.4666 
  7.3 CGA 0.106 0.0795 
  7.4 AGC 0.100 0.8279 
  8.1 GAA 0.648 0.4763 
8 9-11 8.2 AAA 0.216 0.4772 
  8.3 GCA 0.070 0.5768 
9 10-12 9.1 AAC 0.837 0.7446 
  9.2 CAC 0.069 0.5917 
10 11-13 10.1 ACG 0.455 0.8274 
  10.2 ACA 0.452 0.8988 
11 12-14 11.1 CAC 0.459 0.8682 
  11.2 CGC 0.310 0.5615 
  11.3 CGG 0.178 0.5601 
12 13-15 12.1 ACT 0.455 0.9174 
  12.2 GCT 0.342 0.4549 
  12.3 GGT 0.157 0.4904 
13 14-16 13.1 CTG 0.649 0.0783 
  13.2 CTA 0.148 0.2306 
  13.3 GTA 0.096 0.5712 
  13.4 GTG 0.062 0.6755 
14 15-17 14.1 TGC 0.651 0.2045 
  14.2 TAT 0.210 0.3246 
  14.3 TGT 0.059 0.6398 
15 16-18 15.1 GCA 0.663 0.3920 
  15.2 ATA 0.204 0.6525 
  15.3 GTA 0.061 0.9321 
16 17-19 16.1 CAC 0.373 0.1805 
  16.2 CAT 0.323 0.0517 
  16.3 TAC 0.262 0.6861 
17 18-20 17.1 ACC 0.604 0.0427 
  17.2 ATT 0.323 0.0812 
18 19-21 18.1 CCC 0.639 0.0214 
  18.2 TTA 0.313 0.0736 
19 20-22 19.1 CCG 0.458 0.0818 
  19.2 TAG 0.283 0.1601 
  19.3 CCT 0.186 0.7886 
20 21-23 20.1 CGC 0.458 0.0673 
  20.2 AGC 0.273 0.3512 
  20.3 CTT 0.185 0.7601 
21 22-24 21.1 GCG 0.682 0.2523 
  21.2 TTG 0.218 0.8272 
22 23-25 22.1 CGC 0.447 0.8048 
  22.2 TGC 0.259 0.5685 
  22.3 CGT 0.242 0.6478 
23 24-26 23.1 GCT 0.447 0.8163 
  23.2 GCC 0.258 0.5876 
  23.3 GTT 0.243 0.7714 
24 25-27 24.1 CTG 0.432 0.5947 
  24.2 CCG 0.254 0.5528 
  24.3 TTC 0.239 0.9799 
  24.4 CTC 0.066 0.5816 
25 26-28 25.1 TGG 0.359 0.8365 
  25.2 TCG 0.282 0.5159 
  25.3 CGG 0.256 0.6064 
  25.4 TGA 0.079 0.3057 
26 27-29 26.1 GGC 0.578 0.4424 
  26.2 CGC 0.284 0.6172 
  26.3 GAG 0.077 0.4781 
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27 28-30 27.1 GCA 0.862 0.0853 
  27.2 AGC 0.095 0.3022 
28 29-31 28.1 CAT 0.843 0.1248 
  28.2 GCT 0.100 0.2100 
29 30-32 29.1 ATC 0.876 0.2199 
  29.2 CTT 0.097 0.1788 
30 31-33 30.1 TCG 0.551 0.7242 
  30.2 TCT 0.326 0.2006 
  30.3 TTT 0.099 0.2016 
31 32-34 31.1 CGG 0.552 0.7539 
  31.2 CTG 0.349 0.2430 
  31.3 TTT 0.099 0.1806 
32 33-35 32.1 GGT 0.555 0.8344 
  32.2 TGC 0.312 0.2148 
  32.3 TTT 0.096 0.1279 
33 34-36 33.1 GTG 0.587 0.8058 
  33.2 GCC 0.285 0.3614 
  33.3 TTG 0.095 0.0787 
34 35-37 34.1 TGG 0.658 0.2047 
  34.2 CCG 0.285 0.3617 
35 36-38 35.1 GGA 0.681 0.2879 
  35.2 CGA 0.280 0.3193 
36 37-39 36.1 GAT 0.546 0.7071 
  36.2 GAC 0.415 0.6345 
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Fig. 37: Sliding window analysis of 2- and 3-marker haplotypes for APP – Swedish study 
cohort 
 
 
Tab. 69: Results from sliding window analysis of 2-marker haplotypes for APP – Swedish 
study cohort 
 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 15-16 1.1 TG 0.727 0.4463 
  1.2 TA 0.235 0.7944 
2 16-17 2.1 GC 0.660 0.8463 
  2.2 AT 0.228 0.0786 
  2.3 GT 0.076 0.2203 
3 17-18 3.1 CA 0.693 0.5801 
  3.2 TA 0.262 0.7313 
4 18-20 4.1 AC 0.620 0.6947 
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  4.2 AT 0.336 0.5412 
5 20-21 5.1 CC 0.644 0.0617 
  5.2 TA 0.276 0.2853 
  5.3 TC 0.062 0.0015 
6 21-22 6.1 CG 0.551 0.6850 
  6.2 AG 0.248 0.7157 
  6.3 CT 0.156 0.3985 
7 22-23 7.1 GC 0.739 0.6104 
  7.2 TT 0.189 0.2211 
  7.3 GT 0.060 0.2573 
8 23-25 8.1 CC 0.496 0.4486 
  8.2 CT 0.254 0.2525 
  8.3 TC 0.241 0.6246 
9 35-36 9.1 TG 0.685 0.4230 
  9.2 CC 0.246 0.0165 
  9.3 CG 0.060 1.35E-06 
 
 
Tab. 70: Results from sliding window analysis of 3-marker haplotypes for APP – Swedish 
study cohort 
 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 15-17 1.1 TGC 0.649 0.8961 
  1.2 TAT 0.202 0.3731 
  1.3 TGT 0.075 0.2156 
2 16-18 2.1 GCA 0.659 0.9040 
  2.2 ATA 0.190 0.2166 
  2.3 GTA 0.073 0.2411 
3 17-20 3.1 CAC 0.373 0.5186 
  3.2 CAT 0.319 0.8148 
  3.3 TAC 0.248 0.3171 
4 18-21 4.1 ACC 0.607 0.1192 
  4.2 ATA 0.274 0.2955 
  4.3 ATC 0.062 0.0014 
5 20-22 5.1 CCG 0.490 0.3053 
  5.2 TAG 0.230 0.0777 
  5.3 CCT 0.154 0.2990 
  5.4 TCG 0.060 0.0027 
6 21-23 6.1 CGC 0.492 0.9283 
  6.2 AGC 0.246 0.5290 
  6.3 CTT 0.147 0.0586 
  6.4 CGT 0.057 0.4037 
7 22-25 7.1 GCC 0.488 0.2333 
  7.2 GCT 0.250 0.3916 
  7.3 TTC 0.186 0.2116 
  7.4 GTC 0.054 0.3916 
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Fig. 38: Sliding window analysis of 2- and 3-marker haplotypes for APP – Swedish study 
cohort 
 
 
Tab. 71: Results from sliding window analysis of 2-marker haplotypes for APP – pooled 
study cohort 
 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 15-16 1.1 TG 0.715 0.0704 
  1.2 TA 0.245 0.0601 
2 16-17 2.1 GC 0.657 0.1669 
  2.2 AT 0.240 0.4411 
  2.3 GT 0.068 0.9849 
3 17-18 3.1 CA 0.689 0.3445 
  3.2 TA 0.270 0.2662 
4 18-20 4.1 AC 0.616 0.3335 
  4.2 AT 0.344 0.3410 
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5 20-21 5.1 CC 0.646 0.6930 
  5.2 TA 0.291 0.2250 
  5.3 TC 0.053 0.6088 
6 21-22 6.1 CG 0.539 0.1328 
  6.2 AG 0.255 0.4505 
  6.3 CT 0.164 0.2579 
7 22-23 7.1 GC 0.741 0.2745 
  7.2 TT 0.197 0.1602 
  7.3 GT 0.054 0.8640 
8 23-25 8.1 CC 0.495 0.5337 
 8.2 CT 0.254 0.0775 
  8.3 TC 0.245 0.2760 
9 35-36 9.1 TG 0.688 0.3054 
 9.2 CC 0.260 0.0308 
 
 
Tab. 72: Results from sliding window analysis of 3-marker haplotypes for APP – pooled 
study cohort 
 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 15-17 1.1 TGC 0.647 0.0956 
  1.2 TAT 0.211 0.2280 
  1.3 TGT 0.066 0.9348 
2 16-18 2.1 GCA 0.655 0.1665 
  2.2 ATA 0.203 0.3393 
  2.3 GTA 0.067 0.8984 
3 17-20 3.1 CAC 0.357 0.6025 
  3.2 CAT 0.331 0.1368 
  3.3 TAC 0.259 0.5614 
4 18-21 4.1 ACC 0.608 0.6873 
  4.2 ATA 0.290 0.2337 
  4.3 ATC 0.053 0.6097 
5 20-22 5.1 CCG 0.485 0.2094 
  5.2 TAG 0.248 0.2018 
  5.3 CCT 0.161 0.2426 
  5.4 TCG 0.051 0.6475 
6 21-23 6.1 CGC 0.488 0.0993 
  6.2 AGC 0.253 0.4442 
  6.3 CTT 0.156 0.1627 
  6.4 CGT 0.051 0.8619 
7 22-25 7.1 GCC 0.489 0.6239 
  7.2 GCT 0.252 0.0974 
  7.3 TTC 0.195 0.1733 
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7.4.2 Results from Sliding Window Analyses for BACE1 
 
Tab. 73: Results from sliding window analysis of 2-marker haplotypes for BACE1– 
complete Munich cohort 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 1-2 1.1 AT 0.584 0.8009 
  1.2 TT 0.367 0.9540 
2 2-3 2.1 TC 0.887 0.4526 
  2.2 TG 0.064 0.5574 
3 3-4 3.1 CG 0.593 0.8745 
  3.2 CC 0.340 0.6887 
  3.3 GC 0.063 0.6378 
4 4-5 4.1 GT 0.597 0.8757 
  4.2 CT 0.316 0.4818 
  4.3 CC 0.087 0.3744 
5 5-6 5.1 TG 0.768 0.2605 
  5.2 TC 0.145 0.5260 
  5.3 CG 0.087 0.3719 
6 6-7 6.1 GA 0.523 0.2240 
  6.2 GG 0.332 0.4134 
  6.3 CA 0.145 0.5280 
7 7-8 7.1 AT 0.347 0.9845 
  7.2 GT 0.331 0.3930 
  7.3 AG 0.321 0.4003 
8 8-9 8.1 TA 0.408 0.5081 
  8.2 GG 0.322 0.3854 
  8.3 TG 0.270 0.8565 
9 9-10 9.1 GA 0.591 0.5751 
  9.2 AA 0.313 0.5020 
  9.3 AG 0.094 0.9601 
10 10-11 10.1 AA 0.561 0.3955 
  10.2 AC 0.344 0.3288 
  10.3 GC 0.092 0.9093 
 
 
Tab. 74: Results from sliding window analysis of 3-marker haplotypes for BACE1– 
complete Munich cohort 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 1-3 1.1 ATC 0.519 0.5868 
  1.2 TTC 0.367 0.9413 
  1.3 ATG 0.065 0.5718 
2 2-4 2.1 TCG 0.545 0.9567 
  2.2 TCC 0.340 0.6685 
  2.3 TGC 0.063 0.6250 
3 3-5 3.1 CGT 0.593 0.9028 
  3.2 CCT 0.256 0.3677 
  3.3 CCC 0.085 0.4146 
  3.4 GCT 0.061 0.7349 
4 4-6 4.1 GTG 0.452 0.7767 
  4.2 CTG 0.316 0.4781 
 
 4.3 GTC 0.145 0.5311 
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  4.4 CCG 0.087 0.3744 
5 5-7 5.1 TGA 0.523 0.2303 
  5.2 TGG 0.244 0.7752 
  5.3 TCA 0.145 0.5280 
  5.4 CGG 0.087 0.3673 
6 6-8 6.1 GGT 0.331 0.3963 
  6.2 GAG 0.322 0.3838 
  6.3 GAT 0.201 0.6151 
  6.4 CAT 0.145 0.5528 
7 7-9 7.1 GTA 0.331 0.3725 
  7.2 AGG 0.322 0.3936 
  7.3 ATG 0.268 0.8479 
  7.4 ATA 0.079 0.6942 
8 8-10 8.1 GGA 0.322 0.3852 
  8.2 TAA 0.314 0.4859 
  8.3 TGA 0.269 0.7899 
  8.4 TAG 0.094 0.9626 
9 9-11 9.1 GAA 0.523 0.4321 
  9.2 AAC 0.276 0.4237 
  9.3 AGC 0.092 0.9771 
  9.4 GAC 0.068 0.7540 
 
 
7.4.3 Results from Sliding Window Analyses for ADAM10 
 
Tab. 75: Results from sliding window analysis of 2-marker haplotypes for ADAM10– 
complete Munich cohort 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 1-2 1.1 GA 0.671 0.9598 
  1.2 GG 0.217 0.9252 
  1.3 TA 0.112 0.9619 
2 2-3 2.1 AA 0.668 0.6879 
  2.2 GA 0.217 0.9331 
  2.3 AG 0.115 0.6283 
3 3-4 3.1 AG 0.880 0.5749 
  3.2 GT 0.117 0.5225 
4 4-5 4.1 GT 0.880 0.6449 
  4.2 TC 0.117 0.5199 
5 5-6 5.1 TA 0.628 0.8865 
  5.2 TG 0.255 0.8515 
  5.3 CG 0.117 0.6389 
6 6-7 6.1 AC 0.624 0.8413 
  6.2 GT 0.330 0.9320 
7 7-8 7.1 CG 0.666 0.9331 
  7.2 TG 0.223 0.7953 
  7.3 TA 0.109 0.6156 
8 8-9 8.1 GA 0.881 0.6184 
  8.2 AG 0.111 0.7723 
9 9-10 9.1 AA 0.880 0.6438 
  9.2 GT 0.119 0.6178 
10 10-11 10.1 AG 0.883 0.7611 
  10.2 TA 0.107 0.7442 
11 11-12 11.1 GA 0.880 0.4470 
  11.2 AC 0.106 0.6396 
12 12-13 12.1 AA 0.877 0.5317 
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  12.2 CT 0.115 0.6582 
13 13-14 13.1 AC 0.880 0.6729 
  13.2 TG 0.117 0.5593 
14 14-15 14.1 CC 0.771 0.9431 
  14.2 GC 0.118 0.4901 
  14.3 CT 0.111 0.5391 
15 15-16 15.1 CA 0.759 0.7144 
  15.2 CG 0.127 0.4032 
  15.3 TG 0.114 0.7017 
16 16-17 16.1 AC 0.755 0.7884 
  16.2 GT 0.234 0.7218 
17 17-18 17.1 CT 0.767 0.8129 
  17.2 TT 0.124 0.8620 
  17.3 TC 0.107 0.7307 
18 18-19 18.1 TG 0.750 0.6723 
  18.2 TC 0.142 0.6893 
  18.3 CG 0.108 0.8881 
19 19-20 19.1 GG 0.587 0.6888 
  19.2 GA 0.272 0.8908 
  19.3 CG 0.141 0.6960 
20 20-21 20.1 GC 0.580 0.4101 
  20.2 GA 0.148 0.2893 
  20.3 AC 0.144 0.6346 
  20.4 AA 0.128 0.6836 
21 21-22 21.1 CC 0.723 0.5686 
  21.2 AC 0.169 0.7897 
  21.3 AA 0.108 0.6173 
22 22-23 22.1 CG 0.889 0.7047 
  22.2 AA 0.106 0.6242 
23 23-24 23.1 GG 0.886 0.7083 
  23.2 AA 0.108 0.4882 
24 24-25 24.1 GG 0.695 0.9938 
  24.2 GA 0.195 0.5265 
  24.3 AA 0.102 0.2988 
25 25-26 25.1 GA 0.683 0.9433 
  25.2 AG 0.260 0.4623 
26 26-27 26.1 AT 0.712 0.7762 
  26.2 GC 0.267 0.4378 
 
 
Tab. 76: Results from sliding window analysis of 3-marker haplotypes for ADAM10– 
complete Munich cohort 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 1-3 1.1 GAA 0.665 0.6759 
  1.2 GGA 0.217 0.9484 
  1.3 TAG 0.113 0.6963 
2 2-4 2.1 AAG 0.664 0.6454 
  2.2 GAG 0.217 0.9316 
  2.3 AGT 0.117 0.5225 
3 3-5 3.1 AGT 0.880 0.5911 
  3.2 GTC 0.117 0.5377 
4 4-6 4.1 GTA 0.627 0.8617 
  4.2 GTG 0.252 0.8801 
  4.3 TCG 0.117 0.5199 
5 5-7 5.1 TAC 0.624 0.8203 
  5.2 TGT 0.215 0.7184 
  5.3 CGT 0.116 0.7062 
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6 6-8 6.1 ACG 0.624 0.8418 
  6.2 GTG 0.221 0.6627 
  6.3 GTA 0.109 0.6408 
7 7-9 7.1 CGA 0.665 0.9411 
  7.2 TGA 0.217 0.7880 
  7.3 TAG 0.110 0.7373 
8 8-10 8.1 GAA 0.880 0.6438 
  8.2 AGT 0.111 0.7724 
9 9-11 9.1 AAG 0.880 0.6439 
  9.2 GTA 0.108 0.6473 
10 10-12 10.1 AGA 0.879 0.5728 
  10.2 TAC 0.107 0.6479 
11 11-13 11.1 GAA 0.880 0.3830 
  11.2 ACT 0.108 0.6390 
12 12-14 12.1 AAC 0.875 0.6713 
  12.2 CTG 0.117 0.6426 
13 13-15 13.1 ACC 0.769 0.8935 
  13.2 TGC 0.117 0.5620 
  13.3 ACT 0.111 0.5391 
14 14-16 14.1 CCA 0.756 0.7673 
  14.2 CTG 0.119 0.7657 
  14.3 GCG 0.118 0.5575 
15 15-17 15.1 CAC 0.755 0.7959 
  15.2 CGT 0.119 0.4240 
  15.3 TGT 0.114 0.7193 
16 16-18 16.1 ACT 0.753 0.9050 
  16.2 GTT 0.126 0.8957 
  16.3 GTC 0.108 0.7217 
17 17-19 17.1 CTG 0.625 0.6036 
  17.2 CTC 0.141 0.6991 
  17.3 TTG 0.124 0.8431 
  17.4 TCG 0.107 0.7112 
18 18-20 18.1 TGG 0.579 0.5737 
  18.2 TGA 0.171 0.8152 
  18.3 TCG 0.141 0.6962 
  18.4 CGA 0.106 0.7648 
19 19-21 19.1 GGC 0.573 0.6272 
  19.2 GAC 0.143 0.7021 
  19.3 GAA 0.137 0.9936 
  19.4 CGA 0.131 0.4775 
20 20-22 20.1 GCC 0.577 0.4978 
  20.2 ACC 0.146 0.8156 
  20.3 GAC 0.144 0.6183 
  20.4 AAA 0.105 0.6859 
21 21-23 21.1 CCG 0.720 0.6872 
  21.2 ACG 0.170 0.7978 
  21.3 AAA 0.106 0.7051 
22 22-24 22.1 CGG 0.886 0.6502 
  22.2 AAA 0.109 0.5044 
23 23-25 23.1 GGG 0.693 0.9737 
  23.2 GGA 0.192 0.7331 
  23.3 AAA 0.100 0.3434 
24 24-26 24.1 GGA 0.683 0.8978 
  24.2 GAG 0.159 0.9057 
  24.3 AAG 0.103 0.3175 
25 25-27 25.1 GAT 0.679 0.9028 
  25.2 AGC 0.258 0.3560 
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7.4.4 Results from Sliding Window Analyses for ABCA1 
 
Tab. 77: Results from sliding window analysis of 2-marker haplotypes for ABCA1 – 
complete Munich cohort 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 1-2 1.1 TG 0.512 0.1751 
  1.2 CG 0.365 0.0273 
  1.3 TC 0.081 0.3463 
2 2-3 2.1 GG 0.755 0.2023 
  2.2 GA 0.122 0.6240 
  2.3 CG 0.121 0.2897 
3 3-4 3.1 GT 0.751 0.8708 
  3.2 AT 0.125 0.6005 
  3.3 GC 0.124 0.4606 
4 4-5 4.1 TG 0.734 0.7056 
  4.2 TA 0.142 0.7111 
  4.3 CA 0.122 0.2707 
5 5-6 5.1 GG 0.651 0.8671 
  5.2 AG 0.265 0.5741 
  5.3 GA 0.084 0.5447 
6 6-7 6.1 GT 0.863 0.3654 
  6.2 AT 0.084 0.5328 
  6.3 GG 0.052 0.5367 
7 7-8 7.1 TC 0.912 0.6536 
8 8-9 8.1 CA 0.879 0.2430 
  8.2 CG 0.073 0.6303 
9 9-10 9.1 AG 0.857 0.1928 
  9.2 GG 0.115 0.1825 
10 10-11 10.1 GA 0.908 0.3810 
  10.2 GC 0.065 0.3628 
11 11-12 11.1 AC 0.828 0.3477 
  11.2 AG 0.104 0.6243 
  11.3 CC 0.067 0.4146 
12 12-13 12.1 CA 0.850 0.4553 
  12.2 GA 0.104 0.6228 
13 13-14 13.1 AA 0.882 0.9377 
  13.2 AG 0.072 0.7253 
14 14-15 14.1 AG 0.783 0.8274 
  14.2 AT 0.145 0.9976 
  14.3 GG 0.072 0.7253 
15 15-16 15.1 GG 0.693 0.7130 
  15.2 GA 0.162 0.6235 
  15.3 TA 0.145 0.9743 
16 16-17 16.1 GG 0.685 0.7953 
  16.2 AA 0.269 0.4722 
17 17-18 17.1 GG 0.631 0.1352 
  17.2 AG 0.219 0.6691 
  17.3 GA 0.090 0.1024 
  17.4 AA 0.060 0.7459 
18 18-19 18.1 GG 0.542 0.4005 
  18.2 GA 0.308 0.7151 
  18.3 AA 0.147 0.1414 
19 19-20 19.1 GC 0.544 0.5085 
  19.2 AC 0.434 0.2750 
20 20-21 20.1 CG 0.653 0.3603 
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  20.2 CA 0.326 0.6459 
21 21-22 21.1 GC 0.634 0.5915 
  21.2 AC 0.237 0.4736 
  21.3 AG 0.090 0.7522 
22 22-23 22.1 CC 0.614 0.9967 
  22.2 CT 0.257 0.9043 
  22.3 GT 0.127 0.8440 
23 23-24 23.1 CA 0.434 0.7060 
  23.2 TA 0.347 0.9120 
  23.3 CG 0.182 0.6934 
24 24-25 24.1 AG 0.609 0.2731 
  24.2 AA 0.174 0.4318 
  24.3 GG 0.173 0.7988 
25 25-26 25.1 GT 0.444 0.4144 
  25.2 GC 0.338 0.8862 
  25.3 AT 0.214 0.2287 
26 26-27 26.1 TG 0.361 0.4327 
  26.2 CA 0.312 0.7880 
  26.3 TA 0.296 0.4860 
27 27-28 27.1 AA 0.587 0.5455 
  27.2 GG 0.285 0.1584 
  27.3 GA 0.108 0.1496 
28 28-29 28.1 AA 0.402 0.1037 
  28.2 GA 0.304 0.1272 
  28.3 AG 0.295 0.8329 
29 29-30 29.1 AG 0.568 0.6663 
  29.2 GA 0.290 0.9912 
  29.3 AA 0.139 0.5064 
 
 
Tab. 78: Results from sliding window analysis of 3-marker haplotypes for ABCA1 – 
complete Munich cohort 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 1-3 1.1 TGG 0.423 0.3211 
  1.2 CGG 0.332 0.0254 
  1.3 TGA 0.088 0.5086 
  1.4 TCG 0.082 0.3400 
2 2-4 2.1 GGT 0.632 0.6520 
  2.2 GAT 0.123 0.6773 
  2.3 GGC 0.122 0.3531 
  2.4 CGT 0.120 0.3433 
3 3-5 3.1 GTG 0.734 0.6831 
  3.2 ATA 0.130 0.6874 
  3.3 GCA 0.124 0.2020 
4 4-6 4.1 TGG 0.649 0.9977 
  4.2 TAG 0.142 0.7168 
  4.3 CAG 0.122 0.2712 
  4.4 TGA 0.084 0.5448 
5 5-7 5.1 GGT 0.627 0.9645 
  5.2 AGT 0.236 0.4500 
  5.3 GAT 0.084 0.5462 
6 6-8 6.1 GTC 0.842 0.5895 
  6.2 ATC 0.070 0.1932 
7 7-9 7.1 TCA 0.843 0.4265 
  7.2 TCG 0.069 0.5012 
8 8-10 8.1 CAG 0.854 0.2345 
  8.2 CGG 0.070 0.6033 
9 9-11 9.1 AGA 0.857 0.1978 
  9.2 GGC 0.065 0.4070 
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10 10-12 10.1 GAC 0.829 0.4286 
  10.2 GAG 0.079 0.8359 
  10.3 GCC 0.065 0.3702 
11 11-13 11.1 ACA 0.824 0.3048 
  11.2 AGA 0.104 0.6237 
12 12-14 12.1 CAA 0.777 0.6653 
  12.2 GAA 0.104 0.6146 
  12.3 CAG 0.072 0.7277 
13 13-15 13.1 AAG 0.783 0.8274 
  13.2 AAT 0.099 0.7177 
  13.3 AGG 0.072 0.7253 
14 14-16 14.1 AGG 0.621 0.8523 
  14.2 AGA 0.162 0.6067 
  14.3 ATA 0.145 0.9743 
  14.4 GGG 0.072 0.7336 
15 15-17 15.1 GGG 0.685 0.7973 
  15.2 TAA 0.137 0.7951 
  15.3 GAA 0.131 0.5031 
16 16-18 16.1 GGG 0.603 0.1740 
  16.2 AAG 0.211 0.5380 
  16.3 GGA 0.082 0.0474 
  16.4 AAA 0.058 0.7723 
17 17-19 17.1 GGG 0.441 0.4410 
  17.2 GGA 0.191 0.3006 
  17.3 AGA 0.118 0.4370 
  17.4 AGG 0.101 0.8724 
  17.5 GAA 0.088 0.0838 
  17.6 AAA 0.060 0.8917 
18 18-20 18.1 GGC 0.542 0.4303 
  18.2 GAC 0.289 0.9127 
  18.3 AAC 0.145 0.1672 
19 19-21 19.1 GCG 0.494 0.9525 
  19.2 ACA 0.276 0.7739 
  19.3 ACG 0.157 0.3058 
  19.4 GCA 0.051 0.2371 
20 20-22 20.1 CGC 0.634 0.5134 
  20.2 CAC 0.237 0.3746 
  20.3 CAG 0.091 0.5640 
21 21-23 21.1 GCC 0.611 0.9463 
  21.2 ACT 0.236 0.4317 
  21.3 AGT 0.091 0.6922 
22 22-24 22.1 CCA 0.432 0.6973 
  22.2 CTA 0.247 0.8018 
  22.3 CCG 0.182 0.6536 
  22.4 GTA 0.101 0.7910 
23 23-25 23.1 CAG 0.349 0.2427 
  23.2 TAG 0.258 0.9598 
  23.3 CGG 0.152 0.9527 
  23.4 TAA 0.089 0.8116 
  23.5 CAA 0.085 0.1877 
24 24-26 24.1 AGT 0.350 0.4928 
  24.2 AGC 0.258 0.5830 
  24.3 AAT 0.171 0.3570 
  24.4 GGT 0.094 0.7858 
  24.5 GGC 0.080 0.5234 
25 25-27 25.1 GCA 0.309 0.7552 
  25.2 GTA 0.262 0.3723 
  25.3 GTG 0.182 0.9980 
  25.4 ATG 0.179 0.3017 
26 26-28 26.1 CAA 0.305 0.8654 
  26.2 TAA 0.282 0.3790 
  26.3 TGG 0.262 0.0986 
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  26.4 TGA 0.101 0.2591 
27 27-29 27.1 AAA 0.302 0.2797 
  27.2 AAG 0.285 0.6784 
  27.3 GGA 0.285 0.1598 
  27.4 GAA 0.100 0.2957 
28 28-30 28.1 AAG 0.335 0.3922 
  28.2 AGA 0.290 0.9910 
  28.3 GAG 0.234 0.1487 
  28.4 GAA 0.071 0.6555 
  28.5 AAA 0.068 0.1800 
 
 
7.4.5 Results from Sliding Window Analyses for LIPC 
 
Tab. 79: Results from sliding window analysis of 2-marker haplotypes for LIPC – 
complete Munich cohort 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 1-2 1.1 AC 0.52 0.9982 
  1.2 CC 0.266 0.1649 
  1.3 CT 0.197 0.1471 
2 2-3 2.1 CT 0.45 0.5998 
  2.2 CC 0.335 0.4996 
  2.3 TC 0.215 0.1581 
3 3-4 3.1 TG 0.44 0.6028 
  3.2 CA 0.282 0.8651 
  3.3 CG 0.269 0.8656 
4 4-5 4.1 GG 0.529 0.7672 
  4.2 AG 0.19 0.0873 
  4.3 GC 0.183 0.3569 
  4.4 AC 0.098 0.1205 
5 5-6 5.1 GA 0.553 0.7796 
  5.2 CA 0.279 0.0791 
  5.3 GG 0.165 0.0675 
6 6-7 6.1 AT 0.53 0.4295 
  6.2 AC 0.302 0.5984 
  6.3 GT 0.143 0.1083 
7 7-8 7.1 TT 0.587 0.6074 
  7.2 CT 0.327 0.7151 
  7.3 TA 0.086 0.7710 
8 8-9 8.1 TC 0.802 0.7458 
  8.2 TT 0.112 0.5078 
  8.3 AC 0.086 0.7769 
9 9-10 9.1 CC 0.843 0.7638 
  9.2 TG 0.153 0.9512 
10 10-11 10.1 CC 0.562 0.5151 
  10.2 CG 0.285 0.4891 
  10.3 GG 0.151 0.8850 
11 11-12 11.1 GG 0.449 0.4425 
  11.2 CC 0.415 0.6364 
  11.3 CG 0.127 0.7215 
12 12-13 12.1 CT 0.419 0.5259 
  12.2 GC 0.356 0.3681 
  12.3 GT 0.22 0.7162 
13 13-14 13.1 TC 0.49 0.6809 
  13.2 CC 0.319 0.3371 
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  13.3 TG 0.15 0.0669 
14 14-15 14.1 CT 0.627 0.8983 
  14.2 GC 0.195 0.1421 
  14.3 CC 0.178 0.1740 
15 15-16 15.1 TG 0.552 0.2027 
  15.2 CG 0.259 0.4804 
  15.3 CA 0.115 0.4597 
  15.4 TA 0.074 0.0319 
16 16-17 16.1 GG 0.791 0.5020 
  16.2 AG 0.188 0.3998 
17 17-18 17.1 GC 0.976 0.6069 
18 18-19 18.1 CG 0.945 0.7268 
19 19-20 19.1 GG 0.666 0.7640 
  19.2 GT 0.298 0.5619 
20 20-21 20.1 GC 0.56 0.9986 
  20.2 TC 0.319 0.7496 
  20.3 GT 0.122 0.6509 
21 21-22 21.1 CG 0.866 0.9775 
  21.2 TG 0.121 0.6618 
22 22-23 22.1 GA 0.988 0.1688 
23 23-24 23.1 AC 0.865 0.9528 
  23.2 AA 0.123 0.7620 
24 24-25 24.1 CT 0.511 0.4385 
  24.2 CC 0.365 0.5624 
  24.3 AT 0.123 0.7418 
 
 
Tab. 80: Results from sliding window analysis of 3-marker haplotypes for LIPC – 
complete Munich cohort 
Window Marker Haplotyp ID Sequence Frequency p-values 
1 1-3 1.1 ACT 0.439 0.8344 
  1.2 CCC 0.255 0.1705 
  1.3 CTC 0.195 0.1230 
  1.4 ACC 0.079 0.5030 
2 2-4 2.1 CTG 0.439 0.6020 
  2.2 CCG 0.259 0.9291 
  2.3 TCA 0.202 0.1693 
  2.4 CCA 0.078 0.0959 
3 3-5 3.1 TGG 0.437 0.5744 
  3.2 CAG 0.192 0.1211 
  3.3 CGC 0.189 0.4438 
  3.4 CAC 0.089 0.0542 
  3.5 CGG 0.081 0.1117 
4 4-6 4.1 GGA 0.510 0.9832 
  4.2 GCA 0.190 0.4878 
  4.3 AGG 0.155 0.0804 
  4.4 ACA 0.089 0.0675 
5 5-7 5.1 GAT 0.315 0.6067 
  5.2 GAC 0.238 0.8349 
  5.3 CAT 0.216 0.1146 
  5.4 GGT 0.142 0.1045 
  5.5 CAC 0.063 0.5580 
6 6-8 6.1 ATT 0.477 0.8693 
  6.2 ACT 0.303 0.6089 
  6.3 GTT 0.110 0.2846 
  6.4 ATA 0.053 0.1582 
7 7-9 7.1 TTC 0.476 0.9865 
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  7.2 CTC 0.323 0.7710 
  7.3 TTT 0.110 0.4320 
  7.4 TAC 0.086 0.7769 
8 8-10 8.1 TCC 0.757 0.6634 
  8.2 TTG 0.153 0.9506 
  8.3 ACC 0.086 0.7813 
9 9-11 9.1 CCC 0.560 0.4931 
  9.2 CCG 0.284 0.5112 
  9.3 TGG 0.149 0.9836 
10 10-12 10.1 CCC 0.412 0.7195 
  10.2 CGG 0.301 0.5035 
  10.3 GGG 0.148 0.7597 
  10.4 CCG 0.127 0.6541 
11 11-13 11.1 CCT 0.410 0.5965 
  11.2 GGC 0.246 0.2460 
  11.3 GGT 0.203 0.7909 
  11.4 CGC 0.110 0.8401 
12 12-14 12.1 GCC 0.314 0.3882 
  12.2 CTC 0.306 0.7849 
  12.3 GTC 0.183 0.8214 
  12.4 CTG 0.113 0.1700 
13 13-15 13.1 TCT 0.331 0.7749 
  13.2 CCT 0.296 0.6811 
  13.3 TCC 0.156 0.3927 
  13.4 TGC 0.152 0.0805 
14 14-16 14.1 CTG 0.555 0.0868 
  14.2 GCG 0.194 0.2401 
  14.3 CCA 0.113 0.1606 
  14.4 CTA 0.071 0.0065 
  14.5 CCG 0.062 0.8279 
15 15-17 15.1 TGG 0.545 0.2335 
  15.2 CGG 0.246 0.4484 
  15.3 CAG 0.115 0.4501 
  15.4 TAG 0.074 0.0306 
16 16-18 16.1 GGC 0.791 0.5029 
  16.2 AGC 0.186 0.3676 
17 17-19 17.1 GCG 0.944 0.8279 
18 18-20 18.1 CGG 0.655 0.8132 
  18.2 CGT 0.290 0.6745 
19 19-21 19.1 GGC 0.545 0.9588 
  19.2 GTC 0.298 0.5906 
  19.3 GGT 0.122 0.6512 
20 20-22 20.1 GCG 0.560 0.9984 
  20.2 TCG 0.306 0.9933 
  20.3 GTG 0.122 0.6515 
21 21-23 21.1 CGA 0.866 0.9775 
  21.2 TGA 0.121 0.6618 
22 22-24 22.1 GAC 0.864 0.8774 
  22.2 GAA 0.123 0.7621 
23 23-25 23.1 ACT 0.500 0.5952 
  23.2 ACC 0.365 0.5647 
  23.3 AAT 0.123 0.7432 
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7.5 Applied Primers 
7.5.1 Applied Primers for Genotyping 
7.5.1.1 Applied Primers for Genotyping of SNPs in APP 
Tab. 81: Applied primers for genotyping of SNPs in APP in initial case-control cohort from Munich 
 
SNP ID  1st Primer 2nd Primer xt Primer AMP 
Len 
rs2040124 ACGTTGGATGTGGCAGTTGTTCGTTCCATC ACGTTGGATGTGCCTACCTGCCAACTAAAC TCTTCCTTATCCCCAAAAT 106 
rs2829955 ACGTTGGATGCAGTCATGCTTTTTAACAG ACGTTGGATGTGGTGCATTTTCGGCTGAAG GAAGCCAGTGTTTTGTT 93 
rs6516704 ACGTTGGATGAACAGGACACAGATGTTTTC ACGTTGGATGTCTTGGACTTCAATTCTGGG CTCTAGATGACTATTGTCCTTTTTTT 99 
rs6516708 ACGTTGGATGAACATCCGCTTCCTGGGTTC ACGTTGGATGTGGCACACGCCTGTTAAGTC CGCCTGTTAAGTCCCAGCTACTC 96 
rs11549660 ACGTTGGATGAGACCCAAAGATACGTGGAC ACGTTGGATGCGTTTGTTTCTTCGTGCCTG CATTAGGCATTGAGACTTCAAGCTTTT 108 
rs373521 ACGTTGGATGTATTGTGTCTGTGCAGAGG ACGTTGGATGCTTCCTCATGGCTAAGCTAC CCAGCCCTACCACGAC 118 
rs2070653 ACGTTGGATGAAAGGTAAGAGTCTGCACTG ACGTTGGATGTTGTCTTAAATAGTCTGGC CCCTAAATAGTCTGGCCTCTCAA 99 
rs2829975 ACGTTGGATGGGATTTGCATTCTTAACTCCC ACGTTGGATGCTTGCCAATGAAAACCATGC GCTTCAAAAAGCTAAATGTCTT 100 
rs1783016 ACGTTGGATGACCTCTGGGATTTTTGAGTC ACGTTGGATGTTGGCCTGGTAGAGAGTTTG TTGTACAAGGCAGCAC 116 
rs2829983 ACGTTGGATGGCAGTAATTACACATGATAC ACGTTGGATGCAAGAATCAGCTTTATGGAAC AGCTTTATGGAACATCATTGACTTATC 113 
rs216781 ACGTTGGATGGAACATATTACGTATGTGCTC ACGTTGGATGCTAATGGGTGGATTGAGAGC GATTGAGAGCATATTACATACA 113 
rs2186301 ACGTTGGATGAAAGAATACACTTTCTAGG ACGTTGGATGTCTGCCAGAATGGTAGAGAG TGGTAGAGAGCGCAAT 104 
rs216762 ACGTTGGATGCATTTGTTTGCCTTTCTGAAG ACGTTGGATGTTTAATGCCAGGAGTTGAGC AAGTCTCCTGCAAAATTTATC 103 
rs762479 ACGTTGGATGCACCTGCTTTAACAGTGTGG ACGTTGGATGTCGGCCTCGCAAAGTGTTG CCCAGCCCAGATTTTTTT 120 
rs9978555 ACGTTGGATGCTTCAGTCCCATGTGTGAAC ACGTTGGATGGAAGCTGCAATCATCCAATC CTGCAATCATCCAATCAGAGCCAG 113 
rs9941877 ACGTTGGATGCTGTCTCTATAGATTTGCCC ACGTTGGATGGAAGTCGGACACAAAAGACC CCATGTATTATATGATCCCACTTA 100 
rs2830012 ACGTTGGATGGAAAGATGACCTGATGCATGT ACGTTGGATGAAACAGCGCTAGTTAGTGCC GATCTCAAACACGGTAAAT 113 
rs2830019 ACGTTGGATGGCTTCCTATCTGAACTTTTC ACGTTGGATGGCCAGAATATCATTTTCCCC CTCTTTAAACATACTTTTTATGATGCC 98 
rs768039 ACGTTGGATGATTACAAGCACCCGCCACAC ACGTTGGATGCTAACACAGAGAAACCCCG CCCGTGTCTACTAAAAAATC 92 
rs3787644 ACGTTGGATGGAGGAAAAGTGTGACTCTAC ACGTTGGATGGATTGAACCCAGTGGTCCAT CGTTGTCCATGGGGGTTGCTGAATT 114 
rs2070655 ACGTTGGATGGGTTCCTAATATATTGGGTC ACGTTGGATGAACAGTGAGTGGTAGAGTAG TGGTAGAGTAGATGTGTTTCATT 106 
rs3991 ACGTTGGATGCAGACAGTAAGTGCCAAACC ACGTTGGATGATCTAGTCGTCAGCAGATTG CGTCAGCAGATTGACTAAGG 96 
rs2830035 ACGTTGGATGGGAGTAAGAGTCTGAAATGG ACGTTGGATGGTGTATATGAAAATGACAGC TGACAGCTACAGATAAATGTTTTCTTA 97 
rs743532 ACGTTGGATGTCTTGAACCTTGCCCTTGAC ACGTTGGATGGTTACTGGGTTGTTTTGTTG TGCCCTTGATTCTTTGA 110 
rs1041420 ACGTTGGATGGAGAGGGAAACTGAAGATGG ACGTTGGATGCCATCCTATTACCCCAAACG TCTTCCAGGTCAGCAATCCAAAGTCAC 96 
rs2830046 ACGTTGGATGTTATCACCTGGGTTTTGCTG ACGTTGGATGGGGATACTCTATTTCAGGGC ATTATGTCTAGAGCTCATAACTCTTA 118 
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rs8130594 ACGTTGGATGCTTCCCATTCTCTCATGACC ACGTTGGATGCATCCATCCTATTAAGTCTG GCTGTATTCAAAGGATGAACTGATGA 112 
rs2830053 ACGTTGGATGCTCAGGATTATGATGTGCTAC ACGTTGGATGTGTCATAACTGAGGGTTTCC CTGAGGGTTTCCTAAGTA 94 
rs2246115 ACGTTGGATGATGTGTGTATGTTGACTACC ACGTTGGATGATGAAGACAACATGAGACAG AAGACAACATGAGACAGTTATAG 116 
rs2830069 ACGTTGGATGCTGCTGTTGTTCATAGCATGT ACGTTGGATGTAGCACATCTGAAGAGGCAC CTGAAGAGGCACTTCTATTCT 100 
rs462278 ACGTTGGATGAGCTGTCACTAGATAAAAGG ACGTTGGATGCCATGCCAAAGTACTTTTATC ACTTTTATCTTAAATTGCTTATTTTT 116 
rs2830082 ACGTTGGATGCGGAGGTTTGCTCCTTCATT ACGTTGGATGTGTTCTTAGCGTCTGTGGTC GAAGAGCTCTCTGGTCTTGTTT 110 
rs1788283 ACGTTGGATGTAGCCTTGGCAGCAGACTGA ACGTTGGATGCTTAAGTGATGCTGAGTGAC TTTTGTTTTTTTTCACTTTTTCTTTAC 112 
rs2830092 ACGTTGGATGTAAGAGCCACCTGAAACCAC ACGTTGGATGTTGGACCTTAGATTCGGGAG ATTCGGGAGAAAATCACTGT 80 
rs6516727 ACGTTGGATGGACTTTAGAGACTCACGAGG ACGTTGGATGCACTTAAGTAGGGTACCTTG CACTTAAGTAGGGTACCTTGTACCTAA 110 
rs2830099 ACGTTGGATGGGCTAGCAGATAAGAGAAGG ACGTTGGATGCGTTCTGAACCAAAGCTAAG TCTCCGTGAGCGATTA 98 
rs465984 ACGTTGGATGTGGTGCAGGGTATTCTCAAC ACGTTGGATGTCCTGCATTCAGCCCCTTAC CCTGCATTCAGCCCCTTACCTTTGA 100 
rs1235885 ACGTTGGATGATACTTTCCCCGTGGACAAG ACGTTGGATGTCAGATGGAATAGGCAGCAG GGAATAGGCAGCAGTGGGCAA 120 
rs456565  ACGTTGGATGCAGAAGACAGGAAGATGAGG ACGTTGGATGGCCTGGACTTCACTATTCAT TGACAACCATTTAACCAGT 120 
 
 
Tab. 82: Applied primers for genotyping of SNPs in APP in replication studies 
 
SNP ID  1st Primer 2nd Primer xt Primer AMP_Len 
rs9978555 ACGTTGGATGTGTGAACAGGTGTAGGAAC ACGTTGGATGGAAGCTGCAATCATCCAATC CTAATCCAATCAGAGCCAG 100
rs9941877 ACGTTGGATGCTGTCTCTATAGATTTGCCC ACGTTGGATGGAAGTCGGACACAAAAGACC CATGTATTATATGATCCCACTTA 100
rs2830012 ACGTTGGATGTAGTGCCCATGATTTGATTG ACGTTGGATGGAAAGATGACCTGATGCATGT TTTGTCTGATGCATGTCATCAGTT 100
rs2830019 ACGTTGGATGGCCAGAATATCATTTTCCCC ACGTTGGATGGCTTCCTATCTGAACTTTTC ATCTGAACTTTTCTTTAAAATATCT 98
rs768039 ACGTTGGATGTTTCTTCTCCCACACCAAGC ACGTTGGATGGTTCCAGGATCTGCTTTATG ACTCTACATCCTGGCT 113
rs3787644 ACGTTGGATGTCTGATTGAACCCAGTGGTC ACGTTGGATGGAGGAAAAGTGTGACTCTAC TCTAACATTTCATTTGCTTTAC 113
rs2070655 ACGTTGGATGTATATTGGGTCTGCATGTTG ACGTTGGATGGAAAACAGTGAGTGGTAGAG GTAGAGTAGATGTGTTTCATT 106
rs3991 ACGTTGGATGCAGACAGTAAGTGCCAAACC ACGTTGGATGATCTAGTCGTCAGCAGATTG CGTCAGCAGATTGACTAAGG 96
rs2830035 ACGTTGGATGGTGTATATGAAAATGACAGC ACGTTGGATGGGAGTAAGAGTCTGAAATGG TGAAATGGTAAAATAAAAAATCAC 97
rs1041420 ACGTTGGATGGGAGAGGGAAACTGAAGATG ACGTTGGATGCCCATCCTATTACCCCAAAC CCCTTTCAGCAATCCAAAGTCAC 98
rs6516727 ACGTTGGATGTTTAGAGACTCACGAGGAGG ACGTTGGATGCACTTAAGTAGGGTACCTTG TAGGGTACCTTGTACCTAA 110
rs2830099 ACGTTGGATGGGCTAGCAGATAAGAGAAGG ACGTTGGATGCGTTCTGAACCAAAGCTAAG TCTCCGTGAGCGATTA 98
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7.5.1.2 Applied Primers for Genotyping of SNPs in BACE1 
 
Tab. 83: Applied primers for genotyping of SNPs in BACE1 in initial case-control cohort from Munich 
SNP ID  1st Primer 2nd Primer xt Primer AMP 
Len 
rs644215 ACGTTGGATGCTAGCATCATGACTCTAGAC ACGTTGGATGTTCCTCCTTTCTACCCTCAC ACCCTCCTCTTTCAGGCCCC 109 
rs12292027 ACGTTGGATGCCTAGCTATAGTAAATATGC ACGTTGGATGATGAGAAGTCCTGAGGTATG GAAGGCCTGAGGTATGAAGAGAAC 85 
rs1047964 ACGTTGGATGGAATGATCTTGGGATGCTGG ACGTTGGATGTCCATTTTTCCCAGGACAGG CCGCCAGGAAATATGTCCCCC 102 
rs638405 ACGTTGGATGGTCTCTGGTATACACCCATC ACGTTGGATGTCCTGTCCATTGATCTCCAC CTCCACCCGCACAATGAT 96 
rs507805 ACGTTGGATGAAGTCTAAGCTGAACAGGCC ACGTTGGATGTTCATGTCCTTGGACTATGC GACTATGCAAAGCCACCT 115 
rs609332 ACGTTGGATGGTCAAGGACCCCAGGATTTA ACGTTGGATGATGATTCTTGTTTGGGCCAC TTTTGGAGTAGTCTGTTACC 117 
rs522843 ACGTTGGATGAGCTCAGGTCTGGAAATCAC ACGTTGGATGCAGTTATAGTGACTCCAGGC AGAACCTTGTGAGTCAGC 108 
rs687740 ACGTTGGATGTTGCCCAGGCTGGAGTACAGG ACGTTGGATGATCCAAGTTACTCAGGAGCC TTGAGCCCAGGAGTTA 104 
rs473210 ACGTTGGATGCCAGTTCTGCTGATTTCCTC ACGTTGGATGTTGGGTACTATAGCCAGGTG TAGCCAGGTGTTTCCCAAAATA 99 
rs551662 ACGTTGGATGCATGGTGGTGACAGAGTAAG ACGTTGGATGCAATCTTTGCAATCAATCTGG GACAATCAATCTGGTTTTTTGT 100 
rs525493 ACGTTGGATGTTGGCCTTCAGATATAAGGG ACGTTGGATGGTCTCTTCCTGAAAGATTGC TTACTGAAAGATTGCTTTCTTCATG 101 
 
 
7.5.1.3 Applied Primers for Genotyping of SNPs in ADAM10 
 
Tab. 84: Applied primers for genotyping of SNPs in ADAM10 in initial case-control cohort from Munich 
SNP ID  1st Primer 2nd Primer xt Primer AMP 
Len 
rs12438487 ACGTTGGATGGCTACACCTTTTTCAGAAAC ACGTTGGATGGATGCAGCATTTAGCAACTC TTGAAAACATAAAGCAAGATAAT 117 
rs1869135 ACGTTGGATGACTTCAGTGGTCGAACCATC ACGTTGGATGCTGCACCGCATGAAAACATC CCATCACCCTGCAACCT 105 
rs7166076 ACGTTGGATGGAGTAAGAGGAGATCCTTTTG ACGTTGGATGAGGTTTGAGGAAGGCACATC GATCCTTTTGTAGTTCATAAGTGTG 104 
rs7165035 ACGTTGGATGGTTTCTGCTGTCATATTTTGC ACGTTGGATGGCATTTGGGAAACAGTGCTC TGCTATAATTTTATGCATCTAAGTA 119 
rs2305421 ACGTTGGATGCTTTGACCTACAGTTTGGCC ACGTTGGATGGAGACACAATGCTACGTTAC CCAGATAATTTCCAGCTAAATC 104 
rs12594872 ACGTTGGATGAAAATAGGAAACCATGAGGG ACGTTGGATGGGAAGTATGTAAATATCCTG CATGAGGGAATAAATAAATGAATAC 97 
rs1427282 ACGTTGGATGGCTGTTCTTGTCTCACTTAC ACGTTGGATGTCTGAAGTATTTACAGGGAC GTTCTTGTCTCACTTACTCCCACA 113 
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rs7163733 ACGTTGGATGCTTTGTGATTTTGGTAGAGC ACGTTGGATGTGCAAGTGATAAGGTGAAAG TGTGATTTTGGTAGAGCTTATTAAA 118 
rs7174386 ACGTTGGATGCCCAGCATTTGAAGTTATAC ACGTTGGATGACTTAACACAGGGTTCTCGG GGTTAAGAATTCAATAAGCTG 102 
rs9302203 ACGTTGGATGCAGGTTCCTCCTTCAGAATC ACGTTGGATGACAGGTCTCTGAAAGGATGC GGGATAATCTGTTCTAATACCAGAC 120 
rs6494031 ACGTTGGATGGGTTGCACTATGTAAGAGAC ACGTTGGATGCCTTAGACTTCGAGAAGGTC TTGCACTATGTAAGAGACATTGGT 100 
rs11071392 ACGTTGGATGGTTTCATTCCTCTGCATACG ACGTTGGATGCAATGGTGCCAAAAACATCC TTCCTCTGCATACGGATATCCAGTT 112 
rs8026668 ACGTTGGATGTTAAACTGATGACAACAGTG ACGTTGGATGGGGGACAAAGTTAAAGTGTA GACAACAGTGATTGCATAA 102 
rs11071393 ACGTTGGATGGAAGAGTTGTGATAGAGAAC ACGTTGGATGCAGAGGAAATTCCTGCAAAC ACTACATGTTGTTCAAAAGT 114 
rs1427280 ACGTTGGATGCTTGTCATCTAGTAATGTTC ACGTTGGATGAAGGAGGACACTAAGTCCAG TCATCTAGTAATGTTCTTTGAAT 98 
rs1427281 ACGTTGGATGGAACTACAGTGCATCCTATG ACGTTGGATGCCTCATTTCTAGAAAAAGCC CTATCCTATGATTTAGCATCTCA 101 
rs4775086 ACGTTGGATGAACCATGGTTCACTTGACAG ACGTTGGATGCGGAAGGAGTTCCCTTAAAC CATGGTTCACTTGACAGATTTTTAG 116 
rs2052805 ACGTTGGATGCACATCCTCAGGAACACATC ACGTTGGATGGATGAAGATGAAGTGGCAAC AACACATCACATCAGGA 90 
rs2657125 ACGTTGGATGCAGAAATAGCCTGTTGAATAG ACGTTGGATGGTTCCTTGTATATTCTGGGT TATTTGCAAACTATTCATCTGA 102 
rs347117 ACGTTGGATGCTTTGCACTAGTAAGTTTCC ACGTTGGATGCTTGATTTGCTAGACCTTGTG AATAGTCTATATTGAACCAACAA 98 
rs4238331 ACGTTGGATGCTTTGTTAATTTAGGAGCATC ACGTTGGATGCCCAAATCAATCAATATTGAG ATTTAGGAGCATCAAATGTAT 95 
rs12441313 ACGTTGGATGATGGGAGTCCTGGAATTCTC ACGTTGGATGGAGGGGCTGATTATTTTGTG TATGATCACAGCCCCGT 111 
rs6494038 ACGTTGGATGAGCTTCAAAGTATGTGAAGA ACGTTGGATGGCTTGTTCAGAAAGGAGTGG AAAGTTGATAGAACAGAAAAAAG 114 
rs12439231 ACGTTGGATGCATCTCAGCTACCATTGTCC ACGTTGGATGTGCCCAAAAGACCTGGGTTG AAAAAGGGGGACCTCTG 98 
rs383902 ACGTTGGATGGTCAGCTTATTGATCTAAAG ACGTTGGATGGACTAGGATTAATTTACAGAG CTTATTGATCTAAAGTCTTCAATT 112 
rs653765 ACGTTGGATGTTTCCTTCCCTTGCTCGTTC ACGTTGGATGGTCACGTGGTGAGGAAGGAG CTTCTCTCCCCCCCTCC 100 
rs593742 ACGTTGGATGGAAGGCCAATGCTGGTAAAC ACGTTGGATGACATCCAGCAGGCAGTTTAG GGCCAATGCTGGTAAACATTTCAAC 95 
 
 
 
7.5.1.4 Applied Primers for Genotyping of SNPs in ABCA1 
 
Tab. 85: Applied primers for genotyping of SNPs in ABCA1 in initial case-control cohort from Munich 
SNP ID  1st Primer 2nd Primer xt Primer AMP 
Len 
rs2515606 ACGTTGGATGAGGTAACGTAGAGTGTACCC ACGTTGGATGAGACAGCGGTTTACCTTGAC GAATGGGAAGCTGACATTTTT 105 
rs1331924 ACGTTGGATGGATACAAACTGCTCTTGGAC ACGTTGGATGACTTCTCAGGGTGTGGATTC TGTGGATTCCTGCCCC 84 
rs2066720 ACGTTGGATGCCAGCCCCATGCTTTTTCTT ACGTTGGATGGATGGAGCAATTAGTCATCG GCAATTAGTCATCGAGAAGA 116 
rs2777799 ACGTTGGATGAGCCTCTATTCTTCTTCCCG ACGTTGGATGAGACAGCGGTTTACCTTGAC GCAGACTATAATATAGCATTAATGA 102 
rs2230808 ACGTTGGATGCTGCAGATCGATTTCTCAAC ACGTTGGATGAGACAGCGGTTTACCTTGAC CAGCGGTTTACCTTGACATTATTT 102 
rs2066716 ACGTTGGATGAAGAGGTCCATGATGGTCTG ACGTTGGATGTCTTGCTGTCTTCCCTTTGC CCCTTTGCAGAGACAC 114 
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rs2297401 ACGTTGGATGTGACTCAAGGTTTGCTGCTG ACGTTGGATGAGACAGCGGTTTACCTTGAC CCACCAAGCTGCTCCCAC 103 
rs3818689 ACGTTGGATGCAAGAGCATACGTGTTACAG ACGTTGGATGTTCATTATGCCTGCCAAAAG GCCAAAAGTTACGTGC 98 
rs4149313 ACGTTGGATGGTTTGGCGAGGAAAGTGATG ACGTTGGATGAGACAGCGGTTTACCTTGAC CAACAGCACTTACTTTCTGA 102 
rs2066718 ACGTTGGATGTACTCACAGCGAAGATCTTG ACGTTGGATGCATCTACTTCACGCTGTACC CCTGTGTGTGGCATGGCAGGACTAC 109 
rs2297398 ACGTTGGATGATCTCCCTGTGTCTTGGTAG ACGTTGGATGAGACAGCGGTTTACCTTGAC GACAGTCTACATGTAACATCATGC 94 
rs2487062 ACGTTGGATGGTGTCAGGCAATGAAAAAGC ACGTTGGATGAGACAGCGGTTTACCTTGAC TGTGAGCCACTGCACC 115 
rs914544 ACGTTGGATGCCTTTTAGGTCCACATGTTG ACGTTGGATGAGACAGCGGTTTACCTTGAC GAGGACAGAGATTACTCTGA 101 
rs1175293 ACGTTGGATGGTGTGATACAGTCCCTGATG ACGTTGGATGTCCATTCTTTAGGTCCCCAC GTCCCCACTTAGAGGATGTTTC 107 
rs2472445 ACGTTGGATGCACGGTGACTCATGCCTTTA ACGTTGGATGAGACAGCGGTTTACCTTGAC TGATCTGCCCACCTCG 113 
rs2230806 ACGTTGGATGCTTATTGATGCAGGAAACTC ACGTTGGATGAGACAGCGGTTTACCTTGAC ACCTTTTTCCTTCCCTATTTAT 108 
rs2230805 ACGTTGGATGCCTGGTGGACAATGAAACCT ACGTTGGATGCAGCATCTTGTCCACAGTAG GGAGAGAGAGGTTGTGATA 99 
rs13301006 ACGTTGGATGATGACCTGATGTGATTTGGG ACGTTGGATGTTTCCCTAACTCACTGCAAG CTCCTTTTCTTCTCTGCAATCG 90 
rs2000069 ACGTTGGATGCAGGTTTGATCACATGCACG ACGTTGGATGAGACAGCGGTTTACCTTGAC GGAAATGGTAAAAGCCACTTGTT 106 
rs1999429 ACGTTGGATGACTGTAGAAGGAGAACTGCC ACGTTGGATGTGTCCCAAGTCTACACAACC GATTGGAATAAATCACGGCTAAA 112 
rs2275542 ACGTTGGATGGCCACAGACAGTGATGTACT ACGTTGGATGAGACAGCGGTTTACCTTGAC CTCCAAGTCTGTAGTATTCTTC 107 
rs3847305 ACGTTGGATGCCATAATGGCATATCCTGGC ACGTTGGATGAGACAGCGGTTTACCTTGAC CTCCCTCTAGAAACCAAA 101 
rs2575875 ACGTTGGATGAGGCTGAACATAGCGTTTCT ACGTTGGATGAGACAGCGGTTTACCTTGAC AAATCATACATAAAGCCTGTGTGCTGC 103 
rs3758294 ACGTTGGATGACAACTATATGACCCATAC ACGTTGGATGAGACAGCGGTTTACCTTGAC GAAGGTATTAATTTGAATGGTATTGA 116 
rs2487042 ACGTTGGATGCCCTGGCATCTTCTAATTAC ACGTTGGATGAGACAGCGGTTTACCTTGAC GGGGAGGCCACAGCTGCCTGAAG 101 
rs2487035 ACGTTGGATGCCTGGAGTTCAAATATGGTC ACGTTGGATGAGACAGCGGTTTACCTTGAC CACATCTGAGACAGAGAGAGA 86 
rs2472516 ACGTTGGATGAGCAAAGATCCTATGTGCTA ACGTTGGATGAGACAGCGGTTTACCTTGAC GGAGAAAGCCAAACATCTGA 108 
rs4397467 ACGTTGGATGCAAGCTAGTGAAACAGAACG ACGTTGGATGAGACAGCGGTTTACCTTGAC GTCTTTAGACTTGGTCTCCTC 107 
rs4743776 ACGTTGGATGGAACACTAATCCTTTGTCTC ACGTTGGATGAGACAGCGGTTTACCTTGAC GGCACAGACTAGAAAGATA 81 
rs737623 ACGTTGGATGAAAACCTCGCACCATTTGGC ACGTTGGATGAGACAGCGGTTTACCTTGAC GGAGGCAGGTTGTACCAA 112 
 
 
Tab. 86: Applied primers for genotyping of SNPs in ABCA1 in replication studies 
SNP ID  1st Primer 2nd Primer xt Primer AMP_Len 
rs2515606 ACGTTGGATGCAATTACCTTTGAGCCTTAC ACGTTGGATGAGACAGCGGTTTACCTTGAC TAGAGTGTACCCATTAAAAAAGA 105 
rs2066720 ACGTTGGATGTCATTCTCTTGACATACAGG ACGTTGGATGAGACAGCGGTTTACCTTGAC GGGCAATTAGTCATCGAGAAGA 86 
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7.5.1.5 Applied Primers for Genotyping of SNPs in LIPC 
 
Tab. 87: Applied primers for genotyping of SNPs in LIPC in initial case-control cohort from Munich 
 
SNP ID  1st Primer 2nd Primer xt Primer AMP 
Len 
rs4774297 ACGTTGGATGCAGCAGGTCATGTTGATGGG ACGTTGGATGGTGTGACCTAGTCCTCTGTC TTACCTAGTCCTCTGTCATCAGT 97 
rs1800588 ACGTTGGATGTTGTGGTCAAAGTGTGGTGC ACGTTGGATGAGGGCATCTTTGCTTCTTCG TCAGCTCCTTTTGACA 95 
rs17190517 ACGTTGGATGTGCAGTTTAACAAGTGTTGC ACGTTGGATGGCTTTTCAAGCCCAAATACC AAAAAGAAAAAATATCCCATAGAA 119 
rs261341 ACGTTGGATGATGGTATATTGACTTTCATG ACGTTGGATGCCAGGATCACTGATCTAGTC TTATCTAGTCAAACTCCTTTATTT 113 
rs483140 ACGTTGGATGCTGGTGTGGACTTACTACTC ACGTTGGATGTTTGAGCTTCAGCAACTCTC CCCAAGCAACTCTCCGGAAG 115 
rs261336 ACGTTGGATGTGGTCTTTCGCGTTTCTGAG ACGTTGGATGGGTTGTGATGCACACTCAAG GAGAACCAGTGACCTAA 114 
rs3825776 ACGTTGGATGAAGCCTCTTGTGTGTAGCAG ACGTTGGATGTACTCCCACATGGTGACCAC GGGAACCACAGTGCATGGCAATT 102 
rs10518976 ACGTTGGATGCATCAGAGTATGTCCATGGC ACGTTGGATGGGAGATGTATAGCCTTCTCA GATCAATGTTCTATGACCTAGC 115 
rs10518978 ACGTTGGATGACTGATCCATTACTTTCATC ACGTTGGATGGACCCGAAAAGCAAAAAGCC AGATACAAGAGTCCACAATGA 111 
rs6494011 ACGTTGGATGAGCTTTGGTTCTCAAACGGG ACGTTGGATGGAAACTCTGAGAATGAGGGC CCCTCCACAATCTGGGTTTTAG 106 
rs1968685 ACGTTGGATGCATCAGATCTTCCCTGAACC ACGTTGGATGTGAGCACAGGGGTAAGTGGT GTTGCTGTGGGGAACCAGAGGGGACA 111 
rs1869137 ACGTTGGATGACTCTCTCATGTCACTGTCC ACGTTGGATGATGCTCTGGGTGAGACTCAT GGTCATCCAAGGAGTGGGACTCT 113 
rs1973028 ACGTTGGATGCTGAGAACACTTGCTCAAATC ACGTTGGATGGAAGAATGGAGAGACAGTGC CCCAGGGAACATGCACA 118 
rs2899631 ACGTTGGATGTTTTTAATTGGTGATACCAG ACGTTGGATGGATAGGAATGCTGTCAATGG CTATTTACCAGTCAAAATTTTAGTT 104 
rs4774302 ACGTTGGATGGAGATCATTGATCATCTTGG ACGTTGGATGAAGGGGACAGAAGAAATGCT CCATAATAATGGTGGAAAAATATCTAC 120 
rs2899632 ACGTTGGATGCCCTGTTTGCAGAGCTCTTC ACGTTGGATGCCCCAGTCTCCAGTGAAATG CTGCGCTATTCTGTAAATATTCAGTC 109 
rs12899928 ACGTTGGATGTCAGGCAAGTCTCAAAGAAG ACGTTGGATGTCACAGAGGTTGAGGTCATG TCAGCTTTCCTGAGGC 116 
rs4775072 ACGTTGGATGCTACTTTTAGGAAACTACAC ACGTTGGATGGCCCTATTACAAACAATTCTC CCCGATTACAAACAATTCTCTGATGAT 114 
rs6078 ACGTTGGATGACCATCTGCCAGATCCAGTT ACGTTGGATGAAAGGAAACTAGTGCGACCC ACTCCCCCTCCTCAGGTGGACGGC 98 
rs2242064 ACGTTGGATGGTCACTTTGAAGTTTAGCAC ACGTTGGATGGACCATCAGGATGGTGTATG GGATGGTGTATGGGCTTTATTT 115 
rs871804 ACGTTGGATGGAGAATTGGGAAACAGTCGC ACGTTGGATGAGGTTCCTTGTGAGAGAGTG AAGACCTTGTGAGAGAGTGAGAATG 98 
rs2414594 ACGTTGGATGAGTGGGCGAGCAAGCATAAC ACGTTGGATGTTTGCGCTGCTATGAGGATC CCACTGCTCTGACAGG 97 
rs3829462 ACGTTGGATGGTCTCTCTCTCTAGTTTATC ACGTTGGATGGTTCCGAGTAGTGACATGGT GGTTGATGAACTGGATCTT 119 
rs6074 ACGTTGGATGCTCATCTGATCTTTCGCTTTG ACGTTGGATGACAGATGACCTACTACTTCG ACCTACTACTTCGCCCAAC 111 
rs4774308 ACGTTGGATGTTATCTCATCCTACCCGAGC ACGTTGGATGGCATGGCATGGCCACAAATC CCGCCACAAATCATTTCACC 117 
 
 
7   Appendix 
207 
7.6 Index of Figures 
 
Fig. 1: Schematic of a normal and an AD affected neuron:......................................... 13 
Fig. 2: Two possibilities of the proteolytic cleavage of APP: ..................................... 14 
Fig. 3: Regulation of ABCA1-mediated cholesterol efflux ......................................... 25 
Fig. 4.: Primer extension adjustment according to the double 4-step method .............. 38 
Fig. 5.: Schematic of iPLEX reaction ........................................................................... 40 
Fig. 6.: Schematic of MALDI TOF mass spectrometry according to Griffin TJ et al. . 42 
Fig. 7.: MALDI TOF MS analysis of the primer extension reaction product............... 43 
Fig. 8.: MALDI TOF MS analysis of a multiplex reaction........................................... 44 
Fig. 9.: MALDI TOF MS analyses of extension primers for APP ............................... 45 
Fig. 10.: Schematic of RTQ-PCR ................................................................................... 47 
Fig. 11.: Alignment map for TaqMan® gene expression assay for APP........................ 48 
Fig. 12.: Alignment map for TaqMan® gene expression assay for ABCA1.................. 48 
Fig. 13: Schematic of the APP gene. ............................................................................. 69 
Fig. 14: LD structure of the APP gene, including the haplotype block structure. ......... 77 
Fig. 15: Sliding window analysis of 2- and 3-marker haplotypes for APP ................... 80 
Fig. 16: Calibration line for determination of APP mRNA ........................................... 84 
Fig. 17: Effect of rs1041420 (SNP # 25) genotypes on APP expression....................... 86 
Fig. 18: Western Blot analysis for APP in brain samples .............................................. 87 
Fig. 19: Boxplot of Aβ42 levels in CSF for significant SNP rs2830099 (# 36) ............ 90 
Fig. 20: Schematic of the BACE1 gene.......................................................................... 93 
Fig. 21: LD structure of the the BACE1 gene, including the haplotype block structure.
.......................................................................................................................... 96 
Fig. 22: Sliding window analysis of 2- and 3-marker haplotypes for BACE1............... 98 
Fig. 23: Schematic of the ADAM10 gene..................................................................... 101 
Fig. 24: LD structure of the ADAM10 gene, including the haplotype block structure. 105 
Fig. 25: Sliding window analysis of 2- and 3-marker haplotypes for ADAM10.......... 107 
Fig. 26: Schematic of the ABCA1 gene........................................................................ 110 
Fig. 27: LD structure of the ABCA1 gene, including the haplotype block structure.... 117 
Fig. 28: Sliding window analysis of 2- and 3-marker haplotypes for ABCA1............. 120 
Fig. 29: Calibration line for determination of ABCA1 mRNA levels. ......................... 124 
Fig. 30: Schematic of the LIPC gene. .......................................................................... 127 
Fig. 31: LD structure of the LIPC gene, including the haplotype block structure....... 130 
Fig. 32: Sliding window analysis of 2- and 3-marker haplotypes for LIPC ................ 133 
Fig. 33: Sliding window analysis of 2- and 3-marker haplotypes for APP – Munich 
EOAD subcollective ....................................................................................... 167 
Fig. 34: Sliding window analysis of 2- and 3-marker haplotypes for APP – Munich 
LOAD subcollective ....................................................................................... 172 
Fig. 35: Sliding window analysis of 2- and 3-marker haplotypes for APP – Munich 
ApoE ε4 subcollective .................................................................................... 177 
7   Appendix 
208 
Fig. 36: Sliding window analysis of 2- and 3-marker haplotypes for APP – Munich 
nonApoE ε4 subcollective .............................................................................. 182 
Fig. 37: Sliding window analysis of 2- and 3-marker haplotypes for APP – Swedish 
study cohort .................................................................................................... 187 
Fig. 38: Sliding window analysis of 2- and 3-marker haplotypes for APP – Swedish 
study cohort .................................................................................................... 189 
 
 
 
7.7 Index of Tables 
 
Tab. 1: Standard temperature profiles for PCR ............................................................ 35 
Tab. 2: Pipetting scheme for PCR master mix.............................................................. 36 
Tab. 3: Pipetting scheme for SAP master mix.............................................................. 37 
Tab. 4: Conditions for SAP reaction............................................................................. 37 
Tab. 5: Pipetting scheme for iPLEX master mix .......................................................... 38 
Tab. 6: Conditions for iPLEX -reaction........................................................................ 39 
Tab. 7: Pipetting scheme cDNA synthesis.................................................................... 46 
Tab. 8: Conditions for cDNA synthesis ........................................................................ 46 
Tab. 9: Pipetting scheme RTQ-PCR............................................................................. 49 
Tab. 10: Conditions for RTQ-PCR ................................................................................. 49 
Tab. 11: Buffers used for Western Blot .......................................................................... 51 
Tab. 12: List of materials and providers – part 1 ............................................................ 55 
Tab. 13: List of materials and providers – part 2 ............................................................ 56 
Tab. 14: List of enzymes and providers.......................................................................... 58 
Tab. 15: Participating clinics in the sib-pairs cohort study............................................. 65 
Tab. 16: Selected SNPs from the chromosomal region covering the APP gene. ........... 67 
Tab. 17: Results from allelic tests for the APP gene. ..................................................... 71 
Tab. 18: Results from genotypic tests for the APP gene. ............................................... 74 
Tab. 19: Haplotype blocks and frequencies for APP in Munich collective.................... 78 
Tab. 20: Results of replication for selected SNPs of APP in independent studies – part 1
.......................................................................................................................... 82 
Tab. 21: Results of statistical analysis of APP genotypes in brain samples ................... 84 
Tab. 22: Results from the statistical analysis measuring the influence of sequence 
variation on gene expression levels of APP ..................................................... 85 
Tab. 23: Results from the statistical analysis measuring the influence of sequence 
variation on total Aβ content. ........................................................................... 88 
Tab. 24: Results of statistical analysis of Aβ42 levels in CSF ....................................... 89 
Tab. 25: Selected SNPs from the BACE1 gene............................................................... 92 
Tab. 26: Results from allelic tests for the BACE1 gene.................................................. 94 
Tab. 27: Results from genotypic tests for the BACE1 gene............................................ 95 
Tab. 28: Haplotype blocks and frequencies for BACE1 in Munich collective ............... 97 
Tab. 29: Selected SNPs from the ADAM10 gene. .......................................................... 99 
7   Appendix 
209 
Tab. 30: Results from allelic tests for the ADAM10 gene............................................. 102 
Tab. 31: Results from genotypic tests for the ADAM10 gene. .................................... 103 
Tab. 32: Haplotype blocks and frequencies for ADAM10 in the Munich collective .... 106 
Tab. 33: Selected SNPs from the ABCA1 gene............................................................. 109 
Tab. 34: Results from allelic tests for ABCA1 gene...................................................... 112 
Tab. 35: Results from genotypic tests for ABCA1 gene................................................ 114 
Tab. 36: Haplotype blocks and frequencies for ABCA1 in the Munich collective ....... 118 
Tab. 37: Results of replication for selected SNPs of ABCA1 in independent studies – 
part 1 ............................................................................................................... 122 
Tab. 38: Results of statistical analysis of ABCA1 genotypes in brain samples ............ 123 
Tab. 39 Results of statistical analysis of gene expression of ABCA1 .......................... 124 
Tab. 40: Selected SNPs from the LIPC gene. ............................................................... 126 
Tab. 41: Results from allelic tests for LIPC gene. ........................................................ 128 
Tab. 42: Results from genotypic tests for the LIPC gene. ............................................ 129 
Tab. 43: Haplotype blocks and frequencies for LIPC in Munich collective ................ 131 
Tab. 44: AD diagnostic according to CERAD criteria ................................................. 151 
Tab. 45: Statistics and composition of the Munich study cohort, including sub-
collectives ....................................................................................................... 152 
Tab. 46: Statistics and composition of the replication study cohorts, including sub-
collectives ....................................................................................................... 152 
Tab. 47: Statistics and composition of the cerebrospinal fluid samples ....................... 152 
Tab. 48: Results from genotypic tests for APP gene in the ApoE ε4/non ApoE ε4 
subcollectives of the Munich study cohort ..................................................... 153 
Tab. 49: Results from allelic tests for APP gene in the Swedish and pooled study 
cohorts ............................................................................................................ 154 
Tab. 50: Results from linear regression tests for APP gene - association between 
genotypes and Mini-Mental State Examination (MMSE).............................. 155 
Tab. 51: Results from linear regression tests for APP gene - association between 
genotypes and age at onset ............................................................................. 156 
Tab. 52: Results from allelic tests for BACE1 gene in the sub-collectives of the Munich 
study cohort .................................................................................................... 157 
Tab. 53: Results from allelic tests for ADAM10 gene in the sub-collectives of the 
Munich study cohort ....................................................................................... 157 
Tab. 54: Results from genotypic tests for ABCA1 gene in the ApoE ε4/non ApoE ε4 
subcollectives of the Munich study cohort ..................................................... 158 
Tab. 55: Results from allelic tests for ABCA1 gene in the Swedish and pooled study 
cohorts ............................................................................................................ 159 
Tab. 56: Results from linear regression tests for ABCA1 gene - association between 
genotypes and Mini-Mental State Examination (MMSE).............................. 160 
Tab. 57: Results from linear regression tests for ABCA1 gene - association between 
genotypes and age at onset ............................................................................. 161 
Tab. 58: Results from allelic tests for LIPC gene in the sub-collectives of the Munich 
study cohort .................................................................................................... 162 
Tab. 59: Results from sliding window analysis of 2-marker haplotypes for APP – 
complete Munich cohort ................................................................................. 163 
7   Appendix 
210 
Tab. 60: Results from sliding window analysis of 3-marker haplotypes for APP – 
complete Munich cohort ................................................................................. 165 
Tab. 61: Results from sliding window analysis of 2-marker haplotypes for APP – 
Munich EOAD subcollective.......................................................................... 168 
Tab. 62: Results from sliding window analysis of 3-marker haplotypes for APP – 
Munich EOAD subcollective.......................................................................... 170 
Tab. 63: Results from sliding window analysis of 2-marker haplotypes for APP – 
Munich LOAD subcollective.......................................................................... 173 
Tab. 64: Results from sliding window analysis of 3-marker haplotypes for APP – 
Munich LOAD subcollective.......................................................................... 175 
Tab. 65: Results from sliding window analysis of 2-marker haplotypes for APP – 
Munich ApoE ε4 subcollective....................................................................... 178 
Tab. 66: Results from sliding window analysis of 3-marker haplotypes for APP – 
Munich ApoE ε4 subcollective....................................................................... 180 
Tab. 67: Results from sliding window analysis of 2-marker haplotypes for APP – 
Munich nonApoE ε4 subcollective................................................................. 183 
Tab. 68: Results from sliding window analysis of 3-marker haplotypes for APP – 
Munich nonApoE ε4 subcollective................................................................. 184 
Tab. 69: Results from sliding window analysis of 2-marker haplotypes for APP – 
Swedish study cohort...................................................................................... 187 
Tab. 70: Results from sliding window analysis of 3-marker haplotypes for APP – 
Swedish study cohort...................................................................................... 188 
Tab. 71: Results from sliding window analysis of 2-marker haplotypes for APP – pooled 
study cohort .................................................................................................... 189 
Tab. 72: Results from sliding window analysis of 3-marker haplotypes for APP – pooled 
study cohort .................................................................................................... 190 
Tab. 73: Results from sliding window analysis of 2-marker haplotypes for BACE1– 
complete Munich cohort ................................................................................. 191 
Tab. 74: Results from sliding window analysis of 3-marker haplotypes for BACE1– 
complete Munich cohort ................................................................................. 191 
Tab. 75: Results from sliding window analysis of 2-marker haplotypes for ADAM10– 
complete Munich cohort ................................................................................. 192 
Tab. 76: Results from sliding window analysis of 3-marker haplotypes for ADAM10– 
complete Munich cohort ................................................................................. 193 
Tab. 77: Results from sliding window analysis of 2-marker haplotypes for ABCA1 – 
complete Munich cohort ................................................................................. 195 
Tab. 78: Results from sliding window analysis of 3-marker haplotypes for ABCA1 – 
complete Munich cohort ................................................................................. 196 
Tab. 79: Results from sliding window analysis of 2-marker haplotypes for LIPC – 
complete Munich cohort ................................................................................. 198 
Tab. 80: Results from sliding window analysis of 3-marker haplotypes for LIPC – 
complete Munich cohort ................................................................................. 199 
Tab. 81: Applied primers for genotyping of SNPs in APP in initial case-control cohort 
from Munich ................................................................................................... 201 
Tab. 82: Applied primers for genotyping of SNPs in APP in replication studies ........ 202 
7   Appendix 
211 
Tab. 83: Applied primers for genotyping of SNPs in BACE1 in initial case-control 
cohort from Munich........................................................................................ 203 
Tab. 84: Applied primers for genotyping of SNPs in ADAM10 in initial case-control 
cohort from Munich........................................................................................ 203 
Tab. 85: Applied primers for genotyping of SNPs in ABCA1 in initial case-control 
cohort from Munich........................................................................................ 204 
Tab. 86: Applied primers for genotyping of SNPs in ABCA1 in replication studies.... 205 
Tab. 87: Applied primers for genotyping of SNPs in LIPC in initial case-control cohort 
from Munich ................................................................................................... 206 
 
7   Appendix 
212 
 
7.8 Publications 
 
 
1 S.M. Laws, K. Eckart, P. Friedrich, A. Kurz, H. Förstl and M. Riemenschneider; Lack 
of evidence to support the association of polymorphisms within the alpha- and beta-secretase 
genes (ADAM10/BACE1) with Alzheimer's disease; Neurobiol Aging 2009 
 
2 S.M. Laws, K. Eckart, P. Friedrich, T. Eisele, A. Kurz, H. Förstl and M. 
Riemenschneider; No association of lipase C polymorphisms with Alzheimer’s disease; 
Neurobiol Aging 2008 
 
3 P. Friedrich; T.M. Feulner; S.M. Laws; K. Eckart; R. Perneczky; A. Kurz; H. Förstl; 
M. Riemenschneider; No association of Tachykinin receptor 2 (TACR2) polymorphisms with 
Alzheimer's disease; Neurobiol Aging 2008 
 
4 K. Eckart, S.M. Laws, P. Friedrich, S. Wagenpfeil, C. Riehle, T. Eisele, J. Müller, 
R.M. Page, C. Haass, C. Graff, B.F. Björk, H. Förstl, A. Kurz and M. Riemenschneider; 
Common APP variants are associated with Alzheimer’s disease and cause alterations of gene 
expression and APP processing; to be submitted soon 
 
7   Appendix 
213 
 
7.9 Curriculum Vitae 
 
Personal Data: Kerstin Eckart 
   St.-Cajetan-Str. 31 
   81669 München 
   * 14. April 1977 in Bad Windsheim 
 
Education: 
since 05/2005 Ph.D. student, Klinik und Poliklinik für Psychiatrie und Psychotherapie,  
Klinikum rechts der Isar, Technische Universität München  
11/2003 – 07/2004 Post-graduate programme English-speaking countries in conjunction 
with general & business English (ESL), Ludwig-Maximilians-
Universität, München 
06/2003 Graduation to Dipl.-Biol. univ. (biology diploma: plantphysiology, 
zoology, anorganic chemistry, organic chemistry, physical chemistry) 
1996 – 2003 Study of chemistry and biology at Ludwig-Maximilians-Universität, 
München 
06/1996 Graduation with “Allgemeine Hochschulreife” (Abitur) from Georg-
Wilhelm-Steller-Gymnasium, Bad Windsheim 
1983 –1996  Primary and secondary school education 
 
 
Professional and Work Experience: 
since 07/2003 BioProof AG, München 
Working areas: Pharmacokinetics, statistics, medical writing 
04/2002 – 12/2002 Diploma work: Massspectrometical characterisation of membrane 
proteins of the chloroplastic outer envelope in Pisum sativum  
Publications: - Eckart, K. et al., A Toc75-like protein import channel is 
abundant in chloroplasts, EMBO Rep., June 2002 
- Schleiff, E. et al., Prediction of the plant beta-barrel 
proteome: a case study of the chloroplast outer envelope, 
Protein Sci., April 2003  
11/2000 – 12/2002 Complementary scientist 
Phytochemical chair, Ludwig-Maximilians-Universität, München 
 
7   Appendix 
214 
 
7.10 References 
 
Ando, T., S. S. Monroe, et al. (1997). "A one-tube method of reverse transcription-PCR to efficiently amplify a 
3-kilobase region from the RNA polymerase gene to the poly(A) tail of small round-structured viruses 
(Norwalk-like viruses)." J Clin Microbiol 35(3): 570-7. 
Athan, E. S., J. H. Lee, et al. (2002). "Polymorphisms in the promoter of the human APP gene: functional 
evaluation and allele frequencies in Alzheimer disease." Arch Neurol 59(11): 1793-9. 
Balistreri, C. R., M. P. Grimaldi, et al. (2006). "Association between the polymorphism of CCR5 and 
Alzheimer's disease: results of a study performed on male and female patients from Northern Italy." Ann 
N Y Acad Sci 1089: 454-61. 
Baroni, M. G., A. Berni, et al. (2003). "Genetic study of common variants at the Apo E, Apo AI, Apo CIII, Apo 
B, lipoprotein lipase (LPL) and hepatic lipase (LIPC) genes and coronary artery disease (CAD): variation 
in LIPC gene associates with clinical outcomes in patients with established CAD." BMC Med Genet 4: 8. 
Barrachina, M., T. Maes, et al. (2006). "Lysosome-associated membrane protein 1 (LAMP-1) in Alzheimer's 
disease." Neuropathol Appl Neurobiol 32(5): 505-16. 
Barrett, J. C., B. Fry, et al. (2005). "Haploview: analysis and visualization of LD and haplotype maps." 
Bioinformatics 21(2): 263-5. 
Bassiony, M. M., A. Rosenblatt, et al. (2004). "Falls and age in patients with Alzheimer's disease." J Nerv Ment 
Dis 192(8): 570-2. 
Bauer, J., M. Hull, et al. (1995). "[Pathogenetic factors of Alzheimer disease]." Z Gerontol Geriatr 28(3): 155. 
Becaria, A., A. Campbell, et al. (2002). "Aluminum as a toxicant." Toxicol Ind Health 18(7): 309-20. 
Bertram, L., D. Blacker, et al. (2000). "Evidence for genetic linkage of Alzheimer's disease to chromosome 10q." 
Science 290(5500): 2302-3. 
Bertram, L., M. B. McQueen, et al. (2007). "Systematic meta-analyses of Alzheimer disease genetic association 
studies: the AlzGene database." Nat Genet 39(1): 17-23. 
Bickeboller, H. and C. Fischer (2007). Einführung in die Genetische Epidemiologie, Springer. 
Bickel, H. (2000). "[Dementia syndrome and Alzheimer disease: an assessment of morbidity and annual 
incidence in Germany]." Gesundheitswesen 62(4): 211-8. 
Bickel, H. (2001). "[Dementia in advanced age: estimating incidence and health care costs]." Z Gerontol Geriatr 
34(2): 108-15. 
Blacker, D., L. Bertram, et al. (2003). "Results of a high-resolution genome screen of 437 Alzheimer's disease 
families." Hum Mol Genet 12(1): 23-32. 
Bleck, O., J. A. McGrath, et al. (2001). "Searching for candidate genes in the new millennium." Clin Exp 
Dermatol 26(3): 279-83. 
Bodzioch, M., E. Orso, et al. (1999). "The gene encoding ATP-binding cassette transporter 1 is mutated in 
Tangier disease." Nat Genet 22(4): 347-51. 
Bouwman, F. H., N. S. Schoonenboom, et al. (2008). "CSF biomarker levels in early and late onset Alzheimer's 
disease." Neurobiol Aging. 
Brooks-Wilson, A., M. Marcil, et al. (1999). "Mutations in ABC1 in Tangier disease and familial high-density 
lipoprotein deficiency." Nat Genet 22(4): 336-45. 
Brown, R. C., A. H. Lockwood, et al. (2005). "Neurodegenerative diseases: an overview of environmental risk 
factors." Environ Health Perspect 113(9): 1250-6. 
Buee, L., T. Bussiere, et al. (2000). "Tau protein isoforms, phosphorylation and role in neurodegenerative 
disorders." Brain Res Brain Res Rev 33(1): 95-130. 
Cai, S. J., D. M. Wong, et al. (1989). "Structure of the human hepatic triglyceride lipase gene." Biochemistry 
28(23): 8966-71. 
Candore, G., C. R. Balistreri, et al. (2006). "Age-related inflammatory diseases: role of genetics and gender in 
the pathophysiology of Alzheimer's disease." Ann N Y Acad Sci 1089: 472-86. 
Canevari, L. and J. B. Clark (2007). "Alzheimer's disease and cholesterol: the fat connection." Neurochem Res 
32(4-5): 739-50. 
7   Appendix 
215 
Chu, L. W., Y. Li, et al. (2007). "A novel intronic polymorphism of ABCA1 gene reveals risk for sporadic 
Alzheimer's disease in Chinese." Am J Med Genet B Neuropsychiatr Genet 144B(8): 1007-13. 
Colucci, M., S. Cammarata, et al. (2006). "The number of pregnancies is a risk factor for Alzheimer's disease." 
Eur J Neurol 13(12): 1374-7. 
Combs, C. K., P. Bates, et al. (2001). "Regulation of beta-amyloid stimulated proinflammatory responses by 
peroxisome proliferator-activated receptor alpha." Neurochem Int 39(5-6): 449-57. 
Coon, K. D., A. J. Myers, et al. (2007). "A high-density whole-genome association study reveals that APOE is 
the major susceptibility gene for sporadic late-onset Alzheimer's disease." J Clin Psychiatry 68(4): 613-8. 
Corder, E. H., E. Ghebremedhin, et al. (2004). "The biphasic relationship between regional brain senile plaque 
and neurofibrillary tangle distributions: modification by age, sex, and APOE polymorphism." Ann N Y 
Acad Sci 1019: 24-8. 
Cribbs, D. H., W. W. Poon, et al. (2004). "Caspase-mediated degeneration in Alzheimer's disease." Am J Pathol 
165(2): 353-5. 
Crowther, M. A. and D. J. Cook (2007). "Trials and tribulations of systematic reviews and meta-analyses." 
Hematology Am Soc Hematol Educ Program 2007: 493-7. 
Cruts, M., H. Backhovens, et al. (1995). "Molecular genetic analysis of familial early-onset Alzheimer's disease 
linked to chromosome 14q24.3." Hum Mol Genet 4(12): 2363-71. 
Davis, J., M. R. Wagner, et al. (2003). "Amyloid beta-protein stimulates the expression of urokinase-type 
plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells." J 
Biol Chem 278(21): 19054-61. 
Daw, E. W., H. Payami, et al. (2000). "The number of trait loci in late-onset Alzheimer disease." Am J Hum 
Genet 66(1): 196-204. 
De Jager, C. A., E. Hogervorst, et al. (2003). "Sensitivity and specificity of neuropsychological tests for mild 
cognitive impairment, vascular cognitive impairment and Alzheimer's disease." Psychol Med 33(6): 1039-
50. 
de la Chapelle, A. and F. A. Wright (1998). "Linkage disequilibrium mapping in isolated populations: the 
example of Finland revisited." Proc Natl Acad Sci U S A 95(21): 12416-23. 
De Leon, M. J., A. E. George, et al. (1997). "Frequency of hippocampal formation atrophy in normal aging and 
Alzheimer's disease." Neurobiol Aging 18(1): 1-11. 
Dickson, D. W. (2004). "Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect?" J 
Clin Invest 114(1): 23-7. 
Edbauer, D., E. Winkler, et al. (2003). "Reconstitution of gamma-secretase activity." Nat Cell Biol 5: 486-488. 
Ehehalt, R., B. Michel, et al. (2002). "Splice variants of the beta-site APP-cleaving enzyme BACE1 in human 
brain and pancreas." Biochem Biophys Res Commun 293(1): 30-7. 
Feulner, T. M., S. M. Laws, et al. (2009). "Examination of the current top candidate genes for AD in a genome-
wide association study." Mol Psychiatry. 
Folstein, M. F., S. E. Folstein, et al. (1975). "'Mini Mental State'. A practical method for grading the cognitive 
state of patients for the clinician." J Psychiat Res 12: 189-198. 
Forstl, H. (2000). "Clinical issues in current drug therapy for dementia." Alzheimer Dis Assoc Disord 14 Suppl 
1: S103-8. 
Gabriel, S. B., S. F. Schaffner, et al. (2002). "The structure of haplotype blocks in the human genome." Science 
296(5576): 2225-9. 
Garcia, T. and D. Jay (2004). "[Phosphorylation of tau and Alzheimer's disease]." Gac Med Mex 140(3): 329-33. 
Gasparini, L., W. J. Netzer, et al. (2002). "Does insulin dysfunction play a role in Alzheimer's disease?" Trends 
Pharmacol Sci 23(6): 288-93. 
Goate, A., M. C. Chartier-Harlin, et al. (1991). "Segregation of a missense mutation in the amyloid precursor 
protein gene with familial Alzheimer's disease." Nature 349(6311): 704-6. 
Goate, A. M., A. R. Haynes, et al. (1989). "Predisposing locus for Alzheimer's disease on chromosome 21." 
Lancet 1(8634): 352-5. 
Gomez-Ramos, A., M. A. Smith, et al. (2004). "Tau phosphorylation and assembly." Acta Neurobiol Exp (Wars) 
64(1): 33-9. 
Gong, C. X., F. Liu, et al. (2005). "Post-translational modifications of tau protein in Alzheimer's disease." J 
Neural Transm 112(6): 813-38. 
7   Appendix 
216 
Griffin, T. J. and L. M. Smith (2000). "Genetic identification by mass spectrometric analysis of single-nucleotide 
polymorphisms: ternary encoding of genotypes." Anal Chem 72(14): 3298-302. 
Grossberg, G. T. (2005). "Effect of rivastigmine in the treatment of behavioral disturbances associated with 
dementia: review of neuropsychiatric impairment in Alzheimer's disease." Curr Med Res Opin 21(10): 
1631-9. 
Grossman, H., C. Bergmann, et al. (2006). "Dementia: a brief review." Mt Sinai J Med 73(7): 985-92. 
Gut, I. G. (2001). "Automation in genotyping of single nucleotide polymorphisms." Hum Mutat 17(6): 475-92. 
Guyant-Marechal, L., A. Rovelet-Lecrux, et al. (2007). "Variations in the APP gene promoter region and risk of 
Alzheimer disease." Neurology 68(9): 684-7. 
Haniu, M., P. Denis, et al. (2000). "Characterization of Alzheimer's beta -secretase protein BACE. A pepsin 
family member with unusual properties." J Biol Chem 275(28): 21099-106. 
Hardy, J. and D. J. Selkoe (2002). "The amyloid hypothesis of Alzheimer's disease: progress and problems on 
the road to therapeutics." Science 297(5580): 353-6. 
Hardy, J. A. and G. A. Higgins (1992). "Alzheimer's disease: the amyloid cascade hypothesis." Science 
256(5054): 184-5. 
Hartmann, A. P., S. M. Almeida, et al. (2004). "Hyperphosphorylated tau protein in the cerebrospinal fluid of 
patients with Alzheimer's disease and other dementias: preliminary findings." Arq Neuropsiquiatr 62(3B): 
751-5. 
Hellstrom-Lindahl, E., M. Mousavi, et al. (2004). "Reduced levels of Abeta 40 and Abeta 42 in brains of 
smoking controls and Alzheimer's patients." Neurobiol Dis 15(2): 351-60. 
Hillenkamp, F., M. Karas, et al. (1991). "Matrix-assisted laser desorption/ionization mass spectrometry of 
biopolymers." Anal Chem 63(24): 1193A-1203A. 
Hirsch-Reinshagen, V., B. L. Burgess, et al. (2008). "Why lipids are important for Alzheimer disease?" Mol Cell 
Biochem. 
Huang, W., C. Qiu, et al. (2004). "APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-
year follow-up study." Arch Neurol 61(12): 1930-4. 
Itzhaki, R. (2004). "Herpes simplex virus type 1, apolipoprotein E and Alzheimer' disease." Herpes 11 Suppl 2: 
77A-82A. 
Itzhaki, R. F., C. B. Dobson, et al. (2004). "The role of viruses and of APOE in dementia." Ann N Y Acad Sci 
1019: 15-8. 
Jarvenpaa, T., J. O. Rinne, et al. (2002). "Characteristics of two telephone screens for cognitive impairment." 
Dement Geriatr Cogn Disord 13(3): 149-55. 
Jellinger, K., W. Danielczyk, et al. (1990). "Clinicopathological analysis of dementia disorders in the elderly." J 
Neurol Sci 95(3): 239-58. 
Jorm, A. F., R. Scott, et al. (1988). "Educational level differences on the Mini-Mental State: the role of test bias." 
Psychol Med 18(3): 727-31. 
Juan, D., D. H. Zhou, et al. (2004). "A 2-year follow-up study of cigarette smoking and risk of dementia." Eur J 
Neurol 11(4): 277-82. 
Karas, M. and F. Hillenkamp (1988). "Laser desorption ionization of proteins with molecular masses exceeding 
10,000 daltons." Anal Chem 60(20): 2299-301. 
Karp, A., I. Kareholt, et al. (2004). "Relation of education and occupation-based socioeconomic status to 
incident Alzheimer's disease." Am J Epidemiol 159(2): 175-83. 
Kathiresan, S., O. Melander, et al. (2008). "Polymorphisms associated with cholesterol and risk of 
cardiovascular events." N Engl J Med 358(12): 1240-9. 
Katzov, H., K. Chalmers, et al. (2004). "Genetic variants of ABCA1 modify Alzheimer disease risk and 
quantitative traits related to beta-amyloid metabolism." Hum Mutat 23(4): 358-67. 
Kehoe, P., F. Wavrant-De Vrieze, et al. (1999). "A full genome scan for late onset Alzheimer's disease." Hum 
Mol Genet 8(2): 237-45. 
Kirpekar, F., E. Nordhoff, et al. (1998). "DNA sequence analysis by MALDI mass spectrometry." Nucleic Acids 
Res 26(11): 2554-9. 
Knoblauch, H., A. Bauerfeind, et al. (2004). "Haplotypes and SNPs in 13 lipid-relevant genes explain most of 
the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol." Hum Mol Genet 
13(10): 993-1004. 
7   Appendix 
217 
Kojro, E. and F. Fahrenholz (2005). "The non-amyloidogenic pathway: structure and function of alpha-
secretases." Subcell Biochem 38: 105-27. 
Koldamova, R., M. Staufenbiel, et al. (2005). "Lack of ABCA1 considerably decreases brain ApoE level and 
increases amyloid deposition in APP23 mice." J Biol Chem 280(52): 43224-35. 
Koldamova, R. P., I. M. Lefterov, et al. (2003). "22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-
binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta 
secretion." J Biol Chem 278(15): 13244-56. 
Kolsch, H., D. Lutjohann, et al. (2006). "Polymorphism in ABCA1 influences CSF 24S-hydroxycholesterol 
levels but is not a major risk factor of Alzheimer's disease." Int J Mol Med 17(5): 791-4. 
Kowalska, A., D. Pruchnik-Wolinska, et al. (2004). "Genetic study of familial cases of Alzheimer's disease." 
Acta Biochim Pol 51(1): 245-52. 
Kowalska, A., D. Pruchnik-Wolinska, et al. (2004). "Amyloid precursor protein gene analysis in familial 
Alzheimer's disease cases: a lack of mutations in exons 16 and 17." Folia Neuropathol 42(1): 1-7. 
Lahiri, D. K., Y. W. Ge, et al. (2005). "Characterization of the APP proximal promoter and 5'-untranslated 
regions: identification of cell type-specific domains and implications in APP gene expression and 
Alzheimer's disease." FASEB J 19(6): 653-5. 
Laird, N. M., S. Horvath, et al. (2000). "Implementing a unified approach to family-based tests of association." 
Genet Epidemiol 19 Suppl 1: S36-42. 
Lamb, B. T., S. S. Sisodia, et al. (1993). "Introduction and expression of the 400 kilobase amyloid precursor 
protein gene in transgenic mice [corrected]." Nat Genet 5(1): 22-30. 
Lammich, S., E. Kojro, et al. (1999). "Constitutive and regulated alpha-secretase cleavage of Alzheimer's 
amyloid precursor protein by a disintegrin metalloprotease." Proc Natl Acad Sci U S A 96(7): 3922-7. 
Laws, S. M., K. Eckart, et al. (2008). "No association of lipase C polymorphisms with Alzheimer’s disease." 
Neurobiol Aging NBA-S-08-00664-1. 
Laws, S. M., K. Eckart, et al. (2009). "Lack of evidence to support the association of polymorphisms within the 
alpha- and beta-secretase genes (ADAM10/BACE1) with Alzheimer's disease." Neurobiol Aging NBA-
08-634R1. 
Lee, J. H., R. Cheng, et al. (2006). "Expanded genomewide scan implicates a novel locus at 3q28 among 
Caribbean hispanics with familial Alzheimer disease." Arch Neurol 63(11): 1591-8. 
Letenneur, L. (2004). "Risk of dementia and alcohol and wine consumption: a review of recent results." Biol Res 
37(2): 189-93. 
Letenneur, L., S. Larrieu, et al. (2004). "Alcohol and tobacco consumption as risk factors of dementia: a review 
of epidemiological studies." Biomed Pharmacother 58(2): 95-9. 
Levy-Lahad, E., E. M. Wijsman, et al. (1995). "A familial Alzheimer's disease locus on chromosome 1." Science 
269(5226): 970-3. 
Lewis, C. M. (2002). "Genetic association studies: design, analysis and interpretation." Brief Bioinform 3(2): 
146-53. 
Li, H., S. Wetten, et al. (2008). "Candidate single-nucleotide polymorphisms from a genomewide association 
study of Alzheimer disease." Arch Neurol 65(1): 45-53. 
Li, L., R. Perry, et al. (1998). "Polymorphic tetranucleotide repeat site within intron 7 of the beta-amyloid 
precursor protein gene and its lack of association with Alzheimer's disease." Hum Genet 103(1): 86-9. 
Li, Y., K. Tacey, et al. (2004). "Association of ABCA1 with late-onset Alzheimer's disease is not observed in a 
case-control study." Neurosci Lett 366(3): 268-71. 
Ling, Y., K. Morgan, et al. (2003). "Amyloid precursor protein (APP) and the biology of proteolytic processing: 
relevance to Alzheimer's disease." Int J Biochem Cell Biol 35(11): 1505-35. 
Lottspeich, F. (1998). Bioanalytik, Spektrum Verlag. 
Lovestone, S. and C. H. Reynolds (1997). "The phosphorylation of tau: a critical stage in neurodevelopment and 
neurodegenerative processes." Neuroscience 78(2): 309-24. 
Luchsinger, J. A. and R. Mayeux (2004). "Dietary factors and Alzheimer's disease." Lancet Neurol 3(10): 579-
87. 
Luchsinger, J. A., M. X. Tang, et al. (2004). "Hyperinsulinemia and risk of Alzheimer disease." Neurology 
63(7): 1187-92. 
7   Appendix 
218 
Luciani, M. F., F. Denizot, et al. (1994). "Cloning of two novel ABC transporters mapping on human 
chromosome 9." Genomics 21(1): 150-9. 
Luo, Y., B. Bolon, et al. (2001). "Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal 
phenotype and abolished beta-amyloid generation." Nat Neurosci 4(3): 231-2. 
Mahley, R. W. and S. C. Rall, Jr. (2000). "Apolipoprotein E: far more than a lipid transport protein." Annu Rev 
Genomics Hum Genet 1: 507-37. 
Malhotra, K., L. Foltz, et al. (1998). "Interaction and effect of annealing temperature on primers used in 
differential display RT-PCR." Nucleic Acids Res 26(3): 854-6. 
Martins, I. J., E. Hone, et al. (2006). "Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence 
of risk factors for Alzheimer's disease and cardiovascular disease." Mol Psychiatry 11(8): 721-36. 
Martins, R. N., R. Clarnette, et al. (1995). "ApoE genotypes in Australia: roles in early and late onset 
Alzheimer's disease and Down's syndrome." Neuroreport 6(11): 1513-6. 
Matsui, T., M. Ingelsson, et al. (2007). "Expression of APP pathway mRNAs and proteins in Alzheimer's 
disease." Brain Res 1161: 116-23. 
Melchor, J. P., R. Pawlak, et al. (2003). "The tissue plasminogen activator-plasminogen proteolytic cascade 
accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration." J Neurosci 
23(26): 8867-71. 
Merched, A., Y. Xia, et al. (2000). "Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI 
concentrations are highly correlated with the severity of Alzheimer's disease." Neurobiol Aging 21(1): 27-
30. 
Mueller, J. C., E. Lohmussaar, et al. (2005). "Linkage disequilibrium patterns and tagSNP transferability among 
European populations." Am J Hum Genet 76(3): 387-98. 
Myers, A., P. Holmans, et al. (2000). "Susceptibility locus for Alzheimer's disease on chromosome 10." Science 
290(5500): 2304-5. 
Myers, A., F. Wavrant De-Vrieze, et al. (2002). "Full genome screen for Alzheimer disease: stage II analysis." 
Am J Med Genet 114(2): 235-44. 
Nagy, Z., N. J. Hindley, et al. (1999). "The progression of Alzheimer's disease from limbic regions to the 
neocortex: clinical, radiological and pathological relationships." Dement Geriatr Cogn Disord 10(2): 115-
20. 
Nechiporuk, A., P. Fain, et al. (1993). "Linkage of familial Alzheimer disease to chromosome 14 in two large 
early-onset pedigrees: effects of marker allele frequencies on lod scores." Am J Med Genet 48(1): 63-6. 
Nowotny, P., X. Simcock, et al. (2007). "Association studies testing for risk for late-onset Alzheimer's disease 
with common variants in the beta-amyloid precursor protein (APP)." Am J Med Genet B Neuropsychiatr 
Genet 144B(4): 469-74. 
Olarte, L., N. Schupf, et al. (2006). "Apolipoprotein E epsilon4 and age at onset of sporadic and familial 
Alzheimer disease in Caribbean Hispanics." Arch Neurol 63(11): 1586-90. 
Olson, J. M., K. A. Goddard, et al. (2002). "A second locus for very-late-onset Alzheimer disease: a genome 
scan reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region." Am J 
Hum Genet 71(1): 154-61. 
Oram, J. F. and R. M. Lawn (2001). "ABCA1. The gatekeeper for eliminating excess tissue cholesterol." J Lipid 
Res 42(8): 1173-9. 
Ott, A., K. Andersen, et al. (2004). "Effect of smoking on global cognitive function in nondemented elderly." 
Neurology 62(6): 920-4. 
Ott, A., A. J. Slooter, et al. (1998). "Smoking and risk of dementia and Alzheimer's disease in a population-based 
cohort study: the Rotterdam Study." Lancet 351(9119): 1840-3. 
Ozturk, A., R. L. Minster, et al. (2007). "Association of tagSNPs in the urokinase-plasminogen activator (PLAU) 
gene with Alzheimer's disease and associated quantitative traits." Am J Med Genet B Neuropsychiatr 
Genet 144B(1): 79-82. 
Pantel, J., P. Schonknecht, et al. (2004). "[Neuropsychological correlates of cerebral atrophy in Alzheimer's 
dementia]." Fortschr Neurol Psychiatr 72(4): 192-203. 
Pastor, P. and A. M. Goate (2004). "Molecular genetics of Alzheimer's disease." Curr Psychiatry Rep 6(2): 125-
33. 
7   Appendix 
219 
Pearson, J. V., M. J. Huentelman, et al. (2007). "Identification of the genetic basis for complex disorders by use 
of pooling-based genomewide single-nucleotide-polymorphism association studies." Am J Hum Genet 
80(1): 126-39. 
Pericak-Vance, M. A., M. L. Bass, et al. (1998). "Complete genomic screen in late-onset familial Alzheimer's 
disease." Neurobiol Aging 19(1 Suppl): S39-42. 
Perry, G., L. M. Sayre, et al. (2002). "The role of iron and copper in the aetiology of neurodegenerative 
disorders: therapeutic implications." CNS Drugs 16(5): 339-52. 
Pfaffl, M. W. (2004). BIOspektrum, Sonderausgabe PCR  
Postina, R. (2008). "A closer look at alpha-secretase." Curr Alzheimer Res 5(2): 179-86. 
Postina, R., A. Schroeder, et al. (2004). "A disintegrin-metalloproteinase prevents amyloid plaque formation and 
hippocampal defects in an Alzheimer disease mouse model." J Clin Invest 113(10): 1456-64. 
Potyk, D. (2005). "Treatments for Alzheimer disease." South Med J 98(6): 628-35. 
Prasher, V. P., M. J. Farrer, et al. (1998). "Molecular mapping of Alzheimer-type dementia in Down's 
syndrome." Ann Neurol 43(3): 380-3. 
Priller, C., T. Bauer, et al. (2006). "Synapse formation and function is modulated by the amyloid precursor 
protein." J Neurosci 26(27): 7212-21. 
Prinzen, C., U. Muller, et al. (2005). "Genomic structure and functional characterization of the human ADAM10 
promoter." FASEB J 19(11): 1522-4. 
Qi-Takahara, Y., M. Morishima-Kawashima, et al. (2005). "Longer forms of amyloid beta protein: implications 
for the mechanism of intramembrane cleavage by gamma-secretase." J Neurosci 25(2): 436-45. 
Qiu, C., A. Karp, et al. (2003). "Lifetime principal occupation and risk of Alzheimer's disease in the 
Kungsholmen project." Am J Ind Med 43(2): 204-11. 
Rademakers, R., M. Cruts, et al. (2003). "Genetics of early-onset Alzheimer dementia." ScientificWorldJournal 
3: 497-519. 
Rebeck, G. W., M. J. LaDu, et al. (2006). "The generation and function of soluble apoE receptors in the CNS." 
Mol Neurodegener 1: 15. 
Reid, P. C., Y. Urano, et al. (2007). "Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins." J 
Cell Mol Med 11(3): 383-92. 
Reiman, E. M., J. A. Webster, et al. (2007). "GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers." 
Neuron 54(5): 713-20. 
Riemenschneider, M., K. Blennow, et al. (2006). "The cathepsin D rs17571 polymorphism: effects on CSF tau 
concentrations in Alzheimer disease." Hum Mutat 27(6): 532-7. 
Rissman, R. A., W. W. Poon, et al. (2004). "Caspase-cleavage of tau is an early event in Alzheimer disease 
tangle pathology." J Clin Invest 114(1): 121-30. 
Rodriguez-Rodriguez, E., I. Mateo, et al. (2007). "Association of genetic variants of ABCA1 with Alzheimer's 
disease risk." Am J Med Genet B Neuropsychiatr Genet 144B(7): 964-8. 
Rosler, N., I. Wichart, et al. (2001). "CSF Abeta40 and Abeta42: Natural course and clinical usefulness." J 
Alzheimers Dis 3(6): 599-600. 
Rostoks, N., S. Mudie, et al. (2005). "Genome-wide SNP discovery and linkage analysis in barley based on 
genes responsive to abiotic stress." Mol Genet Genomics 274(5): 515-27. 
Rottkamp, C. A., A. K. Raina, et al. (2001). "Redox-active iron mediates amyloid-beta toxicity." Free Radic Biol 
Med 30(4): 447-50. 
Rovelet-Lecrux, A., D. Hannequin, et al. (2006). "APP locus duplication causes autosomal dominant early-onset 
Alzheimer disease with cerebral amyloid angiopathy." Nat Genet 38(1): 24-6. 
Ruitenberg, A., J. C. van Swieten, et al. (2002). "Alcohol consumption and risk of dementia: the Rotterdam 
Study." Lancet 359(9303): 281-6. 
Rumble, B., R. Retallack, et al. (1989). "Amyloid A4 protein and its precursor in Down's syndrome and 
Alzheimer's disease." N Engl J Med 320(22): 1446-52. 
Rust, S., M. Rosier, et al. (1999). "Tangier disease is caused by mutations in the gene encoding ATP-binding 
cassette transporter 1." Nat Genet 22(4): 352-5. 
Saiki, R. K., D. H. Gelfand, et al. (1988). "Primer-directed enzymatic amplification of DNA with a thermostable 
DNA polymerase." Science 239(4839): 487-91. 
7   Appendix 
220 
Santamarina-Fojo, S., K. Peterson, et al. (2000). "Complete genomic sequence of the human ABCA1 gene: 
analysis of the human and mouse ATP-binding cassette A promoter." Proc Natl Acad Sci U S A 97(14): 
7987-92. 
Saunders, A. M., W. J. Strittmatter, et al. (1993). "Association of apolipoprotein E allele epsilon 4 with late-
onset familial and sporadic Alzheimer's disease." Neurology 43(8): 1467-72. 
Schmitz, G., W. E. Kaminski, et al. (2000). "ABC transporters in cellular lipid trafficking." Curr Opin Lipidol 
11(5): 493-501. 
Schork, N. J., D. Fallin, et al. (2001). "The future of genetic case-control studies." Adv Genet 42: 191-212. 
Schupf, N., B. Patel, et al. (2001). "Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults 
with Down syndrome." Neurosci Lett 301(3): 199-203. 
Scott, W. K., E. R. Hauser, et al. (2003). "Ordered-subsets linkage analysis detects novel Alzheimer disease loci 
on chromosomes 2q34 and 15q22." Am J Hum Genet 73(5): 1041-51. 
Sennvik, K., N. Bogdanovic, et al. (2004). "Beta-secretase-cleaved amyloid precursor protein in Alzheimer 
brain: a morphologic study." J Cell Mol Med 8(1): 127-34. 
SEQUENOM, i. G. A., November 2006. 
Sergeant, N., A. Delacourte, et al. (2005). "Tau protein as a differential biomarker of tauopathies." Biochim 
Biophys Acta 1739(2-3): 179-97. 
Shibata, N., T. Kawarai, et al. (2006). "Association studies of cholesterol metabolism genes (CH25H, ABCA1 
and CH24H) in Alzheimer's disease." Neurosci Lett 391(3): 142-6. 
Smith, A. D. and K. A. Jobst (1996). "Use of structural imaging to study the progression of Alzheimer's disease." 
Br Med Bull 52(3): 575-86. 
Smyth, K. A., T. Fritsch, et al. (2004). "Worker functions and traits associated with occupations and the 
development of AD." Neurology 63(3): 498-503. 
Sparks, D. L., S. W. Scheff, et al. (1994). "Induction of Alzheimer-like beta-amyloid immunoreactivity in the 
brains of rabbits with dietary cholesterol." Exp Neurol 126(1): 88-94. 
Spielman, R. S. and W. J. Ewens (1998). "A sibship test for linkage in the presence of association: the sib 
transmission/disequilibrium test." Am J Hum Genet 62(2): 450-8. 
Spielman, R. S., R. E. McGinnis, et al. (1993). "Transmission test for linkage disequilibrium: the insulin gene 
region and insulin-dependent diabetes mellitus (IDDM)." Am J Hum Genet 52(3): 506-16. 
Stern, Y., B. Gurland, et al. (1994). "Influence of education and occupation on the incidence of Alzheimer's 
disease." Jama 271(13): 1004-10. 
Strittmatter, W. J., K. H. Weisgraber, et al. (1993). "Binding of human apolipoprotein E to synthetic amyloid 
beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease." Proc Natl Acad 
Sci U S A 90(17): 8098-102. 
Tanahashi, H. and T. Tabira (2001). "Three novel alternatively spliced isoforms of the human beta-site amyloid 
precursor protein cleaving enzyme (BACE) and their effect on amyloid beta-peptide production." 
Neurosci Lett 307(1): 9-12. 
Teri, L., S. M. McCurry, et al. (1997). "Memory, thinking, and aging. What we know about what we know." 
West J Med 167(4): 269-75. 
Theuns, J., N. Brouwers, et al. (2006). "Promoter mutations that increase amyloid precursor-protein expression 
are associated with Alzheimer disease." Am J Hum Genet 78(6): 936-46. 
Todd, S., A. J. McKnight, et al. (2008). "BACE1 Polymorphisms Do Not Influence Platelet Membrane beta-
secretase Activity or Genetic Susceptibility for Alzheimer's Disease in the Northern Irish Population." 
Neuromolecular Med. 
Truelsen, T., D. Thudium, et al. (2002). "Amount and type of alcohol and risk of dementia: the Copenhagen City 
Heart Study." Neurology 59(9): 1313-9. 
Turner, P. R., K. O'Connor, et al. (2003). "Roles of amyloid precursor protein and its fragments in regulating 
neural activity, plasticity and memory." Prog Neurobiol 70(1): 1-32. 
van Duijn, C. M. and A. Hofman (1991). "Relation between nicotine intake and Alzheimer's disease." BMJ 
302(6791): 1491-4. 
Vanderstichele, H., E. Van Kerschaver, et al. (2000). "Standardization of measurement of beta-amyloid(1-42) in 
cerebrospinal fluid and plasma." Amyloid 7(4): 245-58. 
7   Appendix 
221 
Vassar, R., B. Bennett, et al. (1999). "b-secretase cleavage of Alzheimer´s Amyloid precursor protein by the 
transmembrane aspartic protease BACE." Science 286: 735-741. 
Vassar, R., B. D. Bennett, et al. (1999). "Beta-secretase cleavage of Alzheimer's amyloid precursor protein by 
the transmembrane aspartic protease BACE." Science 286(5440): 735-41. 
Verdile, G., S. Fuller, et al. (2004). "The role of beta amyloid in Alzheimer's disease: still a cause of everything 
or the only one who got caught?" Pharmacol Res 50(4): 397-409. 
von Arnim, C. A., A. Kinoshita, et al. (2005). "The low density lipoprotein receptor-related protein (LRP) is a 
novel beta-secretase (BACE1) substrate." J Biol Chem 280(18): 17777-85. 
Wahrle, S. E., H. Jiang, et al. (2008). "Overexpression of ABCA1 reduces amyloid deposition in the PDAPP 
mouse model of Alzheimer disease." J Clin Invest 118(2): 671-82. 
Wahrle, S. E., A. R. Shah, et al. (2007). "Apolipoprotein E levels in cerebrospinal fluid and the effects of 
ABCA1 polymorphisms." Mol Neurodegener 2: 7. 
Wang, F. and J. P. Jia (2007). "[Correlation of cholesterol 24-hydroxylase and ATP-binding cassette transporter 
A1 polymorphisms with Alzheimer's disease]." Zhonghua Yi Xue Za Zhi 87(9): 614-8. 
Wang, N. and A. R. Tall (2003). "Regulation and mechanisms of ATP-binding cassette transporter A1-mediated 
cellular cholesterol efflux." Arterioscler Thromb Vasc Biol 23(7): 1178-84. 
Wang, S. C., B. Oelze, et al. (2008). "Age-specific epigenetic drift in late-onset Alzheimer's disease." PLoS ONE 
3(7): e2698. 
Whitehouse, P. J. (1987). "Neurotransmitter receptor alterations in Alzheimer disease: a review." Alzheimer Dis 
Assoc Disord 1(1): 9-18. 
Whittemore, A. S. and I. P. Tu (2000). "Detection of disease genes by use of family data. I. Likelihood-based 
theory." Am J Hum Genet 66(4): 1328-40. 
Willem, M., A. N. Garratt, et al. (2006). "Control of peripheral nerve myelination by the beta-secretase BACE1." 
Science 314(5799): 664-6. 
Wolfsberg, T. G., P. Primakoff, et al. (1995). "ADAM, a novel family of membrane proteins containing A 
Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell-matrix 
interactions." J Cell Biol 131(2): 275-8. 
Wollmer, M. A., K. Sleegers, et al. (2007). "Association study of cholesterol-related genes in Alzheimer's 
disease." Neurogenetics 8(3): 179-88. 
Wollmer, M. A., J. R. Streffer, et al. (2003). "ABCA1 modulates CSF cholesterol levels and influences the age at 
onset of Alzheimer's disease." Neurobiol Aging 24(3): 421-6. 
Xu, W. L., C. X. Qiu, et al. (2004). "Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year 
follow-up study." Neurology 63(7): 1181-6. 
Yoshikai, S., H. Sasaki, et al. (1990). "Genomic organization of the human amyloid beta-protein precursor 
gene." Gene 87(2): 257-63. 
Zekanowski, C., D. Religa, et al. (2004). "Genetic aspects of Alzheimer's disease." Acta Neurobiol Exp (Wars) 
64(1): 19-31. 
Zheng, H. and E. H. Koo (2006). "The amyloid precursor protein: beyond amyloid." Mol Neurodegener 1: 5. 
Zhu, H., J. W. Taylor, et al. (2008). "Lack of association of hepatic lipase polymorphisms with late-onset 
Alzheimer's disease." Neurobiol Aging 29(5): 793-4. 
 
 
